"cell_ID","sample_ID","cell","UMAP_1","UMAP_2","orig.ident","samples","Broad_cell_identity","Cell_type_identity","clusters_res.2","CNV_pos","malignant","aml","ap_aml_age","age_group","sex.x","inflammation_group","occupancy_score","GSM","date","cell_ID.1","cell_type_original","Sample.ID","sex.y","Age","Sequencing","Institution","Manuscript.ID","Dx","DxELN_Cytogenetic","Cytogenetics","Overall.survival","Flow.report.summary","RAS.pathway","NPM1","IDH","TET2","TP53","RUNX1","CBF","MLL.rearranged","IDH1","IDH2","ASXL1","BCOR","CBL","CEBPAdm","CSF3R","DNMT3A","ETV6","FLT3.TKD","FLT3.ITD","GATA2","JAK2","KIT","NPM1.1","NRAS","KRAS","PTPN11","PHF6","RAD21","RUNX1.1","SETBP1","SMC1A","STAG2","SRSF2","SF3B1","TET2.1","U2AF1","WT1","TP53.1","ZRSR2","health_status","case_or_control","cell_type","cell_subtype","total_counts_raw","mito_counts","frac_mito","nr_genes","counts_upper_threshold","counts_lower_threshold","genes_lower_threshold","counts_upper_filter","counts_lower_filter","genes_lower_filter","cell_filter","threshold_celltype_size","celltype_size_cf","celltype_size_filter","cell_type_ID","total_counts_raw_cf_ctf_gf","total_counts_raw_cf_ctf_gf_sf","bares_mutation"
"2020.09.15.AML0024.CCTCAACAGTTCCATG","AML-0024","2020-09-15-AML0024:CCTCAACAGTTCCATG",-0.971509675413925,-17.4919233552185,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",80,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CCTCAACAGTTCCATG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2845.24060407425,44.333479741988,0.015581627676234,2161,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2843.28312483307,2843.28312483307,"malignant"
"2020.09.15.AML0024.CCTATCGCAGAACGCA","AML-0024","2020-09-15-AML0024:CCTATCGCAGAACGCA",-1.09063396874126,-16.6452665559021,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CCTATCGCAGAACGCA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2640.65364305772,35.3601114981541,0.0133906662053601,1926,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2631.77978757496,2631.77978757496,"malignant"
"2020.09.15.AML0024.AACAAAGAGTCACGCC","AML-0024","2020-09-15-AML0024:AACAAAGAGTCACGCC",-0.536077598959762,-16.0073671570984,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AACAAAGAGTCACGCC","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2826.79713584534,36.6067585541403,0.0129499064824803,3203,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2820.84169185677,2820.84169185677,"malignant"
"2020.09.15.AML0024.AACCATGCAATAAGGT","AML-0024","2020-09-15-AML0024:AACCATGCAATAAGGT",-1.64155815067943,-16.236207031366,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AACCATGCAATAAGGT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2636.4071901132,41.9277511919099,0.0159033670326584,2376,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2624.15090817149,2624.15090817149,"malignant"
"2020.09.15.AML0024.AACCCAAGTTAAGACA","AML-0024","2020-09-15-AML0024:AACCCAAGTTAAGACA",-0.533172051340896,-15.8141327134338,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AACCCAAGTTAAGACA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2685.46798138017,33.3500762058698,0.0124187204752037,2466,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2678.66697165784,2678.66697165784,"malignant"
"2020.09.15.AML0024.AAGAACACATCTATCT","AML-0024","2020-09-15-AML0024:AAGAACACATCTATCT",-1.31997356835063,-16.2914686433044,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AAGAACACATCTATCT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2743.75047447051,34.4857700627984,0.0125688434074726,2395,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2740.83350150864,2740.83350150864,"malignant"
"2020.09.15.AML0024.AAGACAACAGCGCGTT","AML-0024","2020-09-15-AML0024:AAGACAACAGCGCGTT",-0.722372869879562,-15.9097481003967,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AAGACAACAGCGCGTT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",3057.02261931823,42.6474156475869,0.0139506379109155,3732,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",3049.49825772396,3049.49825772396,"malignant"
"2020.09.15.AML0024.AAGCGTTAGAAAGCGA","AML-0024","2020-09-15-AML0024:AAGCGTTAGAAAGCGA",-2.83003077927287,-15.8886327973572,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AAGCGTTAGAAAGCGA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2963.27759120022,39.0418678458269,0.013175231359278,3280,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2959.29481617396,2959.29481617396,"malignant"
"2020.09.15.AML0024.AAGGTAAGTGTAACGG","AML-0024","2020-09-15-AML0024:AAGGTAAGTGTAACGG",-0.651372651488143,-15.8008156052795,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AAGGTAAGTGTAACGG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2623.36318551668,36.9514605377433,0.0140855298807838,2245,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2614.90122762524,2614.90122762524,"malignant"
"2020.09.15.AML0024.AAGGTAATCCGACATA","AML-0024","2020-09-15-AML0024:AAGGTAATCCGACATA",-2.2118857902592,-15.8386621705261,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AAGGTAATCCGACATA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2775.09172680596,33.8548424479419,0.0121995399722905,2525,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2767.15348016299,2767.15348016299,"malignant"
"2020.09.15.AML0024.AAGTACCAGCAGATAT","AML-0024","2020-09-15-AML0024:AAGTACCAGCAGATAT",-1.32969532433208,-16.5817327729431,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AAGTACCAGCAGATAT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2924.28496200129,34.1810047754738,0.0116886709809845,2580,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2916.06303810862,2916.06303810862,"malignant"
"2020.09.15.AML0024.ACATCCCTCACGGTCG","AML-0024","2020-09-15-AML0024:ACATCCCTCACGGTCG",-2.06417284432109,-15.6832494965759,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.ACATCCCTCACGGTCG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2814.59364798675,44.1940653901488,0.0157017569558435,2792,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2797.8179015705,2797.8179015705,"malignant"
"2020.09.15.AML0024.ACATTTCCAGAACTCT","AML-0024","2020-09-15-AML0024:ACATTTCCAGAACTCT",-1.7119622034138,-16.9105558625427,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.ACATTTCCAGAACTCT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2505.03844944746,43.5000658512359,0.0173650292117596,1937,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2493.97222062692,2493.97222062692,"malignant"
"2020.09.15.AML0024.ACCACAATCACCCTTG","AML-0024","2020-09-15-AML0024:ACCACAATCACCCTTG",-1.88275788250621,-15.6645717850891,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.ACCACAATCACCCTTG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2783.53970113507,34.092417605794,0.0122478646853472,2461,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2777.12917069619,2777.12917069619,"malignant"
"2020.09.15.AML0024.ACCTGAATCTAGAGCT","AML-0024","2020-09-15-AML0024:ACCTGAATCTAGAGCT",-1.2142290872639,-16.5503301850525,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.ACCTGAATCTAGAGCT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2594.83946766469,41.7358645471665,0.0160841797988867,1964,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2587.41505743526,2587.41505743526,"malignant"
"2020.09.15.AML0024.ACGATCAGTCGAACGA","AML-0024","2020-09-15-AML0024:ACGATCAGTCGAACGA",-0.958927492529708,-15.940043472406,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.ACGATCAGTCGAACGA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2569.66337613126,33.780589958815,0.0131459203071467,1862,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2563.08911910374,2563.08911910374,"malignant"
"2020.09.15.AML0024.ACGTACAAGAGCATTA","AML-0024","2020-09-15-AML0024:ACGTACAAGAGCATTA",-0.360245714814025,-16.6109705201355,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.ACGTACAAGAGCATTA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2509.04853831631,43.8566207033797,0.017479383134138,1784,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2503.85829321001,2503.85829321001,"malignant"
"2020.09.15.AML0024.ACTATTCCACTCCTTG","AML-0024","2020-09-15-AML0024:ACTATTCCACTCCTTG",-2.29655681076701,-15.6095657578674,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.ACTATTCCACTCCTTG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2592.33966554816,30.9684484649791,0.0119461384156349,2400,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2588.59374420982,2588.59374420982,"malignant"
"2020.09.15.AML0024.ACTGTGACAGAACTTC","AML-0024","2020-09-15-AML0024:ACTGTGACAGAACTTC",-2.09993229332622,-16.4588461152283,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.ACTGTGACAGAACTTC","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2465.54084659357,45.3168394238815,0.0183800805760293,1870,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2458.28886087182,2458.28886087182,"malignant"
"2020.09.15.AML0024.ACTTAGGGTACAAGCG","AML-0024","2020-09-15-AML0024:ACTTAGGGTACAAGCG",-1.96850238266643,-15.767472290155,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.ACTTAGGGTACAAGCG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2785.6899501153,34.5578076377726,0.0124054752167743,2281,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2779.06913319187,2779.06913319187,"malignant"
"2020.09.15.AML0024.ACTTCCGAGTACAGAT","AML-0024","2020-09-15-AML0024:ACTTCCGAGTACAGAT",-1.75012598457988,-15.5387945405212,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.ACTTCCGAGTACAGAT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2635.52536482522,32.0453677176204,0.0121590056181249,2261,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2622.34803312514,2622.34803312514,"malignant"
"2020.09.15.AML0024.CATTGCCAGAGGTGCT","AML-0024","2020-09-15-AML0024:CATTGCCAGAGGTGCT",-1.58131382885631,-16.5110349885193,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CATTGCCAGAGGTGCT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2586.27167807121,32.2230504164456,0.0124592674039863,2083,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2583.02192043939,2583.02192043939,"malignant"
"2020.09.15.AML0024.CCACCATTCGCGTGAC","AML-0024","2020-09-15-AML0024:CCACCATTCGCGTGAC",11.221868177026,-2.38929011737975,"2020-09-15-AML0024","AML0024","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.337349397590361,"GSM5613779","2020-09-15","2020.09.15.AML0024.CCACCATTCGCGTGAC","Ery","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Ery","Ery",1408.84441132203,40.698433631691,0.0288878128092941,585,30000,1100,500,"True","True","True","True",5,27,"True","Ery_AML-0024",1408.84441132203,1408.84441132203,"malignant"
"2020.09.15.AML0024.AGGTTGTTCTAAGCCA","AML-0024","2020-09-15-AML0024:AGGTTGTTCTAAGCCA",-1.63578627529796,-15.8876686326233,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AGGTTGTTCTAAGCCA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2669.85395479849,34.447102337872,0.0129022421904242,2222,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2664.49009942864,2664.49009942864,"malignant"
"2020.09.15.AML0024.AGTACTGGTGTTAGCT","AML-0024","2020-09-15-AML0024:AGTACTGGTGTTAGCT",-0.324150691658813,-16.6859426728454,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AGTACTGGTGTTAGCT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2781.64673032361,41.2395924327573,0.0148256038350203,2536,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2771.09137776093,2771.09137776093,"malignant"
"2020.09.15.AML0024.AGTCAACCATCCGAAT","AML-0024","2020-09-15-AML0024:AGTCAACCATCCGAAT",-1.27150140228923,-16.2695570222107,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AGTCAACCATCCGAAT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2566.35409047098,39.8854756880128,0.0155416884350097,1940,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2557.69014577086,2557.69014577086,"malignant"
"2020.09.15.AML0024.AGTGCCGGTTTACGAC","AML-0024","2020-09-15-AML0024:AGTGCCGGTTTACGAC",-0.513233224779922,-16.2351064912048,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AGTGCCGGTTTACGAC","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2324.4068894323,49.8832621492605,0.0214606411536853,1362,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2314.78215943387,2314.78215943387,"malignant"
"2020.09.15.AML0024.AGTGTTGAGCCTCCAG","AML-0024","2020-09-15-AML0024:AGTGTTGAGCCTCCAG",-2.78573570671733,-15.4827776185242,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AGTGTTGAGCCTCCAG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2692.25124414542,34.5470638942654,0.0128320356316639,2201,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2685.68394802618,2685.68394802618,"malignant"
"2020.09.15.AML0024.AGTTCCCGTTGCTCGG","AML-0024","2020-09-15-AML0024:AGTTCCCGTTGCTCGG",-2.65939317169841,-16.1618204346863,"2020-09-15-AML0024","AML0024","CD16+ monocyte","CD16+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AGTTCCCGTTGCTCGG","CD16+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2415.55589601288,33.1355785515621,0.0137175788837078,1808,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2408.58023756507,2408.58023756507,"malignant"
"2020.09.15.AML0024.ATTCACTAGGAAAGGT","AML-0024","2020-09-15-AML0024:ATTCACTAGGAAAGGT",-0.952009419829208,-16.6282911530701,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.ATTCACTAGGAAAGGT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2862.38514342684,40.912808430514,0.0142932576786411,2626,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2854.09538659595,2854.09538659595,"malignant"
"2020.09.15.AML0024.CAACAACCACTTTAGG","AML-0024","2020-09-15-AML0024:CAACAACCACTTTAGG",-1.09214232388194,-15.6471796265808,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CAACAACCACTTTAGG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2626.74498005141,39.9277440301492,0.0152004645800704,2122,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2623.4280886208,2623.4280886208,"malignant"
"2020.09.15.AML0024.CAACCAACAAAGCACG","AML-0024","2020-09-15-AML0024:CAACCAACAAAGCACG",-1.85834501209911,-15.9473848572937,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CAACCAACAAAGCACG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2739.71884588404,35.3296193460273,0.0128953448632527,2271,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2734.08661736448,2734.08661736448,"malignant"
"2020.09.15.AML0024.CAAGCTAAGATGTTAG","AML-0024","2020-09-15-AML0024:CAAGCTAAGATGTTAG",-1.6669958633488,-15.565980934259,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CAAGCTAAGATGTTAG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2706.04321888353,37.4195785783254,0.0138281526019988,2519,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2697.47159416367,2697.47159416367,"malignant"
"2020.09.15.AML0024.CAAGCTAAGCGATTCT","AML-0024","2020-09-15-AML0024:CAAGCTAAGCGATTCT",-0.258582482964355,-16.2128381959167,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CAAGCTAAGCGATTCT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2688.78300740278,37.2910782826334,0.0138691289627922,2281,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2681.53205487651,2681.53205487651,"malignant"
"2020.09.15.AML0024.CAATCGAAGCGCTGAA","AML-0024","2020-09-15-AML0024:CAATCGAAGCGCTGAA",-1.1139397424763,-16.37220861828,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",80,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CAATCGAAGCGCTGAA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2714.66234768738,43.4922722292056,0.0160212456132,1705,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2705.78843813229,2705.78843813229,"malignant"
"2020.09.15.AML0024.CAGGGCTGTGGATTTC","AML-0024","2020-09-15-AML0024:CAGGGCTGTGGATTTC",-0.333732257515746,-15.9487257233826,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CAGGGCTGTGGATTTC","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2760.77430040618,41.7852164508666,0.0151353250588862,2510,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2756.52953358004,2756.52953358004,"malignant"
"2020.09.15.AML0024.CAGGTATTCTGGGCAC","AML-0024","2020-09-15-AML0024:CAGGTATTCTGGGCAC",0.318398107855958,-16.329670929071,"2020-09-15-AML0024","AML0024","Granulocyte","Granulocytes",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CAGGTATTCTGGGCAC","Granulocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Gran","Gran",2869.66831083355,38.0837936921062,0.0132711482885783,2678,30000,1100,500,"True","True","True","True",5,452,"True","Gran_AML-0024",2861.41916044837,2861.41916044837,"malignant"
"2020.09.15.AML0024.CATACCCCAGCGTATT","AML-0024","2020-09-15-AML0024:CATACCCCAGCGTATT",0.18494146045987,-16.3331690064636,"2020-09-15-AML0024","AML0024","Granulocyte","Granulocytes",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CATACCCCAGCGTATT","Granulocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Gran","Gran",2668.83024838338,39.362670925066,0.0147490350684198,2451,30000,1100,500,"True","True","True","True",5,452,"True","Gran_AML-0024",2660.25021096423,2660.25021096423,"malignant"
"2020.09.15.AML0024.AGATCGTTCAGGAAAT","AML-0024","2020-09-15-AML0024:AGATCGTTCAGGAAAT",-0.245934854180175,-16.384888671991,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.AGATCGTTCAGGAAAT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2679.23364549243,37.9995304659092,0.0141829849478936,2568,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2670.14835177086,2670.14835177086,"malignant"
"2020.09.15.AML0024.TGATGCAGTAAGGAGA","AML-0024","2020-09-15-AML0024:TGATGCAGTAAGGAGA",-1.71173069897349,-16.3431120148865,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TGATGCAGTAAGGAGA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2593.83369724803,39.5386160344497,0.015243311888653,2091,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2586.12308187179,2586.12308187179,"malignant"
"2020.09.15.AML0024.TGCACGGTCATCGACA","AML-0024","2020-09-15-AML0024:TGCACGGTCATCGACA",-1.59458265724834,-16.5516844025818,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TGCACGGTCATCGACA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2221.01019737302,48.3907853265436,0.0217877366721592,1574,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2208.86961300688,2208.86961300688,"malignant"
"2020.09.15.AML0024.CCTCCAATCCGGGACT","AML-0024","2020-09-15-AML0024:CCTCCAATCCGGGACT",-0.515753428370315,-15.9941911927429,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CCTCCAATCCGGGACT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2955.13038061771,34.6691779822213,0.0117318607021916,2918,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2944.4198434893,2944.4198434893,"malignant"
"2020.09.15.AML0024.CGAGGCTCACTTTAGG","AML-0024","2020-09-15-AML0024:CGAGGCTCACTTTAGG",-2.55800805512126,-16.0221662751404,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CGAGGCTCACTTTAGG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2620.98025871914,43.9189781253028,0.0167566993224,2243,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2612.57881298332,2612.57881298332,"malignant"
"2020.09.15.AML0024.CGATGCGAGCTGAGCA","AML-0024","2020-09-15-AML0024:CGATGCGAGCTGAGCA",-0.514036456972915,-16.5612993470398,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CGATGCGAGCTGAGCA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2585.55741535693,41.8229079136683,0.0161755866124886,2496,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2580.89027398754,2580.89027398754,"malignant"
"2020.09.15.AML0024.CGTGATATCCCGAAAT","AML-0024","2020-09-15-AML0024:CGTGATATCCCGAAAT",-0.772551814944106,-15.7093897095886,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CGTGATATCCCGAAAT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2533.78340080888,34.1918214802709,0.0134943742505202,1992,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2526.27249530457,2526.27249530457,"malignant"
"2020.09.15.AML0024.CGTTCTGTCACTGTCC","AML-0024","2020-09-15-AML0024:CGTTCTGTCACTGTCC",-0.866990129381973,-16.547314666864,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.CGTTCTGTCACTGTCC","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2549.61839195356,42.8789597696831,0.0168177951276969,1915,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2536.50146536139,2536.50146536139,"malignant"
"2020.09.15.AML0024.CTGGACGCAGCTGTAT","AML-0024","2020-09-15-AML0024:CTGGACGCAGCTGTAT",-3.17433271828349,9.82144067371217,"2020-09-15-AML0024","AML0024","gd T","gd T",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0025391451544646,"GSM5613779","2020-09-15","2020.09.15.AML0024.CTGGACGCAGCTGTAT","gd T","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","T","gd_T",1910.77312246549,33.655841360451,0.0176137297331379,902,30000,1100,500,"True","True","True","True",5,65,"True","T_AML-0024",1910.77312246549,1910.77312246549,"microenvironment"
"2020.09.15.AML0024.GAAATGACAAAGGAGA","AML-0024","2020-09-15-AML0024:GAAATGACAAAGGAGA",-2.0300158065861,-16.0229959717956,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GAAATGACAAAGGAGA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2455.5733697336,42.1951473686131,0.0171834195176953,1833,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2446.10620902374,2446.10620902374,"malignant"
"2020.09.15.AML0024.TCGTGGGGTCACAGTT","AML-0024","2020-09-15-AML0024:TCGTGGGGTCACAGTT",-0.63457820835765,-16.369559311029,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TCGTGGGGTCACAGTT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2658.35571304019,36.039144650573,0.0135569308779062,2071,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2654.81766965238,2654.81766965238,"malignant"
"2020.09.15.AML0024.TCTACATAGGGTAATT","AML-0024","2020-09-15-AML0024:TCTACATAGGGTAATT",-0.82725558701213,-15.6745701066223,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TCTACATAGGGTAATT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2680.89617866733,38.1955997171994,0.014247325212044,2210,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2671.67484549312,2671.67484549312,"malignant"
"2020.09.15.AML0024.TCTATACAGCTGTTCA","AML-0024","2020-09-15-AML0024:TCTATACAGCTGTTCA",-0.704014281660873,-16.2020311585632,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TCTATACAGCTGTTCA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2848.20492733043,34.7153993419156,0.0121885188136563,2752,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2842.66358815689,2842.66358815689,"malignant"
"2020.09.15.AML0024.TCTCACGCATCATCCC","AML-0024","2020-09-15-AML0024:TCTCACGCATCATCCC",-0.609050731093246,-15.7285623780456,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TCTCACGCATCATCCC","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2853.77435897003,32.3511942046598,0.0113362831588184,2687,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2851.20098691233,2851.20098691233,"malignant"
"2020.09.15.AML0024.TGACGCGAGAGGGCGA","AML-0024","2020-09-15-AML0024:TGACGCGAGAGGGCGA",-2.51824198189433,-16.2987375489441,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TGACGCGAGAGGGCGA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2598.891503207,37.8697820971359,0.0145715132972673,2091,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2589.65911242173,2589.65911242173,"malignant"
"2020.09.15.AML0024.GCAGTTACAAGTCCCG","AML-0024","2020-09-15-AML0024:GCAGTTACAAGTCCCG",-2.53778491440471,-15.6039142838684,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GCAGTTACAAGTCCCG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2848.95245731696,34.1951761049785,0.0120027191107227,2464,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2840.58703586848,2840.58703586848,"malignant"
"2020.09.15.AML0024.GCCATGGTCGGATTAC","AML-0024","2020-09-15-AML0024:GCCATGGTCGGATTAC",0.0551623912410855,-15.8931942216125,"2020-09-15-AML0024","AML0024","Granulocyte","Granulocytes",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GCCATGGTCGGATTAC","Granulocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Gran","Gran",2494.06279160409,36.7897357025714,0.0147509260097295,1890,30000,1100,500,"True","True","True","True",5,452,"True","Gran_AML-0024",2489.63404759209,2489.63404759209,"malignant"
"2020.09.15.AML0024.GCCATTCTCGTCTAAG","AML-0024","2020-09-15-AML0024:GCCATTCTCGTCTAAG",-1.80185423317607,-16.533455871698,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GCCATTCTCGTCTAAG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2579.60521273564,37.3148838676077,0.0144653467450686,2036,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2574.05508624001,2574.05508624001,"malignant"
"2020.09.15.AML0024.GCGTTTCCAGTGGCTC","AML-0024","2020-09-15-AML0024:GCGTTTCCAGTGGCTC",-2.33483992043193,-15.6320114365784,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GCGTTTCCAGTGGCTC","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2792.87535169179,39.6464661773657,0.0141955730868368,2696,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2774.92644833752,2774.92644833752,"malignant"
"2020.09.15.AML0024.GCTTCACAGTCATGGG","AML-0024","2020-09-15-AML0024:GCTTCACAGTCATGGG",-1.1988893550938,-15.9301071397034,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GCTTCACAGTCATGGG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2315.26441481925,26.8661853117854,0.011603938254233,1666,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2309.58730607541,2309.58730607541,"malignant"
"2020.09.15.AML0024.GCTTTCGAGTCCTGCG","AML-0024","2020-09-15-AML0024:GCTTTCGAGTCCTGCG",-1.31844351711925,-15.7004814377991,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GCTTTCGAGTCCTGCG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2880.42455559757,33.1252594323105,0.0115001308983906,2614,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2873.35023964411,2873.35023964411,"malignant"
"2020.09.15.AML0024.GGAATCTGTAGCTGAG","AML-0024","2020-09-15-AML0024:GGAATCTGTAGCTGAG",-1.69621727886851,-15.6602850190369,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GGAATCTGTAGCTGAG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2975.68615440908,31.5849213743466,0.0106143322028592,3353,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2968.03240189962,2968.03240189962,"malignant"
"2020.09.15.AML0024.GGCTTGGTCGAATGCT","AML-0024","2020-09-15-AML0024:GGCTTGGTCGAATGCT",-1.22100780430492,-16.7703314057556,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GGCTTGGTCGAATGCT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2819.05544594625,34.1589030536526,0.0121171448056378,2459,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2810.77878864276,2810.77878864276,"malignant"
"2020.09.15.AML0024.GGCTTTCGTGGTAACG","AML-0024","2020-09-15-AML0024:GGCTTTCGTGGTAACG",0.508298863738221,-16.3203649750915,"2020-09-15-AML0024","AML0024","Granulocyte","Granulocytes",79,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GGCTTTCGTGGTAACG","Granulocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Gran","Gran",3060.45036086202,40.857880219374,0.0133502835863235,3012,30000,1100,500,"True","True","True","True",5,452,"True","Gran_AML-0024",3042.75450043896,3042.75450043896,"malignant"
"2020.09.15.AML0024.GGTTCTCTCCGCGAGT","AML-0024","2020-09-15-AML0024:GGTTCTCTCCGCGAGT",-1.01084349575694,-15.7783994904724,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GGTTCTCTCCGCGAGT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2895.82172570548,39.13829957542,0.0135154382011845,2405,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2887.57963410464,2887.57963410464,"malignant"
"2020.09.15.AML0024.GTAATGCCAGAGAATT","AML-0024","2020-09-15-AML0024:GTAATGCCAGAGAATT",-1.63310728493388,-16.4884367219177,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GTAATGCCAGAGAATT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2710.61193001791,35.4451190377834,0.0130764270035325,2326,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2704.49483982984,2704.49483982984,"malignant"
"2020.09.15.AML0024.GTACAACCAGAACCGA","AML-0024","2020-09-15-AML0024:GTACAACCAGAACCGA",-2.67742119255717,-16.2599992982117,"2020-09-15-AML0024","AML0024","HLA-II+ monocyte","HLA-II+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GTACAACCAGAACCGA","HLA-II+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2665.48302342193,41.4463050534569,0.0155492661890033,2142,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2657.13088527096,2657.13088527096,"malignant"
"2020.09.15.AML0024.GTAGAAAAGTTTAGGA","AML-0024","2020-09-15-AML0024:GTAGAAAAGTTTAGGA",-2.28900394859965,-15.5984325638977,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GTAGAAAAGTTTAGGA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2720.88184425989,39.3458310544608,0.0144606908004722,2246,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2717.66953010393,2717.66953010393,"malignant"
"2020.09.15.AML0024.GTGTTCCGTGGTCCGT","AML-0024","2020-09-15-AML0024:GTGTTCCGTGGTCCGT",-1.13327155533488,-15.6055202714172,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GTGTTCCGTGGTCCGT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2686.99735232378,41.5863202130274,0.0154768742801561,2217,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2681.96401656664,2681.96401656664,"malignant"
"2020.09.15.AML0024.GTTCGCTCAGTTCCAA","AML-0024","2020-09-15-AML0024:GTTCGCTCAGTTCCAA",-0.721959392458755,-16.1219606629578,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GTTCGCTCAGTTCCAA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2647.40334410139,38.6092399931771,0.0145838147705,2347,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2640.79143495362,2640.79143495362,"malignant"
"2020.09.15.AML0024.GTTCGCTGTAAGTAGT","AML-0024","2020-09-15-AML0024:GTTCGCTGTAAGTAGT",-2.19405661049541,-16.3327474824158,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GTTCGCTGTAAGTAGT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2780.71740069641,36.0928551137498,0.0129796918970301,2326,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2775.92289882751,2775.92289882751,"malignant"
"2020.09.15.AML0024.TACTTGTAGAAGCGCT","AML-0024","2020-09-15-AML0024:TACTTGTAGAAGCGCT",0.668901284306687,-16.2145471802917,"2020-09-15-AML0024","AML0024","Granulocyte","Granulocytes",79,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TACTTGTAGAAGCGCT","Granulocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Gran","Gran",2551.33884448721,43.816088267626,0.0171737628509445,2257,30000,1100,500,"True","True","True","True",5,452,"True","Gran_AML-0024",2543.74795734854,2543.74795734854,"malignant"
"2020.09.15.AML0024.TAGGTTGAGACGGAAA","AML-0024","2020-09-15-AML0024:TAGGTTGAGACGGAAA",-2.66437540474589,-15.4607839814392,"2020-09-15-AML0024","AML0024","CD16+ monocyte","CD16+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TAGGTTGAGACGGAAA","CD16+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2510.85744948737,31.2185945149274,0.012433439628881,2143,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2504.09420898039,2504.09420898039,"malignant"
"2020.09.15.AML0024.TCCCAGTGTTCGCGTG","AML-0024","2020-09-15-AML0024:TCCCAGTGTTCGCGTG",-0.701694349676925,-16.3930711976257,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TCCCAGTGTTCGCGTG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2585.52027591505,35.0284230764611,0.0135479204718532,2057,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2576.96888504649,2576.96888504649,"malignant"
"2020.09.15.AML0024.TCCTAATCAAGCTCTA","AML-0024","2020-09-15-AML0024:TCCTAATCAAGCTCTA",-2.03620968285258,-15.5331392518249,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TCCTAATCAAGCTCTA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",3021.01831799709,30.3390604105083,0.0100426601949977,3061,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",3012.73567274515,3012.73567274515,"malignant"
"2020.09.15.AML0024.TCCTTTCAGAGTTCGG","AML-0024","2020-09-15-AML0024:TCCTTTCAGAGTTCGG",-0.753962795168716,-16.6971903077331,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TCCTTTCAGAGTTCGG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2332.56590207976,34.4163812847878,0.0147547305111943,1857,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2326.55375668242,2326.55375668242,"malignant"
"2020.09.15.AML0024.TCGAAGTAGACGGTCA","AML-0024","2020-09-15-AML0024:TCGAAGTAGACGGTCA",-0.938848773867446,-17.2920351258484,"2020-09-15-AML0024","AML0024","Granulocyte","Granulocytes",80,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TCGAAGTAGACGGTCA","Granulocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Gran","Gran",2681.4975211888,37.0105258597936,0.0138021853711749,1659,30000,1100,500,"True","True","True","True",5,452,"True","Gran_AML-0024",2676.25294083026,2676.25294083026,"malignant"
"2020.09.15.AML0024.TCGAAGTTCCCGAATA","AML-0024","2020-09-15-AML0024:TCGAAGTTCCCGAATA",-1.90399287167247,-16.6669416657654,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TCGAAGTTCCCGAATA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2908.01333135503,36.0946714850286,0.012412140995313,2837,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2900.3873588817,2900.3873588817,"malignant"
"2020.09.15.AML0024.TCGACGGCAAGGTCAG","AML-0024","2020-09-15-AML0024:TCGACGGCAAGGTCAG",-1.44181929054912,-16.0192575684753,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TCGACGGCAAGGTCAG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2593.62772037176,38.8633048931586,0.0149841492624038,1901,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2584.99124366499,2584.99124366499,"malignant"
"2020.09.15.AML0024.GAAGAATAGTGCTAGG","AML-0024","2020-09-15-AML0024:GAAGAATAGTGCTAGG",-0.816139559180099,-15.9972315064636,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GAAGAATAGTGCTAGG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2969.05961176541,34.8708794457858,0.0117447555810614,2734,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2962.82005947345,2962.82005947345,"malignant"
"2020.09.15.AML0024.GAATCGTCAACAAAGT","AML-0024","2020-09-15-AML0024:GAATCGTCAACAAAGT",-1.34209201756175,-16.4800443879333,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GAATCGTCAACAAAGT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2855.67592196278,37.9902618117163,0.0133034219742991,2751,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2848.0101304642,2848.0101304642,"malignant"
"2020.09.15.AML0024.GACCGTGGTCAAATCC","AML-0024","2020-09-15-AML0024:GACCGTGGTCAAATCC",-1.19009218636211,-16.1335439912048,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GACCGTGGTCAAATCC","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2673.1704271846,28.1580923493244,0.0105335941408647,2330,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2665.68458215907,2665.68458215907,"malignant"
"2020.09.15.AML0024.GAGCCTGGTTGGTGTT","AML-0024","2020-09-15-AML0024:GAGCCTGGTTGGTGTT",-1.7816917699879,-16.5267248383728,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GAGCCTGGTTGGTGTT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2304.72769919881,45.3995824474029,0.0196984582877991,1548,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2294.72824752886,2294.72824752886,"malignant"
"2020.09.15.AML0024.GAGGGATTCTCCGCAT","AML-0024","2020-09-15-AML0024:GAGGGATTCTCCGCAT",-0.810256819159347,-16.054280304071,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GAGGGATTCTCCGCAT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2686.24389094977,34.0967793032166,0.0126931063177443,2354,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2681.73682067422,2681.73682067422,"malignant"
"2020.09.15.AML0024.GAGTTACGTCGCATGC","AML-0024","2020-09-15-AML0024:GAGTTACGTCGCATGC",-0.345767359167892,-16.2813749543396,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.GAGTTACGTCGCATGC","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2525.49417290006,28.0767213093687,0.011117317794928,2178,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2523.30644540696,2523.30644540696,"malignant"
"2020.09.15.AML0024.TGTTTGTAGCGCCTCA","AML-0024","2020-09-15-AML0024:TGTTTGTAGCGCCTCA",-1.540186504752,-15.4787407151428,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TGTTTGTAGCGCCTCA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2780.101161345,31.2181022257267,0.0112291245584112,2609,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2772.20216079208,2772.20216079208,"malignant"
"2020.09.15.AML0024.TGCATCCGTCCGCAGT","AML-0024","2020-09-15-AML0024:TGCATCCGTCCGCAGT",-1.33067880097087,-15.7050495377746,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TGCATCCGTCCGCAGT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2673.06462662878,42.761579950339,0.0159972114120822,2248,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2668.36584623405,2668.36584623405,"malignant"
"2020.09.15.AML0024.TGCTTGCCACTAAACC","AML-0024","2020-09-15-AML0024:TGCTTGCCACTAAACC",9.83118691024129,6.9072055586609,"2020-09-15-AML0024","AML0024","B","Activated AP-1",2,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0045335242185635,"GSM5613779","2020-09-15","2020.09.15.AML0024.TGCTTGCCACTAAACC","B","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","B","B",1831.30917722196,39.7253898510205,0.0216923446598365,936,30000,1100,500,"True","True","True","True",5,58,"True","B_AML-0024",1826.55836577075,1826.55836577075,"microenvironment"
"2020.09.15.AML0024.TGGGAAGAGCGGCTCT","AML-0024","2020-09-15-AML0024:TGGGAAGAGCGGCTCT",-1.85549090328868,-16.1742754212585,"2020-09-15-AML0024","AML0024","HLA-II+ monocyte","HLA-II+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TGGGAAGAGCGGCTCT","HLA-II+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2212.68924085315,49.7790705350762,0.0224970906966958,1123,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2205.96882447708,2205.96882447708,"malignant"
"2020.09.15.AML0024.TGGGATTGTATGCGGA","AML-0024","2020-09-15-AML0024:TGGGATTGTATGCGGA",-0.0478554320638955,-15.845392250177,"2020-09-15-AML0024","AML0024","Granulocyte","Granulocytes",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TGGGATTGTATGCGGA","Granulocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Gran","Gran",2754.44575888503,40.3207573838084,0.0146384285309469,2273,30000,1100,500,"True","True","True","True",5,452,"True","Gran_AML-0024",2747.11719229153,2747.11719229153,"malignant"
"2020.09.15.AML0024.TGGTTAGCATAACGGG","AML-0024","2020-09-15-AML0024:TGGTTAGCATAACGGG",-2.90949831429179,-15.8312416306702,"2020-09-15-AML0024","AML0024","CD16+ monocyte","CD16+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TGGTTAGCATAACGGG","CD16+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2795.92831665804,37.8566661576699,0.0135399273050461,2331,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2788.30048978491,2788.30048978491,"malignant"
"2020.09.15.AML0024.TGTTCCGCATGAATCC","AML-0024","2020-09-15-AML0024:TGTTCCGCATGAATCC",-1.47250256958659,-15.9598875275818,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TGTTCCGCATGAATCC","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2745.64087478681,34.2361415924911,0.0124692715303306,2301,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2737.39102573644,2737.39102573644,"malignant"
"2020.09.15.AML0024.TTAGGGTAGCCTGTCG","AML-0024","2020-09-15-AML0024:TTAGGGTAGCCTGTCG",-0.713449100882369,-16.5752840272156,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TTAGGGTAGCCTGTCG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2445.12448156949,38.9688866524844,0.0159373835345474,2066,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2438.67807503309,2438.67807503309,"malignant"
"2020.09.15.AML0024.TTCCTAATCCTGGTCT","AML-0024","2020-09-15-AML0024:TTCCTAATCCTGGTCT",-1.97020326080974,-16.1282911530701,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TTCCTAATCCTGGTCT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2934.44501437629,32.3730495346376,0.0110320859229044,2695,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2926.94511438606,2926.94511438606,"malignant"
"2020.09.15.AML0024.TTGATGGGTGACTGTT","AML-0024","2020-09-15-AML0024:TTGATGGGTGACTGTT",-2.53217945519145,-15.6480541459289,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TTGATGGGTGACTGTT","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2824.65268243688,28.2269589153041,0.0099930724548237,2474,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2814.11978565175,2814.11978565175,"malignant"
"2020.09.15.AML0024.TTGCCTGCAGTTAAAG","AML-0024","2020-09-15-AML0024:TTGCCTGCAGTTAAAG",-1.10904941979106,-16.2891378632751,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TTGCCTGCAGTTAAAG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2695.84672904081,38.4414965472904,0.0142595260083529,2342,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2688.38732271289,2688.38732271289,"malignant"
"2020.09.15.AML0024.TTGCTGCTCACGACTA","AML-0024","2020-09-15-AML0024:TTGCTGCTCACGACTA",-1.82234023037608,-16.2639646760193,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+ IFN+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TTGCTGCTCACGACTA","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2612.99783301743,47.4892496403203,0.0181742399631005,2068,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2601.74054357347,2601.74054357347,"malignant"
"2020.09.15.AML0024.TTGGGTAAGCCTTTGA","AML-0024","2020-09-15-AML0024:TTGGGTAAGCCTTTGA",-2.7209840816563,-15.8272962800232,"2020-09-15-AML0024","AML0024","CD16+ monocyte","CD16+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TTGGGTAAGCCTTTGA","CD16+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",3016.74402097905,35.2626970308173,0.0116889921006202,2745,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",3002.4133470045,3002.4133470045,"malignant"
"2020.09.15.AML0024.TTGGGTAAGGTGGTTG","AML-0024","2020-09-15-AML0024:TTGGGTAAGGTGGTTG",-1.68003986302074,-16.4620504609314,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TTGGGTAAGGTGGTTG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2839.13670599577,38.7214644382402,0.0136384642403682,2344,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2831.73717583084,2831.73717583084,"malignant"
"2020.09.15.AML0024.TTGGGTATCAGTAGGG","AML-0024","2020-09-15-AML0024:TTGGGTATCAGTAGGG",-0.681102494627792,-15.6311645737854,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TTGGGTATCAGTAGGG","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2887.50547127805,36.5671163254187,0.0126639123939854,2998,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2883.07100496899,2883.07100496899,"malignant"
"2020.09.15.AML0024.TTGTGTTCAACCACGC","AML-0024","2020-09-15-AML0024:TTGTGTTCAACCACGC",-1.26629076424297,-15.9429464570251,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TTGTGTTCAACCACGC","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2658.17735433196,40.3919898619845,0.0151953705407048,1910,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2650.16761221139,2650.16761221139,"malignant"
"2020.09.15.AML0024.TTGTTCAAGAAGCCAC","AML-0024","2020-09-15-AML0024:TTGTTCAAGAAGCCAC",-0.976493100554305,-15.9786405793396,"2020-09-15-AML0024","AML0024","CD14+ monocyte","CD14+",7,"CNV+","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",1,"GSM5613779","2020-09-15","2020.09.15.AML0024.TTGTTCAAGAAGCCAC","CD14+ monocyte","U-06-0024","M",64,"CITE-seq","OSU","AML0024","AML","Adverse","48,XY,+8,+8,i(8)(p10),t(9;15)(q33;q15),del(10)(q22.1q24),del(13)(q14q21)",137,"","","","","","","",NA,NA,"0+T2:BL24","0,46","0","0,99",0,0,"0","0",0,"0,06",0,0,0,0,"0,17",0,"0","0,17",0,0,"0",0,0,0,"0",0,"0","0,45",0,"0",0,"AML","case","Mono","Mono",2442.19506785049,37.3172551609037,0.0152802106810201,1942,30000,1100,500,"True","True","True","True",5,5451,"True","Mono_AML-0024",2433.76614687959,2433.76614687959,"malignant"
"2019.07.01.count.1.GTCGCGAAGGAAGTCC","AML-0160","2019-07-01-count-1:GTCGCGAAGGAAGTCC",2.19850816306416,-8.3989877930847,"2019-07-01-count-1","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GTCGCGAAGGAAGTCC","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",1869.96581217301,47.1754388567043,0.0252279686342948,976,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",1865.39454616656,1865.39454616656,"malignant"
"2019.07.01.count.1.TCCGATCTCCTGCCAT","AML-0160","2019-07-01-count-1:TCCGATCTCCTGCCAT",5.32347406920735,-4.97405340587767,"2019-07-01-count-1","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TCCGATCTCCTGCCAT","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2376.69942584249,41.7521840709023,0.0175672967380391,1618,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2373.33391469955,2373.33391469955,"malignant"
"2019.07.01.count.1.AGAAGTATCAACTACG","AML-0160","2019-07-01-count-1:AGAAGTATCAACTACG",-7.99389491501506,2.25759694660035,"2019-07-01-count-1","AML0160","MPP","MPP_GMP",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.487113402061856,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.AGAAGTATCAACTACG","MPP","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2454.63801248901,43.0918699372053,0.0175552850228657,2568,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2446.52709434215,2446.52709434215,"microenvironment"
"2019.07.01.count.1.CGGGTCATCGCATAGT","AML-0160","2019-07-01-count-1:CGGGTCATCGCATAGT",-7.82428155365642,4.28042171085206,"2019-07-01-count-1","AML0160","HSC","HSC",16,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.675675675675676,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CGGGTCATCGCATAGT","HSC","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",1907.40453656846,36.0052595236441,0.0188765722390594,1659,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",1901.99926430596,1901.99926430596,"microenvironment"
"2019.07.01.count.1.TTACTGTGTATGCGTT","AML-0160","2019-07-01-count-1:TTACTGTGTATGCGTT",2.98730482634847,-9.60634329235228,"2019-07-01-count-1","AML0160","HLA-II+ monocyte","HLA-II+",13,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0051915945611866,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TTACTGTGTATGCGTT","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",1960.07389633876,52.0228936497557,0.0265412920129847,916,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",1956.331871466,1956.331871466,"microenvironment"
"2019.07.01.count.1.CCATAAGAGGGTACAC","AML-0160","2019-07-01-count-1:CCATAAGAGGGTACAC",-7.56865868988689,3.80711219394533,"2019-07-01-count-1","AML0160","HSC","HSC",16,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.675675675675676,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CCATAAGAGGGTACAC","HSC","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2025.6503304645,34.129370536787,0.0168485991997251,1521,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2016.41962048004,2016.41962048004,"microenvironment"
"2019.07.01.count.3.ACCCTCACAATCGCAT","AML-0160","2019-07-01-count-3:ACCCTCACAATCGCAT",1.92608847197835,-4.65138389980467,"2019-07-01-count-3","AML0160","cDC2","cDC2",36,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0741127348643006,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.ACCCTCACAATCGCAT","cDC2","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","DC","cDC",2441.88100364881,41.5703995707567,0.0170239252071004,1836,30000,1100,500,"True","True","True","True",5,123,"True","DC_AML-0160",2438.05437503502,2438.05437503502,"microenvironment"
"2019.07.01.count.3.TGAGGTTTCAAGCCTA","AML-0160","2019-07-01-count-3:TGAGGTTTCAAGCCTA",-7.61977754059489,1.11128161037294,"2019-07-01-count-3","AML0160","MPP","MPP_GMP",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.487113402061856,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.TGAGGTTTCAAGCCTA","MPP","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2641.56196130739,43.8845727011084,0.0166131150220639,2367,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2631.34820356136,2631.34820356136,"microenvironment"
"2019.07.01.count.3.GATGACTGTGACTCTA","AML-0160","2019-07-01-count-3:GATGACTGTGACTCTA",1.81961347636525,-8.8027496567932,"2019-07-01-count-3","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GATGACTGTGACTCTA","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2328.70711873495,43.315989894011,0.018600874942806,1502,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2321.39964889534,2321.39964889534,"malignant"
"2019.07.01.count.1.GCCGTGACAGCGTGCT","AML-0160","2019-07-01-count-1:GCCGTGACAGCGTGCT",2.11061038550679,-9.06566431438597,"2019-07-01-count-1","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GCCGTGACAGCGTGCT","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2281.28278809112,41.0548610864948,0.0179963927755085,1553,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2277.93627768156,2277.93627768156,"malignant"
"2019.07.01.count.3.TATTCCAAGAACGCGT","AML-0160","2019-07-01-count-3:TATTCCAAGAACGCGT",1.56036998805348,-8.97818376934203,"2019-07-01-count-3","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.TATTCCAAGAACGCGT","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2202.56185993334,40.2061686126202,0.0182542744174445,1482,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2195.88246263211,2195.88246263211,"malignant"
"2019.07.01.count.2.CTGTCGTCAAGTGTCT","AML-0160","2019-07-01-count-2:CTGTCGTCAAGTGTCT",2.50839891013448,-10.2435865632263,"2019-07-01-count-2","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CTGTCGTCAAGTGTCT","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2020.64872329932,47.4904592371022,0.0235025804779961,1118,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2017.75470616261,2017.75470616261,"malignant"
"2019.07.01.count.2.GAAGAATTCCCTATTA","AML-0160","2019-07-01-count-2:GAAGAATTCCCTATTA",1.83787002143208,-9.01609327709349,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GAAGAATTCCCTATTA","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2310.60966151142,44.1640010857182,0.0191135706828256,1666,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2303.45315072489,2303.45315072489,"malignant"
"2019.07.01.count.3.TCAGCCTAGACTTGTC","AML-0160","2019-07-01-count-3:TCAGCCTAGACTTGTC",-6.73468194428142,4.575168586615,"2019-07-01-count-3","AML0160","MPP","MPP_MEP",39,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0298913043478261,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.TCAGCCTAGACTTGTC","MPP","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",1994.53294562137,39.283830513829,0.0196957541363603,1436,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",1988.47230391646,1988.47230391646,"microenvironment"
"2019.07.01.count.3.ACTCCCATCTTTGCGC","AML-0160","2019-07-01-count-3:ACTCCCATCTTTGCGC",1.54655887660329,-8.01256563579711,"2019-07-01-count-3","AML0160","Granulocyte","Granulocytes",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.ACTCCCATCTTTGCGC","Granulocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Gran","Gran",2515.61000082914,44.79270167775,0.0178059006217126,1835,30000,1100,500,"True","True","True","True",5,171,"True","Gran_AML-0160",2512.52769960723,2512.52769960723,"malignant"
"2019.07.01.count.2.CTGTCGTCATAGAGGC","AML-0160","2019-07-01-count-2:CTGTCGTCATAGAGGC",1.78499581393544,-8.9235821000305,"2019-07-01-count-2","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CTGTCGTCATAGAGGC","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2114.62460155675,44.6629131825063,0.0211209654657504,1290,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2109.53239171851,2109.53239171851,"malignant"
"2019.07.01.count.1.GACAGCCCACAGCTGC","AML-0160","2019-07-01-count-1:GACAGCCCACAGCTGC",-7.90493855896648,3.55006311023561,"2019-07-01-count-1","AML0160","HSC","HSC",16,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.675675675675676,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GACAGCCCACAGCTGC","HSC","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2371.56877884344,38.5121594379065,0.0162391071182376,2284,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2356.30134295545,2356.30134295545,"microenvironment"
"2019.07.01.count.2.AAACGAAAGCGGTAAC","AML-0160","2019-07-01-count-2:AAACGAAAGCGGTAAC",1.1280036168987,9.67571256244508,"2019-07-01-count-2","AML0160","CD4+ T","CD4+ Naive",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0064620355411954,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.AAACGAAAGCGGTAAC","CD4+ T","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","T","CD4_T",1863.13098929045,34.9860306478715,0.0187780842297059,1117,30000,1100,500,"True","True","True","True",5,27,"True","T_AML-0160",1859.18574089918,1859.18574089918,"microenvironment"
"2019.07.01.count.3.GTGGGAAGTTTGTTGG","AML-0160","2019-07-01-count-3:GTGGGAAGTTTGTTGG",1.50309922274892,-8.96855070507201,"2019-07-01-count-3","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GTGGGAAGTTTGTTGG","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2229.8137930749,43.8758437858021,0.0196769093105741,1362,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2225.94460142556,2225.94460142556,"malignant"
"2019.07.01.count.1.CCTTCAGTCGGTGTAT","AML-0160","2019-07-01-count-1:CCTTCAGTCGGTGTAT",1.8128078180248,-8.67499067699584,"2019-07-01-count-1","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CCTTCAGTCGGTGTAT","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2465.44828589029,37.1050151949609,0.0150500075005881,1791,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2463.36616406091,2463.36616406091,"malignant"
"2019.07.01.count.2.CATCCACTCCTTGACC","AML-0160","2019-07-01-count-2:CATCCACTCCTTGACC",2.01939608630483,-10.0106849900452,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CATCCACTCCTTGACC","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2628.03696805267,37.2906196265582,0.0141895338915989,1956,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2619.99972022074,2619.99972022074,"malignant"
"2019.07.01.count.1.CAACAACTCGCTCATC","AML-0160","2019-07-01-count-1:CAACAACTCGCTCATC",1.83966161784474,-8.76324942028197,"2019-07-01-count-1","AML0160","Granulocyte","Granulocytes",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CAACAACTCGCTCATC","Granulocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Gran","Gran",2447.7676597688,42.482867243227,0.0173557596750174,1742,30000,1100,500,"True","True","True","True",5,171,"True","Gran_AML-0160",2442.35007556489,2442.35007556489,"malignant"
"2019.07.01.count.1.TGACCCTTCTATCCAT","AML-0160","2019-07-01-count-1:TGACCCTTCTATCCAT",2.62387885627095,-10.1199579468933,"2019-07-01-count-1","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TGACCCTTCTATCCAT","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2636.95015216287,35.4274504758698,0.0134350095495023,1893,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2630.79830729376,2630.79830729376,"malignant"
"2019.07.01.count.2.TCCTCTTTCATACGGT","AML-0160","2019-07-01-count-2:TCCTCTTTCATACGGT",2.13665928420369,-8.80901720440062,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.TCCTCTTTCATACGGT","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2398.81313677004,44.9715134668182,0.0187474016952281,1542,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2396.33552518299,2396.33552518299,"malignant"
"2019.07.01.count.1.CGATGCGAGACCGTTT","AML-0160","2019-07-01-count-1:CGATGCGAGACCGTTT",-7.26761517944987,3.92838618839113,"2019-07-01-count-1","AML0160","MPP","MPP_GMP",16,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.675675675675676,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CGATGCGAGACCGTTT","MPP","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2172.22862896913,42.5575212385405,0.0195916399733379,1470,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2165.32225701274,2165.32225701274,"microenvironment"
"2019.07.01.count.2.GCTTTCGTCAGTGTTG","AML-0160","2019-07-01-count-2:GCTTTCGTCAGTGTTG",5.4129020172054,-4.48756840145262,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",14,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.444444444444444,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GCTTTCGTCAGTGTTG","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2128.75724936887,45.2298255236576,0.0212470564866273,1156,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2115.20463893257,2115.20463893257,"microenvironment"
"2019.07.01.count.1.TCCAGAAGTTAGGCCC","AML-0160","2019-07-01-count-1:TCCAGAAGTTAGGCCC",-8.12772212448772,0.999242044332899,"2019-07-01-count-1","AML0160","GMP","GMP",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.487113402061856,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TCCAGAAGTTAGGCCC","GMP","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2715.01362293333,35.8289191143424,0.0131965890748027,3064,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2706.74457283701,2706.74457283701,"microenvironment"
"2019.07.01.count.2.CGAGTGCTCTCTGCTG","AML-0160","2019-07-01-count-2:CGAGTGCTCTCTGCTG",1.9787481027538,-8.83071806347045,"2019-07-01-count-2","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CGAGTGCTCTCTGCTG","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2441.87802777013,39.5277771675206,0.0161874494622553,1741,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2437.67684089974,2437.67684089974,"malignant"
"2019.07.01.count.2.TGGGCGTCAATTGCAC","AML-0160","2019-07-01-count-2:TGGGCGTCAATTGCAC",-7.19043431702312,1.0313111313614,"2019-07-01-count-2","AML0160","MPP","MPP_GMP",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.487113402061856,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.TGGGCGTCAATTGCAC","MPP","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2262.24013206267,42.4700192967106,0.0187734355406325,2042,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2254.51439464402,2254.51439464402,"microenvironment"
"2019.07.01.count.1.ATTCTTGAGCTGACTT","AML-0160","2019-07-01-count-1:ATTCTTGAGCTGACTT",1.58461370047871,-8.20715620433959,"2019-07-01-count-1","AML0160","Granulocyte","Granulocytes",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.ATTCTTGAGCTGACTT","Granulocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Gran","Gran",2457.48234694682,42.9394198402571,0.0174729311458148,1981,30000,1100,500,"True","True","True","True",5,171,"True","Gran_AML-0160",2452.22632107368,2452.22632107368,"malignant"
"2019.07.01.count.3.TTGAGTGTCATGCCAA","AML-0160","2019-07-01-count-3:TTGAGTGTCATGCCAA",4.42069925841634,-8.58181002056273,"2019-07-01-count-3","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.TTGAGTGTCATGCCAA","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2053.93799259345,38.5724423010627,0.0187797501385903,1260,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2049.04213323422,2049.04213323422,"malignant"
"2019.07.01.count.2.GTAGAGGGTAAGTTGA","AML-0160","2019-07-01-count-2:GTAGAGGGTAAGTTGA",-9.72401557388957,2.56419704044191,"2019-07-01-count-2","AML0160","MPP","MPP_GMP",1,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.827586206896552,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GTAGAGGGTAAGTTGA","MPP","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2197.19078399194,47.0523642906664,0.021414783201111,2072,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2190.5185810703,2190.5185810703,"malignant"
"2019.07.01.count.3.TGCTGAACACGTACTA","AML-0160","2019-07-01-count-3:TGCTGAACACGTACTA",-2.11190114441569,-11.736351989862,"2019-07-01-count-3","AML0160","Granulocyte","Granulocytes",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.TGCTGAACACGTACTA","Granulocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Gran","Gran",2468.4361038241,43.7739940064202,0.0177334928534733,1664,30000,1100,500,"True","True","True","True",5,171,"True","Gran_AML-0160",2463.88877350254,2463.88877350254,"malignant"
"2019.07.01.count.1.GAGGCCTAGACAGCTG","AML-0160","2019-07-01-count-1:GAGGCCTAGACAGCTG",-9.35878405991252,4.92582128131715,"2019-07-01-count-1","AML0160","HSC","HSC",16,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.675675675675676,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GAGGCCTAGACAGCTG","HSC","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2132.61577689219,34.6964552976663,0.0162694357200286,1665,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2122.36835296897,2122.36835296897,"microenvironment"
"2019.07.01.count.1.CAGCGTGCACTCCACT","AML-0160","2019-07-01-count-1:CAGCGTGCACTCCACT",-7.88939700546916,2.03842077339021,"2019-07-01-count-1","AML0160","GMP","GMP",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.487113402061856,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CAGCGTGCACTCCACT","GMP","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2518.60002272482,40.7896042646821,0.0161953481682862,2346,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2512.86299127723,2512.86299127723,"microenvironment"
"2019.07.01.count.2.GGGTCACAGCCACAAG","AML-0160","2019-07-01-count-2:GGGTCACAGCCACAAG",5.10182680663411,-5.25382950222167,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GGGTCACAGCCACAAG","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2371.8189305064,38.4792865056809,0.0162235346091387,1879,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2365.56863039458,2365.56863039458,"malignant"
"2019.07.01.count.1.GTCCTCATCGTCTACC","AML-0160","2019-07-01-count-1:GTCCTCATCGTCTACC",1.82345583018605,-9.34059431469115,"2019-07-01-count-1","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GTCCTCATCGTCTACC","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2484.52623483993,41.3682783199752,0.0166503688871856,1748,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2472.25246427568,2472.25246427568,"malignant"
"2019.07.01.count.3.TGCATCCGTCCTCCAT","AML-0160","2019-07-01-count-3:TGCATCCGTCCTCCAT",-8.08048377457317,2.41245052898256,"2019-07-01-count-3","AML0160","MPP","MPP_MEP",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.487113402061856,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.TGCATCCGTCCTCCAT","MPP","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",1842.844091477,41.4596485375225,0.0224976430340851,1341,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",1839.96530014047,1839.96530014047,"microenvironment"
"2019.07.01.count.3.CATTTCACATTGCAAC","AML-0160","2019-07-01-count-3:CATTTCACATTGCAAC",1.83763947066609,-8.94466307079466,"2019-07-01-count-3","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CATTTCACATTGCAAC","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2087.78369966268,43.0857978779001,0.0206370985101864,1188,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2085.01429063629,2085.01429063629,"malignant"
"2019.07.01.count.3.CGGGCATCAGAGAGGG","AML-0160","2019-07-01-count-3:CGGGCATCAGAGAGGG",1.76600744304005,-8.69672968303832,"2019-07-01-count-3","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CGGGCATCAGAGAGGG","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2011.52756126626,46.2591672974789,0.0229970337907568,1231,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2006.47343326031,2006.47343326031,"malignant"
"2019.07.01.count.3.CAGCACGTCTCGACCT","AML-0160","2019-07-01-count-3:CAGCACGTCTCGACCT",2.08851637420003,-8.10002138530882,"2019-07-01-count-3","AML0160","Granulocyte","Granulocytes",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CAGCACGTCTCGACCT","Granulocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Gran","Gran",2280.77363323021,40.832810965483,0.0179030528810754,1474,30000,1100,500,"True","True","True","True",5,171,"True","Gran_AML-0160",2278.41746979669,2278.41746979669,"malignant"
"2019.07.01.count.1.AGATGCTTCGTGCAGC","AML-0160","2019-07-01-count-1:AGATGCTTCGTGCAGC",11.0489050346309,-0.767888926621996,"2019-07-01-count-1","AML0160","Ery","Ery-3",58,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0689655172413793,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.AGATGCTTCGTGCAGC","Ery","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Ery","Ery",1526.04710735011,50.0836785746333,0.0328192218532497,1299,30000,1100,500,"True","True","True","True",5,8,"True","Ery_AML-0160",1522.20486189759,1522.20486189759,"microenvironment"
"2019.07.01.count.1.CTCTCGAGTGAATAAC","AML-0160","2019-07-01-count-1:CTCTCGAGTGAATAAC",2.39463533934895,-8.26862432872923,"2019-07-01-count-1","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CTCTCGAGTGAATAAC","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2438.84379406658,43.2584810238417,0.0177372905673928,1748,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2432.65371001222,2432.65371001222,"malignant"
"2019.07.01.count.3.GGGTGTCCACACAGCC","AML-0160","2019-07-01-count-3:GGGTGTCCACACAGCC",-8.14729056778606,1.11777434432832,"2019-07-01-count-3","AML0160","MPP","MPP_GMP",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.487113402061856,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GGGTGTCCACACAGCC","MPP","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2703.05256601166,43.0849948983505,0.0159393847682075,2600,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2692.11196256462,2692.11196256462,"microenvironment"
"2019.07.01.count.1.TCTCACGAGTCTAACC","AML-0160","2019-07-01-count-1:TCTCACGAGTCTAACC",2.82408442076985,-2.84282996570738,"2019-07-01-count-1","AML0160","DC precursor","DC precursor",14,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.444444444444444,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TCTCACGAGTCTAACC","DC precursor","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","DC","pDC",2774.48079095641,42.3021645539757,0.0152468759891444,2271,30000,1100,500,"True","True","True","True",5,123,"True","DC_AML-0160",2768.20153922354,2768.20153922354,"microenvironment"
"2019.07.01.count.1.CTAACTTTCGCTACGG","AML-0160","2019-07-01-count-1:CTAACTTTCGCTACGG",1.79512216624562,-9.82668878948363,"2019-07-01-count-1","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CTAACTTTCGCTACGG","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2422.15339251641,40.6997470587948,0.0168031253448037,1807,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2412.68452423302,2412.68452423302,"malignant"
"2019.07.01.count.2.GCAGTTAGTGTTGCCG","AML-0160","2019-07-01-count-2:GCAGTTAGTGTTGCCG",1.67756774005238,-8.75363447582396,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GCAGTTAGTGTTGCCG","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2376.71259271305,41.6851957825646,0.017539014145156,1590,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2372.01705676418,2372.01705676418,"malignant"
"2019.07.01.count.3.GTCGTTCTCGCAATGT","AML-0160","2019-07-01-count-3:GTCGTTCTCGCAATGT",7.4772707420284,6.91875312412111,"2019-07-01-count-3","AML0160","B","Atypical memory",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0151515151515152,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GTCGTTCTCGCAATGT","B","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","B","B",1512.15019042495,44.3858429992569,0.0293528005884015,626,30000,1100,500,"True","True","True","True",5,45,"True","B_AML-0160",1510.13236858836,1510.13236858836,"microenvironment"
"2019.07.01.count.2.AGGACGACAGCGAGTA","AML-0160","2019-07-01-count-2:AGGACGACAGCGAGTA",4.22508062896077,-7.93095877086791,"2019-07-01-count-2","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.AGGACGACAGCGAGTA","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2407.00041544141,37.0187285464945,0.0153796103685781,1681,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2402.71497994178,2402.71497994178,"malignant"
"2019.07.01.count.1.TGGATCACACTTCTCG","AML-0160","2019-07-01-count-1:TGGATCACACTTCTCG",2.40226807174031,-9.13205339824828,"2019-07-01-count-1","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TGGATCACACTTCTCG","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",1610.56732152285,30.7974189136776,0.0191220935021564,675,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",1610.56732152285,1610.56732152285,"malignant"
"2019.07.01.count.3.GAAGGACAGCGTTCAT","AML-0160","2019-07-01-count-3:GAAGGACAGCGTTCAT",1.8619188266689,-3.95335295116576,"2019-07-01-count-3","AML0160","cDC2","cDC2",36,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0741127348643006,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GAAGGACAGCGTTCAT","cDC2","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","DC","cDC",2225.98927162653,46.2155652803132,0.0207618095331355,1406,30000,1100,500,"True","True","True","True",5,123,"True","DC_AML-0160",2221.10778479435,2221.10778479435,"microenvironment"
"2019.07.01.count.2.GGAACCCTCTCGCTTG","AML-0160","2019-07-01-count-2:GGAACCCTCTCGCTTG",2.2434524494106,-9.14544680034789,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GGAACCCTCTCGCTTG","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2054.18573805485,45.4989379457895,0.0221493787552402,1100,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2046.04989034697,2046.04989034697,"malignant"
"2019.07.01.count.3.TTCCTAACATGATCTG","AML-0160","2019-07-01-count-3:TTCCTAACATGATCTG",1.73511149463002,-8.54928400432738,"2019-07-01-count-3","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.TTCCTAACATGATCTG","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2140.84642528688,41.82328108724,0.0195358623548326,1334,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2132.18305951135,2132.18305951135,"malignant"
"2019.07.01.count.1.ACGCACGGTGATAGTA","AML-0160","2019-07-01-count-1:ACGCACGGTGATAGTA",2.23640241202657,-10.4509239426819,"2019-07-01-count-1","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.ACGCACGGTGATAGTA","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2349.2798838967,45.9690730925831,0.019567303754517,1753,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2347.31102877111,2347.31102877111,"malignant"
"2019.07.01.count.3.CCTCAGTAGATCCGAG","AML-0160","2019-07-01-count-3:CCTCAGTAGATCCGAG",1.9575740295345,-9.22655584728392,"2019-07-01-count-3","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CCTCAGTAGATCCGAG","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2149.57503544047,43.8501399600669,0.0203994460472888,1229,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2144.0511251583,2144.0511251583,"malignant"
"2019.07.01.count.1.CCGATGGTCATTGCTT","AML-0160","2019-07-01-count-1:CCGATGGTCATTGCTT",-3.69002280655559,-9.71100809490355,"2019-07-01-count-1","AML0160","cDC1","cDC1",62,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.625,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CCGATGGTCATTGCTT","cDC1","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","DC","cDC",2455.21026866168,38.9041408702727,0.0158455434008424,1786,30000,1100,500,"True","True","True","True",5,123,"True","DC_AML-0160",2448.18264058363,2448.18264058363,"microenvironment"
"2019.07.01.count.1.AGTCATGTCCTACCGT","AML-0160","2019-07-01-count-1:AGTCATGTCCTACCGT",1.87582757052724,-8.97010519420775,"2019-07-01-count-1","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.AGTCATGTCCTACCGT","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2455.69948698918,42.7593785000478,0.0174123009458592,1632,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2452.24895413568,2452.24895413568,"malignant"
"2019.07.01.count.2.GGTGAAGGTCGCTTGG","AML-0160","2019-07-01-count-2:GGTGAAGGTCGCTTGG",2.08380403098409,-9.10823633587035,"2019-07-01-count-2","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GGTGAAGGTCGCTTGG","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2296.8686422242,37.9694150895667,0.016530947565551,1609,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2293.70858781921,2293.70858781921,"malignant"
"2019.07.01.count.1.CTTCTAAAGCCATTCA","AML-0160","2019-07-01-count-1:CTTCTAAAGCCATTCA",-7.96752391281779,2.25567100131837,"2019-07-01-count-1","AML0160","MPP","MPP_GMP",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.487113402061856,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CTTCTAAAGCCATTCA","MPP","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2359.75214105496,49.7758741948707,0.0210936874805071,2385,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2353.11071821759,2353.11071821759,"microenvironment"
"2019.07.01.count.1.TCTATACCACTATGTG","AML-0160","2019-07-01-count-1:TCTATACCACTATGTG",2.48578514632527,-9.0880165330139,"2019-07-01-count-1","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TCTATACCACTATGTG","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2438.34190041401,39.2345262531825,0.01609065826516,1750,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2431.0836897596,2431.0836897596,"malignant"
"2019.07.01.count.1.GTGAGCCAGCTCTGTA","AML-0160","2019-07-01-count-1:GTGAGCCAGCTCTGTA",2.19898666915242,-8.71557810222777,"2019-07-01-count-1","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GTGAGCCAGCTCTGTA","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2380.04369782348,40.9293628935437,0.0171968955574106,1952,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2374.07643675028,2374.07643675028,"malignant"
"2019.07.01.count.2.TCATCATGTGCAGGAT","AML-0160","2019-07-01-count-2:TCATCATGTGCAGGAT",1.79443933543507,-9.07860853588256,"2019-07-01-count-2","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.TCATCATGTGCAGGAT","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2314.73561169101,36.451216091054,0.0157474641626241,1655,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2312.63853881063,2312.63853881063,"malignant"
"2019.07.01.count.3.CGGACACTCATACAGC","AML-0160","2019-07-01-count-3:CGGACACTCATACAGC",2.76187600669209,-7.7813382378784,"2019-07-01-count-3","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CGGACACTCATACAGC","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2509.77615538311,39.4600667860304,0.0157225442999744,1757,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2508.68771778435,2508.68771778435,"malignant"
"2019.07.01.count.3.TATCAGGGTATGTCAC","AML-0160","2019-07-01-count-3:TATCAGGGTATGTCAC",2.51251997527425,-9.37860586559447,"2019-07-01-count-3","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.TATCAGGGTATGTCAC","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2001.82075776602,46.9502512435819,0.0234537738013953,1075,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",1998.79991265147,1998.79991265147,"malignant"
"2019.07.01.count.1.GGGATCCGTGCTGATT","AML-0160","2019-07-01-count-1:GGGATCCGTGCTGATT",-8.7242959541386,4.93491456592409,"2019-07-01-count-1","AML0160","HSC","HSC",1,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.827586206896552,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GGGATCCGTGCTGATT","HSC","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",1872.75751975072,34.5955096903714,0.0184730320532774,1349,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",1868.68261734323,1868.68261734323,"malignant"
"2019.07.01.count.1.CCTTGTGGTTCGTTCC","AML-0160","2019-07-01-count-1:CCTTGTGGTTCGTTCC",1.79893257197682,-9.05556776439818,"2019-07-01-count-1","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CCTTGTGGTTCGTTCC","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2347.5368948982,45.0561145513822,0.0191929313866379,1544,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2346.34262216598,2346.34262216598,"malignant"
"2019.07.01.count.2.ATCGGCGCATGACAAA","AML-0160","2019-07-01-count-2:ATCGGCGCATGACAAA",2.24968065795247,-9.0952186814514,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.ATCGGCGCATGACAAA","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2180.66530190317,39.1064460534554,0.0179332637701555,1418,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2177.19972091329,2177.19972091329,"malignant"
"2019.07.01.count.2.TACACCCGTCGCTTGG","AML-0160","2019-07-01-count-2:TACACCCGTCGCTTGG",1.71569194373433,-8.7827358475891,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.TACACCCGTCGCTTGG","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2270.88696092861,42.743336503629,0.0188223091853724,1589,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2264.3914815926,2264.3914815926,"malignant"
"2019.07.01.count.2.CACTGGGTCTCCGAGG","AML-0160","2019-07-01-count-2:CACTGGGTCTCCGAGG",1.68536831912343,-8.92556860363158,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CACTGGGTCTCCGAGG","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2157.79196449664,43.2278604036924,0.0200333772277146,1405,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2148.64851058833,2148.64851058833,"malignant"
"2019.07.01.count.2.GTTCTATAGGGTACGT","AML-0160","2019-07-01-count-2:GTTCTATAGGGTACGT",8.09703602370564,6.17898175800172,"2019-07-01-count-2","AML0160","B","Memory",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0151515151515152,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GTTCTATAGGGTACGT","B","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","B","B",1836.14396929401,46.5078362399397,0.0253290793193204,973,30000,1100,500,"True","True","True","True",5,45,"True","B_AML-0160",1829.98605422718,1829.98605422718,"microenvironment"
"2019.07.01.count.1.GTTGTGAAGGATACAT","AML-0160","2019-07-01-count-1:GTTGTGAAGGATACAT",2.35198511657063,-8.58094122326048,"2019-07-01-count-1","AML0160","HLA-II+ monocyte","HLA-II+",36,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0741127348643006,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GTTGTGAAGGATACAT","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2414.86997174919,39.5575256635372,0.0163808097853335,2039,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2411.84814975827,2411.84814975827,"microenvironment"
"2019.07.01.count.1.TTCCTCTCATAGAATG","AML-0160","2019-07-01-count-1:TTCCTCTCATAGAATG",-7.87613044205363,1.11409280383912,"2019-07-01-count-1","AML0160","MPP","MPP_GMP",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.487113402061856,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TTCCTCTCATAGAATG","MPP","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2576.60848291566,42.0436545654912,0.0163174400939312,2879,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2571.00698260327,2571.00698260327,"microenvironment"
"2019.07.01.count.2.CATTCTAAGGCACTAG","AML-0160","2019-07-01-count-2:CATTCTAAGGCACTAG",-1.70187507095988,-12.033419632074,"2019-07-01-count-2","AML0160","HLA-II+ monocyte","HLA-II+",68,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.285714285714286,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CATTCTAAGGCACTAG","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2142.8747402248,40.7606266421371,0.0190214695600271,1306,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2137.76707494561,2137.76707494561,"microenvironment"
"2019.07.01.count.3.GTGCTTCTCCCAATAG","AML-0160","2019-07-01-count-3:GTGCTTCTCCCAATAG",1.90712549266164,-8.62320043956908,"2019-07-01-count-3","AML0160","Granulocyte","Granulocytes",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GTGCTTCTCCCAATAG","Granulocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Gran","Gran",2235.02353702575,40.9989047178142,0.0183438357756059,1523,30000,1100,500,"True","True","True","True",5,171,"True","Gran_AML-0160",2233.93459758662,2233.93459758662,"malignant"
"2019.07.01.count.1.AGACTCAGTTTCAGAC","AML-0160","2019-07-01-count-1:AGACTCAGTTTCAGAC",-8.32609878006633,3.36415050113527,"2019-07-01-count-1","AML0160","HSC","HSC",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.487113402061856,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.AGACTCAGTTTCAGAC","HSC","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2277.56092152033,43.6797472071104,0.0191783002572563,2411,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2269.57866103157,2269.57866103157,"microenvironment"
"2019.07.01.count.3.GAACACTAGCAATTAG","AML-0160","2019-07-01-count-3:GAACACTAGCAATTAG",8.9690977531368,7.51540086353151,"2019-07-01-count-3","AML0160","B","Activated AP-1",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0151515151515152,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GAACACTAGCAATTAG","B","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","B","B",1796.88392747533,42.1060939260409,0.0234328401975308,812,30000,1100,500,"True","True","True","True",5,45,"True","B_AML-0160",1785.35374860451,1785.35374860451,"microenvironment"
"2019.07.01.count.1.TACCTGCTCATTGGTG","AML-0160","2019-07-01-count-1:TACCTGCTCATTGGTG",1.4680686193401,-8.59286215221556,"2019-07-01-count-1","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TACCTGCTCATTGGTG","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2583.9706908248,39.8118711839814,0.0154072456492429,2194,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2575.58102279937,2575.58102279937,"malignant"
"2019.07.01.count.3.CCTCATGGTGACACAG","AML-0160","2019-07-01-count-3:CCTCATGGTGACACAG",-7.39582953873332,4.37027881229249,"2019-07-01-count-3","AML0160","HSC","HSC",65,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.012987012987013,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CCTCATGGTGACACAG","HSC","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",1894.37658286355,35.8377544684515,0.0189179674161084,1232,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",1886.24967252551,1886.24967252551,"microenvironment"
"2019.07.01.count.3.TCTATCATCCTTCTGG","AML-0160","2019-07-01-count-3:TCTATCATCCTTCTGG",1.72006263312642,-8.73214819347533,"2019-07-01-count-3","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.TCTATCATCCTTCTGG","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2468.03680445327,36.3966921302945,0.0147472242166815,1703,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2464.73830342446,2464.73830342446,"malignant"
"2019.07.01.count.3.TCTTTGACAAGCGAGT","AML-0160","2019-07-01-count-3:TCTTTGACAAGCGAGT",2.27114882048909,-8.92449476635131,"2019-07-01-count-3","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.TCTTTGACAAGCGAGT","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2072.80747271309,43.2823755009172,0.020881039879823,1139,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2069.84886958356,2069.84886958356,"malignant"
"2019.07.01.count.2.GCAGTTAAGCTCACTA","AML-0160","2019-07-01-count-2:GCAGTTAAGCTCACTA",2.02947356280629,-9.13413336193236,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GCAGTTAAGCTCACTA","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2219.81734897955,41.4520771488132,0.018673643202162,1384,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2213.77051765899,2213.77051765899,"malignant"
"2019.07.01.count.2.GAATAGAGTACGCTTA","AML-0160","2019-07-01-count-2:GAATAGAGTACGCTTA",1.84647001799886,-9.38889124309691,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GAATAGAGTACGCTTA","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2060.07576134533,45.2701088490403,0.0219749728133672,1164,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2050.16600196703,2050.16600196703,"malignant"
"2019.07.01.count.1.TGAGCGCGTGACACAG","AML-0160","2019-07-01-count-1:TGAGCGCGTGACACAG",2.37442626532857,-9.32798006450804,"2019-07-01-count-1","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TGAGCGCGTGACACAG","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2227.67633647045,45.1503458333054,0.0202679110488923,1423,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2226.45801925681,2226.45801925681,"malignant"
"2019.07.01.count.2.CCCGGAAAGGGATCGT","AML-0160","2019-07-01-count-2:CCCGGAAAGGGATCGT",-0.738509039313155,11.9480571516785,"2019-07-01-count-2","AML0160","CD8+ T","CD8+ NK-like",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0136108887109688,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CCCGGAAAGGGATCGT","CD8+ T","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","T","CD8_T",1827.47240519143,41.599589244904,0.0227634568526064,936,30000,1100,500,"True","True","True","True",5,27,"True","T_AML-0160",1825.90191995202,1825.90191995202,"microenvironment"
"2019.07.01.count.1.GACCGTGCATCCGTTC","AML-0160","2019-07-01-count-1:GACCGTGCATCCGTTC",1.44605638560597,-8.43676950847777,"2019-07-01-count-1","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GACCGTGCATCCGTTC","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2393.22582373522,25.2255126197419,0.0105403812584519,1635,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2386.56345324311,2386.56345324311,"malignant"
"2019.07.01.count.3.CAACCTCGTATACGGG","AML-0160","2019-07-01-count-3:CAACCTCGTATACGGG",2.67687072333638,-9.4447174302307,"2019-07-01-count-3","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CAACCTCGTATACGGG","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",1917.27536209355,54.1623952188073,0.0282496694474106,949,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",1915.55276083095,1915.55276083095,"malignant"
"2019.07.01.count.3.GTGCAGCCAGCGAACA","AML-0160","2019-07-01-count-3:GTGCAGCCAGCGAACA",1.80916335162465,-8.83311941539916,"2019-07-01-count-3","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GTGCAGCCAGCGAACA","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2107.21535303057,41.2958255677019,0.0195973446702117,1243,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2107.21535303057,2107.21535303057,"malignant"
"2019.07.01.count.1.CGAGAAGAGAGACAAG","AML-0160","2019-07-01-count-1:CGAGAAGAGAGACAAG",8.85162128981892,6.84731671893922,"2019-07-01-count-1","AML0160","B","Activated AP-1",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0151515151515152,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CGAGAAGAGAGACAAG","B","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","B","B",1728.29026411915,40.7075422894534,0.0235536490221454,896,30000,1100,500,"True","True","True","True",5,45,"True","B_AML-0160",1720.3584747573,1720.3584747573,"microenvironment"
"2019.07.01.count.2.GCATTAGAGTAATACG","AML-0160","2019-07-01-count-2:GCATTAGAGTAATACG",2.11053218421285,-8.93363001262816,"2019-07-01-count-2","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GCATTAGAGTAATACG","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2495.79242621456,42.2909576210949,0.016944901818313,1892,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2489.03725273623,2489.03725273623,"malignant"
"2019.07.01.count.2.CGGGTGTCATTCCTAT","AML-0160","2019-07-01-count-2:CGGGTGTCATTCCTAT",1.46524776992146,-8.60836889660033,"2019-07-01-count-2","AML0160","Granulocyte","Granulocytes",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CGGGTGTCATTCCTAT","Granulocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Gran","Gran",2272.92765574421,28.5988198580496,0.0125823713683864,1832,30000,1100,500,"True","True","True","True",5,171,"True","Gran_AML-0160",2268.53779200088,2268.53779200088,"malignant"
"2019.07.01.count.1.CGGAACCGTTTGCCGG","AML-0160","2019-07-01-count-1:CGGAACCGTTTGCCGG",2.95345582541768,-8.85318281566771,"2019-07-01-count-1","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CGGAACCGTTTGCCGG","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2182.50746121036,41.7215806390426,0.0191163518936631,1524,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2179.18244977211,2179.18244977211,"malignant"
"2019.07.01.count.2.TTCCAATTCAAGTAAG","AML-0160","2019-07-01-count-2:TTCCAATTCAAGTAAG",1.99056448516194,-8.65419676220091,"2019-07-01-count-2","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.TTCCAATTCAAGTAAG","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2298.81431439234,41.4595287196506,0.0180351794662501,1488,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2295.33625193094,2295.33625193094,"malignant"
"2019.07.01.count.1.CGGACACCATGGAGAC","AML-0160","2019-07-01-count-1:CGGACACCATGGAGAC",2.23097528991048,-8.32797720348509,"2019-07-01-count-1","AML0160","HLA-II+ monocyte","HLA-II+",36,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0741127348643006,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CGGACACCATGGAGAC","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2557.91541375202,29.9494443019697,0.0117085358417068,2248,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2549.97817965088,2549.97817965088,"microenvironment"
"2019.07.01.count.2.GTGGAAGAGATAGGGA","AML-0160","2019-07-01-count-2:GTGGAAGAGATAGGGA",2.18934883651082,-9.65839579021605,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GTGGAAGAGATAGGGA","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","Mono","Mono",2006.95008129152,48.7523377537978,0.0242917540442384,1095,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2002.43570679037,2002.43570679037,"malignant"
"2019.07.01.count.3.TCGCAGGGTACAGCGA","AML-0160","2019-07-01-count-3:TCGCAGGGTACAGCGA",-9.02945075455363,1.90863940799562,"2019-07-01-count-3","AML0160","MPP","MPP_GMP",1,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.827586206896552,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.TCGCAGGGTACAGCGA","MPP","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0",0,0,"0","0",0,"0",0,0,0,0,"0",0,"0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0",0,"0",0,"AML","case","HSPC","HSPC",2426.21658405605,42.5140849190055,0.0175227905036953,2386,30000,1100,500,"True","True","True","True",5,319,"True","HSPC_AML-0160",2416.14487160134,2416.14487160134,"malignant"
"2019.07.01.count.1.TTATTGCCAGTGTACT","AML-0160","2019-07-01-count-1:TTATTGCCAGTGTACT",1.91286828097646,-9.11503889476927,"2019-07-01-count-1","AML0160","HLA-II+ monocyte","HLA-II+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TTATTGCCAGTGTACT","HLA-II+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0.0",0,"0",0,"AML","case","Mono","Mono",2369.10999036406,42.9218986296865,0.018117309371141,1595,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2361.25926818811,2361.25926818811,"malignant"
"2019.07.01.count.2.CACTTCGCAACGATTC","AML-0160","2019-07-01-count-2:CACTTCGCAACGATTC",1.47445013102834,-8.63155271923216,"2019-07-01-count-2","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CACTTCGCAACGATTC","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0.0",0,"0",0,"AML","case","Mono","Mono",2290.56338239251,41.392558591526,0.0180709073190069,1791,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2280.10122841348,2280.10122841348,"malignant"
"2019.07.01.count.3.GAGACCCCAGATTAAG","AML-0160","2019-07-01-count-3:GAGACCCCAGATTAAG",1.98151292380635,-9.17025949871215,"2019-07-01-count-3","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GAGACCCCAGATTAAG","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0.0",0,"0",0,"AML","case","Mono","Mono",1852.20452640286,45.0599334124518,0.0243277309660623,947,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",1850.59820440419,1850.59820440419,"malignant"
"2019.07.01.count.1.GGTGTCGGTCGTGCCA","AML-0160","2019-07-01-count-1:GGTGTCGGTCGTGCCA",2.12074627456014,-9.38366415416869,"2019-07-01-count-1","AML0160","CD14+ monocyte","CD14+",51,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_low",0.966314398943197,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GGTGTCGGTCGTGCCA","CD14+ monocyte","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0.0",0,"0",0,"AML","case","Mono","Mono",2414.85370980825,36.9219587907675,0.0152895219452855,1730,30000,1100,500,"True","True","True","True",5,1456,"True","Mono_AML-0160",2409.04285909847,2409.04285909847,"malignant"
"2019.07.01.count.2.AGGATCTTCGCTCATC","AML-0160","2019-07-01-count-2:AGGATCTTCGCTCATC",8.73880829390828,7.91777608478395,"2019-07-01-count-2","AML0160","B","Activated AP-1",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_low",0.0151515151515152,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.AGGATCTTCGCTCATC","B","U-16-0160","M",74,"CITE-seq","OSU","AML0160","AML","Adverse","46,XY[30]",3,"Blasts/promonocytes (30%) and monocytes (33%) represent the majority of the differential count of the bone marrow aspirates. Flow cytometric analysis demonstrates 11% CD34 positive myeloid blasts. The findings are those of an acute myeloid leukemia which in the absence of recurrent cytogenetic/molecular abnormalities, is best classified as acute myelomonocytic leukemia. The blasts represent 10.7% of
the total events analyzed and express CD34+, CD33+, CD13+, HLA-DR+, CD117+
with subsets expressing CD4 (29.1%), CD8 (12.4%), and CD11b (7.1%).","","","","x","","x",NA,NA,"0","0","0,45","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0,76",0,0,0,"0",0,"0,43","0.0",0,"0",0,"AML","case","B","B",1983.15726930029,39.5396362382894,0.0199377209515209,1141,30000,1100,500,"True","True","True","True",5,45,"True","B_AML-0160",1981.76005274281,1981.76005274281,"microenvironment"
"2021.03.09.AML0693.ACGTAACAGGACATCG","AML-0693","2021-03-09-AML0693:ACGTAACAGGACATCG",9.41075577315633,6.56711051547853,"2021-03-09-AML0693","AML0693","B","Naive B",2,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0393737048123417,"GSM5613784","2021-03-09","2021.03.09.AML0693.ACGTAACAGGACATCG","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1612.50812116085,44.4378387209215,0.0275582108007807,674,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1610.36322644461,1610.36322644461,"microenvironment"
"2021.03.09.AML0693.AAACGCTTCGACGATT","AML-0693","2021-03-09-AML0693:AAACGCTTCGACGATT",-7.78101859512981,-3.21992900287779,"2021-03-09-AML0693","AML0693","Granulocyte","Granulocytes",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.AAACGCTTCGACGATT","Granulocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Gran","Gran",2640.92824976081,1.16179471005825,0.0004399190739708,2037,30000,1100,500,"True","True","True","True",5,302,"True","Gran_AML-0693",2623.68911457295,2623.68911457295,"malignant"
"2021.03.09.AML0693.AAAGGGCCAAACCGGA","AML-0693","2021-03-09-AML0693:AAAGGGCCAAACCGGA",9.96464218673055,6.65914914691774,"2021-03-09-AML0693","AML0693","B","Activated AP-1",2,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0393737048123417,"GSM5613784","2021-03-09","2021.03.09.AML0693.AAAGGGCCAAACCGGA","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1782.65911988025,40.7743828916423,0.0228727873079747,811,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1776.95729079196,1776.95729079196,"microenvironment"
"2021.03.09.AML0693.AAGACTCAGGGCCAAT","AML-0693","2021-03-09-AML0693:AAGACTCAGGGCCAAT",1.0384199815685,9.62917230213014,"2021-03-09-AML0693","AML0693","CD4+ T","CD4+ TCM",4,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0664136622390892,"GSM5613784","2021-03-09","2021.03.09.AML0693.AAGACTCAGGGCCAAT","CD4+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD4_T",1682.49031293727,35.9814416701586,0.0213858239738347,775,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",1665.68993369715,1665.68993369715,"microenvironment"
"2021.03.09.AML0693.AATGCCAAGGGCAAGG","AML-0693","2021-03-09-AML0693:AATGCCAAGGGCAAGG",-4.89031062546428,2.61380312526552,"2021-03-09-AML0693","AML0693","MEP","MEP",39,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.240425531914894,"GSM5613784","2021-03-09","2021.03.09.AML0693.AATGCCAAGGGCAAGG","MEP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2958.79259514242,20.4187876634467,0.0069010540640696,2662,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2956.0973853568,2956.0973853568,"microenvironment"
"2021.03.09.AML0693.ACAGGGAAGTCCGTCG","AML-0693","2021-03-09-AML0693:ACAGGGAAGTCCGTCG",-7.20943580094035,-3.00802256977233,"2021-03-09-AML0693","AML0693","CD14+ monocyte","CD14+",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.ACAGGGAAGTCCGTCG","CD14+ monocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Mono","Mono",2341.7929460655,38.7165404206423,0.0165328623462168,1270,30000,1100,500,"True","True","True","True",5,237,"True","Mono_AML-0693",2328.59197817255,2328.59197817255,"malignant"
"2021.03.09.AML0693.ACCCTTGCATCTTCGC","AML-0693","2021-03-09-AML0693:ACCCTTGCATCTTCGC",-8.49831614914592,-3.56079866802367,"2021-03-09-AML0693","AML0693","GMP","GMP",41,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.988235294117647,"GSM5613784","2021-03-09","2021.03.09.AML0693.ACCCTTGCATCTTCGC","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2737.46951064827,43.7060440294016,0.0159658560065758,2279,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2732.12982591676,2732.12982591676,"malignant"
"2021.03.09.AML0693.ACCTACCGTCGGCACT","AML-0693","2021-03-09-AML0693:ACCTACCGTCGGCACT",-6.92946134033855,3.88399908626405,"2021-03-09-AML0693","AML0693","HSC","HSC",65,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.516693163751987,"GSM5613784","2021-03-09","2021.03.09.AML0693.ACCTACCGTCGGCACT","HSC","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2400.48949088016,34.5218789690883,0.0143811831296252,1512,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2383.2054991644,2383.2054991644,"microenvironment"
"2021.03.09.AML0693.CGTGTCTGTGTTCGTA","AML-0693","2021-03-09-AML0693:CGTGTCTGTGTTCGTA",-6.90872750702556,-2.62570860302123,"2021-03-09-AML0693","AML0693","MPP","MPP_MEP",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.CGTGTCTGTGTTCGTA","MPP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",1442.78014901412,49.8926620198384,0.0345809179963636,607,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",1433.88699345812,1433.88699345812,"malignant"
"2021.03.09.AML0693.CTAACTTAGTGATGGC","AML-0693","2021-03-09-AML0693:CTAACTTAGTGATGGC",-6.953445772559,3.92439649188844,"2021-03-09-AML0693","AML0693","HSC","HSC",65,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.516693163751987,"GSM5613784","2021-03-09","2021.03.09.AML0693.CTAACTTAGTGATGGC","HSC","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2264.22208588534,49.7216551008975,0.0219597076677466,1202,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2244.1789202352,2244.1789202352,"malignant"
"2021.03.09.AML0693.CTAGGTAGTCAGACTT","AML-0693","2021-03-09-AML0693:CTAGGTAGTCAGACTT",-6.96981797638591,3.83450219714967,"2021-03-09-AML0693","AML0693","MPP","MPP_MEP",65,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.516693163751987,"GSM5613784","2021-03-09","2021.03.09.AML0693.CTAGGTAGTCAGACTT","MPP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2340.81803068124,32.7561205355546,0.0139934501982718,1514,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2326.49744118307,2326.49744118307,"microenvironment"
"2021.03.09.AML0693.CTCACTGAGGTAAACT","AML-0693","2021-03-09-AML0693:CTCACTGAGGTAAACT",-2.24870286408122,3.53213927829591,"2021-03-09-AML0693","AML0693","Ery","Heat shock proteins",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.215384615384615,"GSM5613784","2021-03-09","2021.03.09.AML0693.CTCACTGAGGTAAACT","Ery","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Ery","Ery",2743.0721184352,37.4961580837281,0.0136694029412242,1958,30000,1100,500,"True","True","True","True",5,458,"True","Ery_AML-0693",2736.32540191132,2736.32540191132,"microenvironment"
"2021.03.09.AML0693.CTCATTAGTCCATACA","AML-0693","2021-03-09-AML0693:CTCATTAGTCCATACA",14.0828520255977,1.95847604358522,"2021-03-09-AML0693","AML0693","Plasmablast","Plasmablast",69,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.45850622406639,"GSM5613784","2021-03-09","2021.03.09.AML0693.CTCATTAGTCCATACA","Plasmablast","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","Plasma",1156.92365686937,2.84300966479014,0.0024573874411759,1301,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1139.54484512027,1139.54484512027,"microenvironment"
"2021.03.09.AML0693.CTCCACAGTAGGAGTC","AML-0693","2021-03-09-AML0693:CTCCACAGTAGGAGTC",-0.337870637804824,13.070324874762,"2021-03-09-AML0693","AML0693","CD8+ T","CD8+ GZMK+",22,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.018232044198895,"GSM5613784","2021-03-09","2021.03.09.AML0693.CTCCACAGTAGGAGTC","CD8+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD8_T",1979.86914237307,44.935491374628,0.0226961925982484,906,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",1975.99775099759,1975.99775099759,"microenvironment"
"2021.03.09.AML0693.CTCTCAGCACTACCCT","AML-0693","2021-03-09-AML0693:CTCTCAGCACTACCCT",-8.97869525376018,-3.67534758960875,"2021-03-09-AML0693","AML0693","GMP","GMP",11,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",1,"GSM5613784","2021-03-09","2021.03.09.AML0693.CTCTCAGCACTACCCT","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2908.6696978061,48.134689286389,0.0165486955506482,3353,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2896.58746988137,2896.58746988137,"malignant"
"2021.03.09.AML0693.CTGGTCTAGGGTTGCA","AML-0693","2021-03-09-AML0693:CTGGTCTAGGGTTGCA",-8.53198085251506,-3.57027270710143,"2021-03-09-AML0693","AML0693","GMP","GMP",41,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.988235294117647,"GSM5613784","2021-03-09","2021.03.09.AML0693.CTGGTCTAGGGTTGCA","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2907.30441658086,41.3574033267657,0.0142253432736171,3019,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2897.78907697022,2897.78907697022,"malignant"
"2021.03.09.AML0693.CTGGTCTTCTGTCAGA","AML-0693","2021-03-09-AML0693:CTGGTCTTCTGTCAGA",-8.34978805008586,-4.45857241069945,"2021-03-09-AML0693","AML0693","Granulocyte","Granulocytes",11,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",1,"GSM5613784","2021-03-09","2021.03.09.AML0693.CTGGTCTTCTGTCAGA","Granulocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Gran","Gran",2197.68697869606,51.7487706079292,0.0235469250669324,1502,30000,1100,500,"True","True","True","True",5,302,"True","Gran_AML-0693",2186.35714640205,2186.35714640205,"malignant"
"2021.03.09.AML0693.CTGTGAAGTCAGGTAG","AML-0693","2021-03-09-AML0693:CTGTGAAGTCAGGTAG",8.37037338790242,6.28246495807496,"2021-03-09-AML0693","AML0693","B","Naive B",0,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.115445679292357,"GSM5613784","2021-03-09","2021.03.09.AML0693.CTGTGAAGTCAGGTAG","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1635.86889227347,40.5963767455847,0.024816399980053,665,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1631.4924170055,1631.4924170055,"microenvironment"
"2021.03.09.AML0693.GAAGCCCAGAATCGTA","AML-0693","2021-03-09-AML0693:GAAGCCCAGAATCGTA",-6.83530936661418,2.95714876735536,"2021-03-09-AML0693","AML0693","MPP","MPP_MEP",47,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.26,"GSM5613784","2021-03-09","2021.03.09.AML0693.GAAGCCCAGAATCGTA","MPP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2441.63204481747,47.0143132511528,0.0192552818721985,1536,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2428.54147626284,2428.54147626284,"microenvironment"
"2021.03.09.AML0693.GAAGGACGTACAAAGT","AML-0693","2021-03-09-AML0693:GAAGGACGTACAAAGT",-8.88435302200969,-2.72006561672362,"2021-03-09-AML0693","AML0693","GMP","GMP",41,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.988235294117647,"GSM5613784","2021-03-09","2021.03.09.AML0693.GAAGGACGTACAAAGT","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",3388.43496964649,47.0705259278526,0.0138915240662752,4068,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",3379.06677527148,3379.06677527148,"malignant"
"2021.03.09.AML0693.GAGTCATTCATTTGTC","AML-0693","2021-03-09-AML0693:GAGTCATTCATTTGTC",-7.36590753021892,1.80856690490571,"2021-03-09-AML0693","AML0693","MPP","MPP_GMP",65,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.516693163751987,"GSM5613784","2021-03-09","2021.03.09.AML0693.GAGTCATTCATTTGTC","MPP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2550.3806692824,51.0367986954658,0.0200114435112253,2332,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2539.54703177138,2539.54703177138,"microenvironment"
"2021.03.09.AML0693.GAGTTTGGTGATTCAC","AML-0693","2021-03-09-AML0693:GAGTTTGGTGATTCAC",-1.43095586720164,9.69167611682741,"2021-03-09-AML0693","AML0693","CD8+ T","CD8+ Cytotoxic",15,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.0073627844712182,"GSM5613784","2021-03-09","2021.03.09.AML0693.GAGTTTGGTGATTCAC","CD8+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD8_T",1498.62791436388,39.5932636698707,0.0264196758183813,558,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",1491.06092379974,1491.06092379974,"malignant"
"2021.03.09.AML0693.GATAGCTGTGGCTGAA","AML-0693","2021-03-09-AML0693:GATAGCTGTGGCTGAA",11.3851849037105,-3.17826225673827,"2021-03-09-AML0693","AML0693","MEP","MEP",39,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.240425531914894,"GSM5613784","2021-03-09","2021.03.09.AML0693.GATAGCTGTGGCTGAA","MEP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",1702.40913952771,38.8236240238374,0.0228051078453491,723,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",1700.38785385462,1700.38785385462,"microenvironment"
"2021.03.09.AML0693.GCAACATCATTGTCGA","AML-0693","2021-03-09-AML0693:GCAACATCATTGTCGA",8.18895496901814,6.41811606967775,"2021-03-09-AML0693","AML0693","B","Naive B",0,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.115445679292357,"GSM5613784","2021-03-09","2021.03.09.AML0693.GCAACATCATTGTCGA","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1667.03258892185,39.9090790634381,0.0239401912887913,712,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1661.06402799726,1661.06402799726,"microenvironment"
"2021.03.09.AML0693.GCTACCTAGTGCTCGC","AML-0693","2021-03-09-AML0693:GCTACCTAGTGCTCGC",9.80296673354451,7.189914680365,"2021-03-09-AML0693","AML0693","B","Activated AP-1",2,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0393737048123417,"GSM5613784","2021-03-09","2021.03.09.AML0693.GCTACCTAGTGCTCGC","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1672.19398835752,41.459958653714,0.0247937493749976,751,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1666.66651133572,1666.66651133572,"microenvironment"
"2021.03.09.AML0693.GCTTGGGCAGAAATTG","AML-0693","2021-03-09-AML0693:GCTTGGGCAGAAATTG",-9.18605647507365,-4.28288032924803,"2021-03-09-AML0693","AML0693","GMP","GMP",11,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",1,"GSM5613784","2021-03-09","2021.03.09.AML0693.GCTTGGGCAGAAATTG","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2178.1227164844,47.0214162204615,0.0215880472962315,1369,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2170.0507315819,2170.0507315819,"malignant"
"2021.03.09.AML0693.GGAAGTGTCTGAGCAT","AML-0693","2021-03-09-AML0693:GGAAGTGTCTGAGCAT",8.82182087477986,6.11386582935182,"2021-03-09-AML0693","AML0693","B","Naive B",0,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.115445679292357,"GSM5613784","2021-03-09","2021.03.09.AML0693.GGAAGTGTCTGAGCAT","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1677.76645846149,44.6873855483736,0.0266350452549586,728,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1675.79291690184,1675.79291690184,"microenvironment"
"2021.03.09.AML0693.GGATGTTCAAGTAGTA","AML-0693","2021-03-09-AML0693:GGATGTTCAAGTAGTA",8.34002651748006,7.05563256824342,"2021-03-09-AML0693","AML0693","B","Activated NFkB",0,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.115445679292357,"GSM5613784","2021-03-09","2021.03.09.AML0693.GGATGTTCAAGTAGTA","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1481.78829758535,40.5267402914843,0.027349885511665,579,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1474.80239290497,1474.80239290497,"microenvironment"
"2021.03.09.AML0693.GGGATGAAGAGCCTGA","AML-0693","2021-03-09-AML0693:GGGATGAAGAGCCTGA",-7.11385379257854,-2.73359825527342,"2021-03-09-AML0693","AML0693","GMP","GMP",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.GGGATGAAGAGCCTGA","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2847.49062776946,0.105398621385915,3.70145630535324e-05,1956,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2812.39313960382,2812.39313960382,"malignant"
"2021.03.09.AML0693.GGGTTTAGTTCCTTGC","AML-0693","2021-03-09-AML0693:GGGTTTAGTTCCTTGC",-7.07150540772136,4.01114389980165,"2021-03-09-AML0693","AML0693","HSC","HSC",65,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.516693163751987,"GSM5613784","2021-03-09","2021.03.09.AML0693.GGGTTTAGTTCCTTGC","HSC","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2213.81749843264,36.6821480379276,0.0165696350597546,1165,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2194.72757482917,2194.72757482917,"malignant"
"2021.03.09.AML0693.GGTCACGTCATACGGT","AML-0693","2021-03-09-AML0693:GGTCACGTCATACGGT",9.86790623244588,7.28507659519044,"2021-03-09-AML0693","AML0693","B","Activated AP-1",2,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0393737048123417,"GSM5613784","2021-03-09","2021.03.09.AML0693.GGTCACGTCATACGGT","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1641.34676251765,46.9961556274893,0.028632679395183,659,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1632.91937563866,1632.91937563866,"microenvironment"
"2021.03.09.AML0693.GTAACACTCTAGGCCG","AML-0693","2021-03-09-AML0693:GTAACACTCTAGGCCG",1.00580545243565,10.0647353895935,"2021-03-09-AML0693","AML0693","CD4+ T","CD4+ TCM",4,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0664136622390892,"GSM5613784","2021-03-09","2021.03.09.AML0693.GTAACACTCTAGGCCG","CD4+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD4_T",1573.21345168815,35.9062975340982,0.0228235383415827,612,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",1566.97244728948,1566.97244728948,"microenvironment"
"2021.03.09.AML0693.GTAGAAAAGGGAACAA","AML-0693","2021-03-09-AML0693:GTAGAAAAGGGAACAA",-8.22285685959514,-4.28276398098143,"2021-03-09-AML0693","AML0693","Plasmablast","Plasmablast",11,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",1,"GSM5613784","2021-03-09","2021.03.09.AML0693.GTAGAAAAGGGAACAA","Plasmablast","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","Plasma",2445.38146764735,19.5306974419195,0.0079867692220263,1418,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",2422.9018072088,2422.9018072088,"microenvironment"
"2021.03.09.AML0693.GTCAAGTCATTGTGCA","AML-0693","2021-03-09-AML0693:GTCAAGTCATTGTGCA",3.64255156096761,-10.1471758118835,"2021-03-09-AML0693","AML0693","CD16+ monocyte","CD16+",29,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.0841584158415842,"GSM5613784","2021-03-09","2021.03.09.AML0693.GTCAAGTCATTGTGCA","CD16+ monocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Mono","Mono",2889.97992933339,41.8477575112935,0.0144802934741994,2596,30000,1100,500,"True","True","True","True",5,237,"True","Mono_AML-0693",2872.11613491608,2872.11613491608,"malignant"
"2021.03.09.AML0693.GTCATCCCATCCTAAG","AML-0693","2021-03-09-AML0693:GTCATCCCATCCTAAG",-6.97239766541179,-2.64833381092223,"2021-03-09-AML0693","AML0693","CD4+ T","CD4+ TCM",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.GTCATCCCATCCTAAG","CD4+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD4_T",1909.19639586764,46.4311824876502,0.0243197518014114,982,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",1887.74191847719,1887.74191847719,"malignant"
"2021.03.09.AML0693.GTGACGCGTGAGGAAA","AML-0693","2021-03-09-AML0693:GTGACGCGTGAGGAAA",-6.92089257660564,3.97078273380128,"2021-03-09-AML0693","AML0693","HSC","HSC",65,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.516693163751987,"GSM5613784","2021-03-09","2021.03.09.AML0693.GTGACGCGTGAGGAAA","HSC","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2059.04135944388,48.7607413261581,0.0236812830895868,1225,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2052.34012900089,2052.34012900089,"microenvironment"
"2021.03.09.AML0693.GTGAGCCTCTACGCAA","AML-0693","2021-03-09-AML0693:GTGAGCCTCTACGCAA",-6.92371926727946,3.89897391879884,"2021-03-09-AML0693","AML0693","HSC","HSC",65,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.516693163751987,"GSM5613784","2021-03-09","2021.03.09.AML0693.GTGAGCCTCTACGCAA","HSC","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2193.24628022322,36.5864402329294,0.0166814099095181,1164,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2183.75971631261,2183.75971631261,"malignant"
"2021.03.09.AML0693.GTGCTTCTCAGGTGTT","AML-0693","2021-03-09-AML0693:GTGCTTCTCAGGTGTT",-4.99369082871135,3.52915976131288,"2021-03-09-AML0693","AML0693","MEP","MEP",39,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.240425531914894,"GSM5613784","2021-03-09","2021.03.09.AML0693.GTGCTTCTCAGGTGTT","MEP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",3202.35898987974,35.0758005859165,0.0109531132195875,3321,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",3191.51377018655,3191.51377018655,"microenvironment"
"2021.03.09.AML0693.GTGGCGTTCGCATAGT","AML-0693","2021-03-09-AML0693:GTGGCGTTCGCATAGT",-6.84885154190715,3.98939035022584,"2021-03-09-AML0693","AML0693","HSC","HSC",65,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.516693163751987,"GSM5613784","2021-03-09","2021.03.09.AML0693.GTGGCGTTCGCATAGT","HSC","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2220.72475828781,44.8313210237368,0.0201876981181144,1328,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2212.3773790749,2212.3773790749,"microenvironment"
"2021.03.09.AML0693.GTTGAACTCAATCCGA","AML-0693","2021-03-09-AML0693:GTTGAACTCAATCCGA",9.87021030959431,7.05663964832155,"2021-03-09-AML0693","AML0693","B","Activated AP-1",2,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0393737048123417,"GSM5613784","2021-03-09","2021.03.09.AML0693.GTTGAACTCAATCCGA","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1800.47949539574,42.7233093252358,0.023728850805849,836,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1796.74649097509,1796.74649097509,"microenvironment"
"2021.03.09.AML0693.GTTGCGGTCAGAGTTC","AML-0693","2021-03-09-AML0693:GTTGCGGTCAGAGTTC",-9.28249965134319,-4.05036690151366,"2021-03-09-AML0693","AML0693","GMP","GMP",11,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",1,"GSM5613784","2021-03-09","2021.03.09.AML0693.GTTGCGGTCAGAGTTC","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",3059.17868215061,46.9965222044658,0.0153624639445471,3143,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",3044.93070684189,3044.93070684189,"malignant"
"2021.03.09.AML0693.TAACTTCTCAGGACGA","AML-0693","2021-03-09-AML0693:TAACTTCTCAGGACGA",-7.91080460968669,-4.1063270798889,"2021-03-09-AML0693","AML0693","MEP","MEP",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.TAACTTCTCAGGACGA","MEP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2006.9323104163,0,0,1273,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",1989.49163862935,1989.49163862935,"malignant"
"2021.03.09.AML0693.TACTTACAGCTCCACG","AML-0693","2021-03-09-AML0693:TACTTACAGCTCCACG",11.1847855049068,-2.79804041301879,"2021-03-09-AML0693","AML0693","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.830769230769231,"GSM5613784","2021-03-09","2021.03.09.AML0693.TACTTACAGCTCCACG","Ery","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Ery","Ery",1385.39467607721,48.1544064801957,0.0347586195556537,536,30000,1100,500,"True","True","True","True",5,458,"True","Ery_AML-0693",1382.98387253211,1382.98387253211,"malignant"
"2021.03.09.AML0693.TATCTTGCATGTGGTT","AML-0693","2021-03-09-AML0693:TATCTTGCATGTGGTT",-8.780425409705,-4.06024124538573,"2021-03-09-AML0693","AML0693","GMP","GMP",11,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",1,"GSM5613784","2021-03-09","2021.03.09.AML0693.TATCTTGCATGTGGTT","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2865.52965664056,40.6633695528621,0.0141905247634164,2510,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2858.65111474113,2858.65111474113,"malignant"
"2021.03.09.AML0693.TCAAGACCATCCTATT","AML-0693","2021-03-09-AML0693:TCAAGACCATCCTATT",9.36041225966756,7.24283740604249,"2021-03-09-AML0693","AML0693","B","Activated AP-1",2,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0393737048123417,"GSM5613784","2021-03-09","2021.03.09.AML0693.TCAAGACCATCCTATT","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1731.57022177439,52.0545416592183,0.0300620448449826,817,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1727.89120651137,1727.89120651137,"microenvironment"
"2021.03.09.AML0693.TCAAGCATCTCGGCTT","AML-0693","2021-03-09-AML0693:TCAAGCATCTCGGCTT",-7.57183633270915,-2.35752203380736,"2021-03-09-AML0693","AML0693","Granulocyte","Granulocytes (cycling)",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.TCAAGCATCTCGGCTT","Granulocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Gran","Gran",3175.0315301481,25.2325097780082,0.0079471682527925,2837,30000,1100,500,"True","True","True","True",5,302,"True","Gran_AML-0693",3153.32041427065,3153.32041427065,"malignant"
"2021.03.09.AML0693.TCACAAGAGCCGCTTG","AML-0693","2021-03-09-AML0693:TCACAAGAGCCGCTTG",11.0452410179073,-2.58487632190856,"2021-03-09-AML0693","AML0693","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.830769230769231,"GSM5613784","2021-03-09","2021.03.09.AML0693.TCACAAGAGCCGCTTG","Ery","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Ery","Ery",1962.93987623084,46.685063675409,0.0237832366852988,940,30000,1100,500,"True","True","True","True",5,458,"True","Ery_AML-0693",1949.82881920959,1949.82881920959,"malignant"
"2021.03.09.AML0693.TCACATTGTAGTCGGA","AML-0693","2021-03-09-AML0693:TCACATTGTAGTCGGA",-6.99330506745036,3.85128877246705,"2021-03-09-AML0693","AML0693","HSC","HSC",65,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.516693163751987,"GSM5613784","2021-03-09","2021.03.09.AML0693.TCACATTGTAGTCGGA","HSC","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2066.42578376287,46.2020614001265,0.0223584421773884,1048,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2059.76769561505,2059.76769561505,"microenvironment"
"2021.03.09.AML0693.TCACGGGGTCTACGTA","AML-0693","2021-03-09-AML0693:TCACGGGGTCTACGTA",-8.30824218216594,-4.38301279461058,"2021-03-09-AML0693","AML0693","Granulocyte","Granulocytes",11,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",1,"GSM5613784","2021-03-09","2021.03.09.AML0693.TCACGGGGTCTACGTA","Granulocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Gran","Gran",2948.6341183675,49.8223303005817,0.0168967489015442,2682,30000,1100,500,"True","True","True","True",5,302,"True","Gran_AML-0693",2937.52148583451,2937.52148583451,"malignant"
"2021.03.09.AML0693.TCACTCGGTCTCTCAC","AML-0693","2021-03-09-AML0693:TCACTCGGTCTCTCAC",8.01638617095296,6.46773574436036,"2021-03-09-AML0693","AML0693","B","Naive B",0,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.115445679292357,"GSM5613784","2021-03-09","2021.03.09.AML0693.TCACTCGGTCTCTCAC","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1623.72983542955,42.2557541648902,0.0260238823250493,673,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1619.58104351461,1619.58104351461,"microenvironment"
"2021.03.09.AML0693.TCATTCACACAATGTC","AML-0693","2021-03-09-AML0693:TCATTCACACAATGTC",-8.34522757950481,-3.77525331890257,"2021-03-09-AML0693","AML0693","GMP","GMP",41,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.988235294117647,"GSM5613784","2021-03-09","2021.03.09.AML0693.TCATTCACACAATGTC","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2964.26328743491,48.9974081653668,0.0165293711840847,2345,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2957.27428722823,2957.27428722823,"malignant"
"2021.03.09.AML0693.TCCTCTTCAGTAGAGC","AML-0693","2021-03-09-AML0693:TCCTCTTCAGTAGAGC",-7.49877295914348,-2.9593818417755,"2021-03-09-AML0693","AML0693","GMP","GMP",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.TCCTCTTCAGTAGAGC","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",3002.38555299517,10.2495980911548,0.0034138180824011,2065,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2978.56557598582,2978.56557598582,"malignant"
"2021.03.09.AML0693.TCCTTCTTCACAATGC","AML-0693","2021-03-09-AML0693:TCCTTCTTCACAATGC",-0.59761349383052,11.9673194655213,"2021-03-09-AML0693","AML0693","CD8+ T","CD8+ GZMK+",5,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0934510669610007,"GSM5613784","2021-03-09","2021.03.09.AML0693.TCCTTCTTCACAATGC","CD8+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD8_T",1972.99670733157,48.5446590808097,0.0246045312191449,881,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",1969.16105677199,1969.16105677199,"microenvironment"
"2021.03.09.AML0693.TCGAACATCATCTCTA","AML-0693","2021-03-09-AML0693:TCGAACATCATCTCTA",11.9130045371944,-2.79307463085326,"2021-03-09-AML0693","AML0693","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.830769230769231,"GSM5613784","2021-03-09","2021.03.09.AML0693.TCGAACATCATCTCTA","Ery","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Ery","Ery",1338.05555029539,51.5060609134778,0.0384932156980383,508,30000,1100,500,"True","True","True","True",5,458,"True","Ery_AML-0693",1330.78204603307,1330.78204603307,"malignant"
"2021.03.09.AML0693.TCGCACTTCATGCGGC","AML-0693","2021-03-09-AML0693:TCGCACTTCATGCGGC",14.2623144584591,1.89322743499605,"2021-03-09-AML0693","AML0693","Plasmablast","Plasmablast",69,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.45850622406639,"GSM5613784","2021-03-09","2021.03.09.AML0693.TCGCACTTCATGCGGC","Plasmablast","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","Plasma",1369.18354193736,0.241199931488471,0.0001761633295322,1436,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1348.04236990153,1348.04236990153,"microenvironment"
"2021.03.09.AML0693.TCTCTGGCAGCGTAGA","AML-0693","2021-03-09-AML0693:TCTCTGGCAGCGTAGA",9.13165630873982,7.49890468204347,"2021-03-09-AML0693","AML0693","B","Memory",0,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.115445679292357,"GSM5613784","2021-03-09","2021.03.09.AML0693.TCTCTGGCAGCGTAGA","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",2112.18162446845,39.1173478220169,0.0185198788630979,1144,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",2104.15205629778,2104.15205629778,"microenvironment"
"2021.03.09.AML0693.TGAATCGGTTTGTTCT","AML-0693","2021-03-09-AML0693:TGAATCGGTTTGTTCT",-0.0728737813537896,11.2814025648865,"2021-03-09-AML0693","AML0693","CD4+ T","CD4+ TCM",4,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.0664136622390892,"GSM5613784","2021-03-09","2021.03.09.AML0693.TGAATCGGTTTGTTCT","CD4+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD4_T",1621.53012932069,52.5404611113064,0.0324017791351907,663,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",1619.28924989636,1619.28924989636,"malignant"
"2021.03.09.AML0693.TGAGCATTCGCCGAGT","AML-0693","2021-03-09-AML0693:TGAGCATTCGCCGAGT",1.0227179127628,9.68001554096071,"2021-03-09-AML0693","AML0693","CD4+ T","CD4+ Naive",4,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0664136622390892,"GSM5613784","2021-03-09","2021.03.09.AML0693.TGAGCATTCGCCGAGT","CD4+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD4_T",1607.36297829069,31.201341707321,0.0194115094902219,670,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",1607.36297829069,1607.36297829069,"microenvironment"
"2021.03.09.AML0693.TGATCAGCAAGTGGGT","AML-0693","2021-03-09-AML0693:TGATCAGCAAGTGGGT",9.57675137099568,7.69679257953493,"2021-03-09-AML0693","AML0693","B","Memory",2,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0393737048123417,"GSM5613784","2021-03-09","2021.03.09.AML0693.TGATCAGCAAGTGGGT","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1735.18153562263,47.4831829916785,0.0273649655767229,773,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1723.52001622403,1723.52001622403,"microenvironment"
"2021.03.09.AML0693.TGATTCTAGGGCTTCC","AML-0693","2021-03-09-AML0693:TGATTCTAGGGCTTCC",7.9562164741451,7.66820476138917,"2021-03-09-AML0693","AML0693","B","Activated NFkB",0,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.115445679292357,"GSM5613784","2021-03-09","2021.03.09.AML0693.TGATTCTAGGGCTTCC","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1557.14741776985,45.0289438443863,0.0289175856637111,641,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1552.79981688698,1552.79981688698,"microenvironment"
"2021.03.09.AML0693.TGCAGTAGTACTAAGA","AML-0693","2021-03-09-AML0693:TGCAGTAGTACTAAGA",-7.02785764160808,-2.74116423046263,"2021-03-09-AML0693","AML0693","MPP","MPP_MEP",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.TGCAGTAGTACTAAGA","MPP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2048.91094129139,48.2079397796778,0.0235285676932807,1393,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2022.3429312156,2022.3429312156,"malignant"
"2021.03.09.AML0693.TGCGATAGTCACTCTC","AML-0693","2021-03-09-AML0693:TGCGATAGTCACTCTC",-8.21060786667522,-4.27562000667723,"2021-03-09-AML0693","AML0693","Granulocyte","Granulocytes",11,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",1,"GSM5613784","2021-03-09","2021.03.09.AML0693.TGCGATAGTCACTCTC","Granulocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Gran","Gran",2923.00149780676,37.7695731764831,0.0129215031893836,2768,30000,1100,500,"True","True","True","True",5,302,"True","Gran_AML-0693",2911.28540679396,2911.28540679396,"malignant"
"2021.03.09.AML0693.TGGGATTAGTAGCCAG","AML-0693","2021-03-09-AML0693:TGGGATTAGTAGCCAG",7.79038824614827,6.29411790454713,"2021-03-09-AML0693","AML0693","B","Naive B",0,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.115445679292357,"GSM5613784","2021-03-09","2021.03.09.AML0693.TGGGATTAGTAGCCAG","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1529.26708401071,42.1335703262505,0.0275514792456983,630,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1525.01944218772,1525.01944218772,"microenvironment"
"2021.03.09.AML0693.TGGGCGTTCCAGTGTA","AML-0693","2021-03-09-AML0693:TGGGCGTTCCAGTGTA",-6.83989129486735,-2.63054993068846,"2021-03-09-AML0693","AML0693","CD4+ T","CD4+ TCM",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.TGGGCGTTCCAGTGTA","CD4+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD4_T",1719.36840904708,44.8890326616752,0.0261078617156598,688,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",1717.03297322607,1717.03297322607,"malignant"
"2021.03.09.AML0693.TGGGTTACACATTACG","AML-0693","2021-03-09-AML0693:TGGGTTACACATTACG",-7.42185006561931,-2.51918914234313,"2021-03-09-AML0693","AML0693","GMP","GMP",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.TGGGTTACACATTACG","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2923.26776818421,10.9088169008765,0.0037317200359146,2012,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2906.85911842288,2906.85911842288,"malignant"
"2021.03.09.AML0693.TGTGAGTCATTGCCGG","AML-0693","2021-03-09-AML0693:TGTGAGTCATTGCCGG",-7.25237594071086,2.36986515605775,"2021-03-09-AML0693","AML0693","GMP","GMP",47,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.26,"GSM5613784","2021-03-09","2021.03.09.AML0693.TGTGAGTCATTGCCGG","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2535.41857500556,40.7263986956742,0.0160629882170777,1843,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2525.72277131762,2525.72277131762,"microenvironment"
"2021.03.09.AML0693.TGTTACTGTGGCTTAT","AML-0693","2021-03-09-AML0693:TGTTACTGTGGCTTAT",-8.6318887275761,-3.11191489612731,"2021-03-09-AML0693","AML0693","GMP","GMP",41,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.988235294117647,"GSM5613784","2021-03-09","2021.03.09.AML0693.TGTTACTGTGGCTTAT","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2982.88656643297,44.3785152720799,0.0148777079797403,3579,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2972.80671004489,2972.80671004489,"malignant"
"2021.03.09.AML0693.TGTTACTGTTAGCGGA","AML-0693","2021-03-09-AML0693:TGTTACTGTTAGCGGA",-8.68841681900676,-2.99375488674315,"2021-03-09-AML0693","AML0693","Granulocyte","Granulocytes",41,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.988235294117647,"GSM5613784","2021-03-09","2021.03.09.AML0693.TGTTACTGTTAGCGGA","Granulocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Gran","Gran",3102.96039778639,48.3010205061307,0.015566109235744,3280,30000,1100,500,"True","True","True","True",5,302,"True","Gran_AML-0693",3097.98255257551,3097.98255257551,"malignant"
"2021.03.09.AML0693.TGTTGAGCATGCAGGA","AML-0693","2021-03-09-AML0693:TGTTGAGCATGCAGGA",11.8777691322262,-2.56686665928038,"2021-03-09-AML0693","AML0693","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.830769230769231,"GSM5613784","2021-03-09","2021.03.09.AML0693.TGTTGAGCATGCAGGA","Ery","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Ery","Ery",1758.33337211447,38.9165461758157,0.0221326324080495,731,30000,1100,500,"True","True","True","True",5,458,"True","Ery_AML-0693",1753.87839691021,1753.87839691021,"malignant"
"2021.03.09.AML0693.TTAATCCTCATTTACC","AML-0693","2021-03-09-AML0693:TTAATCCTCATTTACC",-1.97220454636272,10.2751254805359,"2021-03-09-AML0693","AML0693","CD8+ T","CD8+ GZMK+",15,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0073627844712182,"GSM5613784","2021-03-09","2021.03.09.AML0693.TTAATCCTCATTTACC","CD8+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD8_T",2017.39740940909,38.8060452488513,0.0192356969766397,960,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",2009.9559207504,2009.9559207504,"microenvironment"
"2021.03.09.AML0693.TTACCGCAGAAGCGAA","AML-0693","2021-03-09-AML0693:TTACCGCAGAAGCGAA",-6.93568787995036,3.58925411784974,"2021-03-09-AML0693","AML0693","HSC","HSC",65,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.516693163751987,"GSM5613784","2021-03-09","2021.03.09.AML0693.TTACCGCAGAAGCGAA","HSC","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2406.89840866118,37.8909542161192,0.0157426479155785,1396,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2394.19747060174,2394.19747060174,"malignant"
"2021.03.09.AML0693.TTACTGTGTGCAATAA","AML-0693","2021-03-09-AML0693:TTACTGTGTGCAATAA",-1.79143462601359,3.73507354343263,"2021-03-09-AML0693","AML0693","Ery","Heat shock proteins",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.215384615384615,"GSM5613784","2021-03-09","2021.03.09.AML0693.TTACTGTGTGCAATAA","Ery","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Ery","Ery",3226.8703229023,23.9806743168398,0.0074315581096147,3881,30000,1100,500,"True","True","True","True",5,458,"True","Ery_AML-0693",3217.27716742027,3217.27716742027,"microenvironment"
"2021.03.09.AML0693.TTCACCGGTCGGCACT","AML-0693","2021-03-09-AML0693:TTCACCGGTCGGCACT",14.09894814071,1.81817588889924,"2021-03-09-AML0693","AML0693","Plasmablast","Plasmablast",69,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.45850622406639,"GSM5613784","2021-03-09","2021.03.09.AML0693.TTCACCGGTCGGCACT","Plasmablast","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","Plasma",1138.13604485106,3.36437331681429,0.0029560379288879,1399,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1117.72448351614,1117.72448351614,"microenvironment"
"2021.03.09.AML0693.TTCCACGAGAGTCACG","AML-0693","2021-03-09-AML0693:TTCCACGAGAGTCACG",-8.30678973618205,-0.412001811620318,"2021-03-09-AML0693","AML0693","GMP","GMP",37,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.160583941605839,"GSM5613784","2021-03-09","2021.03.09.AML0693.TTCCACGAGAGTCACG","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2966.35097015019,39.9306928047542,0.0134612165608753,2975,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2945.80472730237,2945.80472730237,"microenvironment"
"2021.03.09.AML0693.TTCTTCCCAGGACGAT","AML-0693","2021-03-09-AML0693:TTCTTCCCAGGACGAT",-3.34274945679362,-5.80318739330443,"2021-03-09-AML0693","AML0693","Granulocyte","Granulocytes",63,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.0061199510403916,"GSM5613784","2021-03-09","2021.03.09.AML0693.TTCTTCCCAGGACGAT","Granulocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Gran","Gran",2379.94087415626,42.3483560080262,0.0177938689435045,1440,30000,1100,500,"True","True","True","True",5,302,"True","Gran_AML-0693",2377.30347155135,2377.30347155135,"malignant"
"2021.03.09.AML0693.ACTATCTAGGGCGAAG","AML-0693","2021-03-09-AML0693:ACTATCTAGGGCGAAG",-7.56474624100383,-3.50049045002135,"2021-03-09-AML0693","AML0693","CD14+ monocyte","CD14+",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.ACTATCTAGGGCGAAG","CD14+ monocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Mono","Mono",1625.45655871269,24.7395105432839,0.0152200379706713,843,30000,1100,500,"True","True","True","True",5,237,"True","Mono_AML-0693",1611.45770668597,1611.45770668597,"malignant"
"2021.03.09.AML0693.ACTGATGAGAGTCTTC","AML-0693","2021-03-09-AML0693:ACTGATGAGAGTCTTC",10.39582314071,6.21805570209352,"2021-03-09-AML0693","AML0693","B","Activated AP-1",2,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0393737048123417,"GSM5613784","2021-03-09","2021.03.09.AML0693.ACTGATGAGAGTCTTC","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1762.4144265264,44.8503224585834,0.025448227036464,763,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1760.39961468541,1760.39961468541,"microenvironment"
"2021.03.09.AML0693.ACTGATGGTAGAGTTA","AML-0693","2021-03-09-AML0693:ACTGATGGTAGAGTTA",0.8692190843517,9.69226453388063,"2021-03-09-AML0693","AML0693","CD4+ T","CD4+ TCM",4,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0664136622390892,"GSM5613784","2021-03-09","2021.03.09.AML0693.ACTGATGGTAGAGTTA","CD4+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD4_T",1616.83950246187,40.6454313978868,0.0251388163982871,707,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",1613.39822700136,1613.39822700136,"microenvironment"
"2021.03.09.AML0693.AGACACTGTAGGTAGC","AML-0693","2021-03-09-AML0693:AGACACTGTAGGTAGC",-7.01312814179118,3.78191659534303,"2021-03-09-AML0693","AML0693","MPP","MPP_GMP",65,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.516693163751987,"GSM5613784","2021-03-09","2021.03.09.AML0693.AGACACTGTAGGTAGC","MPP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2495.01292285265,38.2053480418108,0.0153126854341616,1856,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2484.43466271371,2484.43466271371,"microenvironment"
"2021.03.09.AML0693.AGACTCAAGCTAAATG","AML-0693","2021-03-09-AML0693:AGACTCAAGCTAAATG",8.71322407302205,8.14399812305299,"2021-03-09-AML0693","AML0693","B","Activated AP-1",0,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.115445679292357,"GSM5613784","2021-03-09","2021.03.09.AML0693.AGACTCAAGCTAAATG","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1968.02967863608,42.2038715821404,0.0214447332986305,1038,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1950.45178820583,1950.45178820583,"microenvironment"
"2021.03.09.AML0693.AGCATCACAATTTCTC","AML-0693","2021-03-09-AML0693:AGCATCACAATTTCTC",0.855805893510026,9.85799596393434,"2021-03-09-AML0693","AML0693","CD4+ T","CD4+ TCM",4,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0664136622390892,"GSM5613784","2021-03-09","2021.03.09.AML0693.AGCATCACAATTTCTC","CD4+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD4_T",1668.97281442555,49.2790676335348,0.0295265849794542,747,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",1666.99148572798,1666.99148572798,"microenvironment"
"2021.03.09.AML0693.AGCTTCCGTCGTTGGC","AML-0693","2021-03-09-AML0693:AGCTTCCGTCGTTGGC",-8.2942307991093,-4.48783781444701,"2021-03-09-AML0693","AML0693","GMP","GMP",11,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",1,"GSM5613784","2021-03-09","2021.03.09.AML0693.AGCTTCCGTCGTTGGC","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2205.25389559925,46.9553808973672,0.0212925055890708,1462,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2190.15161386042,2190.15161386042,"malignant"
"2021.03.09.AML0693.AGGAAATAGTTAACGA","AML-0693","2021-03-09-AML0693:AGGAAATAGTTAACGA",10.2362925010616,6.8280925520691,"2021-03-09-AML0693","AML0693","B","Naive B",2,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0393737048123417,"GSM5613784","2021-03-09","2021.03.09.AML0693.AGGAAATAGTTAACGA","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1814.1221487262,41.3491235129176,0.0227929103571947,866,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1810.57149969958,1810.57149969958,"microenvironment"
"2021.03.09.AML0693.AGGATAATCACATTGG","AML-0693","2021-03-09-AML0693:AGGATAATCACATTGG",-7.7712439102238,-2.60994508182677,"2021-03-09-AML0693","AML0693","Granulocyte","Granulocytes (cycling)",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.AGGATAATCACATTGG","Granulocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Gran","Gran",2455.49602662821,8.63027841287423,0.0035146782235787,1424,30000,1100,500,"True","True","True","True",5,302,"True","Gran_AML-0693",2444.9073526164,2444.9073526164,"malignant"
"2021.03.09.AML0693.AGTCAACTCATGCTAG","AML-0693","2021-03-09-AML0693:AGTCAACTCATGCTAG",-7.24649653855022,-2.8508830300537,"2021-03-09-AML0693","AML0693","GMP","GMP",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.AGTCAACTCATGCTAG","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2362.33508056737,41.4768272559347,0.0175575546403743,1446,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2336.2175550455,2336.2175550455,"malignant"
"2021.03.09.AML0693.AGTCTCCTCCTACAAG","AML-0693","2021-03-09-AML0693:AGTCTCCTCCTACAAG",1.88855924186055,-9.89407732402953,"2021-03-09-AML0693","AML0693","CD14+ monocyte","CD14+",13,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.001241002730206,"GSM5613784","2021-03-09","2021.03.09.AML0693.AGTCTCCTCCTACAAG","CD14+ monocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Mono","Mono",1509.86743612929,38.1371892306903,0.0252586341807988,593,30000,1100,500,"True","True","True","True",5,237,"True","Mono_AML-0693",1507.65152013918,1507.65152013918,"malignant"
"2021.03.09.AML0693.ATATCCTAGGCGCTTC","AML-0693","2021-03-09-AML0693:ATATCCTAGGCGCTTC",8.13013042983357,6.54681346500245,"2021-03-09-AML0693","AML0693","B","Naive B",0,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.115445679292357,"GSM5613784","2021-03-09","2021.03.09.AML0693.ATATCCTAGGCGCTTC","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1738.69563940799,41.4917592087721,0.0238637276521264,795,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1727.44352870831,1727.44352870831,"microenvironment"
"2021.03.09.AML0693.ATCGGCGAGAGCAAGA","AML-0693","2021-03-09-AML0693:ATCGGCGAGAGCAAGA",-7.14224896851237,4.18572805011598,"2021-03-09-AML0693","AML0693","HSC","HSC",65,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.516693163751987,"GSM5613784","2021-03-09","2021.03.09.AML0693.ATCGGCGAGAGCAAGA","HSC","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2047.33116762878,44.5623371670236,0.0217660620185037,1237,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2028.76508423864,2028.76508423864,"microenvironment"
"2021.03.09.AML0693.ATTGGGTCAGAACTTC","AML-0693","2021-03-09-AML0693:ATTGGGTCAGAACTTC",11.5049292045528,-2.47274353420409,"2021-03-09-AML0693","AML0693","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.830769230769231,"GSM5613784","2021-03-09","2021.03.09.AML0693.ATTGGGTCAGAACTTC","Ery","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Ery","Ery",1864.81502691746,40.9329913146286,0.021950161664179,878,30000,1100,500,"True","True","True","True",5,458,"True","Ery_AML-0693",1855.31084170771,1855.31084170771,"malignant"
"2021.03.09.AML0693.CACCAAAAGTTCCAGT","AML-0693","2021-03-09-AML0693:CACCAAAAGTTCCAGT",-6.98789534989055,-3.07490112697753,"2021-03-09-AML0693","AML0693","CD14+ monocyte","CD14+",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.972627737226277,"GSM5613784","2021-03-09","2021.03.09.AML0693.CACCAAAAGTTCCAGT","CD14+ monocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Mono","Mono",2397.06948190268,0,0,1574,30000,1100,500,"True","True","True","True",5,237,"True","Mono_AML-0693",2382.9026166724,2382.9026166724,"malignant"
"2021.03.09.AML0693.CACGTTCCATCAGTGT","AML-0693","2021-03-09-AML0693:CACGTTCCATCAGTGT",-1.05207703533824,11.9110774763855,"2021-03-09-AML0693","AML0693","CD8+ T","CD8+ GZMK+",22,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.018232044198895,"GSM5613784","2021-03-09","2021.03.09.AML0693.CACGTTCCATCAGTGT","CD8+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD8_T",1939.95392232123,45.3663720055972,0.023385283270705,902,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",1936.12651871178,1936.12651871178,"microenvironment"
"2021.03.09.AML0693.CAGCCAGAGTCGTTAC","AML-0693","2021-03-09-AML0693:CAGCCAGAGTCGTTAC",0.346810718148392,11.7246923216614,"2021-03-09-AML0693","AML0693","CD8+ T","CD8+ TRM",5,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0934510669610007,"GSM5613784","2021-03-09","2021.03.09.AML0693.CAGCCAGAGTCGTTAC","CD8+ T","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","T","CD8_T",1764.2501855611,41.6754416417504,0.0236221835104957,735,30000,1100,500,"True","True","True","True",5,450,"True","T_AML-0693",1759.93481367951,1759.93481367951,"microenvironment"
"2021.03.09.AML0693.CATCGTCCAAAGGTTA","AML-0693","2021-03-09-AML0693:CATCGTCCAAAGGTTA",-1.6542069715565,3.33222076976625,"2021-03-09-AML0693","AML0693","Ery","Ery-5",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.215384615384615,"GSM5613784","2021-03-09","2021.03.09.AML0693.CATCGTCCAAAGGTTA","Ery","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Ery","Ery",2800.54580514787,28.2414468150036,0.0100842652753942,2813,30000,1100,500,"True","True","True","True",5,458,"True","Ery_AML-0693",2795.35422468195,2795.35422468195,"microenvironment"
"2021.03.09.AML0693.CCAATTTTCTCATAGG","AML-0693","2021-03-09-AML0693:CCAATTTTCTCATAGG",8.7154127555782,6.59942386234132,"2021-03-09-AML0693","AML0693","B","Naive B",0,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.115445679292357,"GSM5613784","2021-03-09","2021.03.09.AML0693.CCAATTTTCTCATAGG","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1453.1301352142,48.8519158466713,0.0336184039287509,546,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1450.3576249681,1450.3576249681,"microenvironment"
"2021.03.09.AML0693.CCATAAGCAAGAGGCT","AML-0693","2021-03-09-AML0693:CCATAAGCAAGAGGCT",8.55195011672322,6.57975671375123,"2021-03-09-AML0693","AML0693","B","Naive B",0,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.115445679292357,"GSM5613784","2021-03-09","2021.03.09.AML0693.CCATAAGCAAGAGGCT","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1619.9543782412,41.3442569333937,0.0255218649912115,697,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1613.90830591728,1613.90830591728,"microenvironment"
"2021.03.09.AML0693.CCGCAAGGTTCTCGCT","AML-0693","2021-03-09-AML0693:CCGCAAGGTTCTCGCT",-9.04970298233684,-3.11015059864195,"2021-03-09-AML0693","AML0693","GMP","GMP",41,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.988235294117647,"GSM5613784","2021-03-09","2021.03.09.AML0693.CCGCAAGGTTCTCGCT","GMP","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",3192.6719210299,39.3812890353461,0.0123349000490606,3258,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",3184.81110945555,3184.81110945555,"malignant"
"2021.03.09.AML0693.CCGGACACAGTCAGAG","AML-0693","2021-03-09-AML0693:CCGGACACAGTCAGAG",-8.16340766373332,-3.90771105205687,"2021-03-09-AML0693","AML0693","Granulocyte","Granulocytes",41,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.988235294117647,"GSM5613784","2021-03-09","2021.03.09.AML0693.CCGGACACAGTCAGAG","Granulocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Gran","Gran",3107.83248790356,43.693414556681,0.0140591279377979,2898,30000,1100,500,"True","True","True","True",5,302,"True","Gran_AML-0693",3097.33924856257,3097.33924856257,"malignant"
"2021.03.09.AML0693.CGAGAAGCATTGGATC","AML-0693","2021-03-09-AML0693:CGAGAAGCATTGGATC",8.37917961654012,6.24933955753175,"2021-03-09-AML0693","AML0693","B","Naive B",0,"CNV+","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.115445679292357,"GSM5613784","2021-03-09","2021.03.09.AML0693.CGAGAAGCATTGGATC","B","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","B","B",1539.34967231131,34.9641783021578,0.0227136036282514,605,30000,1100,500,"True","True","True","True",5,820,"True","B_AML-0693",1530.53349493088,1530.53349493088,"microenvironment"
"2021.03.09.AML0693.CGAGTGCTCCGAGAAG","AML-0693","2021-03-09-AML0693:CGAGTGCTCCGAGAAG",-6.88532481613811,4.00849220836488,"2021-03-09-AML0693","AML0693","HSC","HSC",65,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.516693163751987,"GSM5613784","2021-03-09","2021.03.09.AML0693.CGAGTGCTCCGAGAAG","HSC","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","HSPC","HSPC",2160.00916262703,39.9281493263963,0.0184851759044555,1203,30000,1100,500,"True","True","True","True",5,1036,"True","HSPC_AML-0693",2146.82869148434,2146.82869148434,"microenvironment"
"2021.03.09.AML0693.CGAGTGCTCCTGGTCT","AML-0693","2021-03-09-AML0693:CGAGTGCTCCTGGTCT",-8.24403891983684,-3.63746025478514,"2021-03-09-AML0693","AML0693","Granulocyte","Granulocytes",41,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.988235294117647,"GSM5613784","2021-03-09","2021.03.09.AML0693.CGAGTGCTCCTGGTCT","Granulocyte","U-11-0693","F",77,"CITE-seq + scTCR-seq","OSU","AML0693","AML","Adverse","74-89<4n>,XXXX,-8,-9,-9,-12,-17,i(17)(q10),+mar1,+mar2,+dmin[cp18]/46,XX[2] .ish dmin(amp CMYC)",47,"Immunohistochemical stains are performed on the bone marrow biopsy for CD34, CD117, CD79a, CD3, MPO, TdT, and CD68 (monocytic marker). The
immature cells are positive for MPO, CD68 and CD117. They are negative for
the rest stains.","","","","","x","",NA,NA,"","","","",NA,0,"","",NA,"0",0,NA,NA,NA,"0",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"mut",NA,"AML","case","Gran","Gran",2279.47933146516,7.7964914150695,0.0034202948486741,1428,30000,1100,500,"True","True","True","True",5,302,"True","Gran_AML-0693",2273.44286616358,2273.44286616358,"malignant"
"2020.09.11.AML4340_AML1371.c1.GAAGGGTCAGCTCCTT","AML-1371","2020-09-11-AML4340_AML1371-c1:GAAGGGTCAGCTCCTT",-4.18444381180461,9.78437707507936,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GAAGGGTCAGCTCCTT","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2586.04521488542,39.756236904816,0.0153733726989679,1693,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2580.14533492292,2580.14533492292,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AAAGGGCCAATTCTCT","AML-1371","2020-09-11-AML4340_AML1371-c1:AAAGGGCCAATTCTCT",-0.648307482630569,8.52189729297487,"2020-09-11-AML4340_AML1371-c1","AML1371","CD4+ T","CD4+ TCM",18,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.123603351955307,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AAAGGGCCAATTCTCT","CD4+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD4_T",2539.77945226612,38.7172676176812,0.0152443424105726,2380,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2528.58744489941,2528.58744489941,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AACACACCATACCATG","AML-1371","2020-09-11-AML4340_AML1371-c1:AACACACCATACCATG",-4.13258252564128,10.1434459456238,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AACACACCATACCATG","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2949.64032865725,38.2291284490874,0.0129606067823497,2208,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2945.62050234554,2945.62050234554,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AACCTGAGTGACACGA","AML-1371","2020-09-11-AML4340_AML1371-c1:AACCTGAGTGACACGA",-2.19635854187663,8.93926808917848,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AACCTGAGTGACACGA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2646.5842005956,40.4002534341676,0.0152650550188714,1880,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2634.95415302566,2634.95415302566,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AGACACTTCACTGCTC","AML-1371","2020-09-11-AML4340_AML1371-c2:AGACACTTCACTGCTC",-4.12629018250163,10.4658174284729,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","CD56dim NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AGACACTTCACTGCTC","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2792.1597689072,42.2845670905046,0.0151440356534662,1782,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2787.02346444393,2787.02346444393,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AGGATAATCCGTCAAA","AML-1371","2020-09-11-AML4340_AML1371-c2:AGGATAATCCGTCAAA",-4.04129157486613,9.84303948963014,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AGGATAATCCGTCAAA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2278.28176089544,40.0880691254774,0.0175957468534188,1278,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2272.36556272697,2272.36556272697,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CATACAGCAACAAGTA","AML-1371","2020-09-11-AML4340_AML1371-c2:CATACAGCAACAAGTA",-0.495801190764266,8.85020349109498,"2020-09-11-AML4340_AML1371-c2","AML1371","CD4+ T","CD4+ TCM",18,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.123603351955307,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CATACAGCAACAAGTA","CD4+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD4_T",2415.94891411796,36.4034945320913,0.0150679901877734,1702,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2397.79791891264,2397.79791891264,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.GATTTCTTCGATTCCC","AML-1371","2020-09-11-AML4340_AML1371-c2:GATTTCTTCGATTCCC",-2.51716695252116,9.01432035053102,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.GATTTCTTCGATTCCC","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2447.40860685919,42.130621740973,0.0172143799866096,1371,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2441.33164516129,2441.33164516129,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.GCATTAGGTACTAAGA","AML-1371","2020-09-11-AML4340_AML1371-c2:GCATTAGGTACTAAGA",-2.76059685173686,9.2641505965027,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.GCATTAGGTACTAAGA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2584.52206920676,44.8506379795305,0.0173535519444398,1848,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2579.10291397103,2579.10291397103,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CTGTCGTCACATCCCT","AML-1371","2020-09-11-AML4340_AML1371-c1:CTGTCGTCACATCCCT",-4.32437453690227,10.7038173445496,"2020-09-11-AML4340_AML1371-c1","AML1371","NK","CD56dim NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CTGTCGTCACATCCCT","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2710.08037113858,42.8285255973322,0.0158034152984691,1746,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2702.05112286121,2702.05112286121,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CTTAGGAGTCGAACGA","AML-1371","2020-09-11-AML4340_AML1371-c1:CTTAGGAGTCGAACGA",1.05268599566762,-6.03926088726195,"2020-09-11-AML4340_AML1371-c1","AML1371","cDC2","cDC2",56,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.965753424657534,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CTTAGGAGTCGAACGA","cDC2","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","DC","cDC",2553.6489197607,39.5771813196404,0.0154982860068913,1772,30000,1100,500,"True","True","True","True",5,156,"True","DC_AML-1371",2550.43323465041,2550.43323465041,"malignant"
"2020.09.11.AML4340_AML1371.c2.TTCGCTGAGCTTCTAG","AML-1371","2020-09-11-AML4340_AML1371-c2:TTCGCTGAGCTTCTAG",-4.23281417313274,11.9109124907288,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","CD56dim NK",26,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0482822655524605,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TTCGCTGAGCTTCTAG","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2681.16739796422,39.8332162012733,0.0148566688642859,1640,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2670.37917238416,2670.37917238416,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AGCTTCCGTACTCGTA","AML-1371","2020-09-11-AML4340_AML1371-c1:AGCTTCCGTACTCGTA",-4.29406104508098,10.0181112059387,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AGCTTCCGTACTCGTA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2449.08075362083,37.1229948996776,0.01515793011104,1473,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2443.77296510872,2443.77296510872,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AGTGACTAGGAACTAT","AML-1371","2020-09-11-AML4340_AML1371-c1:AGTGACTAGGAACTAT",-0.130890573293525,13.1233100661072,"2020-09-11-AML4340_AML1371-c1","AML1371","NK","IFN+ NK",22,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0022459292532285,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AGTGACTAGGAACTAT","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2004.13531769376,49.0246324014788,0.024461737672431,1132,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",1995.01387457841,1995.01387457841,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AGTGATCCAGTAACAA","AML-1371","2020-09-11-AML4340_AML1371-c1:AGTGATCCAGTAACAA",-0.350296000868636,8.50845334613649,"2020-09-11-AML4340_AML1371-c1","AML1371","CD4+ T","CD4+ Naive",18,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.123603351955307,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AGTGATCCAGTAACAA","CD4+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD4_T",2477.66585868525,34.6298177044555,0.0139767909312967,1918,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2472.14394249395,2472.14394249395,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TGGGAGAGTTGACGGA","AML-1371","2020-09-11-AML4340_AML1371-c1:TGGGAGAGTTGACGGA",-4.02018580856975,9.98689076984254,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TGGGAGAGTTGACGGA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2226.49669411577,46.9777613483198,0.021099407635535,1288,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2220.83434361057,2220.83434361057,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CAGATACCAACGAGGT","AML-1371","2020-09-11-AML4340_AML1371-c2:CAGATACCAACGAGGT",-7.09844527664836,1.60931608760682,"2020-09-11-AML4340_AML1371-c2","AML1371","MPP","MPP_GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.354166666666667,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CAGATACCAACGAGGT","MPP","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","HSPC","HSPC",2522.67527920905,36.5291761964476,0.0144803322478749,1321,30000,1100,500,"True","True","True","True",5,71,"True","HSPC_AML-1371",2522.67527920905,2522.67527920905,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.ATATCCTGTGAGTAAT","AML-1371","2020-09-11-AML4340_AML1371-c1:ATATCCTGTGAGTAAT",-4.42927537384685,10.6755456694397,"2020-09-11-AML4340_AML1371-c1","AML1371","NK","CD56dim NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.ATATCCTGTGAGTAAT","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",3012.48433584569,39.8704078557168,0.0132350589781653,2138,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",3005.81897112945,3005.81897112945,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.ATTACCTAGGTCGACA","AML-1371","2020-09-11-AML4340_AML1371-c1:ATTACCTAGGTCGACA",-4.01283965531047,10.2090263136658,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.ATTACCTAGGTCGACA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2672.2996513468,40.1587877521486,0.0150278011419525,1884,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2666.77883013858,2666.77883013858,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CCCTAACCACTGCTTC","AML-1371","2020-09-11-AML4340_AML1371-c2:CCCTAACCACTGCTTC",5.38243212279622,-9.62223055278929,"2020-09-11-AML4340_AML1371-c2","AML1371","CD16+ monocyte","CD16+",50,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0399201596806387,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CCCTAACCACTGCTTC","CD16+ monocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",2747.84313742369,37.9854120673962,0.0138237192473113,2027,30000,1100,500,"True","True","True","True",5,334,"True","Mono_AML-1371",2743.41862115819,2743.41862115819,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CAACCTCGTTGCATAC","AML-1371","2020-09-11-AML4340_AML1371-c1:CAACCTCGTTGCATAC",1.55101694640462,-7.42889120494994,"2020-09-11-AML4340_AML1371-c1","AML1371","CD14+ monocyte","CD14+",56,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.965753424657534,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CAACCTCGTTGCATAC","CD14+ monocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",2803.70014425211,35.8421724440944,0.0127838822270544,2591,30000,1100,500,"True","True","True","True",5,334,"True","Mono_AML-1371",2798.58980720436,2798.58980720436,"malignant"
"2020.09.11.AML4340_AML1371.c1.CACGAATGTGCATGTT","AML-1371","2020-09-11-AML4340_AML1371-c1:CACGAATGTGCATGTT",-4.19641719284709,10.0835799940857,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CACGAATGTGCATGTT","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2594.5318604487,39.7350389237053,0.0153149165479253,1863,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2585.57831731416,2585.57831731416,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CACGTGGTCACAACCA","AML-1371","2020-09-11-AML4340_AML1371-c1:CACGTGGTCACAACCA",-1.3921950859135,8.43725679004518,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CACGTGGTCACAACCA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2374.57267048306,46.9027815535573,0.0197520935604872,1578,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2366.26910645078,2366.26910645078,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CGATGGCCACAAATAG","AML-1371","2020-09-11-AML4340_AML1371-c2:CGATGGCCACAAATAG",3.49690069732015,-7.70494940197142,"2020-09-11-AML4340_AML1371-c2","AML1371","HLA-II+ monocyte","HLA-II+",56,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.965753424657534,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CGATGGCCACAAATAG","HLA-II+ monocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",2702.62667279575,37.3355861141433,0.0138145554803991,1919,30000,1100,500,"True","True","True","True",5,334,"True","Mono_AML-1371",2701.57417678992,2701.57417678992,"malignant"
"2020.09.11.AML4340_AML1371.c2.TATTGGGGTAACGATA","AML-1371","2020-09-11-AML4340_AML1371-c2:TATTGGGGTAACGATA",-4.10563121262248,13.1062068709168,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","CD56bright NK",26,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0482822655524605,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TATTGGGGTAACGATA","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2633.11862412592,40.568116738929,0.0154068701528386,1589,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2626.2491750086,2626.2491750086,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CGTAAGTCAGGATTCT","AML-1371","2020-09-11-AML4340_AML1371-c2:CGTAAGTCAGGATTCT",-3.71791181984599,10.4047965773377,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CGTAAGTCAGGATTCT","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2496.45633740873,47.0614696087295,0.0188513089147709,1633,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2485.06036400002,2485.06036400002,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CGTGTCTGTGACACAG","AML-1371","2020-09-11-AML4340_AML1371-c2:CGTGTCTGTGACACAG",-4.36596904221232,10.7611093291077,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","CD56dim NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CGTGTCTGTGACACAG","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2413.05780366034,40.6553562320734,0.0168480656246211,1343,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2401.06981502528,2401.06981502528,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CTACATTGTATGTCTG","AML-1371","2020-09-11-AML4340_AML1371-c2:CTACATTGTATGTCTG",-4.28529725495036,9.83109662616578,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CTACATTGTATGTCTG","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2800.96801191062,31.8506740244999,0.0113713094505402,1901,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2792.937651813,2792.937651813,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TCAGGGCAGGACTAAT","AML-1371","2020-09-11-AML4340_AML1371-c2:TCAGGGCAGGACTAAT",-3.8713620704716,9.91382215106813,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TCAGGGCAGGACTAAT","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2561.21345995144,38.8991234304167,0.0151877709682012,1719,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2554.17463843874,2554.17463843874,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CTACCTGTCGTTCTGC","AML-1371","2020-09-11-AML4340_AML1371-c2:CTACCTGTCGTTCTGC",-3.92237172547038,9.74244973743287,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","CD56dim NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CTACCTGTCGTTCTGC","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2425.57714656614,36.6796818980376,0.0151220429949897,1357,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2421.09364651218,2421.09364651218,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CCACCATCAGTTCCAA","AML-1371","2020-09-11-AML4340_AML1371-c1:CCACCATCAGTTCCAA",-0.37216422978099,8.90385816181032,"2020-09-11-AML4340_AML1371-c1","AML1371","CD4+ T","CD4+ TCM",18,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.123603351955307,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CCACCATCAGTTCCAA","CD4+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD4_T",2582.60703304816,37.7910421099322,0.0146329045132851,2045,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2572.59385267171,2572.59385267171,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CTGAATGGTCATCAGT","AML-1371","2020-09-11-AML4340_AML1371-c2:CTGAATGGTCATCAGT",-6.98323140564616,1.87607429111329,"2020-09-11-AML4340_AML1371-c2","AML1371","MPP","MPP_GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.354166666666667,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CTGAATGGTCATCAGT","MPP","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","HSPC","HSPC",2615.32588123286,41.5149947228721,0.015873736814512,1640,30000,1100,500,"True","True","True","True",5,71,"True","HSPC_AML-1371",2606.39328323333,2606.39328323333,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CCTATCGAGAGTAACT","AML-1371","2020-09-11-AML4340_AML1371-c1:CCTATCGAGAGTAACT",-3.10069618645366,8.97669313037721,"2020-09-11-AML4340_AML1371-c1","AML1371","gd T","gd T",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CCTATCGAGAGTAACT","gd T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","gd_T",2703.04158221035,41.5520707080923,0.0153723386948839,1823,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2698.50619548783,2698.50619548783,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GGGTGAAAGCTGACTT","AML-1371","2020-09-11-AML4340_AML1371-c1:GGGTGAAAGCTGACTT",-4.43539033356364,10.9044122465881,"2020-09-11-AML4340_AML1371-c1","AML1371","NK","CD56dim NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GGGTGAAAGCTGACTT","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2377.89949937081,43.6774587750821,0.0183680844319279,1357,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2368.98651312133,2368.98651312133,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AATGACCCAAGCTGCC","AML-1371","2020-09-11-AML4340_AML1371-c1:AATGACCCAAGCTGCC",3.97652616080586,-8.2032566300598,"2020-09-11-AML4340_AML1371-c1","AML1371","HLA-II+ monocyte","HLA-II+",56,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.965753424657534,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AATGACCCAAGCTGCC","HLA-II+ monocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",2504.88521031473,33.7604454140572,0.013477841329829,1488,30000,1100,500,"True","True","True","True",5,334,"True","Mono_AML-1371",2501.65790868599,2501.65790868599,"malignant"
"2020.09.11.AML4340_AML1371.c2.TGAGGGAAGTATAGGT","AML-1371","2020-09-11-AML4340_AML1371-c2:TGAGGGAAGTATAGGT",10.9075514274532,6.65039870822755,"2020-09-11-AML4340_AML1371-c2","AML1371","B","Memory",2,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0313443231947992,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TGAGGGAAGTATAGGT","B","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","B","B",2152.62831741185,45.4857751145265,0.0211303431932991,1245,30000,1100,500,"True","True","True","True",5,149,"True","B_AML-1371",2147.05405686291,2147.05405686291,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AATGGAACAGAGATGC","AML-1371","2020-09-11-AML4340_AML1371-c1:AATGGAACAGAGATGC",-2.9145589870518,8.90527246082155,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AATGGAACAGAGATGC","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2602.61946924876,41.1388294151455,0.0158067016331896,1826,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2596.19526504821,2596.19526504821,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.ACAACCATCGTGTGGC","AML-1371","2020-09-11-AML4340_AML1371-c1:ACAACCATCGTGTGGC",3.76068963584248,-8.31313993847045,"2020-09-11-AML4340_AML1371-c1","AML1371","CD14+ monocyte","CD14+",29,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0463917525773196,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.ACAACCATCGTGTGGC","CD14+ monocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",2225.39622861726,47.8252438772421,0.0214906645667132,1130,30000,1100,500,"True","True","True","True",5,334,"True","Mono_AML-1371",2223.7062969918,2223.7062969918,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TGCATGATCCGACATA","AML-1371","2020-09-11-AML4340_AML1371-c2:TGCATGATCCGACATA",-4.32456384125407,9.90580365741578,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TGCATGATCCGACATA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2711.23403628268,40.7595099469911,0.0150335638316475,1897,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2702.59216283053,2702.59216283053,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AGTGCCGAGAAATGGG","AML-1371","2020-09-11-AML4340_AML1371-c2:AGTGCCGAGAAATGGG",-4.16697249832805,10.8074569472107,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","CD56dim NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AGTGCCGAGAAATGGG","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2429.84335379357,46.3215820701845,0.019063608358895,1406,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2424.18432939459,2424.18432939459,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TGTACAGTCACTGGGC","AML-1371","2020-09-11-AML4340_AML1371-c2:TGTACAGTCACTGGGC",-3.07707605782207,12.7579107054505,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","Activated NK",26,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0482822655524605,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TGTACAGTCACTGGGC","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2731.38419127864,41.7909838382019,0.0153002949829033,1848,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2726.72035346626,2726.72035346626,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CTGGACGTCGAGCCAC","AML-1371","2020-09-11-AML4340_AML1371-c1:CTGGACGTCGAGCCAC",-3.85580931130107,9.86885449970094,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CTGGACGTCGAGCCAC","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2702.88421233551,40.1745234322754,0.0148635754535564,2026,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2702.88421233551,2702.88421233551,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AGACTCACACGTGTGC","AML-1371","2020-09-11-AML4340_AML1371-c1:AGACTCACACGTGTGC",-3.11582146111186,9.19579885089723,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AGACTCACACGTGTGC","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2768.96404742724,35.5064384216922,0.0128230044932085,1955,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2757.61237309637,2757.61237309637,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.ATGCATGAGGGCAGGA","AML-1371","2020-09-11-AML4340_AML1371-c2:ATGCATGAGGGCAGGA",-3.70160637322124,9.96681974017946,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.ATGCATGAGGGCAGGA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2652.65075550306,39.6729611172441,0.014955968491118,1635,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2646.10306997283,2646.10306997283,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.ATGGGAGTCAATCCGA","AML-1371","2020-09-11-AML4340_AML1371-c2:ATGGGAGTCAATCCGA",-4.4095815223759,10.4434385069641,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","CD56dim NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.ATGGGAGTCAATCCGA","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2596.08415428408,43.8977070716997,0.0169092003428546,1523,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2593.19232883776,2593.19232883776,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.GTTTGGATCACCTCAC","AML-1371","2020-09-11-AML4340_AML1371-c2:GTTTGGATCACCTCAC",-4.26586614075358,10.1544017561707,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","CD56dim NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.GTTTGGATCACCTCAC","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2653.881966376,46.1185270729244,0.0173777612031108,1778,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2646.77710817763,2646.77710817763,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TGAGACTAGTCCCGGT","AML-1371","2020-09-11-AML4340_AML1371-c1:TGAGACTAGTCCCGGT",10.703009267419,7.68186757648317,"2020-09-11-AML4340_AML1371-c1","AML1371","B","Memory",2,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0313443231947992,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TGAGACTAGTCCCGGT","B","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","B","B",2986.94559669624,43.8870447816782,0.0146929508291749,2945,30000,1100,500,"True","True","True","True",5,149,"True","B_AML-1371",2971.53299184552,2971.53299184552,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GAATAGACACCTCTAC","AML-1371","2020-09-11-AML4340_AML1371-c1:GAATAGACACCTCTAC",-2.80671868744548,8.79766271198121,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GAATAGACACCTCTAC","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2675.75312888472,38.2334051200334,0.0142888387973107,1848,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2672.48759989374,2672.48759989374,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TTTGATCCACTGAGTT","AML-1371","2020-09-11-AML4340_AML1371-c1:TTTGATCCACTGAGTT",-2.9633871120518,8.90525434100953,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TTTGATCCACTGAGTT","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2765.18561761452,37.4438489728049,0.0135411701602539,1991,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2760.98480256686,2760.98480256686,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.GGTAATCTCGTGGGAA","AML-1371","2020-09-11-AML4340_AML1371-c2:GGTAATCTCGTGGGAA",-4.5233715576237,10.2810821303162,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","CD56dim NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.GGTAATCTCGTGGGAA","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2593.13827283291,42.0800340716034,0.0162274547842111,1664,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2590.68795519398,2590.68795519398,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.GGTCTGGGTGATGAAT","AML-1371","2020-09-11-AML4340_AML1371-c2:GGTCTGGGTGATGAAT",1.09649910506551,-7.41982510006102,"2020-09-11-AML4340_AML1371-c2","AML1371","CD14+ monocyte","CD14+",56,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.965753424657534,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.GGTCTGGGTGATGAAT","CD14+ monocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",2643.08206530046,40.7098245688276,0.015402406570452,1665,30000,1100,500,"True","True","True","True",5,334,"True","Mono_AML-1371",2639.31303666475,2639.31303666475,"malignant"
"2020.09.11.AML4340_AML1371.c1.GCAACATTCCGAGATT","AML-1371","2020-09-11-AML4340_AML1371-c1:GCAACATTCCGAGATT",-2.66036830368693,9.80238149249879,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GCAACATTCCGAGATT","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2226.9647448442,46.891654149385,0.0210563073609257,1328,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2219.56449347932,2219.56449347932,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TGTGATGCAGTATACC","AML-1371","2020-09-11-AML4340_AML1371-c1:TGTGATGCAGTATACC",-3.43442259255107,9.17735955798952,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TGTGATGCAGTATACC","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",3124.50153107949,39.3977075475359,0.0126092777217889,3104,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",3114.72182793099,3114.72182793099,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GTCTCACTCCGATAGT","AML-1371","2020-09-11-AML4340_AML1371-c1:GTCTCACTCCGATAGT",10.339110036462,7.8353643187317,"2020-09-11-AML4340_AML1371-c1","AML1371","B","Memory",2,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0313443231947992,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GTCTCACTCCGATAGT","B","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","B","B",2515.56072828269,41.012964211414,0.016303706664801,2183,30000,1100,500,"True","True","True","True",5,149,"True","B_AML-1371",2504.73242304657,2504.73242304657,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.GTCAGCGAGGAAACGA","AML-1371","2020-09-11-AML4340_AML1371-c2:GTCAGCGAGGAAACGA",0.0698603047872006,-6.3947963944641,"2020-09-11-AML4340_AML1371-c2","AML1371","DC precursor","DC precursor",56,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.965753424657534,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.GTCAGCGAGGAAACGA","DC precursor","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","DC","pDC",2932.85719461561,44.4676091558264,0.0151618732877495,2850,30000,1100,500,"True","True","True","True",5,156,"True","DC_AML-1371",2928.02760218649,2928.02760218649,"malignant"
"2020.09.11.AML4340_AML1371.c1.GCTTGGGAGCTCAGAG","AML-1371","2020-09-11-AML4340_AML1371-c1:GCTTGGGAGCTCAGAG",-3.82096109810527,9.69665048206178,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GCTTGGGAGCTCAGAG","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2576.48371951058,37.2678741686632,0.0144646262991883,1761,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2576.48371951058,2576.48371951058,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CCCTTAGAGCACCCAC","AML-1371","2020-09-11-AML4340_AML1371-c2:CCCTTAGAGCACCCAC",-1.68954263153728,8.62925431812135,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ TRM",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CCCTTAGAGCACCCAC","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2513.2874250879,43.4228065224836,0.0172772943074606,1613,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2507.0853457759,2507.0853457759,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TCGCACTTCATGAAAG","AML-1371","2020-09-11-AML4340_AML1371-c2:TCGCACTTCATGAAAG",-3.84194002571757,9.58760640704957,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TCGCACTTCATGAAAG","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2525.37670550155,36.8083539545487,0.01457539141561,1615,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2512.77577502994,2512.77577502994,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CCGGTGATCGGTAGAG","AML-1371","2020-09-11-AML4340_AML1371-c2:CCGGTGATCGGTAGAG",-2.6993924182957,8.8929872282776,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CCGGTGATCGGTAGAG","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2186.65021113208,39.5766553027075,0.0180992163727082,1195,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2182.26281884503,2182.26281884503,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TACAGGTGTGGTACAG","AML-1371","2020-09-11-AML4340_AML1371-c2:TACAGGTGTGGTACAG",-3.63453159752544,9.7177524336609,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TACAGGTGTGGTACAG","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2260.64995413941,44.7450482235662,0.0197930016284187,1343,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2260.64995413941,2260.64995413941,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AGCCAATCATGGGAAC","AML-1371","2020-09-11-AML4340_AML1371-c2:AGCCAATCATGGGAAC",-4.51395879212077,10.2793149718079,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","CD56dim NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AGCCAATCATGGGAAC","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2684.92711813895,37.9691468345941,0.0141415931099509,1708,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2679.88553832649,2679.88553832649,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TTTCACAGTTCATCGA","AML-1371","2020-09-11-AML4340_AML1371-c2:TTTCACAGTTCATCGA",-2.31646714630778,8.9104957350525,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TTTCACAGTTCATCGA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2655.11856975228,47.0424178942719,0.0177176335664214,1843,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2649.4692688809,2649.4692688809,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TATCCTAGTCATCGCG","AML-1371","2020-09-11-AML4340_AML1371-c2:TATCCTAGTCATCGCG",-3.79199562493022,9.59950158679811,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TATCCTAGTCATCGCG","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2336.81802511083,35.5790178008934,0.0152254122565688,1346,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2331.09508029144,2331.09508029144,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CACTAAGCAGCGATTT","AML-1371","2020-09-11-AML4340_AML1371-c2:CACTAAGCAGCGATTT",-1.8272878927296,8.91675660693971,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ Cytotoxic",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CACTAAGCAGCGATTT","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",1994.35797252165,45.8880104514284,0.0230089136873497,997,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",1990.95382373132,1990.95382373132,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TATTTCGCAAGCTGTT","AML-1371","2020-09-11-AML4340_AML1371-c2:TATTTCGCAAGCTGTT",1.05361845073048,-7.1908488503662,"2020-09-11-AML4340_AML1371-c2","AML1371","HLA-II+ monocyte","HLA-II+",56,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.965753424657534,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TATTTCGCAAGCTGTT","HLA-II+ monocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",2861.84861926563,40.9283607449049,0.0143013716621418,2101,30000,1100,500,"True","True","True","True",5,334,"True","Mono_AML-1371",2855.01873305313,2855.01873305313,"malignant"
"2020.09.11.AML4340_AML1371.c1.GTATTTCAGATAGTGT","AML-1371","2020-09-11-AML4340_AML1371-c1:GTATTTCAGATAGTGT",-3.86891446533855,10.4742851027283,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GTATTTCAGATAGTGT","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2293.98653072484,41.1961874502424,0.0179583388561682,1430,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2286.46026722367,2286.46026722367,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TCAAGTGAGGCCGCTT","AML-1371","2020-09-11-AML4340_AML1371-c2:TCAAGTGAGGCCGCTT",-4.16622195664104,10.4683904417786,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","CD56dim NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TCAAGTGAGGCCGCTT","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2682.70846482301,42.0286000697905,0.0156664805814311,1727,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2676.43087970645,2676.43087970645,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TCAATCTGTGTGTACT","AML-1371","2020-09-11-AML4340_AML1371-c2:TCAATCTGTGTGTACT",-4.26848349991496,11.620675063971,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","CD56bright NK",26,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0482822655524605,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TCAATCTGTGTGTACT","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2465.23235798108,46.5075347348568,0.0188653757461404,1546,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2457.29682854456,2457.29682854456,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CTACTATTCCGTGTAA","AML-1371","2020-09-11-AML4340_AML1371-c1:CTACTATTCCGTGTAA",0.527681459754151,-6.53399565136107,"2020-09-11-AML4340_AML1371-c1","AML1371","cDC2","cDC2",56,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.965753424657534,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CTACTATTCCGTGTAA","cDC2","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","DC","cDC",3249.70227006936,33.2097091209657,0.0102193082199672,2892,30000,1100,500,"True","True","True","True",5,156,"True","DC_AML-1371",3244.31058863021,3244.31058863021,"malignant"
"2020.09.11.AML4340_AML1371.c1.TCCATCGAGAGCATCG","AML-1371","2020-09-11-AML4340_AML1371-c1:TCCATCGAGAGCATCG",-3.30196605148967,10.2827071913513,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TCCATCGAGAGCATCG","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2077.43426015606,43.9923180259371,0.0211762744408731,1072,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2071.01709797975,2071.01709797975,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TCATGGAGTATCGATC","AML-1371","2020-09-11-AML4340_AML1371-c2:TCATGGAGTATCGATC",10.4507643180782,7.29617307269899,"2020-09-11-AML4340_AML1371-c2","AML1371","B","Memory",2,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0313443231947992,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TCATGGAGTATCGATC","B","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","B","B",2432.27498348545,46.1999109068716,0.018994526203064,1755,30000,1100,500,"True","True","True","True",5,149,"True","B_AML-1371",2417.18655378755,2417.18655378755,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TTAGTCTTCCCTCGAT","AML-1371","2020-09-11-AML4340_AML1371-c2:TTAGTCTTCCCTCGAT",-4.04251275482829,10.1158313521179,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","IFN+ NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TTAGTCTTCCCTCGAT","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2249.62455398937,40.8867231260498,0.0181749096992844,1145,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2241.43478660402,2241.43478660402,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.ATGTCCCTCAGTCATG","AML-1371","2020-09-11-AML4340_AML1371-c2:ATGTCCCTCAGTCATG",-0.666783372790176,8.44739530170289,"2020-09-11-AML4340_AML1371-c2","AML1371","CD4+ T","CD4+ TCM",18,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.123603351955307,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.ATGTCCCTCAGTCATG","CD4+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD4_T",2426.76381453216,32.0146900207331,0.0131923386318108,1862,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2416.60980939915,2416.60980939915,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TCGGTCTTCGAACCTA","AML-1371","2020-09-11-AML4340_AML1371-c2:TCGGTCTTCGAACCTA",-3.61741886559184,9.97727773273317,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ NK-like",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TCGGTCTTCGAACCTA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2467.5621774794,42.6260000129425,0.0172745393822192,1530,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2457.18135857071,2457.18135857071,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TTGTTTGTCGCGTTTC","AML-1371","2020-09-11-AML4340_AML1371-c2:TTGTTTGTCGCGTTTC",-3.69039164009746,9.80321500385133,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TTGTTTGTCGCGTTTC","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2633.72243821889,40.5351532686003,0.015390822009328,1764,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2633.72243821889,2633.72243821889,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TGAGGTTCACAAGTTC","AML-1371","2020-09-11-AML4340_AML1371-c2:TGAGGTTCACAAGTTC",-0.585985581309158,8.55685613239137,"2020-09-11-AML4340_AML1371-c2","AML1371","CD4+ T","Treg",18,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.123603351955307,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TGAGGTTCACAAGTTC","CD4+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD4_T",2418.60417939389,40.8490511486828,0.0168895148270684,1591,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2412.62260741234,2412.62260741234,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GAGCTGCGTGTACGCC","AML-1371","2020-09-11-AML4340_AML1371-c1:GAGCTGCGTGTACGCC",-2.21482143822368,8.786106086615,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GAGCTGCGTGTACGCC","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2342.56444067801,42.4069495550059,0.0181027889003267,1288,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2341.0365421978,2341.0365421978,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TGTGAGTGTCTACAAC","AML-1371","2020-09-11-AML4340_AML1371-c2:TGTGAGTGTCTACAAC",0.957997937768143,-6.90162756359252,"2020-09-11-AML4340_AML1371-c2","AML1371","HLA-II+ monocyte","HLA-II+",56,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.965753424657534,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TGTGAGTGTCTACAAC","HLA-II+ monocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",3052.31659997217,40.8994159004973,0.0133994671132314,3015,30000,1100,500,"True","True","True","True",5,334,"True","Mono_AML-1371",3050.39839551775,3050.39839551775,"malignant"
"2020.09.11.AML4340_AML1371.c1.TCACTCGGTCATCGCG","AML-1371","2020-09-11-AML4340_AML1371-c1:TCACTCGGTCATCGCG",-3.8797918361729,10.260040260199,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TCACTCGGTCATCGCG","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2190.43650407124,40.0413146877208,0.018280061811104,1245,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2180.50241734225,2180.50241734225,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AAGACTCCAATAGTCC","AML-1371","2020-09-11-AML4340_AML1371-c2:AAGACTCCAATAGTCC",10.2207189994747,7.88796136463014,"2020-09-11-AML4340_AML1371-c2","AML1371","B","Memory",2,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0313443231947992,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AAGACTCCAATAGTCC","B","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","B","B",2549.89022868506,39.6917599829824,0.01556606615315,1974,30000,1100,500,"True","True","True","True",5,149,"True","B_AML-1371",2536.01663789447,2536.01663789447,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AGGTAGGCACGCGCAT","AML-1371","2020-09-11-AML4340_AML1371-c2:AGGTAGGCACGCGCAT",-3.33532247963603,10.3349227675232,"2020-09-11-AML4340_AML1371-c2","AML1371","NK","Activated NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AGGTAGGCACGCGCAT","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2737.44074454833,40.4986431870742,0.0147943451443572,1963,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2727.78345303575,2727.78345303575,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TCATTGTTCTGAGATC","AML-1371","2020-09-11-AML4340_AML1371-c1:TCATTGTTCTGAGATC",-2.91447625580485,9.06705567920534,"2020-09-11-AML4340_AML1371-c1","AML1371","gd T","gd T",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TCATTGTTCTGAGATC","gd T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","gd_T",2668.79410794876,42.4515174843787,0.0159066288995246,1758,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2664.04105504611,2664.04105504611,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GCCATGGCAGCACGAA","AML-1371","2020-09-11-AML4340_AML1371-c1:GCCATGGCAGCACGAA",-4.18912778320964,9.85599801624147,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GCCATGGCAGCACGAA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2606.69101333484,42.6898394823943,0.016377023308098,1798,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2602.79320991488,2602.79320991488,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TGTTCATCAGCGCTTG","AML-1371","2020-09-11-AML4340_AML1371-c2:TGTTCATCAGCGCTTG",3.17504181441609,-7.73364593898924,"2020-09-11-AML4340_AML1371-c2","AML1371","CD14+ monocyte","CD14+",56,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.965753424657534,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TGTTCATCAGCGCTTG","CD14+ monocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",2676.22530223029,38.1230736045679,0.0142450912383189,1686,30000,1100,500,"True","True","True","True",5,334,"True","Mono_AML-1371",2674.97587421894,2674.97587421894,"malignant"
"2020.09.11.AML4340_AML1371.c1.TGATCTTAGGTTGTTC","AML-1371","2020-09-11-AML4340_AML1371-c1:TGATCTTAGGTTGTTC",-3.78972969475444,9.49954221332399,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TGATCTTAGGTTGTTC","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2701.77999201814,41.5632119637941,0.0153836404468847,1921,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2694.24401653787,2694.24401653787,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TGGGAGAAGTTGGCTT","AML-1371","2020-09-11-AML4340_AML1371-c1:TGGGAGAAGTTGGCTT",4.80605091628377,-9.04096319591673,"2020-09-11-AML4340_AML1371-c1","AML1371","CD16+ monocyte","CD16+",56,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.965753424657534,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TGGGAGAAGTTGGCTT","CD16+ monocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",2434.90394691783,39.9050133656463,0.0163887423223241,1356,30000,1100,500,"True","True","True","True",5,334,"True","Mono_AML-1371",2433.44516700646,2433.44516700646,"malignant"
"2020.09.11.AML4340_AML1371.c2.AAACCCAGTCGTGGTC","AML-1371","2020-09-11-AML4340_AML1371-c2:AAACCCAGTCGTGGTC",-0.468546668917495,8.79323384845582,"2020-09-11-AML4340_AML1371-c2","AML1371","CD4+ T","CD4+ TCM",18,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.123603351955307,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AAACCCAGTCGTGGTC","CD4+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD4_T",2367.45227313719,30.849448480409,0.0130306527529399,1817,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2357.45230774924,2357.45230774924,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TGAGGAGTCTCTCGCA","AML-1371","2020-09-11-AML4340_AML1371-c2:TGAGGAGTCTCTCGCA",-2.73056493225749,8.87344071948854,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TGAGGAGTCTCTCGCA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2662.74519868037,43.7502943202485,0.0164305222827669,1680,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2653.13582992836,2653.13582992836,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GCTGAATAGATGCCGA","AML-1371","2020-09-11-AML4340_AML1371-c1:GCTGAATAGATGCCGA",-0.209246109158355,8.35378739917604,"2020-09-11-AML4340_AML1371-c1","AML1371","CD4+ T","CD4+ Naive",18,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.123603351955307,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GCTGAATAGATGCCGA","CD4+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD4_T",2339.15897433343,38.7494913369269,0.0165655655567271,1732,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2329.63818083446,2329.63818083446,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CGTGTCTAGCACCCAC","AML-1371","2020-09-11-AML4340_AML1371-c2:CGTGTCTAGCACCCAC",0.578509767621201,-7.26580383693846,"2020-09-11-AML4340_AML1371-c2","AML1371","HLA-II+ monocyte","HLA-II+",56,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.965753424657534,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CGTGTCTAGCACCCAC","HLA-II+ monocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",2328.30235309751,43.9714768378034,0.018885638619617,1237,30000,1100,500,"True","True","True","True",5,334,"True","Mono_AML-1371",2323.66813853588,2323.66813853588,"malignant"
"2020.09.11.AML4340_AML1371.c1.GTAGAAATCATTACGG","AML-1371","2020-09-11-AML4340_AML1371-c1:GTAGAAATCATTACGG",-4.49510465088542,-4.79880812084349,"2020-09-11-AML4340_AML1371-c1","AML1371","Granulocyte","Granulocytes (cycling)",38,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0322108345534407,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GTAGAAATCATTACGG","Granulocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Gran","Gran",3593.78065963127,39.7999901250067,0.0110746853785702,4203,30000,1100,500,"True","True","True","True",5,64,"True","Gran_AML-1371",3586.45559558757,3586.45559558757,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TCCCATGAGTAAACTG","AML-1371","2020-09-11-AML4340_AML1371-c1:TCCCATGAGTAAACTG",-0.697131852537948,8.78245732868043,"2020-09-11-AML4340_AML1371-c1","AML1371","CD4+ T","CD4+ TCM",18,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.123603351955307,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TCCCATGAGTAAACTG","CD4+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD4_T",2344.06987012684,38.7246269727896,0.0165202528586292,1691,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2337.89062605369,2337.89062605369,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TCATTACTCTGCAGCG","AML-1371","2020-09-11-AML4340_AML1371-c1:TCATTACTCTGCAGCG",1.35622074183766,-7.48877718364867,"2020-09-11-AML4340_AML1371-c1","AML1371","HLA-II+ monocyte","HLA-II+",56,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.965753424657534,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TCATTACTCTGCAGCG","HLA-II+ monocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",2880.43828360487,39.8229516273006,0.0138253097988485,2143,30000,1100,500,"True","True","True","True",5,334,"True","Mono_AML-1371",2877.56224610825,2877.56224610825,"malignant"
"2020.09.11.AML4340_AML1371.c1.GTTTACTCAGCTACCG","AML-1371","2020-09-11-AML4340_AML1371-c1:GTTTACTCAGCTACCG",-4.48899922791179,10.2410678633484,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GTTTACTCAGCTACCG","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2762.35555814872,39.1136941207312,0.0141595436566263,1916,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2759.04308782841,2759.04308782841,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AGCCACGGTAGACGTG","AML-1371","2020-09-11-AML4340_AML1371-c2:AGCCACGGTAGACGTG",-2.47863064232524,8.56749341571657,"2020-09-11-AML4340_AML1371-c2","AML1371","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AGCCACGGTAGACGTG","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2532.10157443778,42.2759035164617,0.0166959745782902,1560,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2522.87970376811,2522.87970376811,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TCATTGTGTGCCTATA","AML-1371","2020-09-11-AML4340_AML1371-c1:TCATTGTGTGCCTATA",5.18426527556722,-9.38023855602416,"2020-09-11-AML4340_AML1371-c1","AML1371","CD16+ monocyte","CD16+",50,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0399201596806387,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TCATTGTGTGCCTATA","CD16+ monocyte","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",2928.26216448963,37.4771851808965,0.0127984391682458,2163,30000,1100,500,"True","True","True","True",5,334,"True","Mono_AML-1371",2922.24064403656,2922.24064403656,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TTTACGTAGGTTGCCC","AML-1371","2020-09-11-AML4340_AML1371-c1:TTTACGTAGGTTGCCC",-4.2677186531132,10.3190536268982,"2020-09-11-AML4340_AML1371-c1","AML1371","NK","CD56dim NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TTTACGTAGGTTGCCC","NK","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","NK","NK",2869.88371159981,38.2707193706578,0.0133352857525101,2161,30000,1100,500,"True","True","True","True",5,507,"True","NK_AML-1371",2859.82493583045,2859.82493583045,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GAGGCCTGTAGTGCGA","AML-1371","2020-09-11-AML4340_AML1371-c1:GAGGCCTGTAGTGCGA",-4.25345693054851,10.5213756331238,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.361592632719393,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GAGGCCTGTAGTGCGA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2595.41011508748,38.4600635289677,0.0148184918080553,1606,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2592.83471024629,2592.83471024629,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GTCCACTCAGGATTCT","AML-1371","2020-09-11-AML4340_AML1371-c1:GTCCACTCAGGATTCT",-0.193420152098495,8.80714700305787,"2020-09-11-AML4340_AML1371-c1","AML1371","CD4+ T","CD4+ Naive",18,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.123603351955307,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GTCCACTCAGGATTCT","CD4+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD4_T",2476.1908607204,39.2877965130148,0.0158662230509908,2155,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2465.1777400052,2465.1777400052,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GGATCTAGTACGTTCA","AML-1371","2020-09-11-AML4340_AML1371-c1:GGATCTAGTACGTTCA",-2.88815937462505,8.76264855945436,"2020-09-11-AML4340_AML1371-c1","AML1371","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.191825613079019,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GGATCTAGTACGTTCA","CD8+ T","U-18-1371","M",78,"CITE-seq","OSU","AML1371","AML","","46,XY (17 metas), -Y in 3 metas",631,"Blasts, defined by CD45 faint 
staining and low side scatter represent 72.4 % of the total events 
analyzed and express CD33+, CD117+ and are negative for the 
remaining markers. ","","x","x","","","",NA,NA,"0","0,48","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0,42",0,"0.0","0",0,0,"0",0,0,0,"0,47",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",2952.4659792441,37.9776385185012,0.0128630232441237,2330,30000,1100,500,"True","True","True","True",5,1882,"True","T_AML-1371",2944.33689928842,2944.33689928842,"microenvironment"
"2020.07.29.AML2123.c2.AAACCCAGTTACCTGA","AML-2123","2020-07-29-AML2123-c2:AAACCCAGTTACCTGA",-1.80832837048228,3.96856973255006,"2020-07-29-AML2123-c2","AML2123","Ery","Heat shock proteins",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.180252583237658,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.AAACCCAGTTACCTGA","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",3122.17468191299,34.772941676723,0.0111374106894677,5293,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",3117.51215884808,3117.51215884808,"microenvironment"
"2020.07.29.AML2123.c2.AAAGTCCGTAACACCT","AML-2123","2020-07-29-AML2123-c2:AAAGTCCGTAACACCT",-7.70909915390666,2.79321286762086,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.AAAGTCCGTAACACCT","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2313.71291499918,44.0026432195449,0.0190181949256917,2349,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2303.93514891703,2303.93514891703,"malignant"
"2020.07.29.AML2123.c2.CTCCTCCCACACTTAG","AML-2123","2020-07-29-AML2123-c2:CTCCTCCCACACTTAG",11.4356771903927,-1.43775322353514,"2020-07-29-AML2123-c2","AML2123","Ery","Ery-3",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.CTCCTCCCACACTTAG","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1479.8672080455,26.4467500657386,0.0178710291855629,625,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1466.23840453058,1466.23840453058,"malignant"
"2020.07.29.AML2123.c2.CTGAGGCCAATCAAGA","AML-2123","2020-07-29-AML2123-c2:CTGAGGCCAATCAAGA",-5.1314939064091,3.63389418208925,"2020-07-29-AML2123-c2","AML2123","MEP","MEP",39,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0377358490566038,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.CTGAGGCCAATCAAGA","MEP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2837.40547211185,45.5562923409974,0.0160556158746992,3364,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2829.14831986933,2829.14831986933,"microenvironment"
"2020.07.29.AML2123.c1.ACATCGAAGGTAACTA","AML-2123","2020-07-29-AML2123-c1:ACATCGAAGGTAACTA",-7.52598557892497,2.5821277865204,"2020-07-29-AML2123-c1","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.ACATCGAAGGTAACTA","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2593.70650558179,39.3626448039866,0.0151762139314052,2703,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2583.53508276052,2583.53508276052,"malignant"
"2020.07.29.AML2123.c1.ACTATCTGTCTAGGTT","AML-2123","2020-07-29-AML2123-c1:ACTATCTGTCTAGGTT",-3.65827689591106,9.81537339771119,"2020-07-29-AML2123-c1","AML2123","CD8+ T","CD8+ NK-like",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0320328542094456,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.ACTATCTGTCTAGGTT","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",2071.27510384709,52.2165131207415,0.0252098395928947,1126,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2058.60624762851,2058.60624762851,"microenvironment"
"2020.07.29.AML2123.c1.AGCTCAAAGAAACACT","AML-2123","2020-07-29-AML2123-c1:AGCTCAAAGAAACACT",-1.99126372757609,3.46536395633546,"2020-07-29-AML2123-c1","AML2123","Ery","Ery-7",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.180252583237658,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.AGCTCAAAGAAACACT","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",3170.8269204565,44.551087235533,0.0140503055994993,4896,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",3158.79027548551,3158.79027548551,"microenvironment"
"2020.07.29.AML2123.c1.AGGAGGTGTCTGTGCG","AML-2123","2020-07-29-AML2123-c1:AGGAGGTGTCTGTGCG",-7.38712726059611,2.49137065494386,"2020-07-29-AML2123-c1","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.AGGAGGTGTCTGTGCG","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2397.10378860743,45.8808968043239,0.0191401377872661,2966,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2384.75373889511,2384.75373889511,"malignant"
"2020.07.29.AML2123.c1.AGGGTGAAGTAAGACT","AML-2123","2020-07-29-AML2123-c1:AGGGTGAAGTAAGACT",-2.53884563866313,3.41171023929445,"2020-07-29-AML2123-c1","AML2123","Ery","Ery-1",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.180252583237658,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.AGGGTGAAGTAAGACT","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",3228.7205446741,13.7484492305614,0.0042581725610288,3966,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",3221.77441173945,3221.77441173945,"microenvironment"
"2020.07.29.AML2123.c1.AGGTGTTGTTACACTG","AML-2123","2020-07-29-AML2123-c1:AGGTGTTGTTACACTG",11.9920736747677,-2.83125450527342,"2020-07-29-AML2123-c1","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.AGGTGTTGTTACACTG","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1897.46990868863,10.9835385252491,0.0057885178968872,2689,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1887.7175860368,1887.7175860368,"malignant"
"2020.07.29.AML2123.c1.ATACCTTAGCGTGAAC","AML-2123","2020-07-29-AML2123-c1:ATACCTTAGCGTGAAC",-1.19251285019572,10.687602973822,"2020-07-29-AML2123-c1","AML2123","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0175554819476648,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.ATACCTTAGCGTGAAC","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",2093.34680433236,41.4941063827196,0.0198218977843729,1228,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2086.11578250017,2086.11578250017,"microenvironment"
"2020.07.29.AML2123.c1.ATCTTCAGTGTTACAC","AML-2123","2020-07-29-AML2123-c1:ATCTTCAGTGTTACAC",11.1439672904903,-1.06382539188536,"2020-07-29-AML2123-c1","AML2123","Ery","Ery-3",58,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.732673267326733,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.ATCTTCAGTGTTACAC","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1193.27240597419,40.6126527595939,0.0340346869300457,716,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1188.75498712246,1188.75498712246,"malignant"
"2020.07.29.AML2123.c1.ATGGATCTCACCCTCA","AML-2123","2020-07-29-AML2123-c1:ATGGATCTCACCCTCA",1.09242047843282,10.7423248060974,"2020-07-29-AML2123-c1","AML2123","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0268987341772152,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.ATGGATCTCACCCTCA","CD4+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD4_T",2082.0881191246,31.0652783745984,0.0149202514962045,1587,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2076.30153047215,2076.30153047215,"microenvironment"
"2020.07.29.AML2123.c1.ATTCATCTCAGAGTGG","AML-2123","2020-07-29-AML2123-c1:ATTCATCTCAGAGTGG",-4.95242057266887,8.91888997638551,"2020-07-29-AML2123-c1","AML2123","CD4+ T","Treg",78,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0625,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.ATTCATCTCAGAGTGG","CD4+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD4_T",1786.073421377,38.2907321641097,0.0214384983874789,746,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",1775.50842783755,1775.50842783755,"microenvironment"
"2020.07.29.AML2123.c1.ATTCCATTCTCCGTGT","AML-2123","2020-07-29-AML2123-c1:ATTCCATTCTCCGTGT",-7.15668998184856,2.66657230937806,"2020-07-29-AML2123-c1","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.ATTCCATTCTCCGTGT","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2585.92242226802,45.9599189766551,0.0177731236563336,2590,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2569.04734830491,2569.04734830491,"malignant"
"2020.07.29.AML2123.c1.CAACGGCAGGTGGCTA","AML-2123","2020-07-29-AML2123-c1:CAACGGCAGGTGGCTA",-3.5763340992039,9.75236413562623,"2020-07-29-AML2123-c1","AML2123","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0320328542094456,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CAACGGCAGGTGGCTA","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",2134.01181140155,40.8051255106993,0.0191213213032312,1199,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2132.57253477877,2132.57253477877,"microenvironment"
"2020.07.29.AML2123.c1.CACCAAATCCACGTAA","AML-2123","2020-07-29-AML2123-c1:CACCAAATCCACGTAA",11.4929558235103,-2.32814767276915,"2020-07-29-AML2123-c1","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CACCAAATCCACGTAA","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1585.18037097867,17.8036703259523,0.0112313214646738,1374,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1580.50184472576,1580.50184472576,"malignant"
"2020.07.29.AML2123.c1.CATCCGTTCTACGGGC","AML-2123","2020-07-29-AML2123-c1:CATCCGTTCTACGGGC",-1.88331447067912,3.4010438689026,"2020-07-29-AML2123-c1","AML2123","Ery","Ery-5",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.180252583237658,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CATCCGTTCTACGGGC","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",2944.52401827635,32.5070564382454,0.0110398340229108,3414,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",2939.40226585719,2939.40226585719,"microenvironment"
"2020.07.29.AML2123.c1.CATTTCAAGTCATCCA","AML-2123","2020-07-29-AML2123-c1:CATTTCAAGTCATCCA",-3.18385968628581,10.3917636641297,"2020-07-29-AML2123-c1","AML2123","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0320328542094456,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CATTTCAAGTCATCCA","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",2122.47025689573,46.0942073011641,0.0217172453425002,1169,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2114.81623120563,2114.81623120563,"microenvironment"
"2020.07.29.AML2123.c1.CATTTCACACCCTTAC","AML-2123","2020-07-29-AML2123-c1:CATTTCACACCCTTAC",10.9420219856197,-0.989192747232042,"2020-07-29-AML2123-c1","AML2123","Ery","Ery-3",58,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.732673267326733,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CATTTCACACCCTTAC","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1494.91548928568,12.9783934231405,0.0086816903805994,992,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1489.82175661328,1489.82175661328,"malignant"
"2020.07.29.AML2123.c1.CCAAGCGCAGCCCAGT","AML-2123","2020-07-29-AML2123-c1:CCAAGCGCAGCCCAGT",11.2980505424434,-2.59954502498778,"2020-07-29-AML2123-c1","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CCAAGCGCAGCCCAGT","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1783.47074712893,35.7060319772744,0.0200205313346209,1223,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1780.09826275055,1780.09826275055,"malignant"
"2020.07.29.AML2123.c1.CCATAAGAGCTCCCTT","AML-2123","2020-07-29-AML2123-c1:CCATAAGAGCTCCCTT",12.5362087684566,-2.45298817073973,"2020-07-29-AML2123-c1","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CCATAAGAGCTCCCTT","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1408.54424228485,19.5124275523982,0.0138529035628631,961,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1404.64694297865,1404.64694297865,"malignant"
"2020.07.29.AML2123.c1.CCCATTGGTGTACAGG","AML-2123","2020-07-29-AML2123-c1:CCCATTGGTGTACAGG",-1.76866481724437,9.23660276019899,"2020-07-29-AML2123-c1","AML2123","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0175554819476648,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CCCATTGGTGTACAGG","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",2140.94956996715,40.5331061519342,0.0189323030866888,1253,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2131.3015148302,2131.3015148302,"microenvironment"
"2020.07.29.AML2123.c1.CCCTCAAAGAGAGCAA","AML-2123","2020-07-29-AML2123-c1:CCCTCAAAGAGAGCAA",-7.56794629517253,2.31768772685853,"2020-07-29-AML2123-c1","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CCCTCAAAGAGAGCAA","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2894.40305540746,46.6117476704561,0.0161040970376858,3252,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2878.80377969344,2878.80377969344,"malignant"
"2020.07.29.AML2123.c1.CCGGACATCATTCGTT","AML-2123","2020-07-29-AML2123-c1:CCGGACATCATTCGTT",11.0923515754635,-2.56511046802672,"2020-07-29-AML2123-c1","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CCGGACATCATTCGTT","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1875.00652250466,31.6811756729097,0.0168965682479811,1471,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1871.90810435639,1871.90810435639,"malignant"
"2020.07.29.AML2123.c1.CGAGTTACAGGCATGA","AML-2123","2020-07-29-AML2123-c1:CGAGTTACAGGCATGA",8.40467037734334,8.25308415973512,"2020-07-29-AML2123-c1","AML2123","B","Activated NFkB",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0166414523449319,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CGAGTTACAGGCATGA","B","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","B","B",1931.42394160298,45.8303726745095,0.0237288001289209,1170,30000,1100,500,"True","True","True","True",5,71,"True","B_AML-2123",1921.16099977709,1921.16099977709,"microenvironment"
"2020.07.29.AML2123.c1.CTAACTTCACGTCATA","AML-2123","2020-07-29-AML2123-c1:CTAACTTCACGTCATA",-7.45009980621989,-1.53800597107085,"2020-07-29-AML2123-c1","AML2123","GMP","GMP",37,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0612244897959184,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CTAACTTCACGTCATA","GMP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2762.52498807054,40.2632356402159,0.014574795092926,2482,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2754.23046139115,2754.23046139115,"microenvironment"
"2020.07.29.AML2123.c1.CTATCTAGTGTTAAAG","AML-2123","2020-07-29-AML2123-c1:CTATCTAGTGTTAAAG",-7.38269935074504,2.7397935160431,"2020-07-29-AML2123-c1","AML2123","HSC","HSC",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CTATCTAGTGTTAAAG","HSC","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2287.23217346127,42.6850711382342,0.0186623254226259,1799,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2276.69119944122,2276.69119944122,"malignant"
"2020.07.29.AML2123.c1.CTCAACCAGAAATTGC","AML-2123","2020-07-29-AML2123-c1:CTCAACCAGAAATTGC",10.9095665412838,-1.06818392192992,"2020-07-29-AML2123-c1","AML2123","Ery","Ery-3",58,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.732673267326733,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CTCAACCAGAAATTGC","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1591.99089945447,25.5571945032481,0.0160536059044092,1541,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1582.3376472308,1582.3376472308,"malignant"
"2020.07.29.AML2123.c1.CTCCAACTCAGGACAG","AML-2123","2020-07-29-AML2123-c1:CTCCAACTCAGGACAG",11.2384211021358,-2.34152295505675,"2020-07-29-AML2123-c1","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CTCCAACTCAGGACAG","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1721.74851295482,19.9604934563499,0.0115931527201346,1017,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1714.49533711077,1714.49533711077,"malignant"
"2020.07.29.AML2123.c1.CTCCGATAGGTCCCTG","AML-2123","2020-07-29-AML2123-c1:CTCCGATAGGTCCCTG",-6.00526652756389,3.1499624022278,"2020-07-29-AML2123-c1","AML2123","MPP","MPP_MEP",54,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.483870967741935,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CTCCGATAGGTCCCTG","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2280.71821835091,41.854196074888,0.0183513227272552,1676,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2273.93884608029,2273.93884608029,"microenvironment"
"2020.07.29.AML2123.c1.CTGCGAGGTGACTAAA","AML-2123","2020-07-29-AML2123-c1:CTGCGAGGTGACTAAA",12.6341902213985,-2.62001874363097,"2020-07-29-AML2123-c1","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.CTGCGAGGTGACTAAA","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1398.0084709088,14.3237479591919,0.0102458234390243,960,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1396.79939159531,1396.79939159531,"malignant"
"2020.07.29.AML2123.c1.GACTCTCTCTGGTGCG","AML-2123","2020-07-29-AML2123-c1:GACTCTCTCTGGTGCG",1.35756434974019,9.5521554716858,"2020-07-29-AML2123-c1","AML2123","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0268987341772152,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.GACTCTCTCTGGTGCG","CD4+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD4_T",1994.63513210219,37.9523751977869,0.0190272268782252,1290,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",1985.53569233321,1985.53569233321,"microenvironment"
"2020.07.29.AML2123.c1.GAGGGTAAGCCACTCG","AML-2123","2020-07-29-AML2123-c1:GAGGGTAAGCCACTCG",-7.26410422745402,-1.48663856899413,"2020-07-29-AML2123-c1","AML2123","MPP","MPP_GMP",66,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.117647058823529,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.GAGGGTAAGCCACTCG","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",1993.18782841628,1.67118231004162,0.0008384469773576,1002,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",1987.59627445532,1987.59627445532,"malignant"
"2020.07.29.AML2123.c1.GGAGGATCAGTGTGCC","AML-2123","2020-07-29-AML2123-c1:GGAGGATCAGTGTGCC",0.361703951924485,9.36454007709352,"2020-07-29-AML2123-c1","AML2123","CD4+ T","CD4+ Naive",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0268987341772152,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.GGAGGATCAGTGTGCC","CD4+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD4_T",1895.31272887362,41.5503145918263,0.0219226695198314,1068,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",1892.40967764044,1892.40967764044,"microenvironment"
"2020.07.29.AML2123.c1.GGGTGTCCACATCATG","AML-2123","2020-07-29-AML2123-c1:GGGTGTCCACATCATG",-2.67159567299541,9.14543531024782,"2020-07-29-AML2123-c1","AML2123","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0175554819476648,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.GGGTGTCCACATCATG","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",1844.49397007908,48.5506726660441,0.0263219470779633,1011,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",1839.97791903539,1839.97791903539,"microenvironment"
"2020.07.29.AML2123.c1.GGTAGAGTCTTGGGCG","AML-2123","2020-07-29-AML2123-c1:GGTAGAGTCTTGGGCG",8.87572350081746,7.83973929965822,"2020-07-29-AML2123-c1","AML2123","B","Activated NFkB",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0166414523449319,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.GGTAGAGTCTTGGGCG","B","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","B","B",1766.92371768349,38.6454366432359,0.0218715931290467,944,30000,1100,500,"True","True","True","True",5,71,"True","B_AML-2123",1764.01013756938,1764.01013756938,"microenvironment"
"2020.07.29.AML2123.c1.TACCGAAGTCACATTG","AML-2123","2020-07-29-AML2123-c1:TACCGAAGTCACATTG",0.882336874573868,9.89061353290407,"2020-07-29-AML2123-c1","AML2123","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0268987341772152,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TACCGAAGTCACATTG","CD4+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD4_T",1918.40761238997,35.6918797851728,0.0186049510826885,1261,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",1911.3259298741,1911.3259298741,"microenvironment"
"2020.07.29.AML2123.c1.TACGCTCTCAAATAGG","AML-2123","2020-07-29-AML2123-c1:TACGCTCTCAAATAGG",-7.75128302994426,2.565234161261,"2020-07-29-AML2123-c1","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TACGCTCTCAAATAGG","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2816.68604494128,39.4152990241455,0.0139935010133397,2715,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2797.61746350059,2797.61746350059,"malignant"
"2020.07.29.AML2123.c1.TACGGTAAGATCACTC","AML-2123","2020-07-29-AML2123-c1:TACGGTAAGATCACTC",0.433542599051636,11.234688735846,"2020-07-29-AML2123-c1","AML2123","CD8+ T","CD8+ Naive",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0314465408805031,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TACGGTAAGATCACTC","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",2068.9565353778,45.4696686049583,0.0219771019001399,1455,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2065.73851008205,2065.73851008205,"microenvironment"
"2020.07.29.AML2123.c1.TATCCTATCTGAGAGG","AML-2123","2020-07-29-AML2123-c1:TATCCTATCTGAGAGG",11.243518491357,-2.26359894191893,"2020-07-29-AML2123-c1","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TATCCTATCTGAGAGG","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1496.29455628384,39.4755051862928,0.0263821752344895,714,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1492.50822619518,1492.50822619518,"malignant"
"2020.07.29.AML2123.c1.TATCTTGCAATGGCAG","AML-2123","2020-07-29-AML2123-c1:TATCTTGCAATGGCAG",-7.61833463135417,2.55938289249269,"2020-07-29-AML2123-c1","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TATCTTGCAATGGCAG","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2578.95177241162,45.0466209087301,0.0174670272591435,2750,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2569.68673140683,2569.68673140683,"malignant"
"2020.07.29.AML2123.c1.TCCTGCATCTACCACC","AML-2123","2020-07-29-AML2123-c1:TCCTGCATCTACCACC",-0.48320565643962,11.5314235457214,"2020-07-29-AML2123-c1","AML2123","CD8+ T","CD8+ NK-like",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0314465408805031,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TCCTGCATCTACCACC","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",2389.56220822471,47.9516187068733,0.0200671146128053,1424,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2377.02494975431,2377.02494975431,"microenvironment"
"2020.07.29.AML2123.c1.TCCTTCTGTATGCTTG","AML-2123","2020-07-29-AML2123-c1:TCCTTCTGTATGCTTG",-8.12038932266887,0.630604780558027,"2020-07-29-AML2123-c1","AML2123","MPP","MPP_GMP",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.103603603603604,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TCCTTCTGTATGCTTG","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2801.65516235667,43.9980500912735,0.0157043060410988,2525,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2782.70973856877,2782.70973856877,"microenvironment"
"2020.07.29.AML2123.c1.TCGCTTGGTCGACTTA","AML-2123","2020-07-29-AML2123-c1:TCGCTTGGTCGACTTA",-7.69956098023112,3.01969955051271,"2020-07-29-AML2123-c1","AML2123","HSC","HSC",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TCGCTTGGTCGACTTA","HSC","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2589.44434329944,40.7456063396435,0.0157352701729538,2233,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2576.69499055799,2576.69499055799,"malignant"
"2020.07.29.AML2123.c1.TCTGTCGAGCCTGCCA","AML-2123","2020-07-29-AML2123-c1:TCTGTCGAGCCTGCCA",10.9552723365719,-2.58324649250182,"2020-07-29-AML2123-c1","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TCTGTCGAGCCTGCCA","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1599.25708758937,39.3461604610314,0.0246027738544148,1042,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1595.26319707786,1595.26319707786,"malignant"
"2020.07.29.AML2123.c1.TGCATGAGTACAGAGC","AML-2123","2020-07-29-AML2123-c1:TGCATGAGTACAGAGC",11.2145754295284,-2.68100764667662,"2020-07-29-AML2123-c1","AML2123","Ery","Ery-5",34,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TGCATGAGTACAGAGC","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",2516.16006251942,37.9397155396697,0.0150784189387701,3598,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",2510.56555389996,2510.56555389996,"malignant"
"2020.07.29.AML2123.c1.TGGTGATGTCAATCTG","AML-2123","2020-07-29-AML2123-c1:TGGTGATGTCAATCTG",-4.89838967743571,-5.67561914837035,"2020-07-29-AML2123-c1","AML2123","Granulocyte","Granulocytes (cycling)",38,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0045180722891566,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TGGTGATGTCAATCTG","Granulocyte","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Gran","Gran",1711.64362391585,28.6502144457354,0.0167384226748032,725,30000,1100,500,"True","True","True","True",5,5,"True","Gran_AML-2123",1711.64362391585,1711.64362391585,"microenvironment"
"2020.07.29.AML2123.c1.TGTAACGAGAAGGCTC","AML-2123","2020-07-29-AML2123-c1:TGTAACGAGAAGGCTC",-3.89624748650249,9.72397611224977,"2020-07-29-AML2123-c1","AML2123","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0320328542094456,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TGTAACGAGAAGGCTC","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",2238.77870675505,43.8577452619466,0.0195900314442043,1271,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2232.89100683076,2232.89100683076,"microenvironment"
"2020.07.29.AML2123.c1.TGTAGACTCTCCTGCA","AML-2123","2020-07-29-AML2123-c1:TGTAGACTCTCCTGCA",-5.82361112061198,3.86538693988649,"2020-07-29-AML2123-c1","AML2123","MEP","MEP",39,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0377358490566038,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TGTAGACTCTCCTGCA","MEP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2618.18832832061,31.355828385534,0.0119761546739637,1953,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2608.89997145038,2608.89997145038,"microenvironment"
"2020.07.29.AML2123.c1.TTGCATTTCTGAGCAT","AML-2123","2020-07-29-AML2123-c1:TTGCATTTCTGAGCAT",-2.88537464562114,10.2053336867127,"2020-07-29-AML2123-c1","AML2123","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0320328542094456,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TTGCATTTCTGAGCAT","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",1523.72587975132,45.0179680436909,0.0295446632769919,612,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",1519.23987887549,1519.23987887549,"microenvironment"
"2020.07.29.AML2123.c1.TTTACCAGTACCCACG","AML-2123","2020-07-29-AML2123-c1:TTTACCAGTACCCACG",9.71210636672322,7.92459342563478,"2020-07-29-AML2123-c1","AML2123","B","Memory",2,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.002868068833652,"GSM5613772","2020-07-29","2020.07.29.AML2123.c1.TTTACCAGTACCCACG","B","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","B","B",2673.84941340606,43.394858093189,0.016229357523134,2455,30000,1100,500,"True","True","True","True",5,71,"True","B_AML-2123",2664.54084654333,2664.54084654333,"microenvironment"
"2020.07.29.AML2123.c2.GAGTGAGTCGGTCATA","AML-2123","2020-07-29-AML2123-c2:GAGTGAGTCGGTCATA",-3.60169873657878,10.3562974699768,"2020-07-29-AML2123-c2","AML2123","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0320328542094456,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.GAGTGAGTCGGTCATA","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",2070.0101818745,41.2015889579289,0.0199040513513894,1093,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2065.36707829911,2065.36707829911,"microenvironment"
"2020.07.29.AML2123.c2.GAGTTGTAGAGTCAGC","AML-2123","2020-07-29-AML2123-c2:GAGTTGTAGAGTCAGC",-1.84965095940288,3.87160656535951,"2020-07-29-AML2123-c2","AML2123","Ery","Heat shock proteins",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.180252583237658,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.GAGTTGTAGAGTCAGC","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",3221.10882688537,42.5350021449017,0.0132050807442078,4477,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",3213.10356026058,3213.10356026058,"microenvironment"
"2020.07.29.AML2123.c2.GATCGTACAAGACAAT","AML-2123","2020-07-29-AML2123-c2:GATCGTACAAGACAAT",11.4298721748287,-2.29330065166625,"2020-07-29-AML2123-c2","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.GATCGTACAAGACAAT","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1587.34045574713,30.7058584848847,0.0193442171612971,1131,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1581.57328769809,1581.57328769809,"malignant"
"2020.07.29.AML2123.c2.GCAACCGCAATTGCTG","AML-2123","2020-07-29-AML2123-c2:GCAACCGCAATTGCTG",-7.64064488831218,0.707834101560987,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.103603603603604,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.GCAACCGCAATTGCTG","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2938.93192265322,43.2324975845319,0.0147102752708549,4332,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2926.79284711027,2926.79284711027,"microenvironment"
"2020.07.29.AML2123.c2.AAGTGAAGTGTATCCA","AML-2123","2020-07-29-AML2123-c2:AAGTGAAGTGTATCCA",-2.77491317215617,3.28689763629762,"2020-07-29-AML2123-c2","AML2123","Ery","Ery-1",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.180252583237658,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.AAGTGAAGTGTATCCA","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",3251.30202713161,16.8791931037945,0.0051915180327574,3743,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",3244.23385558071,3244.23385558071,"microenvironment"
"2020.07.29.AML2123.c2.ACATTTCCACGCGCTA","AML-2123","2020-07-29-AML2123-c2:ACATTTCCACGCGCTA",-7.54633412781413,1.32350931251375,"2020-07-29-AML2123-c2","AML2123","GMP","GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.162162162162162,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.ACATTTCCACGCGCTA","GMP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2607.71561125483,47.7875052430759,0.018325428216492,2155,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2602.68286971573,2602.68286971573,"microenvironment"
"2020.07.29.AML2123.c2.ACCTGTCAGGGCTAAC","AML-2123","2020-07-29-AML2123-c2:ACCTGTCAGGGCTAAC",-1.97981796684917,3.56090853298036,"2020-07-29-AML2123-c2","AML2123","Ery","Ery-1",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.180252583237658,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.ACCTGTCAGGGCTAAC","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",2920.65460610986,40.5318948809534,0.0138776748185707,2638,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",2915.83089153801,2915.83089153801,"microenvironment"
"2020.07.29.AML2123.c2.ACGTAGTGTACCCGCA","AML-2123","2020-07-29-AML2123-c2:ACGTAGTGTACCCGCA",-7.59356294098552,2.61262772167055,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.ACGTAGTGTACCCGCA","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2368.74268011313,47.3867504250754,0.0200050224209294,2247,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2357.67152813686,2357.67152813686,"malignant"
"2020.07.29.AML2123.c2.ACTACGATCGTTCCCA","AML-2123","2020-07-29-AML2123-c2:ACTACGATCGTTCCCA",-7.76196608963664,2.53298399532167,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.ACTACGATCGTTCCCA","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2498.94853409923,39.7404803341986,0.0159028806683781,2745,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2489.51604029763,2489.51604029763,"malignant"
"2020.07.29.AML2123.c2.ACTCCCAAGTTGTCAC","AML-2123","2020-07-29-AML2123-c2:ACTCCCAAGTTGTCAC",1.07479216632192,9.95015237415162,"2020-07-29-AML2123-c2","AML2123","CD4+ T","CD4+ Naive",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0268987341772152,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.ACTCCCAAGTTGTCAC","CD4+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD4_T",2157.05960959631,47.8685988916086,0.0221915976167979,1721,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2144.03772778448,2144.03772778448,"microenvironment"
"2020.07.29.AML2123.c2.ACTGCAAGTCAAGGCA","AML-2123","2020-07-29-AML2123-c2:ACTGCAAGTCAAGGCA",10.888519902795,-2.33830358898314,"2020-07-29-AML2123-c2","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.ACTGCAAGTCAAGGCA","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1561.60643958766,24.4641606848419,0.0156660219019728,857,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1553.75759055205,1553.75759055205,"malignant"
"2020.07.29.AML2123.c2.AGATAGATCCAGCCTT","AML-2123","2020-07-29-AML2123-c2:AGATAGATCCAGCCTT",-7.58974204483684,2.66977975452272,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.AGATAGATCCAGCCTT","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2309.43566706713,46.7438076948224,0.0202403593056934,2571,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2296.2908134662,2296.2908134662,"malignant"
"2020.07.29.AML2123.c2.AGGCCACAGCATTTCG","AML-2123","2020-07-29-AML2123-c2:AGGCCACAGCATTTCG",0.0370761855388105,10.9896840819153,"2020-07-29-AML2123-c2","AML2123","CD8+ T","CD8+ TRM",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0314465408805031,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.AGGCCACAGCATTTCG","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",1805.83577166153,38.6109639370897,0.0213812155806196,1075,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",1802.0135584775,1802.0135584775,"microenvironment"
"2020.07.29.AML2123.c2.AGTCAACAGACTGAGC","AML-2123","2020-07-29-AML2123-c2:AGTCAACAGACTGAGC",-3.48529873314555,10.9187516936096,"2020-07-29-AML2123-c2","AML2123","NK","Activated NK",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0320328542094456,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.AGTCAACAGACTGAGC","NK","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","NK","NK",2196.43620771925,45.9140242592387,0.0209038733280195,1296,30000,1100,500,"True","True","True","True",5,26,"True","NK_AML-2123",2192.32053303648,2192.32053303648,"microenvironment"
"2020.07.29.AML2123.c2.ATCCACCAGTCGTCTA","AML-2123","2020-07-29-AML2123-c2:ATCCACCAGTCGTCTA",-7.59260497513469,2.60330555522767,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.ATCCACCAGTCGTCTA","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2729.7100333914,43.4532607667585,0.015918636131755,2932,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2712.30706771461,2712.30706771461,"malignant"
"2020.07.29.AML2123.c2.ATTCTTGTCCGGCAAC","AML-2123","2020-07-29-AML2123-c2:ATTCTTGTCCGGCAAC",-7.0397199195927,2.47470924938051,"2020-07-29-AML2123-c2","AML2123","GMP","GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.ATTCTTGTCCGGCAAC","GMP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2197.72709641155,49.2480169315098,0.0224086134315411,1269,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2186.18924240453,2186.18924240453,"malignant"
"2020.07.29.AML2123.c2.CAAGGGACATAGTCGT","AML-2123","2020-07-29-AML2123-c2:CAAGGGACATAGTCGT",-7.85965619507487,1.20920167053071,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.103603603603604,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.CAAGGGACATAGTCGT","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2755.30422207736,35.9390863644487,0.0130436000774363,2955,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2745.60982590023,2745.60982590023,"microenvironment"
"2020.07.29.AML2123.c2.CACGTGGCACTTCCTG","AML-2123","2020-07-29-AML2123-c2:CACGTGGCACTTCCTG",-7.54778943482097,1.40704605663148,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.CACGTGGCACTTCCTG","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2729.42839376826,50.0001127280281,0.018318895209776,2920,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2716.17822218679,2716.17822218679,"malignant"
"2020.07.29.AML2123.c2.CCCGGAATCATCCTAT","AML-2123","2020-07-29-AML2123-c2:CCCGGAATCATCCTAT",-8.3391412300175,0.500801659468092,"2020-07-29-AML2123-c2","AML2123","GMP","GMP",27,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.103603603603604,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.CCCGGAATCATCCTAT","GMP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2748.3541116736,43.1691119299569,0.0157072597547007,2476,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2744.55384358205,2744.55384358205,"microenvironment"
"2020.07.29.AML2123.c2.CGAAGGACACACGCCA","AML-2123","2020-07-29-AML2123-c2:CGAAGGACACACGCCA",11.8890339332515,-2.59603979503783,"2020-07-29-AML2123-c2","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.CGAAGGACACACGCCA","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1663.87088206736,37.5078278741574,0.0225425111277588,1078,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1654.77561516891,1654.77561516891,"malignant"
"2020.07.29.AML2123.c2.CGATGGCAGTAGTCTC","AML-2123","2020-07-29-AML2123-c2:CGATGGCAGTAGTCTC",-1.7946666282719,10.1479100950989,"2020-07-29-AML2123-c2","AML2123","CD8+ T","CD8+ Cytotoxic",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0175554819476648,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.CGATGGCAGTAGTCTC","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",2109.00840418768,46.6468161505152,0.0221178901221506,1241,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2102.4153684909,2102.4153684909,"microenvironment"
"2020.07.29.AML2123.c2.CGGACACGTACTAACC","AML-2123","2020-07-29-AML2123-c2:CGGACACGTACTAACC",-3.28571305695232,10.4545039900574,"2020-07-29-AML2123-c2","AML2123","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0320328542094456,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.CGGACACGTACTAACC","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",2143.49413143423,45.4934311523882,0.0212239588087644,1255,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2140.76926474047,2140.76926474047,"microenvironment"
"2020.07.29.AML2123.c2.CGGGTCATCTGGGCGT","AML-2123","2020-07-29-AML2123-c2:CGGGTCATCTGGGCGT",-3.45203242722209,3.3102133044037,"2020-07-29-AML2123-c2","AML2123","Ery","Ery-2",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.180252583237658,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.CGGGTCATCTGGGCGT","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",3132.44533813977,37.3860387221803,0.0119350969247503,4692,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",3128.54299384042,3128.54299384042,"microenvironment"
"2020.07.29.AML2123.c2.CTCAAGAGTAGCCAGA","AML-2123","2020-07-29-AML2123-c2:CTCAAGAGTAGCCAGA",-7.70380435410197,2.56775043094484,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.CTCAAGAGTAGCCAGA","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2507.6358333024,43.5535501015125,0.0173683712455788,1899,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2500.49893391475,2500.49893391475,"malignant"
"2020.07.29.AML2123.c2.TTGTTTGCAGAGATGC","AML-2123","2020-07-29-AML2123-c2:TTGTTTGCAGAGATGC",-7.89927421036418,2.89351294124452,"2020-07-29-AML2123-c2","AML2123","GMP","GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TTGTTTGCAGAGATGC","GMP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2154.99267327841,49.1444756763137,0.022804938636543,2225,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2149.42548270394,2149.42548270394,"malignant"
"2020.07.29.AML2123.c2.CTTCGGTAGAACCCGA","AML-2123","2020-07-29-AML2123-c2:CTTCGGTAGAACCCGA",-2.84267459335979,3.52532265270082,"2020-07-29-AML2123-c2","AML2123","Ery","Ery-1",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.180252583237658,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.CTTCGGTAGAACCCGA","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",2814.9971146084,8.67571934404709,0.003081963849634,3069,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",2814.00192058326,2814.00192058326,"microenvironment"
"2020.07.29.AML2123.c2.GAACGTTGTTGCGAAG","AML-2123","2020-07-29-AML2123-c2:GAACGTTGTTGCGAAG",-3.68061004105266,9.88588903034059,"2020-07-29-AML2123-c2","AML2123","CD8+ T","CD8+ Cytotoxic",9,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0320328542094456,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.GAACGTTGTTGCGAAG","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",1824.04579156185,41.6100180115377,0.0228119371805403,900,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",1817.30664697532,1817.30664697532,"microenvironment"
"2020.07.29.AML2123.c2.GACTGATGTGAGCTCC","AML-2123","2020-07-29-AML2123-c2:GACTGATGTGAGCTCC",0.505273719399613,11.5658607252869,"2020-07-29-AML2123-c2","AML2123","NK","Activated NK",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0314465408805031,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.GACTGATGTGAGCTCC","NK","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","NK","NK",2153.68669957126,39.6749378471536,0.0184218706718353,1115,30000,1100,500,"True","True","True","True",5,26,"True","NK_AML-2123",2145.44540235979,2145.44540235979,"microenvironment"
"2020.07.29.AML2123.c2.TACCGGGTCAAATGCC","AML-2123","2020-07-29-AML2123-c2:TACCGGGTCAAATGCC",-7.06506190720256,2.59536168659059,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TACCGGGTCAAATGCC","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2311.85007903486,45.3736454425283,0.0196265518486694,2135,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2302.00026627818,2302.00026627818,"malignant"
"2020.07.29.AML2123.c2.GCATCTCCAGCCGTCA","AML-2123","2020-07-29-AML2123-c2:GCATCTCCAGCCGTCA",-2.80612597885783,3.98828909480897,"2020-07-29-AML2123-c2","AML2123","Ery","Ery-2",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.180252583237658,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.GCATCTCCAGCCGTCA","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",3044.410542782,40.4521185604944,0.0132873401901732,3756,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",3037.82446372608,3037.82446372608,"microenvironment"
"2020.07.29.AML2123.c2.GCCGATGTCTACTCAT","AML-2123","2020-07-29-AML2123-c2:GCCGATGTCTACTCAT",0.896677930920762,11.33420178974,"2020-07-29-AML2123-c2","AML2123","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0268987341772152,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.GCCGATGTCTACTCAT","CD4+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD4_T",2028.01405331624,32.0599993422189,0.0158085686288978,1433,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2022.91128297546,2022.91128297546,"microenvironment"
"2020.07.29.AML2123.c2.GCTGAATAGCAACTCT","AML-2123","2020-07-29-AML2123-c2:GCTGAATAGCAACTCT",-9.16916976395305,-4.55366279995116,"2020-07-29-AML2123-c2","AML2123","GMP","GMP",11,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",1,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.GCTGAATAGCAACTCT","GMP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2144.09697388401,44.11907585288,0.0205769964653039,1675,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2139.4613357322,2139.4613357322,"malignant"
"2020.07.29.AML2123.c2.GGGAAGTAGGGCTTCC","AML-2123","2020-07-29-AML2123-c2:GGGAAGTAGGGCTTCC",-4.10030732575114,12.658158279303,"2020-07-29-AML2123-c2","AML2123","NK","CD56bright NK",26,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0034030140982012,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.GGGAAGTAGGGCTTCC","NK","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","NK","NK",2815.66790810277,51.0909051272076,0.018145216976825,2300,30000,1100,500,"True","True","True","True",5,26,"True","NK_AML-2123",2806.79695882635,2806.79695882635,"microenvironment"
"2020.07.29.AML2123.c2.GGGACCTGTAGTTACC","AML-2123","2020-07-29-AML2123-c2:GGGACCTGTAGTTACC",8.67188133773152,7.89723155582277,"2020-07-29-AML2123-c2","AML2123","B","Activated NFkB",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0166414523449319,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.GGGACCTGTAGTTACC","B","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","B","B",1992.84464772847,35.7059212564807,0.0179170620736442,1404,30000,1100,500,"True","True","True","True",5,71,"True","B_AML-2123",1987.04953150004,1987.04953150004,"microenvironment"
"2020.07.29.AML2123.c2.GGTAATCCAAGTACCT","AML-2123","2020-07-29-AML2123-c2:GGTAATCCAAGTACCT",11.4389683204586,-1.61587848579558,"2020-07-29-AML2123-c2","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.GGTAATCCAAGTACCT","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1372.94324273802,47.6337692341657,0.0346946383152527,1292,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1371.19487657538,1371.19487657538,"malignant"
"2020.07.29.AML2123.c2.TAGTGCAGTCACCTTC","AML-2123","2020-07-29-AML2123-c2:TAGTGCAGTCACCTTC",-7.51935134354289,2.39481041515199,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TAGTGCAGTCACCTTC","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2591.36178886426,44.5936148657792,0.0172085638745656,2526,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2581.02352193201,2581.02352193201,"malignant"
"2020.07.29.AML2123.c2.TCACGGGGTTTGCCGG","AML-2123","2020-07-29-AML2123-c2:TCACGGGGTTTGCCGG",11.0339275794918,-0.794833981153093,"2020-07-29-AML2123-c2","AML2123","Ery","Ery-3",58,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.732673267326733,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TCACGGGGTTTGCCGG","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1191.73443132966,44.1623996673574,0.0370572490870166,741,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1181.8165288271,1181.8165288271,"malignant"
"2020.07.29.AML2123.c2.TCCGATCAGGGAGGAC","AML-2123","2020-07-29-AML2123-c2:TCCGATCAGGGAGGAC",-7.52581010285075,2.5959262617859,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TCCGATCAGGGAGGAC","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2533.1926528074,49.3504562518953,0.0194815251012207,2338,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2521.06642042311,2521.06642042311,"malignant"
"2020.07.29.AML2123.c2.TCCTTCTTCTTGCAGA","AML-2123","2020-07-29-AML2123-c2:TCCTTCTTCTTGCAGA",0.881087620824021,9.84094140613405,"2020-07-29-AML2123-c2","AML2123","CD4+ T","CD4+ Naive",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0268987341772152,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TCCTTCTTCTTGCAGA","CD4+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD4_T",1867.27062410821,37.5222208414972,0.0200946881277144,1129,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",1859.31935744762,1859.31935744762,"microenvironment"
"2020.07.29.AML2123.c2.TGCGGCATCCCGAACG","AML-2123","2020-07-29-AML2123-c2:TGCGGCATCCCGAACG",10.9135004478389,-2.64719536220702,"2020-07-29-AML2123-c2","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TGCGGCATCCCGAACG","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1711.58840466438,38.5995116870066,0.022551865613144,848,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1700.69044271445,1700.69044271445,"malignant"
"2020.07.29.AML2123.c2.TGCTTCGCATTGACCA","AML-2123","2020-07-29-AML2123-c2:TGCTTCGCATTGACCA",0.420734574168366,10.7974529036316,"2020-07-29-AML2123-c2","AML2123","CD4+ T","CD4+ Naive",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0268987341772152,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TGCTTCGCATTGACCA","CD4+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD4_T",1998.7427332777,34.0927210712888,0.0170570831871798,1129,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",1991.56815348106,1991.56815348106,"microenvironment"
"2020.07.29.AML2123.c2.TCTATCAGTATCGCGC","AML-2123","2020-07-29-AML2123-c2:TCTATCAGTATCGCGC",11.7963739829952,-3.02744295513304,"2020-07-29-AML2123-c2","AML2123","Ery","Erythrocytes",34,"CNV+","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.845070422535211,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TCTATCAGTATCGCGC","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",1793.64110654478,43.5416709955515,0.0242755759982714,1300,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",1789.42028636448,1789.42028636448,"malignant"
"2020.07.29.AML2123.c2.TCTCCGAAGCCTATCA","AML-2123","2020-07-29-AML2123-c2:TCTCCGAAGCCTATCA",-2.14284835282024,9.68338773334352,"2020-07-29-AML2123-c2","AML2123","CD8+ T","CD8+ GZMK+",15,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0175554819476648,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TCTCCGAAGCCTATCA","CD8+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD8_T",2164.20924222445,44.6644903423208,0.020637787451833,1279,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2162.80696093388,2162.80696093388,"microenvironment"
"2020.07.29.AML2123.c2.TCTTTGACAGCTACTA","AML-2123","2020-07-29-AML2123-c2:TCTTTGACAGCTACTA",-7.6220568222111,1.70265386188356,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TCTTTGACAGCTACTA","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2951.16964518729,41.6888465781333,0.0141262114992673,3980,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2932.4849188624,2932.4849188624,"malignant"
"2020.07.29.AML2123.c2.TTACGCCGTTTAGAGA","AML-2123","2020-07-29-AML2123-c2:TTACGCCGTTTAGAGA",-7.60852132263835,2.82646606052247,"2020-07-29-AML2123-c2","AML2123","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","female","Inflammation_high",0.882539682539683,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TTACGCCGTTTAGAGA","MPP","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","HSPC","HSPC",2850.45813864372,44.3972383771311,0.015575474614146,2927,30000,1100,500,"True","True","True","True",5,394,"True","HSPC_AML-2123",2834.05585128306,2834.05585128306,"malignant"
"2020.07.29.AML2123.c2.TTCCTAATCGAATGCT","AML-2123","2020-07-29-AML2123-c2:TTCCTAATCGAATGCT",-3.87476764145549,2.8311671980652,"2020-07-29-AML2123-c2","AML2123","Ery","Ery-2",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.180252583237658,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TTCCTAATCGAATGCT","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",3269.3056331046,38.0875598531882,0.0116500456450196,5148,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",3259.90614014555,3259.90614014555,"microenvironment"
"2020.07.29.AML2123.c2.TTCCTTCAGACGCCCT","AML-2123","2020-07-29-AML2123-c2:TTCCTTCAGACGCCCT",1.55482806739156,11.033212638739,"2020-07-29-AML2123-c2","AML2123","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.0268987341772152,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TTCCTTCAGACGCCCT","CD4+ T","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","T","CD4_T",2382.98934524519,36.1517408965254,0.0151707522187036,2040,30000,1100,500,"True","True","True","True",5,251,"True","T_AML-2123",2373.73580941623,2373.73580941623,"microenvironment"
"2020.07.29.AML2123.c2.TGTCCTGTCCTCTCGA","AML-2123","2020-07-29-AML2123-c2:TGTCCTGTCCTCTCGA",-2.65760336342509,3.35860250079957,"2020-07-29-AML2123-c2","AML2123","Ery","Ery-7",53,"CNV-","microenvironment","AML","adult_AML","adult_60up","female","Inflammation_high",0.180252583237658,"GSM5613773","2020-07-29","2020.07.29.AML2123.c2.TGTCCTGTCCTCTCGA","Ery","U-16-2123","F",71,"CITE-seq","OSU","AML2123","AML","Intermediate","46,XX",1807,"Immunophenotypic analysis demonstrates an abnormal myeloid 
HLA-DR+CD13+CD33+CD34+MPO(var)+ myeloblast population, 
consistent with acute myeloid leukemia. Correlation with bone 
marrow morphology and cytogenetic studies is recommended. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 23.0 % of the total events 
analyzed. Of the lymphocytes: 7.0 % are B cells (CD19+) with a 
Kappa:Lambda ratio of 3:2 , 88.0 % are T cells (CD3+) with a 
CD4:CD8 ratio of 1.9 and 5.6 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). Blasts, defined by CD45 faint 
staining and low side scatter represent 44.4 % of the total events 
analyzed and express HLA-DR+, CD13+, CD33+, CD34+ with 
subpopulation(s) expressing cMPO+ ( 44%) and are negative for 
the remaining markers analyzed. ","","","x","","","",NA,NA,"0,25","0","0","0.0",0,0,"0.0","0",0,"0",0,0,0,0,"0",0,"0.0","0",0,0,"0",0,0,0,"0",NA,"","",NA,"",NA,"AML","case","Ery","Ery",3264.17454786301,38.1953305475159,0.0117013750298745,4606,30000,1100,500,"True","True","True","True",5,505,"True","Ery_AML-2123",3256.91590536669,3256.91590536669,"microenvironment"
"2019.07.01.count.1.TGGTACACAGCAGTTT","AML-3133","2019-07-01-count-1:TGGTACACAGCAGTTT",1.20237006720845,10.2178640135559,"2019-07-01-count-1","AML3133","CD4+ T","CD4+ Naive",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TGGTACACAGCAGTTT","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0","0","0.0",0,0,"0.0","0,44",0,"0",0,0,0,0,"0,44",0,"0.0","0.05
0.08",0,0,"0",0,0,0,"0",0,"0","0.0",0,"0",0,"AML","case","T","CD4_T",2103.02939035802,33.263042750205,0.0158167274802291,1297,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",2095.36163749081,2095.36163749081,"microenvironment"
"2019.07.01.count.2.TTAGGGTAGATTTGCC","AML-3133","2019-07-01-count-2:TTAGGGTAGATTTGCC",-1.56949112835582,9.36954019153444,"2019-07-01-count-2","AML3133","CD8+ T","CD8+ GZMK+",5,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.193189259986902,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.TTAGGGTAGATTTGCC","CD8+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0","0","0.0",0,0,"0.0","0,44",0,"0",0,0,0,0,"0,44",0,"0.0","0.05
0.08",0,0,"0",0,0,0,"0",0,"0","0.0",0,"0",0,"AML","case","T","CD8_T",1792.41426124843,34.3857898860877,0.0191840639909536,762,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1787.55150267457,1787.55150267457,"microenvironment"
"2019.07.01.count.1.GGTAATCAGCAACAAT","AML-3133","2019-07-01-count-1:GGTAATCAGCAACAAT",8.5344988304073,7.52184388721315,"2019-07-01-count-1","AML3133","B","Activated NFkB",0,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0784499054820416,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GGTAATCAGCAACAAT","B","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0","0","0.0",0,0,"0.0","0,44",0,"0",0,0,0,0,"0,44",0,"0.0","0.05
0.08",0,0,"0",0,0,0,"0",0,"0","0.0",0,"0",0,"AML","case","B","B",1977.55404032804,34.2163562590211,0.0173023621915006,1091,30000,1100,500,"True","True","True","True",5,240,"True","B_AML-3133",1974.54123125517,1974.54123125517,"microenvironment"
"2019.07.01.count.2.GACCTTCGTACCAATC","AML-3133","2019-07-01-count-2:GACCTTCGTACCAATC",-1.44818983498271,3.62297127330629,"2019-07-01-count-2","AML3133","Ery","Ery-5",53,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0110803324099723,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GACCTTCGTACCAATC","Ery","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0","0","0.0",0,0,"0.0","0,44",0,"0",0,0,0,0,"0,44",0,"0.0","0.05
0.08",0,0,"0",0,0,0,"0",0,"0","0.0",0,"0",0,"AML","case","Ery","Ery",2911.62385619809,37.9112880129556,0.0130206681512972,4277,30000,1100,500,"True","True","True","True",5,46,"True","Ery_AML-3133",2908.1303516976,2908.1303516976,"microenvironment"
"2019.07.01.count.2.GGAGGTATCTAATTCC","AML-3133","2019-07-01-count-2:GGAGGTATCTAATTCC",1.31923880156819,10.8022298582825,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GGAGGTATCTAATTCC","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0","0","0.0",0,0,"0.0","0,44",0,"0",0,0,0,0,"0,44",0,"0.0","0.05
0.08",0,0,"0",0,0,0,"0",0,"0","0.0",0,"0",0,"AML","case","T","CD4_T",1976.70624695936,27.3052409874268,0.0138135046769993,1264,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1969.36674302881,1969.36674302881,"microenvironment"
"2019.07.01.count.2.AACACACCATGTGTCA","AML-3133","2019-07-01-count-2:AACACACCATGTGTCA",1.18615915355031,10.4412488707337,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.AACACACCATGTGTCA","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0","0","0.0",0,0,"0.0","0,44",0,"0",0,0,0,0,"0,44",0,"0.0","0.05
0.08",0,0,"0",0,0,0,"0",0,"0","0.0",0,"0",0,"AML","case","T","CD4_T",1953.2264933791,34.7673742250307,0.0177999706346819,1267,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1946.11086484167,1946.11086484167,"microenvironment"
"2019.07.01.count.2.CCCATTGCACAAGCAG","AML-3133","2019-07-01-count-2:CCCATTGCACAAGCAG",0.656023164361161,12.8450174101624,"2019-07-01-count-2","AML3133","NK","IFN+ NK",22,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0849639546858908,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CCCATTGCACAAGCAG","NK","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0","0","0.0",0,0,"0.0","0,44",0,"0",0,0,0,0,"0,44",0,"0.0","0.05
0.08",0,0,"0",0,0,0,"0",0,"0","0.0",0,"0",0,"AML","case","NK","NK",1583.91125171637,49.9059176608131,0.0315080264798508,654,30000,1100,500,"True","True","True","True",5,150,"True","NK_AML-3133",1579.49269404229,1579.49269404229,"microenvironment"
"2019.07.01.count.3.CACACAAAGTGGGAAA","AML-3133","2019-07-01-count-3:CACACAAAGTGGGAAA",4.10018314894978,-10.7370786896911,"2019-07-01-count-3","AML3133","CD16+ monocyte","CD16+",61,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.348251748251748,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CACACAAAGTGGGAAA","CD16+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0","0","0.0",0,0,"0.0","0,44",0,"0",0,0,0,0,"0,44",0,"0.0","0.05
0.08",0,0,"0",0,0,0,"0",0,"0","0.0",0,"0",0,"AML","case","Mono","Mono",2175.85604109558,43.1860455004145,0.0198478413483042,1243,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2173.14142149222,2173.14142149222,"microenvironment"
"2019.07.01.count.3.GAGTCATTCGTTGTTT","AML-3133","2019-07-01-count-3:GAGTCATTCGTTGTTT",1.06462564048116,12.2947158583435,"2019-07-01-count-3","AML3133","CD4+ T","CD4+ Activated",22,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0849639546858908,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GAGTCATTCGTTGTTT","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1769.97622283157,36.0321969561527,0.0203574468918623,882,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1766.71023328639,1766.71023328639,"microenvironment"
"2019.07.01.count.1.CATTGAGTCCACGGAC","AML-3133","2019-07-01-count-1:CATTGAGTCCACGGAC",3.82478394088094,-10.3134651414123,"2019-07-01-count-1","AML3133","HLA-II+ monocyte","HLA-II+",51,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.310810810810811,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CATTGAGTCCACGGAC","HLA-II+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",1975.08673391421,41.0799736830766,0.0207990732648306,911,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",1971.39221020011,1971.39221020011,"microenvironment"
"2019.07.01.count.2.CTCAACCAGTCGCTAT","AML-3133","2019-07-01-count-2:CTCAACCAGTCGCTAT",-2.71613798561748,10.4048175581726,"2019-07-01-count-2","AML3133","CD8+ T","CD8+ Cytotoxic",5,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.193189259986902,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CTCAACCAGTCGCTAT","CD8+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2020.09556436628,34.2370351243983,0.0169482254841438,986,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",2016.6540097369,2016.6540097369,"microenvironment"
"2019.07.01.count.2.GACTATGAGCGTCTCG","AML-3133","2019-07-01-count-2:GACTATGAGCGTCTCG",3.65357961234395,-10.8095960847107,"2019-07-01-count-2","AML3133","CD16+ monocyte","CD16+",61,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.348251748251748,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GACTATGAGCGTCTCG","CD16+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2354.59335169748,44.370453675473,0.018844210888256,1490,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2347.21368331461,2347.21368331461,"microenvironment"
"2019.07.01.count.1.TGATTTCCACCATTCC","AML-3133","2019-07-01-count-1:TGATTTCCACCATTCC",-1.35319707813914,-9.59376718914183,"2019-07-01-count-1","AML3133","Granulocyte","Granulocytes",35,"CNV-","malignant","AML","adult_AML","adult_younger60","male","Inflammation_low",0.965034965034965,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TGATTTCCACCATTCC","Granulocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Gran","Gran",2555.97118813012,44.7667774832257,0.0175145861154937,1727,30000,1100,500,"True","True","True","True",5,23,"True","Gran_AML-3133",2547.83706080323,2547.83706080323,"malignant"
"2019.07.01.count.1.AGACAGGTCAACCTTT","AML-3133","2019-07-01-count-1:AGACAGGTCAACCTTT",4.11960711058919,-10.9016275635925,"2019-07-01-count-1","AML3133","CD16+ monocyte","CD16+",61,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.348251748251748,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.AGACAGGTCAACCTTT","CD16+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2321.48038976693,43.1089707019584,0.0185696036425647,1748,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2318.79535271456,2318.79535271456,"microenvironment"
"2019.07.01.count.1.CAACGATAGCGGCTCT","AML-3133","2019-07-01-count-1:CAACGATAGCGGCTCT",8.78578438338582,7.25781486118165,"2019-07-01-count-1","AML3133","B","Activated NFkB",0,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0784499054820416,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CAACGATAGCGGCTCT","B","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",1856.92407435158,32.1867472552317,0.0173333674218592,945,30000,1100,500,"True","True","True","True",5,240,"True","B_AML-3133",1853.67612075578,1853.67612075578,"microenvironment"
"2019.07.01.count.1.GTCTCACCACTGGATT","AML-3133","2019-07-01-count-1:GTCTCACCACTGGATT",0.263588463037652,-9.81924440776976,"2019-07-01-count-1","AML3133","CD14+ monocyte","CD14+",51,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.310810810810811,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GTCTCACCACTGGATT","CD14+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2174.38663412823,45.5738473611503,0.0209594037444137,1152,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2169.99822009648,2169.99822009648,"microenvironment"
"2019.07.01.count.1.AACGAAAGTTCGGCCA","AML-3133","2019-07-01-count-1:AACGAAAGTTCGGCCA",-7.9516376060551,0.212416551354803,"2019-07-01-count-1","AML3133","MPP","MPP_GMP",27,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0099502487562189,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.AACGAAAGTTCGGCCA","MPP","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2654.93835605903,40.628917756365,0.0153031491912582,2956,30000,1100,500,"True","True","True","True",5,250,"True","HSPC_AML-3133",2649.00075411003,2649.00075411003,"microenvironment"
"2019.07.01.count.3.CTGTGGGTCGGCTGTG","AML-3133","2019-07-01-count-3:CTGTGGGTCGGCTGTG",0.955080767243546,10.7093105086121,"2019-07-01-count-3","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CTGTGGGTCGGCTGTG","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1504.00495620334,45.5469867747059,0.0302838009853925,652,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1498.23325472759,1498.23325472759,"microenvironment"
"2019.07.01.count.2.AGCGCTGAGTCAACAA","AML-3133","2019-07-01-count-2:AGCGCTGAGTCAACAA",8.62719883498494,7.30198237979738,"2019-07-01-count-2","AML3133","B","Activated AP-1",0,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0784499054820416,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.AGCGCTGAGTCAACAA","B","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",1739.24734732679,48.3850357821749,0.0278195254151414,862,30000,1100,500,"True","True","True","True",5,240,"True","B_AML-3133",1730.99628748702,1730.99628748702,"microenvironment"
"2019.07.01.count.1.ACGGTTACAGTGGGTA","AML-3133","2019-07-01-count-1:ACGGTTACAGTGGGTA",1.31928612765614,10.1695451506409,"2019-07-01-count-1","AML3133","CD4+ T","CD4+ Naive",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.ACGGTTACAGTGGGTA","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1891.29323058559,29.6044544197023,0.0156530219327947,1110,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1887.36137486463,1887.36137486463,"microenvironment"
"2019.07.01.count.1.TACGGTAGTTTCGTTT","AML-3133","2019-07-01-count-1:TACGGTAGTTTCGTTT",2.31679596480672,-10.5019989243713,"2019-07-01-count-1","AML3133","CD11c+","CD11c+",35,"CNV-","malignant","AML","adult_AML","adult_younger60","male","Inflammation_low",0.965034965034965,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TACGGTAGTTTCGTTT","CD11c+","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2827.42161934613,45.2030284241442,0.0159873674710735,2572,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2819.3557114365,2819.3557114365,"malignant"
"2019.07.01.count.2.AGAAGTACACCAGGTC","AML-3133","2019-07-01-count-2:AGAAGTACACCAGGTC",1.20591690120046,10.9204063185486,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.AGAAGTACACCAGGTC","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1755.42984781748,31.9726769861845,0.018213588555496,1027,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1751.45663671792,1751.45663671792,"microenvironment"
"2019.07.01.count.2.CAGTGCGCATTGGGAG","AML-3133","2019-07-01-count-2:CAGTGCGCATTGGGAG",-7.38526139679607,0.444252259376921,"2019-07-01-count-2","AML3133","GMP","GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.584821428571429,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CAGTGCGCATTGGGAG","GMP","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2561.85734943413,48.5404385330991,0.0189473619769738,1792,30000,1100,500,"True","True","True","True",5,250,"True","HSPC_AML-3133",2556.3259654302,2556.3259654302,"microenvironment"
"2019.07.01.count.2.ATCTTCATCCGACGGT","AML-3133","2019-07-01-count-2:ATCTTCATCCGACGGT",1.33328320559804,9.54462525928346,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.ATCTTCATCCGACGGT","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1868.39384425747,37.1718695840697,0.0198950931562517,1037,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1864.01551452819,1864.01551452819,"microenvironment"
"2019.07.01.count.1.GAGGGATGTTACACTG","AML-3133","2019-07-01-count-1:GAGGGATGTTACACTG",-2.8055776161259,13.2690887221131,"2019-07-01-count-1","AML3133","NK","Activated NK",6,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0422213769494104,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GAGGGATGTTACACTG","NK","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2209.70702700551,37.8836205795448,0.0171441825167578,1244,30000,1100,500,"True","True","True","True",5,150,"True","NK_AML-3133",2205.30444640365,2205.30444640365,"microenvironment"
"2019.07.01.count.1.CCTCATGCATTAGGAA","AML-3133","2019-07-01-count-1:CCTCATGCATTAGGAA",-2.29192576828654,11.4983415373596,"2019-07-01-count-1","AML3133","CD8+ T","CD8+ Cytotoxic",6,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0422213769494104,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CCTCATGCATTAGGAA","CD8+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",1961.51051182756,37.8242060150971,0.0192832033206164,1030,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1958.63285769918,1958.63285769918,"microenvironment"
"2019.07.01.count.1.AACCCAAAGTCCTGTA","AML-3133","2019-07-01-count-1:AACCCAAAGTCCTGTA",-7.29429374161418,0.848177469614424,"2019-07-01-count-1","AML3133","GMP","GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.584821428571429,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.AACCCAAAGTCCTGTA","GMP","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2195.4930739157,40.9923253827222,0.0186711248920552,1461,30000,1100,500,"True","True","True","True",5,250,"True","HSPC_AML-3133",2188.93642825575,2188.93642825575,"microenvironment"
"2019.07.01.count.1.CTGTATTCAATTGCGT","AML-3133","2019-07-01-count-1:CTGTATTCAATTGCGT",-2.2613550228184,9.87749765003053,"2019-07-01-count-1","AML3133","CD8+ T","CD8+ IFN+",15,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0119920053297801,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CTGTATTCAATTGCGT","CD8+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",1974.25926523659,37.3233797042263,0.0189050042015397,1039,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1972.6932386784,1972.6932386784,"microenvironment"
"2019.07.01.count.1.CCACAAAAGGAGGGTG","AML-3133","2019-07-01-count-1:CCACAAAAGGAGGGTG",1.04031928357427,11.424271560553,"2019-07-01-count-1","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CCACAAAAGGAGGGTG","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2209.18425189963,30.2387434887888,0.0136877417367009,1403,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",2201.84617683444,2201.84617683444,"microenvironment"
"2019.07.01.count.2.ACCACAAAGCGAAACC","AML-3133","2019-07-01-count-2:ACCACAAAGCGAAACC",1.26224865493123,11.7096652754578,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.ACCACAAAGCGAAACC","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1912.26184787331,42.7230983667763,0.0223416570352486,1084,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1908.04075484021,1908.04075484021,"microenvironment"
"2019.07.01.count.1.CCACACTGTCCACAGC","AML-3133","2019-07-01-count-1:CCACACTGTCCACAGC",1.13287128981892,10.2955207594666,"2019-07-01-count-1","AML3133","CD4+ T","CD4+ Naive",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CCACACTGTCCACAGC","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2087.07981778046,38.3493715428424,0.0183746549682157,1282,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",2079.36695578267,2079.36695578267,"microenvironment"
"2019.07.01.count.2.GTTTACTAGTGCACCC","AML-3133","2019-07-01-count-2:GTTTACTAGTGCACCC",1.3541370826656,9.93317601764528,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ Naive",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GTTTACTAGTGCACCC","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1750.59815458033,33.0613343720089,0.0188857358757668,928,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1744.44629551316,1744.44629551316,"microenvironment"
"2019.07.01.count.2.TCCGAAAGTCAGACTT","AML-3133","2019-07-01-count-2:TCCGAAAGTCAGACTT",0.735101540654343,12.4073228606018,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ Activated",22,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0849639546858908,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.TCCGAAAGTCAGACTT","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1901.70990562651,38.5346971935895,0.0202631837167059,981,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1900.12757474541,1900.12757474541,"microenvironment"
"2019.07.01.count.2.TCCGATCAGGTCGTAG","AML-3133","2019-07-01-count-2:TCCGATCAGGTCGTAG",3.87840809401814,-10.7601080170837,"2019-07-01-count-2","AML3133","CD16+ monocyte","CD16+",61,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.348251748251748,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.TCCGATCAGGTCGTAG","CD16+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2014.31617220512,43.2287839854041,0.0214607739251185,998,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2009.37645845322,2009.37645845322,"microenvironment"
"2019.07.01.count.2.CGGCAGTTCTACGCGG","AML-3133","2019-07-01-count-2:CGGCAGTTCTACGCGG",-0.944622139365035,11.3619346388611,"2019-07-01-count-2","AML3133","CD8+ T","CD8+ GZMK+",5,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.193189259986902,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CGGCAGTTCTACGCGG","CD8+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",1787.32274644835,41.1037845523024,0.0229974047127085,825,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1779.99006498381,1779.99006498381,"microenvironment"
"2019.07.01.count.3.CTACAGAAGTTACTCG","AML-3133","2019-07-01-count-3:CTACAGAAGTTACTCG",0.498464902012986,10.4341449507507,"2019-07-01-count-3","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CTACAGAAGTTACTCG","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1574.19002982595,41.3166001131528,0.0262462595559197,742,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1574.19002982595,1574.19002982595,"microenvironment"
"2019.07.01.count.3.AAAGTCCGTATGGAAT","AML-3133","2019-07-01-count-3:AAAGTCCGTATGGAAT",0.449452121823472,9.76808927142946,"2019-07-01-count-3","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.AAAGTCCGTATGGAAT","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1693.05973376526,41.2000757171379,0.024334685242033,819,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1684.62259549475,1684.62259549475,"microenvironment"
"2019.07.01.count.2.TGCTTGCCAATAGTAG","AML-3133","2019-07-01-count-2:TGCTTGCCAATAGTAG",1.2314473586971,10.5966224440369,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.TGCTTGCCAATAGTAG","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1808.63021460641,33.511867251423,0.0185288661998361,1054,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1804.6301361293,1804.6301361293,"microenvironment"
"2019.07.01.count.3.AGATCGTTCTGGGAGA","AML-3133","2019-07-01-count-3:AGATCGTTCTGGGAGA",-1.75607107105907,11.2972545393738,"2019-07-01-count-3","AML3133","CD8+ T","CD8+ Cytotoxic",5,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.193189259986902,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.AGATCGTTCTGGGAGA","CD8+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",1511.19408371954,46.1006162541598,0.0305060857177863,622,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1509.0816697948,1509.0816697948,"microenvironment"
"2019.07.01.count.3.GAGATGGGTGTAGCAG","AML-3133","2019-07-01-count-3:GAGATGGGTGTAGCAG",4.24436106261556,-10.6491508713928,"2019-07-01-count-3","AML3133","CD16+ monocyte","CD16+",61,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.348251748251748,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GAGATGGGTGTAGCAG","CD16+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2038.1129357381,45.0455887979071,0.0221016156700826,1044,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2034.94109582975,2034.94109582975,"microenvironment"
"2019.07.01.count.3.CAGATACGTACGAGCA","AML-3133","2019-07-01-count-3:CAGATACGTACGAGCA",0.217834209173363,11.4831800230774,"2019-07-01-count-3","AML3133","CD4+ T","CD4+ TCM",5,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.193189259986902,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CAGATACGTACGAGCA","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1349.64359682985,43.2832687218863,0.0320701471288816,508,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1347.30939726502,1347.30939726502,"microenvironment"
"2019.07.01.count.1.ATAGAGATCCTAACAG","AML-3133","2019-07-01-count-1:ATAGAGATCCTAACAG",-7.57652364197429,1.15273783290712,"2019-07-01-count-1","AML3133","GMP","GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.584821428571429,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.ATAGAGATCCTAACAG","GMP","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2381.87684129127,43.178077454794,0.0181277540073761,2097,30000,1100,500,"True","True","True","True",5,250,"True","HSPC_AML-3133",2374.30793892909,2374.30793892909,"microenvironment"
"2019.07.01.count.1.GTGCACGTCCGAGAAG","AML-3133","2019-07-01-count-1:GTGCACGTCCGAGAAG",1.03692670640294,8.53472611987916,"2019-07-01-count-1","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GTGCACGTCCGAGAAG","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1791.74015157719,34.4086970623583,0.0192040665227431,1134,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1785.71322189806,1785.71322189806,"microenvironment"
"2019.07.01.count.2.GCCCGAACAGCGGTCT","AML-3133","2019-07-01-count-2:GCCCGAACAGCGGTCT",1.09628500518147,10.7085466154846,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GCCCGAACAGCGGTCT","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1886.78093807762,36.7110244073281,0.0194569616781966,1029,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1879.3277149159,1879.3277149159,"microenvironment"
"2019.07.01.count.1.ACAGCCGGTCCTCATC","AML-3133","2019-07-01-count-1:ACAGCCGGTCCTCATC",1.68309619006459,-10.5813751450744,"2019-07-01-count-1","AML3133","CD11c+","CD11c+",61,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.348251748251748,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.ACAGCCGGTCCTCATC","CD11c+","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2503.86655209426,47.9235436941167,0.019139815440257,1657,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2500.45511682581,2500.45511682581,"microenvironment"
"2019.07.01.count.1.CCCTTAGAGAAACCCG","AML-3133","2019-07-01-count-1:CCCTTAGAGAAACCCG",1.41725053366963,-9.94007685100707,"2019-07-01-count-1","AML3133","CD14+ monocyte","CD14+",10,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.407407407407407,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CCCTTAGAGAAACCCG","CD14+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",1705.42174452028,51.7711900790642,0.0303568253690978,909,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",1700.68896638983,1700.68896638983,"microenvironment"
"2019.07.01.count.3.AGGGCCTAGGAACTAT","AML-3133","2019-07-01-count-3:AGGGCCTAGGAACTAT",-3.15565143051799,12.8935565718445,"2019-07-01-count-3","AML3133","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0422213769494104,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.AGGGCCTAGGAACTAT","NK","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2161.63385251442,31.7053528485718,0.0146673095499925,1025,30000,1100,500,"True","True","True","True",5,150,"True","NK_AML-3133",2158.03152101423,2158.03152101423,"microenvironment"
"2019.07.01.count.1.AGGGTGAAGTCCCTAA","AML-3133","2019-07-01-count-1:AGGGTGAAGTCCCTAA",0.976296265690964,10.9258785017761,"2019-07-01-count-1","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.AGGGTGAAGTCCCTAA","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1754.70248568732,34.6166849969649,0.0197279511936209,923,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1750.19908169501,1750.19908169501,"microenvironment"
"2019.07.01.count.2.AGTCAACTCCCTTCCC","AML-3133","2019-07-01-count-2:AGTCAACTCCCTTCCC",1.47336973723714,11.0024194487366,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.AGTCAACTCCCTTCCC","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1895.52940757884,39.7568858082711,0.0209740274402035,898,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1890.07763083258,1890.07763083258,"microenvironment"
"2019.07.01.count.1.GTTGTGAGTTGTTGAC","AML-3133","2019-07-01-count-1:GTTGTGAGTTGTTGAC",1.4379184442455,-10.3820667496887,"2019-07-01-count-1","AML3133","CD14+ monocyte","CD14+",35,"CNV-","malignant","AML","adult_AML","adult_younger60","male","Inflammation_low",0.965034965034965,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GTTGTGAGTTGTTGAC","CD14+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2484.09045486282,43.9589689204196,0.0176962029842215,1992,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2475.57344176659,2475.57344176659,"malignant"
"2019.07.01.count.2.ACTACGATCGACATCA","AML-3133","2019-07-01-count-2:ACTACGATCGACATCA",1.10210003432576,10.191475845221,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.ACTACGATCGACATCA","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1811.52153930027,36.2344806864162,0.0200022356346987,1033,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1804.62747391826,1804.62747391826,"microenvironment"
"2019.07.01.count.1.AGTTCGAAGGTAACTA","AML-3133","2019-07-01-count-1:AGTTCGAAGGTAACTA",-3.40573988381084,10.1916932829651,"2019-07-01-count-1","AML3133","CD8+ T","CD8+ Cytotoxic",5,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.193189259986902,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.AGTTCGAAGGTAACTA","CD8+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2003.50011350684,35.609659764432,0.0177737248550001,1047,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1995.50182058114,1995.50182058114,"microenvironment"
"2019.07.01.count.3.AGCTACACAGGGTCTC","AML-3133","2019-07-01-count-3:AGCTACACAGGGTCTC",1.75962259349172,-10.1862526169983,"2019-07-01-count-3","AML3133","CD14+ monocyte","CD14+",35,"CNV-","malignant","AML","adult_AML","adult_younger60","male","Inflammation_low",0.965034965034965,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.AGCTACACAGGGTCTC","CD14+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2436.24120857101,49.7061669632015,0.0204028101931487,1600,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2431.69974626521,2431.69974626521,"malignant"
"2019.07.01.count.1.CCTCATGAGGATTCCT","AML-3133","2019-07-01-count-1:CCTCATGAGGATTCCT",8.58253349837605,7.88030765140382,"2019-07-01-count-1","AML3133","B","Activated AP-1",0,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0784499054820416,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CCTCATGAGGATTCCT","B","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",2067.66864510406,32.2462433283517,0.0155954598454188,1170,30000,1100,500,"True","True","True","True",5,240,"True","B_AML-3133",2059.09083761325,2059.09083761325,"microenvironment"
"2019.07.01.count.1.GCCGATGTCGGTGAAG","AML-3133","2019-07-01-count-1:GCCGATGTCGGTGAAG",-7.65594039383586,1.62710163677064,"2019-07-01-count-1","AML3133","MPP","MPP_GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.584821428571429,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GCCGATGTCGGTGAAG","MPP","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2474.43943753727,37.5265795383472,0.0151656892341226,2328,30000,1100,500,"True","True","True","True",5,250,"True","HSPC_AML-3133",2468.65653628982,2468.65653628982,"microenvironment"
"2019.07.01.count.2.TCTACATTCTTGCAAG","AML-3133","2019-07-01-count-2:TCTACATTCTTGCAAG",-8.44758925858195,0.107088937703051,"2019-07-01-count-2","AML3133","MPP","MPP_GMP",37,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0980392156862745,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.TCTACATTCTTGCAAG","MPP","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2812.96576350266,41.8342853104005,0.0148719496885412,2959,30000,1100,500,"True","True","True","True",5,250,"True","HSPC_AML-3133",2800.92979720015,2800.92979720015,"microenvironment"
"2019.07.01.count.3.TGTTTGTTCCATTCGC","AML-3133","2019-07-01-count-3:TGTTTGTTCCATTCGC",1.56989159163777,10.9674262770447,"2019-07-01-count-3","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.TGTTTGTTCCATTCGC","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1757.04469289068,37.3134549440733,0.021236485955679,957,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1755.62330235849,1755.62330235849,"microenvironment"
"2019.07.01.count.1.AGGGCTCTCGTTATCT","AML-3133","2019-07-01-count-1:AGGGCTCTCGTTATCT",-7.89948783341106,4.16186521137086,"2019-07-01-count-1","AML3133","HSC","HSC",16,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.466666666666667,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.AGGGCTCTCGTTATCT","HSC","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2150.57184179856,28.6111284777878,0.0133039631235289,1799,30000,1100,500,"True","True","True","True",5,250,"True","HSPC_AML-3133",2141.34745924685,2141.34745924685,"microenvironment"
"2019.07.01.count.3.TCATTCAGTGTTAAAG","AML-3133","2019-07-01-count-3:TCATTCAGTGTTAAAG",10.9065920310909,-0.648664497491442,"2019-07-01-count-3","AML3133","Ery","Ery-7",58,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.490566037735849,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.TCATTCAGTGTTAAAG","Ery","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Ery","Ery",1381.27728479283,11.8108237718203,0.008550653733216,1139,30000,1100,500,"True","True","True","True",5,46,"True","Ery_AML-3133",1374.28658878483,1374.28658878483,"microenvironment"
"2019.07.01.count.2.GTAGGTTTCATCGCTC","AML-3133","2019-07-01-count-2:GTAGGTTTCATCGCTC",1.81454112109486,-10.2316923371521,"2019-07-01-count-2","AML3133","CD14+ monocyte","CD14+",35,"CNV-","malignant","AML","adult_AML","adult_younger60","male","Inflammation_low",0.965034965034965,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GTAGGTTTCATCGCTC","CD14+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2327.55511643117,45.7812265960376,0.0196692341559816,1611,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2322.41013034351,2322.41013034351,"malignant"
"2019.07.01.count.3.AAACGCTTCATCGCTC","AML-3133","2019-07-01-count-3:AAACGCTTCATCGCTC",1.1042409139568,10.3704719313416,"2019-07-01-count-3","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.AAACGCTTCATCGCTC","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2054.35215541526,41.7923130327379,0.0203433052714812,1189,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",2048.84600893412,2048.84600893412,"microenvironment"
"2019.07.01.count.2.CATTGTTCAGTAGGAC","AML-3133","2019-07-01-count-2:CATTGTTCAGTAGGAC",-7.38190541687663,-0.0099786004987583,"2019-07-01-count-2","AML3133","GMP","GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.584821428571429,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CATTGTTCAGTAGGAC","GMP","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",1528.26133982528,54.3716461538258,0.0355774531076222,606,30000,1100,500,"True","True","True","True",5,250,"True","HSPC_AML-3133",1523.7594968402,1523.7594968402,"microenvironment"
"2019.07.01.count.1.TGTCCTGAGCAGCACA","AML-3133","2019-07-01-count-1:TGTCCTGAGCAGCACA",1.01842453059499,12.5741319426331,"2019-07-01-count-1","AML3133","CD4+ T","CD4+ Activated",22,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0849639546858908,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TGTCCTGAGCAGCACA","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1829.27058718747,29.0646398632802,0.0158886498623298,873,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1827.50508372067,1827.50508372067,"microenvironment"
"2019.07.01.count.1.CCTACGTCAGACAATA","AML-3133","2019-07-01-count-1:CCTACGTCAGACAATA",1.12290944632832,10.2985172041687,"2019-07-01-count-1","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CCTACGTCAGACAATA","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2005.86816822874,39.6112693175413,0.0197476932656645,1166,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1998.96464237069,1998.96464237069,"microenvironment"
"2019.07.01.count.3.CAACCAACAAAGCAAT","AML-3133","2019-07-01-count-3:CAACCAACAAAGCAAT",-2.46891818466838,13.5146732100281,"2019-07-01-count-3","AML3133","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0422213769494104,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CAACCAACAAAGCAAT","NK","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",1844.34094207536,31.3716663419648,0.0170096892750554,798,30000,1100,500,"True","True","True","True",5,150,"True","NK_AML-3133",1844.34094207536,1844.34094207536,"microenvironment"
"2019.07.01.count.1.GCAGGCTCACATATCG","AML-3133","2019-07-01-count-1:GCAGGCTCACATATCG",-1.33267734471019,11.5901145705017,"2019-07-01-count-1","AML3133","CD8+ T","CD8+ Cytotoxic",5,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.193189259986902,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GCAGGCTCACATATCG","CD8+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2202.04285015518,34.7667605609381,0.0157884123637685,1203,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",2200.51186288541,2200.51186288541,"microenvironment"
"2019.07.01.count.2.CGAAGGACAATCCTAG","AML-3133","2019-07-01-count-2:CGAAGGACAATCCTAG",8.44673504409139,7.4237112768921,"2019-07-01-count-2","AML3133","B","Activated AP-1",0,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0784499054820416,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CGAAGGACAATCCTAG","B","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",1765.86396776273,44.8702871900291,0.0254098209200552,884,30000,1100,500,"True","True","True","True",5,240,"True","B_AML-3133",1760.99307116555,1760.99307116555,"microenvironment"
"2019.07.01.count.1.GCATTAGGTTACCCAA","AML-3133","2019-07-01-count-1:GCATTAGGTTACCCAA",-7.51666627350505,0.822102702501692,"2019-07-01-count-1","AML3133","GMP","GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.584821428571429,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GCATTAGGTTACCCAA","GMP","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2469.13867443228,48.1759765719817,0.0195112478172408,1712,30000,1100,500,"True","True","True","True",5,250,"True","HSPC_AML-3133",2464.74157760362,2464.74157760362,"microenvironment"
"2019.07.01.count.3.CAGTGCGGTTACCTGA","AML-3133","2019-07-01-count-3:CAGTGCGGTTACCTGA",3.76821126517598,-11.27139952099,"2019-07-01-count-3","AML3133","CD16+ monocyte","CD16+",61,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.348251748251748,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CAGTGCGGTTACCTGA","CD16+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",1838.99128219083,46.3872610572441,0.0252242963337934,849,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",1837.13679353983,1837.13679353983,"microenvironment"
"2019.07.01.count.2.CCGTAGGGTATCACCA","AML-3133","2019-07-01-count-2:CCGTAGGGTATCACCA",1.03691156682317,11.4477967985901,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CCGTAGGGTATCACCA","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1693.4274404079,43.8433392829841,0.0258902969426451,829,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1688.42231056396,1688.42231056396,"microenvironment"
"2019.07.01.count.2.TACCCACTCCTTGACC","AML-3133","2019-07-01-count-2:TACCCACTCCTTGACC",-7.5420335334843,0.636247969511427,"2019-07-01-count-2","AML3133","GMP","GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.584821428571429,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.TACCCACTCCTTGACC","GMP","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2455.04541230958,46.4744949291546,0.0189301976640154,1384,30000,1100,500,"True","True","True","True",5,250,"True","HSPC_AML-3133",2447.54982060413,2447.54982060413,"microenvironment"
"2019.07.01.count.3.GTCTAGAGTGCATTTG","AML-3133","2019-07-01-count-3:GTCTAGAGTGCATTTG",0.869664509862107,9.5021180876526,"2019-07-01-count-3","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GTCTAGAGTGCATTTG","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1738.34808781684,38.5130065607656,0.0221549451635623,871,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1738.34808781684,1738.34808781684,"microenvironment"
"2019.07.01.count.3.CGAGTGCAGAGGTGCT","AML-3133","2019-07-01-count-3:CGAGTGCAGAGGTGCT",-3.5374780696934,13.4602002867493,"2019-07-01-count-3","AML3133","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0422213769494104,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CGAGTGCAGAGGTGCT","NK","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",1964.18692344854,42.704335257552,0.0217414823140028,867,30000,1100,500,"True","True","True","True",5,150,"True","NK_AML-3133",1962.21967266566,1962.21967266566,"microenvironment"
"2019.07.01.count.3.CACAGATGTTGCACGC","AML-3133","2019-07-01-count-3:CACAGATGTTGCACGC",1.27018656310384,10.3650645979675,"2019-07-01-count-3","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CACAGATGTTGCACGC","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1702.88851849054,40.5455159781694,0.0238098475254913,836,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1698.99500250105,1698.99500250105,"microenvironment"
"2019.07.01.count.3.AGGCATTAGCATTGAA","AML-3133","2019-07-01-count-3:AGGCATTAGCATTGAA",8.00176729735677,7.30166242206422,"2019-07-01-count-3","AML3133","B","Activated NFkB",0,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0784499054820416,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.AGGCATTAGCATTGAA","B","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",1681.23573675235,35.2017713652035,0.0209380342064361,764,30000,1100,500,"True","True","True","True",5,240,"True","B_AML-3133",1675.92203709724,1675.92203709724,"microenvironment"
"2019.07.01.count.1.TGATGCAGTGTCTTCC","AML-3133","2019-07-01-count-1:TGATGCAGTGTCTTCC",1.31137623366658,10.9898862608704,"2019-07-01-count-1","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TGATGCAGTGTCTTCC","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1898.15579546401,29.2813427046104,0.0154262062021376,1268,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1895.94215546178,1895.94215546178,"microenvironment"
"2019.07.01.count.2.AAGCATCAGGACGCAT","AML-3133","2019-07-01-count-2:AAGCATCAGGACGCAT",0.786569495766801,10.4077367552551,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.AAGCATCAGGACGCAT","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1579.2380765924,51.6700242929062,0.0327183247787422,644,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1572.58301458337,1572.58301458337,"microenvironment"
"2019.07.01.count.3.ACCCAAATCCGGCAAC","AML-3133","2019-07-01-count-3:ACCCAAATCCGGCAAC",1.21172751960103,9.94037435138551,"2019-07-01-count-3","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.ACCCAAATCCGGCAAC","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1807.62055431211,34.6694019705628,0.0191795794133113,1006,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1802.01655279127,1802.01655279127,"microenvironment"
"2019.07.01.count.2.GCTACCTCAGTTCACA","AML-3133","2019-07-01-count-2:GCTACCTCAGTTCACA",0.330992003052872,13.8223972090515,"2019-07-01-count-2","AML3133","CD8+ T","CD8+ IFN+",22,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0849639546858908,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GCTACCTCAGTTCACA","CD8+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",1898.55492816361,33.2099696386333,0.0174922353554216,934,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1888.36000683044,1888.36000683044,"microenvironment"
"2019.07.01.count.3.GTGCGTGAGCAGAAAG","AML-3133","2019-07-01-count-3:GTGCGTGAGCAGAAAG",0.712680478661698,10.9076900252136,"2019-07-01-count-3","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GTGCGTGAGCAGAAAG","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1985.59038516431,42.2873031355477,0.0212970930215541,1096,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1982.63332755004,1982.63332755004,"microenvironment"
"2019.07.01.count.1.TCCTTTCGTGGCTTAT","AML-3133","2019-07-01-count-1:TCCTTTCGTGGCTTAT",1.10907806929891,9.2237977751526,"2019-07-01-count-1","AML3133","CD4+ T","CD4+ Naive",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.TCCTTTCGTGGCTTAT","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2027.97987382388,32.0625161188817,0.0158100760923361,1147,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",2023.63947344818,2023.63947344818,"microenvironment"
"2019.07.01.count.2.GCAGTTAAGAGAGGTA","AML-3133","2019-07-01-count-2:GCAGTTAAGAGAGGTA",7.94785704192464,6.74884984577028,"2019-07-01-count-2","AML3133","B","Naive B",0,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0784499054820416,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GCAGTTAAGAGAGGTA","B","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",1689.70844164894,34.0085458579771,0.0201268721986079,801,30000,1100,500,"True","True","True","True",5,240,"True","B_AML-3133",1682.79873581579,1682.79873581579,"microenvironment"
"2019.07.01.count.2.GGGAGATTCTACTTCA","AML-3133","2019-07-01-count-2:GGGAGATTCTACTTCA",1.32088865813557,10.109574294928,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ Naive",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GGGAGATTCTACTTCA","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1666.92445538372,34.7448613943987,0.0208436928753322,878,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1662.38816846761,1662.38816846761,"microenvironment"
"2019.07.01.count.2.AGTGCCGTCTGGTGGC","AML-3133","2019-07-01-count-2:AGTGCCGTCTGGTGGC",8.40003838118855,7.21068427646486,"2019-07-01-count-2","AML3133","B","Activated AP-1",0,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0784499054820416,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.AGTGCCGTCTGGTGGC","B","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",1882.38465794597,36.2314325456426,0.0192476242263777,813,30000,1100,500,"True","True","True","True",5,240,"True","B_AML-3133",1880.36930929785,1880.36930929785,"microenvironment"
"2019.07.01.count.1.AACAACCAGGCGCTTC","AML-3133","2019-07-01-count-1:AACAACCAGGCGCTTC",0.94232209500615,11.5612678297791,"2019-07-01-count-1","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.AACAACCAGGCGCTTC","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2034.56025845147,38.8317459303765,0.0190860633245298,1187,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",2026.50218269321,2026.50218269321,"microenvironment"
"2019.07.01.count.2.CAGGTATGTATCCCAA","AML-3133","2019-07-01-count-2:CAGGTATGTATCCCAA",0.957223852246445,11.5819625624451,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ TCM",22,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0849639546858908,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CAGGTATGTATCCCAA","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1831.39995943444,38.7690841151343,0.0211690973975487,1016,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1827.11434695372,1827.11434695372,"microenvironment"
"2019.07.01.count.1.GCCGATGGTTTCGTGA","AML-3133","2019-07-01-count-1:GCCGATGGTTTCGTGA",9.56164230880086,6.77494094455568,"2019-07-01-count-1","AML3133","pDC","pDC",0,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.0784499054820416,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GCCGATGGTTTCGTGA","pDC","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","DC","pDC",1859.87914129286,43.3549967696892,0.0233106527231397,1055,30000,1100,500,"True","True","True","True",5,9,"True","DC_AML-3133",1859.87914129286,1859.87914129286,"microenvironment"
"2019.07.01.count.3.CACAGGCTCTCATGCC","AML-3133","2019-07-01-count-3:CACAGGCTCTCATGCC",-7.41482625427898,0.520967818144239,"2019-07-01-count-3","AML3133","GMP","GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.584821428571429,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.CACAGGCTCTCATGCC","GMP","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2137.00036262669,51.8316057712569,0.0242543738773859,1161,30000,1100,500,"True","True","True","True",5,250,"True","HSPC_AML-3133",2132.4142730606,2132.4142730606,"microenvironment"
"2019.07.01.count.3.GTAACCAAGGAGACCT","AML-3133","2019-07-01-count-3:GTAACCAAGGAGACCT",1.41336776789967,10.4569587477478,"2019-07-01-count-3","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GTAACCAAGGAGACCT","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1703.20575453087,34.729451032837,0.0203906374438025,948,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1697.68813085893,1697.68813085893,"microenvironment"
"2019.07.01.count.3.ATCAGGTAGCTAGTTC","AML-3133","2019-07-01-count-3:ATCAGGTAGCTAGTTC",-1.75652227822002,11.7386531599793,"2019-07-01-count-3","AML3133","CD8+ T","CD8+ Cytotoxic",5,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.193189259986902,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.ATCAGGTAGCTAGTTC","CD8+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",1828.34489249271,32.6913659601361,0.0178803058954406,851,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1826.50483080619,1826.50483080619,"microenvironment"
"2019.07.01.count.1.GATGAGGAGTTCACTG","AML-3133","2019-07-01-count-1:GATGAGGAGTTCACTG",1.45120396193807,-10.0663986436096,"2019-07-01-count-1","AML3133","CD14+ monocyte","CD14+",35,"CNV-","malignant","AML","adult_AML","adult_younger60","male","Inflammation_low",0.965034965034965,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GATGAGGAGTTCACTG","CD14+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2469.79997665136,29.8392727172041,0.012081655599358,1691,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2464.67052646003,2464.67052646003,"malignant"
"2019.07.01.count.1.CTCCCTCCAAATCGTC","AML-3133","2019-07-01-count-1:CTCCCTCCAAATCGTC",1.35033096846883,10.5997628935608,"2019-07-01-count-1","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CTCCCTCCAAATCGTC","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2038.95310564177,36.643827419586,0.0179718833739691,1294,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",2032.7906601277,2032.7906601277,"microenvironment"
"2019.07.01.count.1.CTCGAGGTCCTCATAT","AML-3133","2019-07-01-count-1:CTCGAGGTCCTCATAT",0.994268079369706,-9.64517977153929,"2019-07-01-count-1","AML3133","CD14+ monocyte","CD14+",35,"CNV-","malignant","AML","adult_AML","adult_younger60","male","Inflammation_low",0.965034965034965,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.CTCGAGGTCCTCATAT","CD14+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2480.87132703485,42.0263827481374,0.0169401702902373,1539,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2479.61874320343,2479.61874320343,"malignant"
"2019.07.01.count.2.GCTACCTTCGTCCTTG","AML-3133","2019-07-01-count-2:GCTACCTTCGTCCTTG",0.642914553254288,10.5018939741882,"2019-07-01-count-2","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GCTACCTTCGTCCTTG","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",1863.46711232244,40.267173583842,0.0216087385270014,995,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1858.8981571903,1858.8981571903,"microenvironment"
"2019.07.01.count.2.GGGAGTAGTACTAACC","AML-3133","2019-07-01-count-2:GGGAGTAGTACTAACC",-0.760470549494582,10.7357454069885,"2019-07-01-count-2","AML3133","CD8+ T","CD8+ TRM",5,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.193189259986902,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GGGAGTAGTACTAACC","CD8+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",1730.09402859349,39.3159155545159,0.022724727618694,813,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1724.72861232172,1724.72861232172,"microenvironment"
"2019.07.01.count.3.GTAATGCGTAATGCTC","AML-3133","2019-07-01-count-3:GTAATGCGTAATGCTC",-0.460636059672195,11.5886554487976,"2019-07-01-count-3","AML3133","CD8+ T","CD8+ GZMK+",5,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.193189259986902,"GSM5613746","2019-07-01-count-3_metadata.csv.gz","2019.07.01.count.3.GTAATGCGTAATGCTC","CD8+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",1989.50660256708,41.4880445244631,0.0208534339473569,988,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",1989.50660256708,1989.50660256708,"microenvironment"
"2019.07.01.count.1.GGGACTCCAGTTGTTG","AML-3133","2019-07-01-count-1:GGGACTCCAGTTGTTG",1.50383557853047,11.3456754454407,"2019-07-01-count-1","AML3133","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.285506825442928,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.GGGACTCCAGTTGTTG","CD4+ T","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2014.31053295864,34.8620368554022,0.0173071809360975,1272,30000,1100,500,"True","True","True","True",5,1256,"True","T_AML-3133",2010.70271440797,2010.70271440797,"microenvironment"
"2019.07.01.count.1.AAAGGATTCAGCTTCC","AML-3133","2019-07-01-count-1:AAAGGATTCAGCTTCC",-7.41123376312907,1.73677477920381,"2019-07-01-count-1","AML3133","GMP","GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.584821428571429,"GSM5613744","2019-07-01-count-1_metadata.csv.gz","2019.07.01.count.1.AAAGGATTCAGCTTCC","GMP","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2740.74988761993,36.562016317915,0.01334015062194,2766,30000,1100,500,"True","True","True","True",5,250,"True","HSPC_AML-3133",2730.71363708185,2730.71363708185,"microenvironment"
"2019.07.01.count.2.GTTAGACGTAGTCGTT","AML-3133","2019-07-01-count-2:GTTAGACGTAGTCGTT",3.7675367790157,-10.711301826593,"2019-07-01-count-2","AML3133","CD16+ monocyte","CD16+",61,"CNV-","microenvironment","AML","adult_AML","adult_younger60","male","Inflammation_low",0.348251748251748,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.GTTAGACGTAGTCGTT","CD16+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2282.53516169768,44.4914791907636,0.0194921331059243,1481,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2281.37528083492,2281.37528083492,"microenvironment"
"2019.07.01.count.2.CAACGATAGCTGTCCG","AML-3133","2019-07-01-count-2:CAACGATAGCTGTCCG",1.25926484641377,-10.1087379685608,"2019-07-01-count-2","AML3133","CD14+ monocyte","CD14+",35,"CNV-","malignant","AML","adult_AML","adult_younger60","male","Inflammation_low",0.965034965034965,"GSM5613745","2019-07-01-count-2_metadata.csv.gz","2019.07.01.count.2.CAACGATAGCTGTCCG","CD14+ monocyte","U-16-3133","M",57,"CITE-seq","OSU","AML3133","AML","Favorable","46,XY[19]/nonclonal[1]",170,"11/4/2016: The amended report includes staining results for cMPO, cCD3, cCD79a, and TdT. The blasts are positive for cMPO. This does not alter the previous diagnosis.  
SAMPLE TYPE: Bone Marrow 
LABORATORY INTERPRETATION: 
Immunophenotypic analysis demonstrates an abnormal myeloid 
blast population (approximately 8% of total events) with aberrant CD7 expression, consistent with a myeloid neoplasm. Correlation with bone marrow morphology and cytogenetic studies is 
recommended. The B cells are unremarkable. The T cells have a mildly elevated CD4:CD8 ratio with no significant loss of T cell antigens as can be seen in reactive T cells. 
PHENOTYPIC DESCRIPTION: Flow cytometric analysis of bone marrow was performed using a ten color technique with a gating strategy based on CD45 staining and light side scatter characteristics. Lymphocytes represent 22.6 % of the total events analyzed. Of the lymphocytes: 11.1 % are B cells (CD19+) with a Kappa:Lambda ratio of 8:5 , 81.6 % are T cells (CD3+) with a 
CD4:CD8 ratio of 4.7 and 6.6 % are NK cells (positive for CD56 and/or CD16 and negative for CD3). Blasts, defined by CD45 faint staining and low side scatter represent 7.8 % of the total events 
analyzed and express CD117+, CD13+, HLA DR+, CD7+, CD33+, MPO+ with subpopulatios sexpressing CD4+ (20%), CD34+ (24%), CD65+ (32%) and are negative for the remaining markers 
analyzed. The monocytes show aberrant expression of CD56/CD16. ","x","x","x","","","",NA,NA,"0,3","0.0","0.0","0.0",0,0,"0","0,44",0,"0.0",0,0,0,0,"0,44",0,"0","0.05
0.08",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2207.84452475191,48.2833386214045,0.0218689939803755,1322,30000,1100,500,"True","True","True","True",5,474,"True","Mono_AML-3133",2198.62053821823,2198.62053821823,"malignant"
"2020.09.11.AML4340_AML1371.c1.AGCTCAAGTCAGCGTC","AML-4340","2020-09-11-AML4340_AML1371-c1:AGCTCAAGTCAGCGTC",1.24637844142262,10.631170249823,"2020-09-11-AML4340_AML1371-c1","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AGCTCAAGTCAGCGTC","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2433.64303972148,36.9563686645909,0.0151856159927302,1638,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2427.91483332852,2427.91483332852,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AAGGAATGTTCTCGCT","AML-4340","2020-09-11-AML4340_AML1371-c1:AAGGAATGTTCTCGCT",-1.85088227215465,13.1424827345642,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","Activated NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AAGGAATGTTCTCGCT","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2494.34943808133,46.3545462203676,0.0185838221031387,1689,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2489.72366227127,2489.72366227127,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.ATGGATCGTTACAGCT","AML-4340","2020-09-11-AML4340_AML1371-c1:ATGGATCGTTACAGCT",0.53399102863614,11.5305137404236,"2020-09-11-AML4340_AML1371-c1","AML4340","CD8+ T","CD8+ TRM",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.ATGGATCGTTACAGCT","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2367.30383604129,38.9259293038209,0.0164431488308296,1682,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2365.23523483222,2365.23523483222,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CGATGCGGTGGCGCTT","AML-4340","2020-09-11-AML4340_AML1371-c1:CGATGCGGTGGCGCTT",8.02666344222371,6.62430188739625,"2020-09-11-AML4340_AML1371-c1","AML4340","B","Activated NFkB",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0329779320605009,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CGATGCGGTGGCGCTT","B","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",1984.45710116255,40.4248933495306,0.0203707569822742,1355,30000,1100,500,"True","True","True","True",5,132,"True","B_AML-4340",1973.47641828041,1973.47641828041,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TTTGACTTCTATTCGT","AML-4340","2020-09-11-AML4340_AML1371-c1:TTTGACTTCTATTCGT",1.28719200667683,11.7547254332337,"2020-09-11-AML4340_AML1371-c1","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TTTGACTTCTATTCGT","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2330.04465355154,38.0094824499556,0.0163127699686013,1933,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2326.05437100135,2326.05437100135,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AACGTCATCTGAGATC","AML-4340","2020-09-11-AML4340_AML1371-c2:AACGTCATCTGAGATC",1.25743164595906,11.0990686186585,"2020-09-11-AML4340_AML1371-c2","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AACGTCATCTGAGATC","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2200.27159913711,34.1930109969564,0.0155403592040028,1618,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2193.18735241172,2193.18735241172,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TTTAGTCTCATATGGC","AML-4340","2020-09-11-AML4340_AML1371-c1:TTTAGTCTCATATGGC",1.27334191378896,11.427803970221,"2020-09-11-AML4340_AML1371-c1","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TTTAGTCTCATATGGC","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2147.0287038052,37.5220207991987,0.0174762548505747,1761,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2141.74072139879,2141.74072139879,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CACGGGTTCTGTGTGA","AML-4340","2020-09-11-AML4340_AML1371-c1:CACGGGTTCTGTGTGA",-9.53365073624309,3.24461267078248,"2020-09-11-AML4340_AML1371-c1","AML4340","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.882165605095541,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CACGGGTTCTGTGTGA","MPP","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2289.94385507632,46.154074407475,0.0201551117968073,2655,30000,1100,500,"True","True","True","True",5,352,"True","HSPC_AML-4340",2284.64997288751,2284.64997288751,"malignant"
"2020.09.11.AML4340_AML1371.c2.AATCGTGGTGGAAGTC","AML-4340","2020-09-11-AML4340_AML1371-c2:AATCGTGGTGGAAGTC",-2.22151050987895,13.0310344466004,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AATCGTGGTGGAAGTC","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2170.73507985067,45.6253045281185,0.0210183660602459,1142,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2164.46703156827,2164.46703156827,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.GAGTCATTCCACTTTA","AML-4340","2020-09-11-AML4340_AML1371-c2:GAGTCATTCCACTTTA",1.36259736594502,11.0714778670105,"2020-09-11-AML4340_AML1371-c2","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.GAGTCATTCCACTTTA","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2122.93365349403,44.0385782157148,0.0207442084415752,1611,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2121.02832480218,2121.02832480218,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CTCCATGGTGTCCAAT","AML-4340","2020-09-11-AML4340_AML1371-c1:CTCCATGGTGTCCAAT",0.804528256028336,11.7280854948792,"2020-09-11-AML4340_AML1371-c1","AML4340","MAIT","MAIT",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CTCCATGGTGTCCAAT","MAIT","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","MAIT",2593.59326994169,38.7640520570189,0.0149460798291979,1820,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2576.09959985522,2576.09959985522,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.GCCGATGGTAAGATTG","AML-4340","2020-09-11-AML4340_AML1371-c2:GCCGATGGTAAGATTG",-9.39744601669963,2.17026159847108,"2020-09-11-AML4340_AML1371-c2","AML4340","GMP","GMP",1,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.583333333333333,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.GCCGATGGTAAGATTG","GMP","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2569.10667814178,44.2812204099463,0.0172360380309216,3066,30000,1100,500,"True","True","True","True",5,352,"True","HSPC_AML-4340",2564.76494102942,2564.76494102942,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CATTGAGTCTGCTCTG","AML-4340","2020-09-11-AML4340_AML1371-c1:CATTGAGTCTGCTCTG",-1.39008245888408,12.0289134749207,"2020-09-11-AML4340_AML1371-c1","AML4340","CD8+ T","CD8+ Cytotoxic",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CATTGAGTCTGCTCTG","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2627.97815275276,37.2218829275608,0.0141636957250088,1895,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2615.2793602871,2615.2793602871,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.GATCGTACATAGGCGA","AML-4340","2020-09-11-AML4340_AML1371-c2:GATCGTACATAGGCGA",-8.73193011704143,3.28376720035402,"2020-09-11-AML4340_AML1371-c2","AML4340","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.882165605095541,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.GATCGTACATAGGCGA","MPP","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2152.84164893982,47.0929531504777,0.0218747872950474,2123,30000,1100,500,"True","True","True","True",5,352,"True","HSPC_AML-4340",2150.97606422172,2150.97606422172,"malignant"
"2020.09.11.AML4340_AML1371.c2.ACTGTCCCATACTGTG","AML-4340","2020-09-11-AML4340_AML1371-c2:ACTGTCCCATACTGTG",6.41120304641072,-10.0445051423279,"2020-09-11-AML4340_AML1371-c2","AML4340","CD11c+","CD11c+",10,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.934959349593496,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.ACTGTCCCATACTGTG","CD11c+","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2398.02227454639,42.1595028626026,0.0175809471455295,2087,30000,1100,500,"True","True","True","True",5,241,"True","Mono_AML-4340",2394.3621097762,2394.3621097762,"malignant"
"2020.09.11.AML4340_AML1371.c2.TTCTAGTAGTTGCGCC","AML-4340","2020-09-11-AML4340_AML1371-c2:TTCTAGTAGTTGCGCC",4.53473486480061,-10.57719614422,"2020-09-11-AML4340_AML1371-c2","AML4340","CD16+ monocyte","CD16+",61,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0210084033613445,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TTCTAGTAGTTGCGCC","CD16+ monocyte","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2765.56274607511,48.6556629433912,0.0175934040955836,2145,30000,1100,500,"True","True","True","True",5,241,"True","Mono_AML-4340",2757.18493502909,2757.18493502909,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.GATGGAGAGCGTATGG","AML-4340","2020-09-11-AML4340_AML1371-c2:GATGGAGAGCGTATGG",-7.69297585907634,3.00774786556093,"2020-09-11-AML4340_AML1371-c2","AML4340","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.882165605095541,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.GATGGAGAGCGTATGG","MPP","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2433.31996298927,43.4371868650666,0.017850996796864,2598,30000,1100,500,"True","True","True","True",5,352,"True","HSPC_AML-4340",2425.11195152148,2425.11195152148,"malignant"
"2020.09.11.AML4340_AML1371.c1.AGTCTCCGTGTTGAGG","AML-4340","2020-09-11-AML4340_AML1371-c1:AGTCTCCGTGTTGAGG",6.71873869475667,-1.11416675960692,"2020-09-11-AML4340_AML1371-c1","AML4340","pDC","pDC",32,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0608108108108108,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AGTCTCCGTGTTGAGG","pDC","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","DC","pDC",2497.86644584002,42.7523922926839,0.0171155637099351,1873,30000,1100,500,"True","True","True","True",5,62,"True","DC_AML-4340",2493.68920411683,2493.68920411683,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.GATAGAACATCCGTGG","AML-4340","2020-09-11-AML4340_AML1371-c2:GATAGAACATCCGTGG",0.605981608002824,9.82423493945924,"2020-09-11-AML4340_AML1371-c2","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.GATAGAACATCCGTGG","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2047.69733121246,38.9335274577758,0.0190133213851107,1241,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2046.38901079623,2046.38901079623,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TGTGCGGGTTCGGCCA","AML-4340","2020-09-11-AML4340_AML1371-c1:TGTGCGGGTTCGGCCA",-3.49460468712505,13.0073575743469,"2020-09-11-AML4340_AML1371-c1","AML4340","CD8+ T","CD8+ NK-like",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TGTGCGGGTTCGGCCA","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2894.35097088788,42.0855669459639,0.0145405886740313,2010,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2893.21081185279,2893.21081185279,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CAATCGAAGTTCTCTT","AML-4340","2020-09-11-AML4340_AML1371-c2:CAATCGAAGTTCTCTT",-3.41579876366313,12.9250144728455,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CAATCGAAGTTCTCTT","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2564.06145438626,41.4846039026035,0.0161792549206015,1570,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2556.00556661075,2556.00556661075,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AAATGGAAGGTGCAGT","AML-4340","2020-09-11-AML4340_AML1371-c2:AAATGGAAGGTGCAGT",-7.85173259201701,2.91366407955018,"2020-09-11-AML4340_AML1371-c2","AML4340","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.882165605095541,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AAATGGAAGGTGCAGT","MPP","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2440.86534714005,47.7240821348676,0.0195521158882384,2213,30000,1100,500,"True","True","True","True",5,352,"True","HSPC_AML-4340",2433.60392359983,2433.60392359983,"malignant"
"2020.09.11.AML4340_AML1371.c2.CATTTCAGTTGAGTCT","AML-4340","2020-09-11-AML4340_AML1371-c2:CATTTCAGTTGAGTCT",6.28868021544759,-10.0392961732117,"2020-09-11-AML4340_AML1371-c2","AML4340","HLA-II+ monocyte","HLA-II+",10,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.934959349593496,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CATTTCAGTTGAGTCT","HLA-II+ monocyte","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2344.60973629979,38.2044868517954,0.0162946038567974,1980,30000,1100,500,"True","True","True","True",5,241,"True","Mono_AML-4340",2339.9821478126,2339.9821478126,"malignant"
"2020.09.11.AML4340_AML1371.c2.CCCTCTCCATATGCGT","AML-4340","2020-09-11-AML4340_AML1371-c2:CCCTCTCCATATGCGT",-1.34863183918651,11.7676381834778,"2020-09-11-AML4340_AML1371-c2","AML4340","CD8+ T","CD8+ Cytotoxic",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CCCTCTCCATATGCGT","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2498.26073706488,39.3615409148587,0.0157555776028019,1676,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2491.31217486576,2491.31217486576,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TAAGCACCAAAGCTCT","AML-4340","2020-09-11-AML4340_AML1371-c2:TAAGCACCAAAGCTCT",-1.95369062843974,12.7056112059387,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","Activated NK",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TAAGCACCAAAGCTCT","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2497.02582608501,46.2115886947347,0.0185066522788785,1501,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2492.95099769399,2492.95099769399,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.ATTCCCGGTTGGTAGG","AML-4340","2020-09-11-AML4340_AML1371-c2:ATTCCCGGTTGGTAGG",1.41877069052998,11.1134509810242,"2020-09-11-AML4340_AML1371-c2","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.ATTCCCGGTTGGTAGG","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2086.06268930079,43.6706755370825,0.0209344981630059,1667,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2077.28293921702,2077.28293921702,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AACTTCTCAAGGGCAT","AML-4340","2020-09-11-AML4340_AML1371-c1:AACTTCTCAAGGGCAT",-2.18906054917033,13.2559060820374,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AACTTCTCAAGGGCAT","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2571.35056906342,40.2450605365985,0.0156513316467996,1584,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2567.49586110595,2567.49586110595,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CCTCAGTTCACCGGGT","AML-4340","2020-09-11-AML4340_AML1371-c2:CCTCAGTTCACCGGGT",-2.15062461319621,13.515767074469,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CCTCAGTTCACCGGGT","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2724.25579999282,37.2550545145255,0.0136753143792972,1859,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2719.69854539537,2719.69854539537,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TCTGCCACACATGACT","AML-4340","2020-09-11-AML4340_AML1371-c2:TCTGCCACACATGACT",1.46869482573811,11.0223626860413,"2020-09-11-AML4340_AML1371-c2","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TCTGCCACACATGACT","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2300.63239516518,39.8979610741113,0.017342171290797,1797,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2293.53076142832,2293.53076142832,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TTTCAGTTCGAGTACT","AML-4340","2020-09-11-AML4340_AML1371-c1:TTTCAGTTCGAGTACT",7.83172192153279,-10.1328678361145,"2020-09-11-AML4340_AML1371-c1","AML4340","CD11c+","CD11c+",10,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.934959349593496,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TTTCAGTTCGAGTACT","CD11c+","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2459.95999547441,44.3282052805834,0.0180198886819842,1678,30000,1100,500,"True","True","True","True",5,241,"True","Mono_AML-4340",2452.64880829996,2452.64880829996,"malignant"
"2020.09.11.AML4340_AML1371.c1.CAGGTATAGATGACAT","AML-4340","2020-09-11-AML4340_AML1371-c1:CAGGTATAGATGACAT",-2.39006743851359,13.4222240217957,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CAGGTATAGATGACAT","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2604.4557791601,42.6806204614056,0.0163875389257596,1628,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2596.6283809753,2596.6283809753,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AACCACATCTCGACGG","AML-4340","2020-09-11-AML4340_AML1371-c2:AACCACATCTCGACGG",-2.53041086617168,13.5071582564148,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AACCACATCTCGACGG","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2529.23764137017,49.8822263266516,0.0197222378438227,1583,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2521.86608058707,2521.86608058707,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.ATCGATGGTGGACCTC","AML-4340","2020-09-11-AML4340_AML1371-c1:ATCGATGGTGGACCTC",1.1531648832256,11.452965713385,"2020-09-11-AML4340_AML1371-c1","AML4340","CD8+ T","CD8+ TRM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.ATCGATGGTGGACCTC","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2286.92621110953,32.3625217517658,0.0141511001074515,1569,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2285.84388580479,2285.84388580479,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CCAAGCGAGCTTCATG","AML-4340","2020-09-11-AML4340_AML1371-c1:CCAAGCGAGCTTCATG",-2.12430057945903,11.9394149550232,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","CD56bright NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CCAAGCGAGCTTCATG","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2574.31204190647,38.4260216112878,0.014926714782731,1886,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2571.1970380953,2571.1970380953,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CATGAGTCAGCAGATG","AML-4340","2020-09-11-AML4340_AML1371-c2:CATGAGTCAGCAGATG",-2.64060173454936,13.3519830473694,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CATGAGTCAGCAGATG","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2695.17531151756,45.9915978491374,0.0170644179072868,1616,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2692.38166215386,2692.38166215386,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CTCCTTTTCATTTGGG","AML-4340","2020-09-11-AML4340_AML1371-c2:CTCCTTTTCATTTGGG",6.56537737426106,-10.0306062928406,"2020-09-11-AML4340_AML1371-c2","AML4340","CD11c+","CD11c+",10,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.934959349593496,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CTCCTTTTCATTTGGG","CD11c+","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2686.68601541481,28.5767739639125,0.0106364397625751,2301,30000,1100,500,"True","True","True","True",5,241,"True","Mono_AML-4340",2681.36296005655,2681.36296005655,"malignant"
"2020.09.11.AML4340_AML1371.c1.ATTTCTGGTTGCTCAA","AML-4340","2020-09-11-AML4340_AML1371-c1:ATTTCTGGTTGCTCAA",-1.90730009499248,13.4584522017273,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.ATTTCTGGTTGCTCAA","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2886.26294769365,43.2745877525907,0.0149932935899588,1969,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2878.28865501166,2878.28865501166,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.ACTATTCGTATTCCGA","AML-4340","2020-09-11-AML4340_AML1371-c2:ACTATTCGTATTCCGA",-2.61850462380107,13.4773282774719,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.ACTATTCGTATTCCGA","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2596.01721570659,42.8966035072566,0.0165240057915336,1554,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2590.54976119461,2590.54976119461,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TTGGATGTCATGGCCG","AML-4340","2020-09-11-AML4340_AML1371-c1:TTGGATGTCATGGCCG",7.45347656783406,-9.50311090862425,"2020-09-11-AML4340_AML1371-c1","AML4340","cDC2","cDC2",10,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.934959349593496,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TTGGATGTCATGGCCG","cDC2","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","DC","cDC",2454.80254567087,37.1260834182967,0.0151238573072893,2118,30000,1100,500,"True","True","True","True",5,62,"True","DC_AML-4340",2451.9249597962,2451.9249597962,"malignant"
"2020.09.11.AML4340_AML1371.c1.CAGCCAGGTCACGTGC","AML-4340","2020-09-11-AML4340_AML1371-c1:CAGCCAGGTCACGTGC",-2.84113798561748,13.2351608046326,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CAGCCAGGTCACGTGC","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2813.35425098511,37.6972987720991,0.0133994141544383,1784,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2801.60934677303,2801.60934677303,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AATTTCCTCGCGTAGC","AML-4340","2020-09-11-AML4340_AML1371-c1:AATTTCCTCGCGTAGC",-0.340990195900756,10.9705753096375,"2020-09-11-AML4340_AML1371-c1","AML4340","CD8+ T","CD8+ Cytotoxic",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AATTTCCTCGCGTAGC","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2227.39386129854,41.0372885266281,0.0184239030373837,1292,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2227.39386129854,2227.39386129854,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TGCATGATCACTGATG","AML-4340","2020-09-11-AML4340_AML1371-c2:TGCATGATCACTGATG",8.77740730819051,7.82087705219118,"2020-09-11-AML4340_AML1371-c2","AML4340","B","Atypical memory",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0329779320605009,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TGCATGATCACTGATG","B","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",2211.7811808935,41.7002132124851,0.0188536793660752,1358,30000,1100,500,"True","True","True","True",5,132,"True","B_AML-4340",2201.08021818756,2201.08021818756,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AGGGCCTGTTGCTGAT","AML-4340","2020-09-11-AML4340_AML1371-c2:AGGGCCTGTTGCTGAT",-2.82658491554912,13.3072280653748,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AGGGCCTGTTGCTGAT","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2517.36404154041,45.1667953603306,0.0179420992017874,1510,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2507.52123399748,2507.52123399748,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.ACCAAACCAGAAACCG","AML-4340","2020-09-11-AML4340_AML1371-c1:ACCAAACCAGAAACCG",6.6534649330074,-0.963750385400377,"2020-09-11-AML4340_AML1371-c1","AML4340","pDC","pDC",32,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0608108108108108,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.ACCAAACCAGAAACCG","pDC","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","DC","pDC",2441.31931671943,42.5851279105524,0.0174434895176994,2033,30000,1100,500,"True","True","True","True",5,62,"True","DC_AML-4340",2436.45360273998,2436.45360273998,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.CTAACTTTCTGCTTTA","AML-4340","2020-09-11-AML4340_AML1371-c1:CTAACTTTCTGCTTTA",1.13559557971303,11.379328704718,"2020-09-11-AML4340_AML1371-c1","AML4340","CD4+ T","Treg",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CTAACTTTCTGCTTTA","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2648.22293140002,31.4850691861701,0.0118891309386574,1924,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2638.34677357256,2638.34677357256,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.ATACCGATCACAACCA","AML-4340","2020-09-11-AML4340_AML1371-c2:ATACCGATCACAACCA",-2.2618387741154,13.0880183943543,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.ATACCGATCACAACCA","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2430.31481568601,40.1733430379642,0.0165300983965834,1411,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2428.87044637508,2428.87044637508,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.GCCAGTGCAGAGTCTT","AML-4340","2020-09-11-AML4340_AML1371-c2:GCCAGTGCAGAGTCTT",-0.0906056267326653,11.8717288740906,"2020-09-11-AML4340_AML1371-c2","AML4340","CD8+ T","CD8+ GZMK+",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.GCCAGTGCAGAGTCTT","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2166.76132874557,42.1708731816532,0.0194626296040033,1286,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2162.82886420394,2162.82886420394,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TTACGCCGTGCTTCAA","AML-4340","2020-09-11-AML4340_AML1371-c2:TTACGCCGTGCTTCAA",-8.04785762253459,1.66276357257692,"2020-09-11-AML4340_AML1371-c2","AML4340","GMP","GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.882165605095541,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TTACGCCGTGCTTCAA","GMP","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2554.14221760608,40.5361672007819,0.0158707557164829,2732,30000,1100,500,"True","True","True","True",5,352,"True","HSPC_AML-4340",2547.96477168953,2547.96477168953,"malignant"
"2020.09.11.AML4340_AML1371.c2.ATCTCTATCGGTGTTA","AML-4340","2020-09-11-AML4340_AML1371-c2:ATCTCTATCGGTGTTA",-3.22296534004863,12.6003217467102,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.ATCTCTATCGGTGTTA","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2481.13926353728,42.8133736669459,0.0172555302703599,1495,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2479.76701660276,2479.76701660276,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AGACCATTCGAAATCC","AML-4340","2020-09-11-AML4340_AML1371-c1:AGACCATTCGAAATCC",-8.77586398544963,4.20585057819215,"2020-09-11-AML4340_AML1371-c1","AML4340","MPP","MPP_GMP",1,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.583333333333333,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AGACCATTCGAAATCC","MPP","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2997.18529254891,45.8968419973672,0.0153133148329094,3804,30000,1100,500,"True","True","True","True",5,352,"True","HSPC_AML-4340",2984.01790826462,2984.01790826462,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.ATTCCATCAATACGCT","AML-4340","2020-09-11-AML4340_AML1371-c2:ATTCCATCAATACGCT",-2.64345608177837,13.3583602675232,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.ATTCCATCAATACGCT","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2675.73836680574,42.4237336423639,0.0158549633135503,1737,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2675.73836680574,2675.73836680574,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GACACGCGTTGAATCC","AML-4340","2020-09-11-AML4340_AML1371-c1:GACACGCGTTGAATCC",-0.553602973849136,10.6971483000549,"2020-09-11-AML4340_AML1371-c1","AML4340","CD8+ T","CD8+ TRM",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GACACGCGTTGAATCC","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2316.23368096391,42.6243727175041,0.0184024492294602,1873,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2312.68118413476,2312.68118413476,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GACTATGAGTTGCTCA","AML-4340","2020-09-11-AML4340_AML1371-c1:GACTATGAGTTGCTCA",-7.66895661774333,2.95103237712709,"2020-09-11-AML4340_AML1371-c1","AML4340","MPP","MPP_GMP",47,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.882165605095541,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GACTATGAGTTGCTCA","MPP","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2586.52736899944,42.8501823262051,0.016566684288665,2959,30000,1100,500,"True","True","True","True",5,352,"True","HSPC_AML-4340",2572.02600202379,2572.02600202379,"malignant"
"2020.09.11.AML4340_AML1371.c2.CAACCAATCGCTGACG","AML-4340","2020-09-11-AML4340_AML1371-c2:CAACCAATCGCTGACG",-1.03719828549083,11.310912109259,"2020-09-11-AML4340_AML1371-c2","AML4340","CD8+ T","CD8+ Cytotoxic",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CAACCAATCGCTGACG","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2515.08046544738,42.6105107078411,0.0169420069430111,1624,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2512.59033854407,2512.59033854407,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CAAGCTACAACCCTAA","AML-4340","2020-09-11-AML4340_AML1371-c2:CAAGCTACAACCCTAA",0.81133004006688,10.5836448439392,"2020-09-11-AML4340_AML1371-c2","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CAAGCTACAACCCTAA","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2248.47192807683,39.7686545057674,0.0176869695410351,1664,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2247.45523512529,2247.45523512529,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GAGCCTGGTGGCAACA","AML-4340","2020-09-11-AML4340_AML1371-c1:GAGCCTGGTGGCAACA",-2.66313205185588,12.8188476332459,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GAGCCTGGTGGCAACA","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2535.69246548341,42.9163367952362,0.0169248981804481,1551,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2530.28150851665,2530.28150851665,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AGGACGAGTTCACCGG","AML-4340","2020-09-11-AML4340_AML1371-c2:AGGACGAGTTCACCGG",0.239226718514603,11.3015565642151,"2020-09-11-AML4340_AML1371-c2","AML4340","CD8+ T","CD8+ TRM",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AGGACGAGTTCACCGG","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2244.99436289038,44.3550139193383,0.0197572941173145,1313,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2239.6301828671,2239.6301828671,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CACTTCGAGTGAATAC","AML-4340","2020-09-11-AML4340_AML1371-c2:CACTTCGAGTGAATAC",6.38193239745442,-10.1728382340637,"2020-09-11-AML4340_AML1371-c2","AML4340","CD14+ monocyte","CD14+",10,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.934959349593496,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CACTTCGAGTGAATAC","CD14+ monocyte","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2764.54189668557,33.3455290739116,0.0120618642509596,2688,30000,1100,500,"True","True","True","True",5,241,"True","Mono_AML-4340",2763.29233200366,2763.29233200366,"malignant"
"2020.09.11.AML4340_AML1371.c1.GCAACATGTGATGGCA","AML-4340","2020-09-11-AML4340_AML1371-c1:GCAACATGTGATGGCA",-2.60122380676921,13.5109042891297,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GCAACATGTGATGGCA","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2600.65269806533,31.6806442342151,0.0121818050744657,1674,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2598.21822129263,2598.21822129263,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TGTGTGAAGCTGGCTC","AML-4340","2020-09-11-AML4340_AML1371-c1:TGTGTGAAGCTGGCTC",-0.340959976345855,11.2097434767517,"2020-09-11-AML4340_AML1371-c1","AML4340","MAIT","MAIT",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TGTGTGAAGCTGGCTC","MAIT","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","MAIT",2445.80902877938,39.1940140991789,0.0160249690952933,1767,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2435.10298342513,2435.10298342513,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.ATCGTCCAGAAACTGT","AML-4340","2020-09-11-AML4340_AML1371-c1:ATCGTCCAGAAACTGT",-2.13917551460918,13.9382800825867,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","CD56dim NK",22,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0039237668161435,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.ATCGTCCAGAAACTGT","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2358.36055497803,41.2760699299927,0.017502018443646,1425,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2353.19049030131,2353.19049030131,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GCAGCTGAGGAGGCAG","AML-4340","2020-09-11-AML4340_AML1371-c1:GCAGCTGAGGAGGCAG",8.02956451949422,8.50839803302614,"2020-09-11-AML4340_AML1371-c1","AML4340","B","Atypical memory",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0329779320605009,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GCAGCTGAGGAGGCAG","B","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",2156.871737514,42.5292494063552,0.0197180243343419,1452,30000,1100,500,"True","True","True","True",5,132,"True","B_AML-4340",2148.2372196052,2148.2372196052,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GCATCTCGTTTCCATT","AML-4340","2020-09-11-AML4340_AML1371-c1:GCATCTCGTTTCCATT",-0.138307834894019,11.317506767157,"2020-09-11-AML4340_AML1371-c1","AML4340","CD8+ T","CD8+ GZMK+",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GCATCTCGTTTCCATT","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2492.51366903296,41.8480113644856,0.0167894811909784,1581,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2487.61955720765,2487.61955720765,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TTACCGCCAAGAAATC","AML-4340","2020-09-11-AML4340_AML1371-c1:TTACCGCCAAGAAATC",1.25459422644917,11.1200656660828,"2020-09-11-AML4340_AML1371-c1","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TTACCGCCAAGAAATC","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2083.72403114449,35.5062880609869,0.0170398227069854,1683,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2081.37764863623,2081.37764863623,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.ATGCCTCCACATTACG","AML-4340","2020-09-11-AML4340_AML1371-c1:ATGCCTCCACATTACG",-0.191825221211273,11.5190477141174,"2020-09-11-AML4340_AML1371-c1","AML4340","CD8+ T","CD8+ Cytotoxic",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.ATGCCTCCACATTACG","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2230.21972592338,39.5077452323734,0.0177147322181522,1443,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2225.55592399116,2225.55592399116,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GGAACCCGTTAGTTCG","AML-4340","2020-09-11-AML4340_AML1371-c1:GGAACCCGTTAGTTCG",-2.11436400833781,13.279761291388,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","Activated NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GGAACCCGTTAGTTCG","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2743.09717363503,41.5968980460296,0.0151642087075272,2446,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2736.10367823417,2736.10367823417,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.GTTCGCTGTATGAAGT","AML-4340","2020-09-11-AML4340_AML1371-c2:GTTCGCTGTATGAAGT",-1.69731173935588,11.6855945357117,"2020-09-11-AML4340_AML1371-c2","AML4340","CD8+ T","CD8+ Cytotoxic",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.GTTCGCTGTATGAAGT","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2281.02782948861,40.9642382093039,0.017958675330361,1474,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2277.40377034688,2277.40377034688,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CCGGACACACTTGGGC","AML-4340","2020-09-11-AML4340_AML1371-c2:CCGGACACACTTGGGC",-2.84031329575236,13.230722404364,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CCGGACACACTTGGGC","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2515.59640008883,43.1688910542361,0.017160499614609,1552,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2510.28309014745,2510.28309014745,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GGGCTACGTTGGCCGT","AML-4340","2020-09-11-AML4340_AML1371-c1:GGGCTACGTTGGCCGT",6.69840540465657,-9.96717646038207,"2020-09-11-AML4340_AML1371-c1","AML4340","CD11c+","CD11c+",10,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.934959349593496,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GGGCTACGTTGGCCGT","CD11c+","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Mono","Mono",2454.41881894279,36.6833183029756,0.01494582669423,2253,30000,1100,500,"True","True","True","True",5,241,"True","Mono_AML-4340",2447.40532914427,2447.40532914427,"malignant"
"2020.09.11.AML4340_AML1371.c1.CACAGATTCTACAGGT","AML-4340","2020-09-11-AML4340_AML1371-c1:CACAGATTCTACAGGT",1.31401469287221,10.5932426222595,"2020-09-11-AML4340_AML1371-c1","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.CACAGATTCTACAGGT","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2305.07515934017,39.2868940287018,0.0170436499085556,1961,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2295.22512621309,2295.22512621309,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CCTCACACAAATAAGC","AML-4340","2020-09-11-AML4340_AML1371-c2:CCTCACACAAATAAGC",1.07640637931172,10.0497751005921,"2020-09-11-AML4340_AML1371-c2","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CCTCACACAAATAAGC","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2295.87602894124,40.9680366720871,0.0178441850324906,1978,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2283.51228445196,2283.51228445196,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GGGTGTCGTGAATTAG","AML-4340","2020-09-11-AML4340_AML1371-c1:GGGTGTCGTGAATTAG",-8.91579661789592,1.79644880378572,"2020-09-11-AML4340_AML1371-c1","AML4340","GMP","GMP",16,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.04,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GGGTGTCGTGAATTAG","GMP","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2700.73658292044,43.7854416802148,0.016212407369573,3274,30000,1100,500,"True","True","True","True",5,352,"True","HSPC_AML-4340",2696.69250736125,2696.69250736125,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GGGTTTAGTCGTTGGC","AML-4340","2020-09-11-AML4340_AML1371-c1:GGGTTTAGTCGTTGGC",-2.8406265777653,13.2907981642517,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GGGTTTAGTCGTTGGC","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",3059.24967869389,44.2043044612283,0.0144493941665137,2636,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",3050.96612977185,3050.96612977185,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GTAATCGAGAACTTCC","AML-4340","2020-09-11-AML4340_AML1371-c1:GTAATCGAGAACTTCC",-2.52240572395976,13.4044828184876,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GTAATCGAGAACTTCC","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2643.79695460087,48.6113905590524,0.0183869606455429,1762,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2640.27385139061,2640.27385139061,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GTACAACAGCGTCAGA","AML-4340","2020-09-11-AML4340_AML1371-c1:GTACAACAGCGTCAGA",7.70202364501302,6.9354734190735,"2020-09-11-AML4340_AML1371-c1","AML4340","B","Memory",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0329779320605009,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GTACAACAGCGTCAGA","B","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",2055.10645638308,42.6487640072177,0.020752581392926,1529,30000,1100,500,"True","True","True","True",5,132,"True","B_AML-4340",2050.2827236192,2050.2827236192,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AAGACTCAGCGCACAA","AML-4340","2020-09-11-AML4340_AML1371-c2:AAGACTCAGCGCACAA",0.210006584494752,11.4368448027405,"2020-09-11-AML4340_AML1371-c2","AML4340","CD8+ T","CD8+ TRM",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AAGACTCAGCGCACAA","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2322.47630137998,45.0555310740185,0.019399780762993,1628,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2315.12773349765,2315.12773349765,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TCACATTTCCGTAGTA","AML-4340","2020-09-11-AML4340_AML1371-c2:TCACATTTCCGTAGTA",1.32996227320973,10.9947118529114,"2020-09-11-AML4340_AML1371-c2","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TCACATTTCCGTAGTA","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2234.77705552902,32.7601943772478,0.0146592673735379,1496,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2226.94136297027,2226.94136297027,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GTCTACCGTCCTACGG","AML-4340","2020-09-11-AML4340_AML1371-c1:GTCTACCGTCCTACGG",1.46278109130208,11.1140041121277,"2020-09-11-AML4340_AML1371-c1","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GTCTACCGTCCTACGG","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2116.45305960235,35.8672060150982,0.0169468469203078,1568,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2108.90393237008,2108.90393237008,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CTCATCGAGCTACAAA","AML-4340","2020-09-11-AML4340_AML1371-c2:CTCATCGAGCTACAAA",0.185841311782044,11.8103933104309,"2020-09-11-AML4340_AML1371-c2","AML4340","CD8+ T","CD8+ GZMK+",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CTCATCGAGCTACAAA","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2498.31145038491,49.6128422814427,0.019858549771206,1530,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2489.03277620444,2489.03277620444,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CTCATTACAGTTGTTG","AML-4340","2020-09-11-AML4340_AML1371-c2:CTCATTACAGTTGTTG",-2.2734833759373,13.6558656462464,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CTCATTACAGTTGTTG","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2473.01011144582,39.4220847883085,0.0159409315011901,1460,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2471.06642119182,2471.06642119182,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.CTCCATGCATAGGAGC","AML-4340","2020-09-11-AML4340_AML1371-c2:CTCCATGCATAGGAGC",0.788937290280503,9.82259461963502,"2020-09-11-AML4340_AML1371-c2","AML4340","CD4+ T","Treg",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.CTCCATGCATAGGAGC","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2122.17652425984,33.173334488148,0.0156317507563222,1305,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2110.63292279801,2110.63292279801,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TAACTTCAGCTGCCAC","AML-4340","2020-09-11-AML4340_AML1371-c1:TAACTTCAGCTGCCAC",-6.76703057709392,-0.0058527297345028,"2020-09-11-AML4340_AML1371-c1","AML4340","GMP","GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.321167883211679,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TAACTTCAGCTGCCAC","GMP","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2870.24817787728,48.9324178793483,0.0170481487477285,2773,30000,1100,500,"True","True","True","True",5,352,"True","HSPC_AML-4340",2862.41589338842,2862.41589338842,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TAAGCGTAGGTACATA","AML-4340","2020-09-11-AML4340_AML1371-c1:TAAGCGTAGGTACATA",1.41559567031209,10.7920465239319,"2020-09-11-AML4340_AML1371-c1","AML4340","CD4+ T","CD4+ Naive",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TAAGCGTAGGTACATA","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2232.33889427677,41.5709934052301,0.01862216956028,1662,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2228.55339622926,2228.55339622926,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.GGCAGTCGTTGCACGC","AML-4340","2020-09-11-AML4340_AML1371-c1:GGCAGTCGTTGCACGC",-5.20911107483562,-5.30039360439452,"2020-09-11-AML4340_AML1371-c1","AML4340","Granulocyte","Granulocytes (cycling)",38,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0060150375939849,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.GGCAGTCGTTGCACGC","Granulocyte","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","Gran","Gran",2163.09801534064,32.8580761704827,0.0151902853858004,1228,30000,1100,500,"True","True","True","True",5,21,"True","Gran_AML-4340",2157.96190750461,2157.96190750461,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TCTATACTCCTTGACC","AML-4340","2020-09-11-AML4340_AML1371-c2:TCTATACTCCTTGACC",-2.32339201393779,13.4251308211121,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","Activated NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TCTATACTCCTTGACC","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2871.89880919157,43.7188455876642,0.0152229756312239,2113,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2858.33284132085,2858.33284132085,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TACTTGTGTTAGGGAC","AML-4340","2020-09-11-AML4340_AML1371-c1:TACTTGTGTTAGGGAC",0.963693161576432,11.5332431563172,"2020-09-11-AML4340_AML1371-c1","AML4340","CD4+ T","CD4+ TCM",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TACTTGTGTTAGGGAC","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2423.4049841601,40.1745497958679,0.0165777284681914,1648,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2416.7361251149,2416.7361251149,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TCTCCGACATGGGATG","AML-4340","2020-09-11-AML4340_AML1371-c2:TCTCCGACATGGGATG",-2.62072287026103,13.2224778898987,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TCTCCGACATGGGATG","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2616.66075561471,45.7619889990998,0.0174886977231977,1662,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2611.53189999896,2611.53189999896,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TAGCACAAGGGCGAGA","AML-4340","2020-09-11-AML4340_AML1371-c1:TAGCACAAGGGCGAGA",7.97862877425496,8.32985303485719,"2020-09-11-AML4340_AML1371-c1","AML4340","B","Activated AP-1",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0329779320605009,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TAGCACAAGGGCGAGA","B","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",2105.72222335316,43.1788240152238,0.0205054700645491,1573,30000,1100,500,"True","True","True","True",5,132,"True","B_AML-4340",2102.09747291762,2102.09747291762,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.AATGCCAAGGAACGTC","AML-4340","2020-09-11-AML4340_AML1371-c1:AATGCCAAGGAACGTC",-0.563173036009628,11.8213987120422,"2020-09-11-AML4340_AML1371-c1","AML4340","CD8+ T","CD8+ Cytotoxic",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.AATGCCAAGGAACGTC","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2493.92474471666,43.3254790021308,0.0173724083270416,1802,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2490.83473545531,2490.83473545531,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.AGCTCAAAGGCTCAAG","AML-4340","2020-09-11-AML4340_AML1371-c2:AGCTCAAAGGCTCAAG",-7.21875319901164,-0.0184558711019383,"2020-09-11-AML4340_AML1371-c2","AML4340","GMP","GMP",42,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.321167883211679,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.AGCTCAAAGGCTCAAG","GMP","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2616.87944029833,33.7340677849433,0.0128909522026347,2337,30000,1100,500,"True","True","True","True",5,352,"True","HSPC_AML-4340",2614.66949539698,2614.66949539698,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TATTGGGGTCCCTGTT","AML-4340","2020-09-11-AML4340_AML1371-c1:TATTGGGGTCCCTGTT",-2.50642619553264,13.233091331366,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","CD56bright NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TATTGGGGTCCCTGTT","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2421.67691546839,41.0922278270137,0.0169685012746904,1416,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2420.26052077055,2420.26052077055,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TCACACCGTCCTATAG","AML-4340","2020-09-11-AML4340_AML1371-c1:TCACACCGTCCTATAG",8.07553829726521,8.47345445239869,"2020-09-11-AML4340_AML1371-c1","AML4340","B","Atypical memory",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0329779320605009,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TCACACCGTCCTATAG","B","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",2209.4403517483,39.7453619813323,0.0179888820940028,1562,30000,1100,500,"True","True","True","True",5,132,"True","B_AML-4340",2205.5572969718,2205.5572969718,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TCACTCGCAGGTTACT","AML-4340","2020-09-11-AML4340_AML1371-c1:TCACTCGCAGGTTACT",8.05026831206624,8.4018230208191,"2020-09-11-AML4340_AML1371-c1","AML4340","B","Atypical memory",0,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.0329779320605009,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TCACTCGCAGGTTACT","B","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","B","B",2300.29701083894,41.5145322109706,0.0180474660512774,1829,30000,1100,500,"True","True","True","True",5,132,"True","B_AML-4340",2297.70772489978,2297.70772489978,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TGGGCTGGTTGGAGGT","AML-4340","2020-09-11-AML4340_AML1371-c2:TGGGCTGGTTGGAGGT",-2.50158153000529,13.292679763678,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TGGGCTGGTTGGAGGT","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2373.24449439263,39.3584553302845,0.0165842396024845,1309,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2367.20533372895,2367.20533372895,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TGGTAGTGTCTACACA","AML-4340","2020-09-11-AML4340_AML1371-c2:TGGTAGTGTCTACACA",-2.78368912163432,12.9415235289368,"2020-09-11-AML4340_AML1371-c2","AML4340","NK","CD56dim NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TGGTAGTGTCTACACA","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2287.80882253652,40.6075290751036,0.0177495290144399,1275,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2279.87730415936,2279.87730415936,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TCGACGGGTCCGGACT","AML-4340","2020-09-11-AML4340_AML1371-c1:TCGACGGGTCCGGACT",1.18054105815236,11.5412521132263,"2020-09-11-AML4340_AML1371-c1","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TCGACGGGTCCGGACT","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2300.9083139492,37.8552060108852,0.0164522878992565,1649,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2295.10262888397,2295.10262888397,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TCGATTTGTACGCTTA","AML-4340","2020-09-11-AML4340_AML1371-c1:TCGATTTGTACGCTTA",-8.36700568619426,4.02198741519777,"2020-09-11-AML4340_AML1371-c1","AML4340","HSC","HSC",47,"CNV-","malignant","AML","adult_AML","adult_60up","male","Inflammation_high",0.882165605095541,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TCGATTTGTACGCTTA","HSC","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","HSPC","HSPC",2414.87509257304,43.2619937547821,0.0179147956297345,2331,30000,1100,500,"True","True","True","True",5,352,"True","HSPC_AML-4340",2404.2483712001,2404.2483712001,"malignant"
"2020.09.11.AML4340_AML1371.c1.TCTCCGACATACACCA","AML-4340","2020-09-11-AML4340_AML1371-c1:TCTCCGACATACACCA",-0.133736873895484,10.4894733198914,"2020-09-11-AML4340_AML1371-c1","AML4340","CD8+ T","CD8+ TRM",5,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.428040854224698,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TCTCCGACATACACCA","CD8+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD8_T",2459.78717152177,38.6430257124926,0.0157099061902115,1826,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2450.72001469614,2450.72001469614,"microenvironment"
"2020.09.11.AML4340_AML1371.c1.TCTGCCAAGTAACAGT","AML-4340","2020-09-11-AML4340_AML1371-c1:TCTGCCAAGTAACAGT",-2.5672803920811,12.7991666563782,"2020-09-11-AML4340_AML1371-c1","AML4340","NK","CD56bright NK",6,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.209915280828365,"GSM5613777","2020-09-11","2020.09.11.AML4340_AML1371.c1.TCTGCCAAGTAACAGT","NK","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","NK","NK",2639.49214420236,48.7182184497789,0.0184574212720384,1919,30000,1100,500,"True","True","True","True",5,613,"True","NK_AML-4340",2633.08074295179,2633.08074295179,"microenvironment"
"2020.09.11.AML4340_AML1371.c2.TTGCTGCGTTTACTGG","AML-4340","2020-09-11-AML4340_AML1371-c2:TTGCTGCGTTTACTGG",1.29151417788808,11.116467452887,"2020-09-11-AML4340_AML1371-c2","AML4340","CD4+ T","CD4+ TCM",4,"CNV-","microenvironment","AML","adult_AML","adult_60up","male","Inflammation_high",0.200779727095517,"GSM5613778","2020-09-11","2020.09.11.AML4340_AML1371.c2.TTGCTGCGTTTACTGG","CD4+ T","U-18-4340","M",80,"CITE-seq","OSU","AML4340","AML","Intermediate","46,XY",455,"Flow cytometric analysis of bone 
marrow was performed using a ten color technique with a gating 
strategy based on CD45 staining and light side scatter 
characteristics. Lymphocytes represent 56.7 % of the total events 
analyzed. Of the lymphocytes: 73.2 % are T cells (CD3+) with a 
CD4:CD8 ratio of 2.3 and 12.0 % are NK cells (positive for CD56 
and/or CD16 and negative for CD3). The B cells represent 13.5 % 
of the lymphocytes (8.0 % of the total events analyzed) and 
express CD19+, CD20+ bright with subpopulation(s) expressing 
CD23+(4%). The B cells are essentially negative for CD10 and 
CD5. Surface immunoglobulin light chains shows a Kappa:Lambda 
ratio of 13:2 with bright staining intensity. Blasts, defined by CD45 
faint staining and low side scatter represent 19.6 % of the total 
events analyzed and express HLA-DR+, CD13+, CD33+, CD34+, 
CD117+, and are negative for the remaining markers analyzed. ","x","","x","","","",NA,NA,"0,37","0.0","0.0","0.0",0,0,"0,34","0",0,"0.0",0,0,0,0,"0",0,"0,24","0",0,0,"0.0",0,0,0,"0.0",0,"0.0","0.0",0,"0.0",0,"AML","case","T","CD4_T",2016.44391472117,34.5288862520009,0.0171236531796995,1425,30000,1100,500,"True","True","True","True",5,1366,"True","T_AML-4340",2010.49303046696,2010.49303046696,"microenvironment"
"2019.08.01.count.2.CAGGTATCATCATTGG","healthy-1","2019-08-01-count-2:CAGGTATCATCATTGG",1.44821621951405,9.80914781177369,"2019-08-01-count-2","Control1","CD4+ T","CD4+ TCM",4,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CAGGTATCATCATTGG","CD4+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1805.27601425462,34.7399120683241,0.0192435460251035,1046,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",1802.55921670227,1802.55921670227,"Control"
"2019.08.01.count.3.GTTGCGGAGATGCTGG","healthy-1","2019-08-01-count-3:GTTGCGGAGATGCTGG",3.3568021255428,-10.336449646112,"2019-08-01-count-3","Control1","HLA-II+ monocyte","HLA-II+",36,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GTTGCGGAGATGCTGG","HLA-II+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2360.42331167071,36.5307633011968,0.0154763610071874,1891,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2357.89455725872,2357.89455725872,"Control"
"2019.08.01.count.4.GCATTAGCAGCTGTCG","healthy-1","2019-08-01-count-4:GCATTAGCAGCTGTCG",-2.7206269306248,-5.87344744121703,"2019-08-01-count-4","Control1","Granulocyte","Granulocytes",63,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GCATTAGCAGCTGTCG","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2421.22331665362,42.2866528493983,0.017464994888552,1891,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2419.43418981338,2419.43418981338,"Control"
"2019.08.01.count.2.GCTGGGTAGCACCTGC","healthy-1","2019-08-01-count-2:GCTGGGTAGCACCTGC",2.66376628455464,-10.8658266297546,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GCTGGGTAGCACCTGC","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2478.50302696517,37.9045200300348,0.0152933119780965,1908,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2472.00430259414,2472.00430259414,"Control"
"2019.08.01.count.2.ACATCCCCAAATCGGG","healthy-1","2019-08-01-count-2:ACATCCCCAAATCGGG",2.30048813399617,-10.7943268052307,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ACATCCCCAAATCGGG","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2465.43770777141,38.3650002465117,0.0155611314476045,2062,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2463.48533570678,2463.48533570678,"Control"
"2019.08.01.count.2.TTTGACTCACTGGATT","healthy-1","2019-08-01-count-2:TTTGACTCACTGGATT",7.79098190841023,7.02281425083009,"2019-08-01-count-2","Control1","B","Activated NFkB",0,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TTTGACTCACTGGATT","B","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1741.60153241678,32.7648244778719,0.0188130429768312,979,30000,1100,500,"True","True","True","True",5,290,"True","B_healthy-1",1736.9050975872,1736.9050975872,"Control"
"2019.08.01.count.2.TCCTGCATCCCTAGGG","healthy-1","2019-08-01-count-2:TCCTGCATCCCTAGGG",1.94365241107289,-10.5054064027038,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCCTGCATCCCTAGGG","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2364.03551999099,42.0064875281827,0.0177689747776475,1936,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2359.25359083158,2359.25359083158,"Control"
"2019.08.01.count.2.CCTAAGAAGTGCCTCG","healthy-1","2019-08-01-count-2:CCTAAGAAGTGCCTCG",-7.55412612381633,4.35246894443361,"2019-08-01-count-2","Control1","HSC","HSC",65,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CCTAAGAAGTGCCTCG","HSC","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2043.64168116623,42.6948225507152,0.0208915403048301,1201,30000,1100,500,"True","True","True","True",5,156,"True","HSPC_healthy-1",2032.81463777476,2032.81463777476,"Control"
"2019.08.01.count.2.AGCGCCACACTTGGCG","healthy-1","2019-08-01-count-2:AGCGCCACACTTGGCG",-4.42413793030437,9.09525296771852,"2019-08-01-count-2","Control1","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AGCGCCACACTTGGCG","CD4+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2959.34570529561,42.7457798458324,0.0144443346951121,3013,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",2953.1578086864,2953.1578086864,"Control"
"2019.08.01.count.4.TGCAGTAGTATCACCA","healthy-1","2019-08-01-count-4:TGCAGTAGTATCACCA",-1.50568566742595,11.1505861052307,"2019-08-01-count-4","Control1","CD8+ T","CD8+ Cytotoxic",5,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TGCAGTAGTATCACCA","CD8+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2009.61454364844,39.6396613769411,0.0197250072170435,1057,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",2004.7408018376,2004.7408018376,"Control"
"2019.08.01.count.3.TGCTTGCTCTTGATTC","healthy-1","2019-08-01-count-3:TGCTTGCTCTTGATTC",11.0948883491451,3.86923167789308,"2019-08-01-count-3","Control1","Pro-B","Pro-B",48,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TGCTTGCTCTTGATTC","Pro-B","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2017.57979389758,44.9597284196888,0.0222839902320964,1045,30000,1100,500,"True","True","True","True",5,290,"True","B_healthy-1",2014.37182071998,2014.37182071998,"Control"
"2019.08.01.count.4.CGATCGGGTTAAACCC","healthy-1","2019-08-01-count-4:CGATCGGGTTAAACCC",2.18519773063008,-10.7800026169983,"2019-08-01-count-4","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CGATCGGGTTAAACCC","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2507.45272288731,34.8160260767032,0.013885017954242,1908,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2497.76160656992,2497.76160656992,"Control"
"2019.08.01.count.4.GGAACCCCACGACAAG","healthy-1","2019-08-01-count-4:GGAACCCCACGACAAG",2.98761643943135,-10.6065483323303,"2019-08-01-count-4","Control1","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GGAACCCCACGACAAG","HLA-II+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2512.55185561799,40.1172750715801,0.0159667451168736,1916,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2508.84411547735,2508.84411547735,"Control"
"2019.08.01.count.4.GGCAGTCGTACTTCCC","healthy-1","2019-08-01-count-4:GGCAGTCGTACTTCCC",11.2812153297359,3.80765626514284,"2019-08-01-count-4","Control1","Pro-B","Pro-B",48,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GGCAGTCGTACTTCCC","Pro-B","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1699.30511659741,18.2474537640402,0.0107381856182355,781,30000,1100,500,"True","True","True","True",5,290,"True","B_healthy-1",1688.4163236407,1688.4163236407,"Control"
"2019.08.01.count.4.CGTGAATTCTCCGAGG","healthy-1","2019-08-01-count-4:CGTGAATTCTCCGAGG",1.68171133574788,-9.75469686901244,"2019-08-01-count-4","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CGTGAATTCTCCGAGG","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2309.76306052278,44.919667385311,0.0194477382347365,1700,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2306.91141640296,2306.91141640296,"Control"
"2019.08.01.count.2.TCGACCTTCACAGAGG","healthy-1","2019-08-01-count-2:TCGACCTTCACAGAGG",-8.11510405960735,0.756971038225569,"2019-08-01-count-2","Control1","MPP","MPP_GMP",27,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCGACCTTCACAGAGG","MPP","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2519.15048929391,39.8281846988059,0.0158101649218937,1798,30000,1100,500,"True","True","True","True",5,156,"True","HSPC_healthy-1",2516.0353514548,2516.0353514548,"Control"
"2019.08.01.count.3.AGTACTGAGCATGTTC","healthy-1","2019-08-01-count-3:AGTACTGAGCATGTTC",-5.87593493881877,-3.2082340947357,"2019-08-01-count-3","Control1","GMP","GMP",57,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AGTACTGAGCATGTTC","GMP","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",3086.5497327932,41.6514227652438,0.0134944926766338,2809,30000,1100,500,"True","True","True","True",5,156,"True","HSPC_healthy-1",3078.34360430423,3078.34360430423,"Control"
"2019.08.01.count.2.CTCAATTCAAAGCACG","healthy-1","2019-08-01-count-2:CTCAATTCAAAGCACG",2.38712729987447,-10.4156389466492,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTCAATTCAAAGCACG","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2491.29116142259,38.7907925453488,0.0155705576072442,2007,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2487.95322141095,2487.95322141095,"Control"
"2019.08.01.count.2.AGGCTGCGTGGATGAC","healthy-1","2019-08-01-count-2:AGGCTGCGTGGATGAC",2.31911100920979,-10.3685522309509,"2019-08-01-count-2","Control1","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AGGCTGCGTGGATGAC","HLA-II+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2400.93822011756,37.5500429189057,0.0156397372511597,1993,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2393.80373604165,2393.80373604165,"Control"
"2019.08.01.count.2.CTCCACAAGGCGATAC","healthy-1","2019-08-01-count-2:CTCCACAAGGCGATAC",3.57312979277913,-11.1010017625061,"2019-08-01-count-2","Control1","CD11c+","CD11c+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTCCACAAGGCGATAC","CD11c+","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2264.41467889747,43.7375400054777,0.0193151636107453,1745,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2259.78565577549,2259.78565577549,"Control"
"2019.08.01.count.2.CTACCTGGTATTGGCT","healthy-1","2019-08-01-count-2:CTACCTGGTATTGGCT",3.02684869345967,-10.8003425828186,"2019-08-01-count-2","Control1","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTACCTGGTATTGGCT","HLA-II+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2554.03071600071,38.2491110101314,0.0149759792513477,2130,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2546.07478739621,2546.07478739621,"Control"
"2019.08.01.count.2.ATTATCCTCATGGCCG","healthy-1","2019-08-01-count-2:ATTATCCTCATGGCCG",0.332459230988663,13.4109248884949,"2019-08-01-count-2","Control1","CD8+ T","CD8+ IFN+",22,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ATTATCCTCATGGCCG","CD8+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1766.97794535757,41.2325014544326,0.0233350402379181,839,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",1761.5492224711,1761.5492224711,"Control"
"2019.08.01.count.4.TACCCGTAGCCAAGTG","healthy-1","2019-08-01-count-4:TACCCGTAGCCAAGTG",1.7885385948116,-9.39194776928099,"2019-08-01-count-4","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TACCCGTAGCCAAGTG","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2444.09483320991,37.5993975096825,0.0153837719383016,1958,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2438.27276966798,2438.27276966798,"Control"
"2019.08.01.count.4.CAGATCATCGCTTAAG","healthy-1","2019-08-01-count-4:CAGATCATCGCTTAAG",2.94908442076985,-10.6381588212219,"2019-08-01-count-4","Control1","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CAGATCATCGCTTAAG","HLA-II+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2264.86961600481,42.8990413297808,0.0189410644333045,1839,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2260.91259043594,2260.91259043594,"Control"
"2019.08.01.count.2.GTCTTTAGTGTATTGC","healthy-1","2019-08-01-count-2:GTCTTTAGTGTATTGC",2.43506588515584,-10.6229582062927,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GTCTTTAGTGTATTGC","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2190.63184264269,44.6795575632908,0.0203957400296853,1485,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2183.00889038048,2183.00889038048,"Control"
"2019.08.01.count.2.AGTCACATCTAGGCCG","healthy-1","2019-08-01-count-2:AGTCACATCTAGGCCG",1.04190667447392,-8.13330747997435,"2019-08-01-count-2","Control1","Granulocyte","Granulocytes",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AGTCACATCTAGGCCG","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2198.30612267863,48.6951730195397,0.0221512247621841,1547,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2196.22325805039,2196.22325805039,"Control"
"2019.08.01.count.4.CCCTAACAGGGAGTTC","healthy-1","2019-08-01-count-4:CCCTAACAGGGAGTTC",-1.7681397003239,13.7343330153259,"2019-08-01-count-4","Control1","NK","CD56dim NK",22,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CCCTAACAGGGAGTTC","NK","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1533.3170897407,45.2506176500517,0.0295115850157935,617,30000,1100,500,"True","True","True","True",5,99,"True","NK_healthy-1",1528.87114688286,1528.87114688286,"Control"
"2019.08.01.count.4.TTCATTGAGTGGGAAA","healthy-1","2019-08-01-count-4:TTCATTGAGTGGGAAA",11.0420443015987,4.03524897182313,"2019-08-01-count-4","Control1","Pro-B","Pro-B",48,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TTCATTGAGTGGGAAA","Pro-B","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1901.8022105436,34.4091636448014,0.0180929244135047,890,30000,1100,500,"True","True","True","True",5,290,"True","B_healthy-1",1896.3233455968,1896.3233455968,"Control"
"2019.08.01.count.3.ATTCAGGCAGTTTCGA","healthy-1","2019-08-01-count-3:ATTCAGGCAGTTTCGA",-5.02587304535564,-5.33642818843993,"2019-08-01-count-3","Control1","Granulocyte","Granulocytes (cycling)",38,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ATTCAGGCAGTTTCGA","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2567.73864511692,41.6685425189359,0.0162277195142805,2238,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2564.09901064627,2564.09901064627,"Control"
"2019.08.01.count.3.TACTTACTCATGACAC","healthy-1","2019-08-01-count-3:TACTTACTCATGACAC",10.924128194421,4.10331294620363,"2019-08-01-count-3","Control1","Pro-B","Pro-B",48,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TACTTACTCATGACAC","Pro-B","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2053.64700469071,34.5018169100383,0.0168002664680118,1058,30000,1100,500,"True","True","True","True",5,290,"True","B_healthy-1",2052.0041928026,2052.0041928026,"Control"
"2019.08.01.count.2.CACAGGCCATGGCACC","healthy-1","2019-08-01-count-2:CACAGGCCATGGCACC",2.38775386390035,-10.7417841187683,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CACAGGCCATGGCACC","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2385.75230810423,42.9749253897508,0.0180131546949648,1758,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2380.18924338511,2380.18924338511,"Control"
"2019.08.01.count.3.GAGTCATTCGCCTTTG","healthy-1","2019-08-01-count-3:GAGTCATTCGCCTTTG",1.74689592894856,-4.86227896129759,"2019-08-01-count-3","Control1","cDC2","cDC2",36,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GAGTCATTCGCCTTTG","cDC2","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2430.53662947445,41.0137626684089,0.0168743651797081,2209,30000,1100,500,"True","True","True","True",5,173,"True","DC_healthy-1",2428.51435792152,2428.51435792152,"Control"
"2019.08.01.count.4.TATCAGGAGTCAACAA","healthy-1","2019-08-01-count-4:TATCAGGAGTCAACAA",-4.30180154267009,3.63016603076784,"2019-08-01-count-4","Control1","MEP","MEP",39,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TATCAGGAGTCAACAA","MEP","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2813.4993919703,44.3549561810016,0.0157650491439914,3886,30000,1100,500,"True","True","True","True",5,156,"True","HSPC_healthy-1",2808.55497211135,2808.55497211135,"Control"
"2019.08.01.count.2.GGATCTATCACTGGGC","healthy-1","2019-08-01-count-2:GGATCTATCACTGGGC",0.802413960068864,9.48001954639284,"2019-08-01-count-2","Control1","CD4+ T","CD4+ TCM",4,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GGATCTATCACTGGGC","CD4+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1915.46681141427,40.9832462445029,0.0213959573720013,1271,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",1910.40090035147,1910.40090035147,"Control"
"2019.08.01.count.4.GTGCTGGAGTGAGTTA","healthy-1","2019-08-01-count-4:GTGCTGGAGTGAGTTA",1.55198874053304,-4.69146873867186,"2019-08-01-count-4","Control1","cDC2","cDC2",36,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GTGCTGGAGTGAGTTA","cDC2","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2392.17557146182,45.9195377245665,0.0191957222004846,1769,30000,1100,500,"True","True","True","True",5,173,"True","DC_healthy-1",2389.27394390917,2389.27394390917,"Control"
"2019.08.01.count.3.CCCAACTTCCCGGTAG","healthy-1","2019-08-01-count-3:CCCAACTTCCCGGTAG",13.9994903999263,1.66742036426393,"2019-08-01-count-3","Control1","Plasma cell","Plasma cell",69,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CCCAACTTCCCGGTAG","Plasma cell","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","Plasma",1182.15292076771,30.1638621716208,0.0255160408113967,1478,30000,1100,500,"True","True","True","True",5,290,"True","B_healthy-1",1169.00551592241,1169.00551592241,"Control"
"2019.08.01.count.2.ACTATCTTCTCGCTTG","healthy-1","2019-08-01-count-2:ACTATCTTCTCGCTTG",1.23800625380818,10.6071500548157,"2019-08-01-count-2","Control1","CD4+ T","CD4+ TCM",4,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ACTATCTTCTCGCTTG","CD4+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1728.9976725306,32.7165582922275,0.0189222685559448,1028,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",1721.43222247693,1721.43222247693,"Control"
"2019.08.01.count.2.GATCCCTCAGACAAGC","healthy-1","2019-08-01-count-2:GATCCCTCAGACAAGC",-5.58554206314738,-5.41519024288329,"2019-08-01-count-2","Control1","Granulocyte","Granulocytes (cycling)",38,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GATCCCTCAGACAAGC","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2895.21780809918,42.8271925774814,0.0147923905613163,3150,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2891.08475412916,2891.08475412916,"Control"
"2019.08.01.count.3.CACGTTCCAGTTACCA","healthy-1","2019-08-01-count-3:CACGTTCCAGTTACCA",2.49356259879414,-10.8868980637756,"2019-08-01-count-3","Control1","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CACGTTCCAGTTACCA","HLA-II+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2426.62796119037,39.3100851509419,0.0161994692963393,1974,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2423.36168730877,2423.36168730877,"Control"
"2019.08.01.count.2.AAGTACCAGCTGAAAT","healthy-1","2019-08-01-count-2:AAGTACCAGCTGAAAT",0.91395409879033,10.9460601576599,"2019-08-01-count-2","Control1","CD4+ T","Treg",4,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AAGTACCAGCTGAAAT","CD4+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2062.72843744404,36.4205558369088,0.0176564957246811,1137,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",2056.80751306423,2056.80751306423,"Control"
"2019.08.01.count.3.AATGCCAGTGCCGTAC","healthy-1","2019-08-01-count-3:AATGCCAGTGCCGTAC",1.58497633513753,-9.2166433564392,"2019-08-01-count-3","Control1","Granulocyte","Granulocytes",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AATGCCAGTGCCGTAC","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2412.62222551387,42.5743057810967,0.0176464866031932,1793,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2407.02987173496,2407.02987173496,"Control"
"2019.08.01.count.1.GCTTTCGTCCCTATTA","healthy-1","2019-08-01-count-1:GCTTTCGTCCCTATTA",1.29893424090688,10.8472451933655,"2019-08-01-count-1","Control1","CD4+ T","CD4+ TCM",4,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613747","2019-08-01-count-1_metadata.csv.gz","2019.08.01.count.1.GCTTTCGTCCCTATTA","CD4+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1960.12040819962,35.3428926559841,0.0180309803969883,1651,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",1949.00662177329,1949.00662177329,"Control"
"2019.08.01.count.2.TGTGATGAGATTCGCT","healthy-1","2019-08-01-count-2:TGTGATGAGATTCGCT",-4.00339160385783,-4.97947313701781,"2019-08-01-count-2","Control1","Granulocyte","Granulocytes",63,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TGTGATGAGATTCGCT","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2768.83400288003,41.5011432378211,0.0149886714749434,3089,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2764.83446982159,2764.83446982159,"Control"
"2019.08.01.count.2.AACTTCTCACGTCATA","healthy-1","2019-08-01-count-2:AACTTCTCACGTCATA",2.37481250342671,-10.5348968735901,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AACTTCTCACGTCATA","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2343.90302837295,35.4206463132238,0.0151118224109345,1568,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2339.62421709052,2339.62421709052,"Control"
"2019.08.01.count.3.GGCACGTTCCCTCATG","healthy-1","2019-08-01-count-3:GGCACGTTCCCTCATG",-3.1434362930363,-4.87504770671996,"2019-08-01-count-3","Control1","DC precursor","DC precursor",62,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GGCACGTTCCCTCATG","DC precursor","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","pDC",2525.40487205842,43.6673822269943,0.0172912401928652,2759,30000,1100,500,"True","True","True","True",5,173,"True","DC_healthy-1",2523.23684282958,2523.23684282958,"Control"
"2019.08.01.count.2.ACCCTCAGTACCACGC","healthy-1","2019-08-01-count-2:ACCCTCAGTACCACGC",1.32385553893391,9.67402837360231,"2019-08-01-count-2","Control1","CD4+ T","CD4+ TCM",4,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ACCCTCAGTACCACGC","CD4+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1757.083552368,41.2268946104686,0.0234632522482539,1078,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",1750.9284084614,1750.9284084614,"Control"
"2019.08.01.count.2.TCCGGGATCTTGGCTC","healthy-1","2019-08-01-count-2:TCCGGGATCTTGGCTC",4.37993111190144,-10.3669624558655,"2019-08-01-count-2","Control1","CD16+ monocyte","CD16+",61,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCCGGGATCTTGGCTC","CD16+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2404.20374148726,46.9822325170561,0.0195417017727427,1954,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2396.82977299209,2396.82977299209,"Control"
"2019.08.01.count.3.GTTCTATAGACACACG","healthy-1","2019-08-01-count-3:GTTCTATAGACACACG",14.0572191673214,1.67545209014741,"2019-08-01-count-3","Control1","Plasma cell","Plasma cell",69,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GTTCTATAGACACACG","Plasma cell","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","Plasma",1388.12698009041,28.9364723665533,0.0208456955174724,1692,30000,1100,500,"True","True","True","True",5,290,"True","B_healthy-1",1369.23468043079,1369.23468043079,"Control"
"2019.08.01.count.4.CGTCAAAAGCCAGAGT","healthy-1","2019-08-01-count-4:CGTCAAAAGCCAGAGT",3.13717736777608,-9.66645815288695,"2019-08-01-count-4","Control1","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CGTCAAAAGCCAGAGT","HLA-II+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2325.8640043425,42.536573465451,0.0182885041369715,1664,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2320.88938370155,2320.88938370155,"Control"
"2019.08.01.count.2.GGTGTTAGTAGACACG","healthy-1","2019-08-01-count-2:GGTGTTAGTAGACACG",1.69957317885701,-9.60311701213988,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GGTGTTAGTAGACACG","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2238.53613247435,44.2768267866336,0.0197793665888665,1601,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2233.93733824029,2233.93733824029,"Control"
"2019.08.01.count.2.CGAGAAGGTTATGGTC","healthy-1","2019-08-01-count-2:CGAGAAGGTTATGGTC",-7.47118411484416,4.31730172717897,"2019-08-01-count-2","Control1","HSC","HSC",65,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CGAGAAGGTTATGGTC","HSC","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",1997.31844027275,31.6606398983607,0.0158515734196282,1265,30000,1100,500,"True","True","True","True",5,156,"True","HSPC_healthy-1",1986.24487223817,1986.24487223817,"Control"
"2019.08.01.count.2.CATTGAGGTGTACATC","healthy-1","2019-08-01-count-2:CATTGAGGTGTACATC",14.0116182762081,1.65838394248811,"2019-08-01-count-2","Control1","Plasmablast","Plasmablast",69,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CATTGAGGTGTACATC","Plasmablast","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","Plasma",1350.94762334505,36.3071099980675,0.0268752906261224,1625,30000,1100,500,"True","True","True","True",5,290,"True","B_healthy-1",1333.5494708507,1333.5494708507,"Control"
"2019.08.01.count.4.CCTAACCCATGCCATA","healthy-1","2019-08-01-count-4:CCTAACCCATGCCATA",-1.64928183975871,13.0966462858948,"2019-08-01-count-4","Control1","NK","Activated NK",6,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CCTAACCCATGCCATA","NK","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2041.64753846955,39.6776065694391,0.0194341118247971,973,30000,1100,500,"True","True","True","True",5,99,"True","NK_healthy-1",2039.80179063986,2039.80179063986,"Control"
"2019.08.01.count.3.CTGCCTAGTAGATTAG","healthy-1","2019-08-01-count-3:CTGCCTAGTAGATTAG",-1.53807220879253,12.7997131117615,"2019-08-01-count-3","Control1","NK","CD56bright NK",6,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTGCCTAGTAGATTAG","NK","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2044.29871044214,44.9407854305459,0.0219834729636092,1119,30000,1100,500,"True","True","True","True",5,99,"True","NK_healthy-1",2039.84969207451,2039.84969207451,"Control"
"2019.08.01.count.3.GTGGAGAAGAATAACC","healthy-1","2019-08-01-count-3:GTGGAGAAGAATAACC",2.87694706496541,-10.3965645066467,"2019-08-01-count-3","Control1","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GTGGAGAAGAATAACC","HLA-II+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2262.20996711534,40.5734061692617,0.0179352963513811,1755,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2257.42540013361,2257.42540013361,"Control"
"2019.08.01.count.3.GATCGTAGTAGTGTGG","healthy-1","2019-08-01-count-3:GATCGTAGTAGTGTGG",1.50238015231435,10.8432559737,"2019-08-01-count-3","Control1","CD4+ T","CD4+ TCM",4,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GATCGTAGTAGTGTGG","CD4+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1758.6829699922,35.1406086647607,0.0199812071102938,1030,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",1757.37136459245,1757.37136459245,"Control"
"2019.08.01.count.3.CTGTATTGTTCCCAAA","healthy-1","2019-08-01-count-3:CTGTATTGTTCCCAAA",1.80195929583852,-9.73712351238402,"2019-08-01-count-3","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTGTATTGTTCCCAAA","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2306.72008155832,44.5134258731131,0.0192972811174565,1799,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2304.07967115974,2304.07967115974,"Control"
"2019.08.01.count.2.AACAAAGAGCAAACAT","healthy-1","2019-08-01-count-2:AACAAAGAGCAAACAT",8.06437363204305,6.9381441839966,"2019-08-01-count-2","Control1","B","Naive B",0,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AACAAAGAGCAAACAT","B","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1930.98785431483,41.4713745555934,0.0214767661344553,981,30000,1100,500,"True","True","True","True",5,290,"True","B_healthy-1",1926.00031140527,1926.00031140527,"Control"
"2019.08.01.count.4.AAGCCATCACCAGTTA","healthy-1","2019-08-01-count-4:AAGCCATCACCAGTTA",6.90360798415486,-1.05566480075987,"2019-08-01-count-4","Control1","pDC","pDC",32,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.AAGCCATCACCAGTTA","pDC","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","pDC",2368.40911337866,46.4314262971125,0.0196044788186428,1381,30000,1100,500,"True","True","True","True",5,173,"True","DC_healthy-1",2354.85809894581,2354.85809894581,"Control"
"2019.08.01.count.2.GTTGAACAGCTGTGCC","healthy-1","2019-08-01-count-2:GTTGAACAGCTGTGCC",2.3871714073116,-10.4555549851623,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GTTGAACAGCTGTGCC","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2049.65131469587,28.4565349961057,0.0138835980501045,1091,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2045.19281662086,2045.19281662086,"Control"
"2019.08.01.count.3.GACTCTCTCGTTCATT","healthy-1","2019-08-01-count-3:GACTCTCTCGTTCATT",1.38378562506978,-9.68085291301879,"2019-08-01-count-3","Control1","Granulocyte","Granulocytes",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GACTCTCTCGTTCATT","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2563.7775305344,36.0589677210567,0.0140647803062462,2136,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2559.80364725972,2559.80364725972,"Control"
"2019.08.01.count.4.TGCATGACATACTGTG","healthy-1","2019-08-01-count-4:TGCATGACATACTGTG",1.45668162879292,-9.29101755535277,"2019-08-01-count-4","Control1","Granulocyte","Granulocytes",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TGCATGACATACTGTG","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2431.35410847662,44.7181958957928,0.018392300710081,1856,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2427.66497573577,2427.66497573577,"Control"
"2019.08.01.count.2.TCTGTCGTCGTTCTAT","healthy-1","2019-08-01-count-2:TCTGTCGTCGTTCTAT",-2.42165074768718,11.0788430937561,"2019-08-01-count-2","Control1","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCTGTCGTCGTTCTAT","CD8+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2032.58649611618,41.4224194024454,0.0203791668800292,954,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",2030.72984777725,2030.72984777725,"Control"
"2019.08.01.count.3.TGGGAAGCAGAGCCCT","healthy-1","2019-08-01-count-3:TGGGAAGCAGAGCCCT",1.27712871608083,9.78721711719362,"2019-08-01-count-3","Control1","CD4+ T","CD4+ Naive",4,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TGGGAAGCAGAGCCCT","CD4+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1757.11620187519,31.8727079143889,0.018139214629274,1020,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",1750.42427411222,1750.42427411222,"Control"
"2019.08.01.count.2.TGACGCGGTATTCCTT","healthy-1","2019-08-01-count-2:TGACGCGGTATTCCTT",-2.46408544006999,13.6698140867981,"2019-08-01-count-2","Control1","NK","CD56dim NK",6,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TGACGCGGTATTCCTT","NK","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2202.69734378263,43.1263802003186,0.0195788950860852,1085,30000,1100,500,"True","True","True","True",5,99,"True","NK_healthy-1",2195.70888842718,2195.70888842718,"Control"
"2019.08.01.count.4.CCTGCATCAAGCGGAT","healthy-1","2019-08-01-count-4:CCTGCATCAAGCGGAT",1.43123545226399,-9.49428465282591,"2019-08-01-count-4","Control1","Granulocyte","Granulocytes",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CCTGCATCAAGCGGAT","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2519.27977413217,46.0440720452836,0.0182766807077411,2169,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2515.37952503271,2515.37952503271,"Control"
"2019.08.01.count.4.GAGTGAGTCAACTTTC","healthy-1","2019-08-01-count-4:GAGTGAGTCAACTTTC",-3.00193081322368,3.65340564334718,"2019-08-01-count-4","Control1","Ery","Ery-1",53,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GAGTGAGTCAACTTTC","Ery","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Ery","Ery",2933.89551857644,43.1476879396604,0.0147066204868114,4704,30000,1100,500,"True","True","True","True",5,51,"True","Ery_healthy-1",2927.83627895825,2927.83627895825,"Control"
"2019.08.01.count.2.GGCTTTCAGAGTGAAG","healthy-1","2019-08-01-count-2:GGCTTTCAGAGTGAAG",1.07019784030263,9.18842218005983,"2019-08-01-count-2","Control1","CD8+ T","CD8+ Naive",4,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GGCTTTCAGAGTGAAG","CD8+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1490.80365641349,32.5441597457251,0.021829943605061,840,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",1482.79975260318,1482.79975260318,"Control"
"2019.08.01.count.2.ACGGTCGCAGTCTGGC","healthy-1","2019-08-01-count-2:ACGGTCGCAGTCTGGC",7.04473366317098,-1.06311895763548,"2019-08-01-count-2","Control1","pDC","pDC",32,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ACGGTCGCAGTCTGGC","pDC","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","pDC",2305.27904466313,44.4951976760199,0.0193014367518888,1718,30000,1100,500,"True","True","True","True",5,173,"True","DC_healthy-1",2289.94943766394,2289.94943766394,"Control"
"2019.08.01.count.4.AACCAACCAAGACGGT","healthy-1","2019-08-01-count-4:AACCAACCAAGACGGT",2.33477987822835,-10.575351738092,"2019-08-01-count-4","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.AACCAACCAAGACGGT","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2453.78440834101,43.7023092112062,0.0178101666400077,1622,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2449.22178506677,2449.22178506677,"Control"
"2019.08.01.count.2.AGGGCTCTCCCAAGCG","healthy-1","2019-08-01-count-2:AGGGCTCTCCCAAGCG",2.03592361983601,-10.1334581605163,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AGGGCTCTCCCAAGCG","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2357.56747285071,42.2038069004096,0.0179014205898327,1918,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2355.24146050867,2355.24146050867,"Control"
"2019.08.01.count.2.TGGGCGTGTGGTCTAT","healthy-1","2019-08-01-count-2:TGGGCGTGTGGTCTAT",14.1660248237545,1.77616999233095,"2019-08-01-count-2","Control1","Plasmablast","Plasmablast",69,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TGGGCGTGTGGTCTAT","Plasmablast","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","Plasma",1445.72962632773,36.1719605132087,0.0250198653015698,1547,30000,1100,500,"True","True","True","True",5,290,"True","B_healthy-1",1434.1209790615,1434.1209790615,"Control"
"2019.08.01.count.3.CTCTCGATCGGCAGTC","healthy-1","2019-08-01-count-3:CTCTCGATCGGCAGTC",-1.18770657005962,13.0134591826233,"2019-08-01-count-3","Control1","NK","Activated NK",6,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTCTCGATCGGCAGTC","NK","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1778.08515768194,37.7144790810517,0.0212107271230021,787,30000,1100,500,"True","True","True","True",5,99,"True","NK_healthy-1",1776.13456506165,1776.13456506165,"Control"
"2019.08.01.count.2.CTCTCGACACTAGGCC","healthy-1","2019-08-01-count-2:CTCTCGACACTAGGCC",2.15212406691853,-10.4243126145569,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTCTCGACACTAGGCC","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2426.35916553842,39.8839613691497,0.0164377813209279,1812,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2422.70881150698,2422.70881150698,"Control"
"2019.08.01.count.3.GAGTCTAGTCCCGGTA","healthy-1","2019-08-01-count-3:GAGTCTAGTCCCGGTA",2.91464342650716,-10.6976289979187,"2019-08-01-count-3","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GAGTCTAGTCCCGGTA","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2398.97988739282,37.642297057519,0.0156909598347772,1927,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2388.15185886138,2388.15185886138,"Control"
"2019.08.01.count.2.CTGTCGTAGGTGAGAA","healthy-1","2019-08-01-count-2:CTGTCGTAGGTGAGAA",1.68434097346608,-4.98724367534789,"2019-08-01-count-2","Control1","cDC2","cDC2",36,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTGTCGTAGGTGAGAA","cDC2","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2450.88362754711,39.1242471387875,0.0159633230639938,2174,30000,1100,500,"True","True","True","True",5,173,"True","DC_healthy-1",2450.15733639155,2450.15733639155,"Control"
"2019.08.01.count.4.CGCATGGAGAATAACC","healthy-1","2019-08-01-count-4:CGCATGGAGAATAACC",1.64705099639241,-9.9420433274475,"2019-08-01-count-4","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CGCATGGAGAATAACC","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2355.42283898253,42.5597967082815,0.018068856259654,1939,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2352.21373867639,2352.21373867639,"Control"
"2019.08.01.count.4.AGTACTGGTGGTCTAT","healthy-1","2019-08-01-count-4:AGTACTGGTGGTCTAT",2.35074963149373,-10.4665184251037,"2019-08-01-count-4","Control1","Granulocyte","Granulocytes",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.AGTACTGGTGGTCTAT","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2321.8118764847,43.7018362092685,0.0188222985039747,1629,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2319.73236484117,2319.73236484117,"Control"
"2019.08.01.count.3.CTCCATGAGCCTCTCT","healthy-1","2019-08-01-count-3:CTCCATGAGCCTCTCT",7.67734350737874,7.24638745868532,"2019-08-01-count-3","Control1","B","Activated AP-1",0,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTCCATGAGCCTCTCT","B","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2018.11009098631,35.7863939388984,0.0177326272232297,1077,30000,1100,500,"True","True","True","True",5,290,"True","B_healthy-1",2008.98997266766,2008.98997266766,"Control"
"2019.08.01.count.2.AGGTAGGTCCTACAAG","healthy-1","2019-08-01-count-2:AGGTAGGTCCTACAAG",2.1800819831783,-10.5286131135193,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AGGTAGGTCCTACAAG","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2322.29566573536,38.2112195264633,0.0164540717576389,1670,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2320.33782712774,2320.33782712774,"Control"
"2019.08.01.count.4.CCCAACTCAAGCGCTC","healthy-1","2019-08-01-count-4:CCCAACTCAAGCGCTC",-1.27487371388133,13.4100227125916,"2019-08-01-count-4","Control1","NK","Activated NK",6,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CCCAACTCAAGCGCTC","NK","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2265.03426276871,40.7484675308662,0.0179902212521308,1298,30000,1100,500,"True","True","True","True",5,99,"True","NK_healthy-1",2253.52939154268,2253.52939154268,"Control"
"2019.08.01.count.3.GATCGTAGTTGTTGTG","healthy-1","2019-08-01-count-3:GATCGTAGTTGTTGTG",-7.81913934174235,1.09682724559633,"2019-08-01-count-3","Control1","MPP","MPP_GMP",27,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GATCGTAGTTGTTGTG","MPP","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2683.69305793053,41.5222569702825,0.0154720588658904,2972,30000,1100,500,"True","True","True","True",5,156,"True","HSPC_healthy-1",2676.89222209812,2676.89222209812,"Control"
"2019.08.01.count.2.ACCCTTGAGCAGGTCA","healthy-1","2019-08-01-count-2:ACCCTTGAGCAGGTCA",2.76647772368733,-10.3945160142151,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ACCCTTGAGCAGGTCA","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2378.97369931109,40.7320984427493,0.0171217102797499,1850,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2371.9956648139,2371.9956648139,"Control"
"2019.08.01.count.4.TCATGGAAGGATTCAA","healthy-1","2019-08-01-count-4:TCATGGAAGGATTCAA",2.64639892157857,-10.6033048859802,"2019-08-01-count-4","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TCATGGAAGGATTCAA","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2267.92159355868,38.7499023118183,0.0170860855251237,1655,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2265.09394232754,2265.09394232754,"Control"
"2019.08.01.count.2.GACTCAACACAGCTGC","healthy-1","2019-08-01-count-2:GACTCAACACAGCTGC",8.13487782058064,7.57985732639161,"2019-08-01-count-2","Control1","B","Activated NFkB",0,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GACTCAACACAGCTGC","B","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1895.36708426737,37.5495303803127,0.0198112179387282,1017,30000,1100,500,"True","True","True","True",5,290,"True","B_healthy-1",1886.40210783751,1886.40210783751,"Control"
"2019.08.01.count.3.GTCAAGTAGGAAAGAC","healthy-1","2019-08-01-count-3:GTCAAGTAGGAAAGAC",2.7187839942867,-10.7092132798401,"2019-08-01-count-3","Control1","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GTCAAGTAGGAAAGAC","HLA-II+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2215.65313115162,41.1036767024486,0.0185514944214595,1708,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2209.23316354312,2209.23316354312,"Control"
"2019.08.01.count.3.TGCTGAATCCTGGCTT","healthy-1","2019-08-01-count-3:TGCTGAATCCTGGCTT",1.40274514731709,-8.58373930370482,"2019-08-01-count-3","Control1","Granulocyte","Granulocytes",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TGCTGAATCCTGGCTT","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2758.95891659255,40.2576275258225,0.0145916009418301,2465,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2752.30424492229,2752.30424492229,"Control"
"2019.08.01.count.4.ACAAGCTTCGTACACA","healthy-1","2019-08-01-count-4:ACAAGCTTCGTACACA",-3.40829596939738,-5.26042463695677,"2019-08-01-count-4","Control1","Granulocyte","Granulocytes",63,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.ACAAGCTTCGTACACA","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2069.29951038897,46.1135010366558,0.0222845947651085,1612,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2064.171772928,2064.171772928,"Control"
"2019.08.01.count.2.CATGCGGGTGAGATAT","healthy-1","2019-08-01-count-2:CATGCGGGTGAGATAT",-3.31785140457805,-5.61003878032836,"2019-08-01-count-2","Control1","Granulocyte","Granulocytes",63,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CATGCGGGTGAGATAT","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2155.9533292773,47.5515016460818,0.0220559049216625,1481,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2150.70088686005,2150.70088686005,"Control"
"2019.08.01.count.2.TCCACCATCATTACGG","healthy-1","2019-08-01-count-2:TCCACCATCATTACGG",1.68067659911458,-9.897412323114,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCCACCATCATTACGG","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2265.18216159797,40.1302798210318,0.0177161380225253,1479,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2264.05966399746,2264.05966399746,"Control"
"2019.08.01.count.2.ACCGTTCCATGTCAGT","healthy-1","2019-08-01-count-2:ACCGTTCCATGTCAGT",3.21097650107686,-10.5444393388,"2019-08-01-count-2","Control1","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ACCGTTCCATGTCAGT","HLA-II+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2326.48677764171,49.3323934817398,0.0212046739125449,1696,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2321.0085133227,2321.0085133227,"Control"
"2019.08.01.count.2.TTTATGCTCTTGAACG","healthy-1","2019-08-01-count-2:TTTATGCTCTTGAACG",1.87809242781941,-10.2839927903381,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TTTATGCTCTTGAACG","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2132.44773496006,36.3752964607679,0.0170580014058113,1474,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2127.34475238834,2127.34475238834,"Control"
"2019.08.01.count.2.CCTCATGAGCCAGACA","healthy-1","2019-08-01-count-2:CCTCATGAGCCAGACA",1.80175962027852,-10.1783361664978,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CCTCATGAGCCAGACA","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2454.55395903183,40.6021167375941,0.0165415458023213,2021,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2451.35217647021,2451.35217647021,"Control"
"2019.08.01.count.3.CAATCGACACCTGCGA","healthy-1","2019-08-01-count-3:CAATCGACACCTGCGA",0.783427258103532,9.38982198322145,"2019-08-01-count-3","Control1","CD8+ T","CD8+ Naive",4,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CAATCGACACCTGCGA","CD8+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1793.15721543253,39.9515050727571,0.0222799789828357,1103,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",1789.47000891592,1789.47000891592,"Control"
"2019.08.01.count.1.AGTTCGAAGCAGGGAG","healthy-1","2019-08-01-count-1:AGTTCGAAGCAGGGAG",1.22451510009114,9.48155400836793,"2019-08-01-count-1","Control1","CD4+ T","CD4+ Naive",4,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613747","2019-08-01-count-1_metadata.csv.gz","2019.08.01.count.1.AGTTCGAAGCAGGGAG","CD4+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1809.86588606512,27.8867658755773,0.0154081946570122,1222,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",1802.08576487422,1802.08576487422,"Control"
"2019.08.01.count.2.AATCGACAGCATCCCG","healthy-1","2019-08-01-count-2:AATCGACAGCATCCCG",1.04178484258,10.5189103850159,"2019-08-01-count-2","Control1","CD4+ T","CD4+ TCM",4,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AATCGACAGCATCCCG","CD4+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2105.18584189902,36.3178608776279,0.0172516174842154,1380,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",2105.18584189902,2105.18584189902,"Control"
"2019.08.01.count.3.TTTCATGGTGCATGAG","healthy-1","2019-08-01-count-3:TTTCATGGTGCATGAG",2.46407665786092,-10.6637821427551,"2019-08-01-count-3","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TTTCATGGTGCATGAG","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2325.12195129795,40.5294710591472,0.0174311162631803,1767,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2323.36576040063,2323.36576040063,"Control"
"2019.08.01.count.2.CATACCCTCAATCTCT","healthy-1","2019-08-01-count-2:CATACCCTCAATCTCT",2.15412249144856,-10.5053835145203,"2019-08-01-count-2","Control1","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CATACCCTCAATCTCT","CD14+ monocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2580.88614879371,37.9204103201723,0.0146927869475746,2114,30000,1100,500,"True","True","True","True",5,1120,"True","Mono_healthy-1",2576.75065762549,2576.75065762549,"Control"
"2019.08.01.count.2.CTCCATGGTTCGGTTA","healthy-1","2019-08-01-count-2:CTCCATGGTTCGGTTA",-5.06401143494304,-5.29756882106932,"2019-08-01-count-2","Control1","Granulocyte","Granulocytes (cycling)",38,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTCCATGGTTCGGTTA","Granulocyte","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2436.56755009507,49.1147249061162,0.0201573417918169,1554,30000,1100,500,"True","True","True","True",5,276,"True","Gran_healthy-1",2434.18290185195,2434.18290185195,"Control"
"2019.08.01.count.2.TAGGTTGGTATGAGGC","healthy-1","2019-08-01-count-2:TAGGTTGGTATGAGGC",1.43848826464955,10.1368503340515,"2019-08-01-count-2","Control1","CD8+ T","CD8+ Naive",4,"Control","Control","Control","control_19to26yrs","control_19to26yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TAGGTTGGTATGAGGC","CD8+ T","1","F",26,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1806.70894866549,38.7263251374789,0.0214347336720083,1162,30000,1100,500,"True","True","True","True",5,667,"True","T_healthy-1",1805.53198870656,1805.53198870656,"Control"
"2019.08.01.count.3.TCACAAGTCTATCGCC","healthy-2","2019-08-01-count-3:TCACAAGTCTATCGCC",1.69014360484425,-9.78329183971556,"2019-08-01-count-3","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TCACAAGTCTATCGCC","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2321.34582696572,42.7180134701962,0.018402261728505,1847,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2318.90829560221,2318.90829560221,"Control"
"2019.08.01.count.4.CCTGTTGGTAACGGTG","healthy-2","2019-08-01-count-4:CCTGTTGGTAACGGTG",1.73751213130299,-9.83609774028929,"2019-08-01-count-4","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CCTGTTGGTAACGGTG","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2295.36946807266,41.327764940045,0.0180048421462827,1602,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2293.31346262455,2293.31346262455,"Control"
"2019.08.01.count.3.TCTTTGACAATCCAGT","healthy-2","2019-08-01-count-3:TCTTTGACAATCCAGT",8.46781220015828,6.91762635791627,"2019-08-01-count-3","Control2","B","Naive B",0,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TCTTTGACAATCCAGT","B","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1653.88290993345,39.1884091164437,0.0236947905326748,704,30000,1100,500,"True","True","True","True",5,134,"True","B_healthy-2",1645.75496406529,1645.75496406529,"Control"
"2019.08.01.count.2.TCTATACCAGCGACCT","healthy-2","2019-08-01-count-2:TCTATACCAGCGACCT",4.39533104476277,-10.6750030747619,"2019-08-01-count-2","Control2","CD16+ monocyte","CD16+",61,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCTATACCAGCGACCT","CD16+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2520.657239388,41.1072483251573,0.0163081468129867,1947,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2519.75654308629,2519.75654308629,"Control"
"2019.08.01.count.4.GTGTGATCACTTCAAG","healthy-2","2019-08-01-count-4:GTGTGATCACTTCAAG",1.31999899920766,10.3496064909729,"2019-08-01-count-4","Control2","CD4+ T","CD4+ Naive",4,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GTGTGATCACTTCAAG","CD4+ T","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1832.59850972033,30.443076776156,0.0166119728978726,1181,30000,1100,500,"True","True","True","True",5,171,"True","T_healthy-2",1825.62229681735,1825.62229681735,"Control"
"2019.08.01.count.2.ACTTTGTCACCTGCGA","healthy-2","2019-08-01-count-2:ACTTTGTCACCTGCGA",1.6233682828838,-4.82613661205443,"2019-08-01-count-2","Control2","cDC2","cDC2",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ACTTTGTCACCTGCGA","cDC2","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2266.54252639349,40.7015864590858,0.0179575657571491,2079,30000,1100,500,"True","True","True","True",5,218,"True","DC_healthy-2",2257.56655690838,2257.56655690838,"Control"
"2019.08.01.count.1.TTCACCGTCAACCTTT","healthy-2","2019-08-01-count-1:TTCACCGTCAACCTTT",0.924752195447129,10.7684602507385,"2019-08-01-count-1","Control2","CD8+ T","CD8+ TRM",4,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613747","2019-08-01-count-1_metadata.csv.gz","2019.08.01.count.1.TTCACCGTCAACCTTT","CD8+ T","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2221.0399093105,29.765572854566,0.0134016380028968,1968,30000,1100,500,"True","True","True","True",5,171,"True","T_healthy-2",2209.20113447055,2209.20113447055,"Control"
"2019.08.01.count.4.CTACCCATCTTCCAGC","healthy-2","2019-08-01-count-4:CTACCCATCTTCCAGC",4.09718050536458,-10.9141082993713,"2019-08-01-count-4","Control2","CD16+ monocyte","CD16+",61,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CTACCCATCTTCCAGC","CD16+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2312.51697468238,43.7382070533795,0.0189136804322861,1381,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2311.17433718394,2311.17433718394,"Control"
"2019.08.01.count.1.GTTAGTGAGGTGATCG","healthy-2","2019-08-01-count-1:GTTAGTGAGGTGATCG",8.47292770919148,6.63589284503785,"2019-08-01-count-1","Control2","B","Naive B",0,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613747","2019-08-01-count-1_metadata.csv.gz","2019.08.01.count.1.GTTAGTGAGGTGATCG","B","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1570.3788890141,34.6151848993878,0.0220425689249551,757,30000,1100,500,"True","True","True","True",5,134,"True","B_healthy-2",1558.58372613012,1558.58372613012,"Control"
"2019.08.01.count.3.GTCATGACAGTCAGTT","healthy-2","2019-08-01-count-3:GTCATGACAGTCAGTT",2.13839044150655,-10.418275856134,"2019-08-01-count-3","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GTCATGACAGTCAGTT","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2403.63312957952,42.9303638456566,0.0178606141333918,1766,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2398.80319188144,2398.80319188144,"Control"
"2019.08.01.count.4.CATCGCTGTGCATTTG","healthy-2","2019-08-01-count-4:CATCGCTGTGCATTTG",1.51643480834309,-9.33274843609007,"2019-08-01-count-4","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CATCGCTGTGCATTTG","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2563.01800670684,41.6310025866982,0.0162429614141451,2180,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2558.52994306554,2558.52994306554,"Control"
"2019.08.01.count.2.CATCAAGAGCTCGACC","healthy-2","2019-08-01-count-2:CATCAAGAGCTCGACC",1.18296243724172,-9.02798178112181,"2019-08-01-count-2","Control2","Granulocyte","Granulocytes",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CATCAAGAGCTCGACC","Granulocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2439.99113416264,45.5955377853973,0.018686763712789,2215,30000,1100,500,"True","True","True","True",5,175,"True","Gran_healthy-2",2435.85191320355,2435.85191320355,"Control"
"2019.08.01.count.2.GCTCAAAAGAAGCTCG","healthy-2","2019-08-01-count-2:GCTCAAAAGAAGCTCG",1.05806948718373,-8.95968439495238,"2019-08-01-count-2","Control2","Granulocyte","Granulocytes",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GCTCAAAAGAAGCTCG","Granulocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2458.64398589788,42.504437675078,0.0172877561447985,2035,30000,1100,500,"True","True","True","True",5,175,"True","Gran_healthy-2",2455.48855518113,2455.48855518113,"Control"
"2019.08.01.count.3.GCCAACGCAAAGGGCT","healthy-2","2019-08-01-count-3:GCCAACGCAAAGGGCT",2.52297224578206,-10.9125213853088,"2019-08-01-count-3","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GCCAACGCAAAGGGCT","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2241.80940320275,37.9895882319217,0.0169459491862457,1514,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2238.5654838535,2238.5654838535,"Control"
"2019.08.01.count.4.ACTTCGCCAAAGGTTA","healthy-2","2019-08-01-count-4:ACTTCGCCAAAGGTTA",-3.53154168549235,-4.61091949855956,"2019-08-01-count-4","Control2","DC precursor","DC precursor",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.ACTTCGCCAAAGGTTA","DC precursor","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","pDC",2973.07238497241,39.3107645979776,0.0132222695944695,3669,30000,1100,500,"True","True","True","True",5,218,"True","DC_healthy-2",2966.82780941585,2966.82780941585,"Control"
"2019.08.01.count.4.GTCCCATCACATATCG","healthy-2","2019-08-01-count-4:GTCCCATCACATATCG",-2.8739107650822,3.69374034488527,"2019-08-01-count-4","Control2","Ery","Ery-1",53,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GTCCCATCACATATCG","Ery","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Ery","Ery",3098.75958007172,43.6903847923044,0.0140993141492097,4574,30000,1100,500,"True","True","True","True",5,54,"True","Ery_healthy-2",3093.62463101023,3093.62463101023,"Control"
"2019.08.01.count.2.GAATCACTCCACTGAA","healthy-2","2019-08-01-count-2:GAATCACTCCACTGAA",1.61905982074086,-9.82473471080931,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GAATCACTCCACTGAA","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2537.32116687573,42.5557652326782,0.0167719269394179,2307,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2533.15088670248,2533.15088670248,"Control"
"2019.08.01.count.3.ACCCTTGTCATACGGT","healthy-2","2019-08-01-count-3:ACCCTTGTCATACGGT",-1.5079701942509,11.8618039854797,"2019-08-01-count-3","Control2","NK","CD56dim NK",5,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ACCCTTGTCATACGGT","NK","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1661.41259471086,51.5615280892455,0.031034752146091,729,30000,1100,500,"True","True","True","True",5,184,"True","NK_healthy-2",1653.2766866523,1653.2766866523,"Control"
"2019.08.01.count.2.AGAACCTCAATTCTCT","healthy-2","2019-08-01-count-2:AGAACCTCAATTCTCT",0.481367905705613,8.95250890338746,"2019-08-01-count-2","Control2","CD4+ T","CD4+ TCM",4,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AGAACCTCAATTCTCT","CD4+ T","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1994.844219829,37.728835975961,0.0189131740719058,1248,30000,1100,500,"True","True","True","True",5,171,"True","T_healthy-2",1988.11759160412,1988.11759160412,"Control"
"2019.08.01.count.2.ATCACGAGTATACCCA","healthy-2","2019-08-01-count-2:ATCACGAGTATACCCA",2.79097094115559,-10.2493572465149,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ATCACGAGTATACCCA","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2303.48972942123,41.7286689311531,0.0181154134955217,1728,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2301.61584547119,2301.61584547119,"Control"
"2019.08.01.count.4.GTTACCCTCCGATCTC","healthy-2","2019-08-01-count-4:GTTACCCTCCGATCTC",1.51805796202962,-9.54829981243285,"2019-08-01-count-4","Control2","Granulocyte","Granulocytes",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GTTACCCTCCGATCTC","Granulocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2425.48618481743,41.6216890495223,0.0171601427004851,1837,30000,1100,500,"True","True","True","True",5,175,"True","Gran_healthy-2",2420.93882162556,2420.93882162556,"Control"
"2019.08.01.count.4.GAGATGGAGGGCGAGA","healthy-2","2019-08-01-count-4:GAGATGGAGGGCGAGA",2.54232039031331,-10.7849703065124,"2019-08-01-count-4","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GAGATGGAGGGCGAGA","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2350.97107334955,39.5906506868785,0.0168401266760257,1638,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2348.92712567533,2348.92712567533,"Control"
"2019.08.01.count.2.CCCGAAGCACCAGCTG","healthy-2","2019-08-01-count-2:CCCGAAGCACCAGCTG",2.26352824744527,-10.7634287110535,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CCCGAAGCACCAGCTG","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2401.02749489994,41.0439649385229,0.0170943335824788,1775,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2398.17277265797,2398.17277265797,"Control"
"2019.08.01.count.4.GTGCACGCACATGACT","healthy-2","2019-08-01-count-4:GTGCACGCACATGACT",3.59390725669209,-10.6365337601868,"2019-08-01-count-4","Control2","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GTGCACGCACATGACT","HLA-II+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2376.23150086155,39.021983574417,0.0164217937352774,1789,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2367.24377370261,2367.24377370261,"Control"
"2019.08.01.count.2.GTGAGGATCTTCCACG","healthy-2","2019-08-01-count-2:GTGAGGATCTTCCACG",1.6970166164333,-4.84610989010008,"2019-08-01-count-2","Control2","cDC2","cDC2",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GTGAGGATCTTCCACG","cDC2","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2305.50707953364,40.7318622867577,0.0176672033013219,1997,30000,1100,500,"True","True","True","True",5,218,"True","DC_healthy-2",2301.11714238492,2301.11714238492,"Control"
"2019.08.01.count.3.GTTCTATGTATGAAAC","healthy-2","2019-08-01-count-3:GTTCTATGTATGAAAC",-2.00820217552837,13.5318641432556,"2019-08-01-count-3","Control2","NK","CD56dim NK",6,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GTTCTATGTATGAAAC","NK","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1731.02522673811,42.1977808501326,0.0243773344248997,760,30000,1100,500,"True","True","True","True",5,184,"True","NK_healthy-2",1726.92604139696,1726.92604139696,"Control"
"2019.08.01.count.4.GTTACAGAGTATTGCC","healthy-2","2019-08-01-count-4:GTTACAGAGTATTGCC",-0.789778391749221,11.6938762434754,"2019-08-01-count-4","Control2","CD8+ T","CD8+ GZMK+",5,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GTTACAGAGTATTGCC","CD8+ T","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1862.815927987,35.9070903002433,0.0192757050016451,917,30000,1100,500,"True","True","True","True",5,171,"True","T_healthy-2",1857.60167143303,1857.60167143303,"Control"
"2019.08.01.count.2.TCGACCTTCGTTCAGA","healthy-2","2019-08-01-count-2:TCGACCTTCGTTCAGA",11.0877195793087,3.78871343219606,"2019-08-01-count-2","Control2","Pro-B","Pro-B",48,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCGACCTTCGTTCAGA","Pro-B","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1524.47609311617,33.5486792113513,0.0220066942097954,617,30000,1100,500,"True","True","True","True",5,134,"True","B_healthy-2",1515.87259116778,1515.87259116778,"Control"
"2019.08.01.count.2.CCTCCAAAGTCTGCGC","healthy-2","2019-08-01-count-2:CCTCCAAAGTCTGCGC",2.8364438014919,-11.0519695512024,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CCTCCAAAGTCTGCGC","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2427.93600023062,36.8018553064121,0.0151576710847883,1677,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2420.39590296839,2420.39590296839,"Control"
"2019.08.01.count.3.TTGGGCGGTAGACGGT","healthy-2","2019-08-01-count-3:TTGGGCGGTAGACGGT",2.33717431601827,-8.25379087841185,"2019-08-01-count-3","Control2","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TTGGGCGGTAGACGGT","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2174.62516337961,39.1441475199212,0.0180004113716255,1325,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2173.38566804526,2173.38566804526,"Control"
"2019.08.01.count.3.TCATTCATCCATTCGC","healthy-2","2019-08-01-count-3:TCATTCATCCATTCGC",-7.14886889877971,3.9139947661194,"2019-08-01-count-3","Control2","HSC","HSC",65,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TCATTCATCCATTCGC","HSC","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2345.4914729854,39.9251756106877,0.0170220936935959,2181,30000,1100,500,"True","True","True","True",5,91,"True","HSPC_healthy-2",2339.35986411413,2339.35986411413,"Control"
"2019.08.01.count.4.ATCATTCTCTCTTGCG","healthy-2","2019-08-01-count-4:ATCATTCTCTCTTGCG",2.35291709479634,-10.8512172929016,"2019-08-01-count-4","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.ATCATTCTCTCTTGCG","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2290.47080882565,38.6710566075299,0.0168834531566709,1523,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2290.47080882565,2290.47080882565,"Control"
"2019.08.01.count.2.CAACGGCGTACCAGAG","healthy-2","2019-08-01-count-2:CAACGGCGTACCAGAG",2.4985314804012,-10.8476772538391,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CAACGGCGTACCAGAG","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2342.30410445957,40.4182937997058,0.0172557840473201,1667,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2335.2893402274,2335.2893402274,"Control"
"2019.08.01.count.4.GGCACGTGTACAGAAT","healthy-2","2019-08-01-count-4:GGCACGTGTACAGAAT",2.04479112204854,-8.91611387645873,"2019-08-01-count-4","Control2","cDC2","cDC2",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GGCACGTGTACAGAAT","cDC2","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2444.61567567244,42.1349275069775,0.0172358084447722,2221,30000,1100,500,"True","True","True","True",5,218,"True","DC_healthy-2",2441.77253540318,2441.77253540318,"Control"
"2019.08.01.count.2.ATCTTCAAGATAACAC","healthy-2","2019-08-01-count-2:ATCTTCAAGATAACAC",2.20692815360371,-10.2385254136291,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ATCTTCAAGATAACAC","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2495.26224147285,43.9529649983559,0.0176145674261525,2058,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2493.1982974266,2493.1982974266,"Control"
"2019.08.01.count.3.GAGAAATCACATATCG","healthy-2","2019-08-01-count-3:GAGAAATCACATATCG",4.51163878020589,-10.7523451081482,"2019-08-01-count-3","Control2","CD16+ monocyte","CD16+",61,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GAGAAATCACATATCG","CD16+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2189.51566191693,43.5674017444532,0.0198981914138535,1493,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2182.9933068591,2182.9933068591,"Control"
"2019.08.01.count.2.TTTGATCTCGGTATGT","healthy-2","2019-08-01-count-2:TTTGATCTCGGTATGT",-1.31417105618175,13.0577096709046,"2019-08-01-count-2","Control2","NK","CD56dim NK",6,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TTTGATCTCGGTATGT","NK","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1642.24019882207,42.2004893854645,0.0256969043966489,680,30000,1100,500,"True","True","True","True",5,184,"True","NK_healthy-2",1635.61127611868,1635.61127611868,"Control"
"2019.08.01.count.2.CAGCAGCCAAAGGCTG","healthy-2","2019-08-01-count-2:CAGCAGCCAAAGGCTG",1.70710553702657,-9.60501863872679,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CAGCAGCCAAAGGCTG","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2465.37810138495,41.6989698771845,0.0169138234227682,2116,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2461.7092044057,2461.7092044057,"Control"
"2019.08.01.count.2.CCGGTAGCATGAGAAT","healthy-2","2019-08-01-count-2:CCGGTAGCATGAGAAT",2.63007297095601,-11.065510772821,"2019-08-01-count-2","Control2","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CCGGTAGCATGAGAAT","HLA-II+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2418.12498775522,41.2721895378874,0.0170678479180685,1921,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2414.72090070085,2414.72090070085,"Control"
"2019.08.01.count.3.GAACACTCAACTGTGT","healthy-2","2019-08-01-count-3:GAACACTCAACTGTGT",1.8673845725948,-9.791211151239,"2019-08-01-count-3","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GAACACTCAACTGTGT","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2214.89887740968,38.5944830847894,0.0174249413724592,1482,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2214.89887740968,2214.89887740968,"Control"
"2019.08.01.count.4.TTACCATTCTTTCCGG","healthy-2","2019-08-01-count-4:TTACCATTCTTTCCGG",4.41878237304036,-10.8859901658264,"2019-08-01-count-4","Control2","CD16+ monocyte","CD16+",61,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TTACCATTCTTTCCGG","CD16+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2477.3379757569,41.8346773300589,0.0168869479011144,1711,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2468.74983835195,2468.74983835195,"Control"
"2019.08.01.count.3.GAATCGTCACACGTGC","healthy-2","2019-08-01-count-3:GAATCGTCACACGTGC",-1.95592961731609,13.1117057570252,"2019-08-01-count-3","Control2","NK","Activated NK",6,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GAATCGTCACACGTGC","NK","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1569.87347933178,39.668991170156,0.0252689096875764,644,30000,1100,500,"True","True","True","True",5,184,"True","NK_healthy-2",1567.69473314626,1567.69473314626,"Control"
"2019.08.01.count.3.TGTAACGAGGGAGGAC","healthy-2","2019-08-01-count-3:TGTAACGAGGGAGGAC",2.54621567305867,-10.6287040940491,"2019-08-01-count-3","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TGTAACGAGGGAGGAC","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2309.64145229049,42.3289023453104,0.018327044790148,1624,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2308.6359899443,2308.6359899443,"Control"
"2019.08.01.count.3.AATGGCTAGACATACA","healthy-2","2019-08-01-count-3:AATGGCTAGACATACA",1.3721008497173,-9.01736071026,"2019-08-01-count-3","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AATGGCTAGACATACA","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2119.83014224086,40.5450352628666,0.0191265490828461,1375,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2119.83014224086,2119.83014224086,"Control"
"2019.08.01.count.4.AATTTCCAGGTGCATG","healthy-2","2019-08-01-count-4:AATTTCCAGGTGCATG",-2.18250070038493,12.9593600996765,"2019-08-01-count-4","Control2","NK","CD56dim NK",6,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.AATTTCCAGGTGCATG","NK","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2084.34839074131,43.4032614452386,0.0208234197498058,985,30000,1100,500,"True","True","True","True",5,184,"True","NK_healthy-2",2080.59334712092,2080.59334712092,"Control"
"2019.08.01.count.4.TGTAAGCAGTCGCCAC","healthy-2","2019-08-01-count-4:TGTAAGCAGTCGCCAC",3.01034869727437,-11.0023422471252,"2019-08-01-count-4","Control2","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TGTAAGCAGTCGCCAC","HLA-II+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2453.64883029338,39.6655558873233,0.0161659465680672,1903,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2452.77052633897,2452.77052633897,"Control"
"2019.08.01.count.2.CCCGAAGAGTGCACCC","healthy-2","2019-08-01-count-2:CCCGAAGAGTGCACCC",2.86402930793111,-10.8773327103821,"2019-08-01-count-2","Control2","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CCCGAAGAGTGCACCC","HLA-II+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2313.91579847151,39.8693819881894,0.017230264824038,1668,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2311.00791774754,2311.00791774754,"Control"
"2019.08.01.count.3.TAACCAGTCGGCTTCT","healthy-2","2019-08-01-count-3:TAACCAGTCGGCTTCT",2.22685255584065,-4.24100639736327,"2019-08-01-count-3","Control2","cDC1","cDC1",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TAACCAGTCGGCTTCT","cDC1","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2622.6676066597,38.9027048196388,0.0148332578329232,2391,30000,1100,500,"True","True","True","True",5,218,"True","DC_healthy-2",2618.46953386048,2618.46953386048,"Control"
"2019.08.01.count.4.TTGTTCACAATGGGTG","healthy-2","2019-08-01-count-4:TTGTTCACAATGGGTG",-1.86636529389079,13.1261424788269,"2019-08-01-count-4","Control2","NK","Activated NK",6,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TTGTTCACAATGGGTG","NK","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1890.42087219594,36.4416901695022,0.019277024870748,843,30000,1100,500,"True","True","True","True",5,184,"True","NK_healthy-2",1888.39614270883,1888.39614270883,"Control"
"2019.08.01.count.4.CCACGAGGTCAAAGCG","healthy-2","2019-08-01-count-4:CCACGAGGTCAAAGCG",2.92947973784749,-10.8935642472473,"2019-08-01-count-4","Control2","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CCACGAGGTCAAAGCG","HLA-II+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2386.69700432209,41.6002633857508,0.0174300563961058,1902,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2380.91120483748,2380.91120483748,"Control"
"2019.08.01.count.2.AGGAAATAGTGAGTTA","healthy-2","2019-08-01-count-2:AGGAAATAGTGAGTTA",4.1599723297054,-10.7581310502258,"2019-08-01-count-2","Control2","CD16+ monocyte","CD16+",61,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AGGAAATAGTGAGTTA","CD16+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2222.31497269971,42.756788635269,0.0192397518625937,1466,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2215.76356149922,2215.76356149922,"Control"
"2019.08.01.count.3.CACGAATCAAGAGGTC","healthy-2","2019-08-01-count-3:CACGAATCAAGAGGTC",2.78038181838338,-10.811758064386,"2019-08-01-count-3","Control2","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CACGAATCAAGAGGTC","HLA-II+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2462.1671771211,38.0418597841083,0.0154505592218108,1993,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2457.41141142242,2457.41141142242,"Control"
"2019.08.01.count.4.GTTCTATAGGAAGTAG","healthy-2","2019-08-01-count-4:GTTCTATAGGAAGTAG",2.3376645046169,-10.6699810258118,"2019-08-01-count-4","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GTTCTATAGGAAGTAG","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2319.00645297275,40.0717072130825,0.0172796876704307,1606,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2311.8069894505,2311.8069894505,"Control"
"2019.08.01.count.4.CAATTTCAGTCGAAAT","healthy-2","2019-08-01-count-4:CAATTTCAGTCGAAAT",3.05187763747517,-10.926857017633,"2019-08-01-count-4","Control2","CD11c+","CD11c+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CAATTTCAGTCGAAAT","CD11c+","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2326.8699349631,38.8297899197519,0.0166875635532107,1838,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2306.26714344025,2306.26714344025,"Control"
"2019.08.01.count.2.TTTACCACATTGCTGA","healthy-2","2019-08-01-count-2:TTTACCACATTGCTGA",2.1282865005428,-10.056462310907,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TTTACCACATTGCTGA","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2431.13100821776,43.1915197745757,0.017766019037468,1918,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2426.88043276805,2426.88043276805,"Control"
"2019.08.01.count.2.TCAAGACAGCTCTATG","healthy-2","2019-08-01-count-2:TCAAGACAGCTCTATG",1.75982560691182,-4.43829967891844,"2019-08-01-count-2","Control2","DC precursor","DC precursor",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCAAGACAGCTCTATG","DC precursor","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","pDC",2759.54165839703,40.3206813787434,0.0146113689771819,2690,30000,1100,500,"True","True","True","True",5,218,"True","DC_healthy-2",2753.28216566388,2753.28216566388,"Control"
"2019.08.01.count.4.TTCAATCAGGCAGCTA","healthy-2","2019-08-01-count-4:TTCAATCAGGCAGCTA",6.94239439544026,-1.20986118232878,"2019-08-01-count-4","Control2","pDC","pDC",32,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TTCAATCAGGCAGCTA","pDC","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","pDC",2101.72503438538,43.897511094153,0.0208864196676376,1186,30000,1100,500,"True","True","True","True",5,218,"True","DC_healthy-2",2085.91839387463,2085.91839387463,"Control"
"2019.08.01.count.4.AAGGTAATCTTCCGTG","healthy-2","2019-08-01-count-4:AAGGTAATCTTCCGTG",-2.86448131027873,3.42016909206239,"2019-08-01-count-4","Control2","Ery","Ery-1",53,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.AAGGTAATCTTCCGTG","Ery","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Ery","Ery",3264.38939021262,43.6276441109091,0.0133647181435262,5383,30000,1100,500,"True","True","True","True",5,54,"True","Ery_healthy-2",3257.62248806066,3257.62248806066,"Control"
"2019.08.01.count.2.GTGCTTCCAGGCATGA","healthy-2","2019-08-01-count-2:GTGCTTCCAGGCATGA",4.42310776290242,-10.4927349320618,"2019-08-01-count-2","Control2","CD16+ monocyte","CD16+",61,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GTGCTTCCAGGCATGA","CD16+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2257.98693246089,43.6661102656826,0.0193385132738978,1732,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2255.40281464236,2255.40281464236,"Control"
"2019.08.01.count.4.CTATAGGCATGGGCAA","healthy-2","2019-08-01-count-4:CTATAGGCATGGGCAA",14.0958448844845,1.87489471519319,"2019-08-01-count-4","Control2","Plasmablast","Plasmablast",69,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CTATAGGCATGGGCAA","Plasmablast","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","Plasma",1152.9356393335,32.0072654278679,0.0277615370155189,1412,30000,1100,500,"True","True","True","True",5,134,"True","B_healthy-2",1134.65550183314,1134.65550183314,"Control"
"2019.08.01.count.2.TCCCACAGTGCATCTA","healthy-2","2019-08-01-count-2:TCCCACAGTGCATCTA",2.08784236487691,-10.5931062928406,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCCCACAGTGCATCTA","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2350.46083756932,38.3135903344599,0.0163004589236556,1837,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2343.74737503185,2343.74737503185,"Control"
"2019.08.01.count.4.GGGACAACAGGACATG","healthy-2","2019-08-01-count-4:GGGACAACAGGACATG",2.42640175399129,-10.1458521119324,"2019-08-01-count-4","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GGGACAACAGGACATG","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2253.33918526198,42.0513766641956,0.0186618050843094,1602,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2252.34537296666,2252.34537296666,"Control"
"2019.08.01.count.4.ACCACAATCCGAGATT","healthy-2","2019-08-01-count-4:ACCACAATCCGAGATT",2.8107451396877,-10.8694048157898,"2019-08-01-count-4","Control2","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.ACCACAATCCGAGATT","HLA-II+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2311.96786272645,43.3895748038344,0.0187673780000843,1761,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2302.80152832742,2302.80152832742,"Control"
"2019.08.01.count.4.GTGATGTGTGCTAGCC","healthy-2","2019-08-01-count-4:GTGATGTGTGCTAGCC",-4.78417001190837,3.6377804049286,"2019-08-01-count-4","Control2","MEP","MEP",39,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GTGATGTGTGCTAGCC","MEP","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2900.80333893181,41.3471844171546,0.0142537013323972,3708,30000,1100,500,"True","True","True","True",5,91,"True","HSPC_healthy-2",2892.24524777302,2892.24524777302,"Control"
"2019.08.01.count.3.CTGTGAAAGAAATGGG","healthy-2","2019-08-01-count-3:CTGTGAAAGAAATGGG",-5.01793179932292,3.03065464580385,"2019-08-01-count-3","Control2","MEP","MEP",39,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTGTGAAAGAAATGGG","MEP","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2640.18236576206,44.1316875285508,0.0167153936413073,3040,30000,1100,500,"True","True","True","True",5,91,"True","HSPC_healthy-2",2631.95852408405,2631.95852408405,"Control"
"2019.08.01.count.4.TTGTTTGCACAAATCC","healthy-2","2019-08-01-count-4:TTGTTTGCACAAATCC",2.59104384955708,-10.9861755601135,"2019-08-01-count-4","Control2","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TTGTTTGCACAAATCC","HLA-II+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2539.77534544489,38.3347893679386,0.0150937717529593,2247,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2534.78417311539,2534.78417311539,"Control"
"2019.08.01.count.4.GTTAGTGAGTGACACG","healthy-2","2019-08-01-count-4:GTTAGTGAGTGACACG",1.58967532691304,-9.58385183727416,"2019-08-01-count-4","Control2","Granulocyte","Granulocytes",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GTTAGTGAGTGACACG","Granulocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2400.66847451743,41.7213543969602,0.0173790570584082,2202,30000,1100,500,"True","True","True","True",5,175,"True","Gran_healthy-2",2398.00990409576,2398.00990409576,"Control"
"2019.08.01.count.3.CAAGACTGTCTTGTCC","healthy-2","2019-08-01-count-3:CAAGACTGTCTTGTCC",2.79458918151204,-11.1454134217468,"2019-08-01-count-3","Control2","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CAAGACTGTCTTGTCC","HLA-II+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2521.30154692161,38.8032177401743,0.0153901534655985,2068,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2516.49127549702,2516.49127549702,"Control"
"2019.08.01.count.3.CGTTGGGCAGACCCGT","healthy-2","2019-08-01-count-3:CGTTGGGCAGACCCGT",-4.66109691086467,-5.36991646206053,"2019-08-01-count-3","Control2","Granulocyte","Granulocytes (cycling)",38,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CGTTGGGCAGACCCGT","Granulocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2757.39306144109,44.4670836197682,0.0161264943477186,2750,30000,1100,500,"True","True","True","True",5,175,"True","Gran_healthy-2",2753.09140759984,2753.09140759984,"Control"
"2019.08.01.count.2.ACCACAACAGAACTAA","healthy-2","2019-08-01-count-2:ACCACAACAGAACTAA",1.82161655005757,-9.53515245830687,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ACCACAACAGAACTAA","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2365.06850009713,48.0817326344917,0.020329953501354,1659,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2361.8687800957,2361.8687800957,"Control"
"2019.08.01.count.4.TCCACGTAGAATCGTA","healthy-2","2019-08-01-count-4:TCCACGTAGAATCGTA",-3.79628930512126,-5.54184152996215,"2019-08-01-count-4","Control2","Granulocyte","Granulocytes",63,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TCCACGTAGAATCGTA","Granulocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2431.01627200344,39.6417444687694,0.0163066553380574,1748,30000,1100,500,"True","True","True","True",5,175,"True","Gran_healthy-2",2427.04064588514,2427.04064588514,"Control"
"2019.08.01.count.3.TAGGTTGTCTAGACAC","healthy-2","2019-08-01-count-3:TAGGTTGTCTAGACAC",8.1729961830074,7.12557981098024,"2019-08-01-count-3","Control2","B","Activated NFkB",0,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TAGGTTGTCTAGACAC","B","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1861.66174729005,38.3882144331535,0.0206204024383236,877,30000,1100,500,"True","True","True","True",5,134,"True","B_healthy-2",1854.52954908228,1854.52954908228,"Control"
"2019.08.01.count.3.GGAGATGAGAGAGCCT","healthy-2","2019-08-01-count-3:GGAGATGAGAGAGCCT",1.1927122074062,9.07847783649293,"2019-08-01-count-3","Control2","CD4+ T","CD4+ TCM",4,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GGAGATGAGAGAGCCT","CD4+ T","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1649.86761728463,32.6052767464762,0.0197623593583456,857,30000,1100,500,"True","True","True","True",5,171,"True","T_healthy-2",1640.52163993424,1640.52163993424,"Control"
"2019.08.01.count.2.CTGAGCGTCTTCGCTG","healthy-2","2019-08-01-count-2:CTGAGCGTCTTCGCTG",-2.88446460190471,3.39892361247865,"2019-08-01-count-2","Control2","Ery","Ery-4",53,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTGAGCGTCTTCGCTG","Ery","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Ery","Ery",2998.29380187245,39.5571858162376,0.0131932320280067,4411,30000,1100,500,"True","True","True","True",5,54,"True","Ery_healthy-2",2996.09790635274,2996.09790635274,"Control"
"2019.08.01.count.2.CTCAGGGGTTCAGCGC","healthy-2","2019-08-01-count-2:CTCAGGGGTTCAGCGC",4.56490196761434,-10.4788274995056,"2019-08-01-count-2","Control2","CD16+ monocyte","CD16+",61,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTCAGGGGTTCAGCGC","CD16+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2399.566010721,43.3051430110808,0.0180470730197036,1789,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2395.71311000956,2395.71311000956,"Control"
"2019.08.01.count.2.CTCAGTCCAAACGTGG","healthy-2","2019-08-01-count-2:CTCAGTCCAAACGTGG",2.27811946448628,-10.5023298493591,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTCAGTCCAAACGTGG","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2495.07063561959,39.1843619072163,0.0157047104590231,1819,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2493.14927641608,2493.14927641608,"Control"
"2019.08.01.count.3.ACACCAACACCTGTCT","healthy-2","2019-08-01-count-3:ACACCAACACCTGTCT",1.78756382045094,-5.00390293514403,"2019-08-01-count-3","Control2","cDC2","cDC2",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ACACCAACACCTGTCT","cDC2","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2446.28220036941,41.2701585292034,0.0168705632256864,2168,30000,1100,500,"True","True","True","True",5,218,"True","DC_healthy-2",2441.19119967769,2441.19119967769,"Control"
"2019.08.01.count.2.TCCGATCGTAACCAGG","healthy-2","2019-08-01-count-2:TCCGATCGTAACCAGG",2.45729388770406,-10.57972814953,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCCGATCGTAACCAGG","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2278.96400418164,37.2719784206219,0.0163547903135951,1666,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2272.35664384866,2272.35664384866,"Control"
"2019.08.01.count.4.AATGCCAGTCTACGTA","healthy-2","2019-08-01-count-4:AATGCCAGTCTACGTA",1.06579210337941,10.7612437971863,"2019-08-01-count-4","Control2","CD8+ T","CD8+ TRM",4,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.AATGCCAGTCTACGTA","CD8+ T","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1587.28280819529,39.6464541803387,0.024977561639073,665,30000,1100,500,"True","True","True","True",5,171,"True","T_healthy-2",1574.65577510629,1574.65577510629,"Control"
"2019.08.01.count.3.TCGCTCATCTGAGTCA","healthy-2","2019-08-01-count-3:TCGCTCATCTGAGTCA",1.8705162006313,-5.21323206340941,"2019-08-01-count-3","Control2","cDC2","cDC2",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TCGCTCATCTGAGTCA","cDC2","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2127.61220915625,43.9681581385481,0.0206654943740827,1575,30000,1100,500,"True","True","True","True",5,218,"True","DC_healthy-2",2123.82543108182,2123.82543108182,"Control"
"2019.08.01.count.3.CATAGACAGTGATAAC","healthy-2","2019-08-01-count-3:CATAGACAGTGATAAC",-7.17966161194499,3.53031013095704,"2019-08-01-count-3","Control2","HSC","HSC",65,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CATAGACAGTGATAAC","HSC","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2431.54162803353,39.4024893278125,0.0162047356596887,2569,30000,1100,500,"True","True","True","True",5,91,"True","HSPC_healthy-2",2419.43494139787,2419.43494139787,"Control"
"2019.08.01.count.1.ATGAAAGAGGTAACTA","healthy-2","2019-08-01-count-1:ATGAAAGAGGTAACTA",2.54883851584737,-10.9367752305237,"2019-08-01-count-1","Control2","CD11c+","CD11c+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613747","2019-08-01-count-1_metadata.csv.gz","2019.08.01.count.1.ATGAAAGAGGTAACTA","CD11c+","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2267.45459225056,45.2084743414022,0.0199379844235516,1446,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2258.07961941788,2258.07961941788,"Control"
"2019.08.01.count.4.TGTTGAGCATAAGCGG","healthy-2","2019-08-01-count-4:TGTTGAGCATAAGCGG",3.06394590911214,-10.3322954407898,"2019-08-01-count-4","Control2","cDC2","cDC2",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TGTTGAGCATAAGCGG","cDC2","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2331.33696337833,37.2818887410234,0.0159916345541909,2223,30000,1100,500,"True","True","True","True",5,218,"True","DC_healthy-2",2327.49472713138,2327.49472713138,"Control"
"2019.08.01.count.4.CCGAACGCAATCGCAT","healthy-2","2019-08-01-count-4:CCGAACGCAATCGCAT",2.17458667334859,-10.2743139497009,"2019-08-01-count-4","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CCGAACGCAATCGCAT","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2304.38307496409,40.5294628359686,0.0175879884192433,1608,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2302.32364251989,2302.32364251989,"Control"
"2019.08.01.count.2.ATACCTTCACGATAGG","healthy-2","2019-08-01-count-2:ATACCTTCACGATAGG",2.40169920501057,-10.6609029999939,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ATACCTTCACGATAGG","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2217.00049290269,42.6476221785768,0.0192366317982811,1593,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2213.02194202154,2213.02194202154,"Control"
"2019.08.01.count.3.ACAAGCTGTTACGATC","healthy-2","2019-08-01-count-3:ACAAGCTGTTACGATC",0.486065854399842,9.78756997669069,"2019-08-01-count-3","Control2","CD8+ T","CD8+ TRM",4,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ACAAGCTGTTACGATC","CD8+ T","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2190.98823058329,37.9575419836269,0.0173243933736338,1361,30000,1100,500,"True","True","True","True",5,171,"True","T_healthy-2",2173.43039579111,2173.43039579111,"Control"
"2019.08.01.count.4.AATGCCATCTACGCAA","healthy-2","2019-08-01-count-4:AATGCCATCTACGCAA",4.46559395369832,-10.7179165116516,"2019-08-01-count-4","Control2","CD16+ monocyte","CD16+",61,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.AATGCCATCTACGCAA","CD16+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2457.75680182231,44.9177532375103,0.018275914526696,1696,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2450.01090250696,2450.01090250696,"Control"
"2019.08.01.count.2.AAACCCAGTCTCCTGT","healthy-2","2019-08-01-count-2:AAACCCAGTCTCCTGT",4.34407295760457,-10.8506384125915,"2019-08-01-count-2","Control2","CD16+ monocyte","CD16+",61,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AAACCCAGTCTCCTGT","CD16+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2236.76052448757,43.2885409822477,0.0193532300433301,1435,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2234.31805350496,2234.31805350496,"Control"
"2019.08.01.count.3.GGAATGGAGCCTGTGC","healthy-2","2019-08-01-count-3:GGAATGGAGCCTGTGC",3.02286448058431,-10.3068962327209,"2019-08-01-count-3","Control2","CD11c+","CD11c+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GGAATGGAGCCTGTGC","CD11c+","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2376.50276449592,41.9466830692569,0.0176505930041088,1777,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2369.08686254174,2369.08686254174,"Control"
"2019.08.01.count.4.ACGATGTCAAAGCACG","healthy-2","2019-08-01-count-4:ACGATGTCAAAGCACG",2.88083161887471,-10.7949257127014,"2019-08-01-count-4","Control2","CD11c+","CD11c+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.ACGATGTCAAAGCACG","CD11c+","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2181.17232784426,42.0503059413216,0.0192787637200962,1574,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2178.36969570422,2178.36969570422,"Control"
"2019.08.01.count.4.TCGTCCAGTCATAAAG","healthy-2","2019-08-01-count-4:TCGTCCAGTCATAAAG",2.81862916526143,-10.9168968430725,"2019-08-01-count-4","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TCGTCCAGTCATAAAG","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2233.29390091857,36.71481042665,0.016439757620593,1607,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2230.33980399936,2230.33980399936,"Control"
"2019.08.01.count.2.CGAGGAAGTAACAGGC","healthy-2","2019-08-01-count-2:CGAGGAAGTAACAGGC",2.38222398337666,-10.8126621476379,"2019-08-01-count-2","Control2","CD11c+","CD11c+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CGAGGAAGTAACAGGC","CD11c+","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2219.50757374136,38.948973266871,0.0175484750435952,1557,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2214.60489849926,2214.60489849926,"Control"
"2019.08.01.count.3.GCACTAAAGGTCTTTG","healthy-2","2019-08-01-count-3:GCACTAAAGGTCTTTG",3.15726317939107,-10.7640590897766,"2019-08-01-count-3","Control2","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GCACTAAAGGTCTTTG","HLA-II+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2429.73074070275,38.6660072282573,0.0159137004691614,1857,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2427.86267554163,2427.86267554163,"Control"
"2019.08.01.count.4.CCTACGTCAACTTCTT","healthy-2","2019-08-01-count-4:CCTACGTCAACTTCTT",2.00983311709706,-10.5155449143616,"2019-08-01-count-4","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CCTACGTCAACTTCTT","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2499.03850339105,38.9336908836299,0.0155794681957877,1832,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2491.39679559438,2491.39679559438,"Control"
"2019.08.01.count.4.CTCAGTCGTACTCAAC","healthy-2","2019-08-01-count-4:CTCAGTCGTACTCAAC",-5.24113736572917,3.20984861934511,"2019-08-01-count-4","Control2","MEP","MEP",39,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CTCAGTCGTACTCAAC","MEP","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2551.8717410906,40.9797740260725,0.016058712264496,2744,30000,1100,500,"True","True","True","True",5,91,"True","HSPC_healthy-2",2544.91822559648,2544.91822559648,"Control"
"2019.08.01.count.4.ACAGAAAGTCCAGTTA","healthy-2","2019-08-01-count-4:ACAGAAAGTCCAGTTA",2.90842117842976,-10.9760198823181,"2019-08-01-count-4","Control2","HLA-II+ monocyte","HLA-II+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.ACAGAAAGTCCAGTTA","HLA-II+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2303.20720966329,39.6034599103448,0.0171949183487206,1753,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2298.23131663055,2298.23131663055,"Control"
"2019.08.01.count.2.CGGGTCACATAACTCG","healthy-2","2019-08-01-count-2:CGGGTCACATAACTCG",2.07499136504475,-10.687300705072,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CGGGTCACATAACTCG","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2317.59594464687,43.9803877361086,0.0189767279484991,1730,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2308.39938015856,2308.39938015856,"Control"
"2019.08.01.count.2.CTAACTTAGGCGAACT","healthy-2","2019-08-01-count-2:CTAACTTAGGCGAACT",1.46898748454396,9.68113896930543,"2019-08-01-count-2","Control2","CD4+ T","CD4+ TCM",4,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTAACTTAGGCGAACT","CD4+ T","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1589.54190637405,37.7414163470176,0.0237435805848684,859,30000,1100,500,"True","True","True","True",5,171,"True","T_healthy-2",1583.77639091636,1583.77639091636,"Control"
"2019.08.01.count.2.CACCGTTTCGTGGTAT","healthy-2","2019-08-01-count-2:CACCGTTTCGTGGTAT",2.06853355941121,-10.0707855454651,"2019-08-01-count-2","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CACCGTTTCGTGGTAT","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2205.96145345793,40.442807346809,0.0183334152477657,1513,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2204.00031552157,2204.00031552157,"Control"
"2019.08.01.count.4.CACTGGGGTGTCCCTT","healthy-2","2019-08-01-count-4:CACTGGGGTGTCCCTT",2.0016139942104,-10.3006792298523,"2019-08-01-count-4","Control2","CD14+ monocyte","CD14+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CACTGGGGTGTCCCTT","CD14+ monocyte","2","M",39,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2437.75550183272,32.3053584542306,0.0132520912905101,2038,30000,1100,500,"True","True","True","True",5,1372,"True","Mono_healthy-2",2434.67486908428,2434.67486908428,"Control"
"2019.08.01.count.4.TCACTATGTGTTCCAA","healthy-3","2019-08-01-count-4:TCACTATGTGTTCCAA",10.4830118614132,7.39520595157472,"2019-08-01-count-4","Control3","B","Naive B",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TCACTATGTGTTCCAA","B","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1946.55736293532,37.8798863488412,0.0194599383866705,1033,30000,1100,500,"True","True","True","True",5,517,"True","B_healthy-3",1938.79696503121,1938.79696503121,"Control"
"2019.08.01.count.4.TTGCATTCAGTCAGTT","healthy-3","2019-08-01-count-4:TTGCATTCAGTCAGTT",-3.96232543411906,10.3912820585999,"2019-08-01-count-4","Control3","CD8+ T","CD8+ NK-like",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TTGCATTCAGTCAGTT","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2141.30471610719,49.6181403969474,0.0231719194487887,1159,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2138.13642826503,2138.13642826503,"Control"
"2019.08.01.count.3.CTATCTACAACTTGCA","healthy-3","2019-08-01-count-3:CTATCTACAACTTGCA",4.083268781274,-7.0850458375183,"2019-08-01-count-3","Control3","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTATCTACAACTTGCA","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2551.44238541522,44.4920152633362,0.0174379854774168,1746,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2548.17635820663,2548.17635820663,"Control"
"2019.08.01.count.4.GGGTCACTCCTGGCTT","healthy-3","2019-08-01-count-4:GGGTCACTCCTGGCTT",0.275084559887093,7.78329465473024,"2019-08-01-count-4","Control3","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GGGTCACTCCTGGCTT","CD4+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1858.66299701155,40.7276662862691,0.0219123457839066,1134,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1856.0832765495,1856.0832765495,"Control"
"2019.08.01.count.2.CGTCAAAAGGATTCAA","healthy-3","2019-08-01-count-2:CGTCAAAAGGATTCAA",3.56081761893575,-8.00311090862425,"2019-08-01-count-2","Control3","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CGTCAAAAGGATTCAA","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2295.90575585779,44.3648289949998,0.019323453883857,1338,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2293.14318427151,2293.14318427151,"Control"
"2019.08.01.count.2.CGAGTTACAGGACTTT","healthy-3","2019-08-01-count-2:CGAGTTACAGGACTTT",0.015284494578284,7.7029123076233,"2019-08-01-count-2","Control3","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CGAGTTACAGGACTTT","CD4+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1859.02185043676,43.952415633444,0.0236427644049034,1088,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1845.37462148983,1845.37462148983,"Control"
"2019.08.01.count.2.ATTCTACTCCTACCAC","healthy-3","2019-08-01-count-2:ATTCTACTCCTACCAC",4.55470861968343,-7.59143593227538,"2019-08-01-count-2","Control3","CD11c+","CD11c+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ATTCTACTCCTACCAC","CD11c+","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2743.7018849254,48.738122629029,0.0177636363836788,2248,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2737.83440820264,2737.83440820264,"Control"
"2019.08.01.count.3.TAGTGCATCTCCTGAC","healthy-3","2019-08-01-count-3:TAGTGCATCTCCTGAC",9.77892365035359,6.9394206770691,"2019-08-01-count-3","Control3","B","Memory",0,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TAGTGCATCTCCTGAC","B","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1914.08359243284,43.1030591862125,0.0225189011371377,1021,30000,1100,500,"True","True","True","True",5,517,"True","B_healthy-3",1907.86956905739,1907.86956905739,"Control"
"2019.08.01.count.3.TTACCGCCAGGTTCGC","healthy-3","2019-08-01-count-3:TTACCGCCAGGTTCGC",1.92083909091298,-6.42471744930419,"2019-08-01-count-3","Control3","Granulocyte","Granulocytes",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TTACCGCCAGGTTCGC","Granulocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2218.93569099445,44.520649952844,0.0200639658614402,1248,30000,1100,500,"True","True","True","True",5,148,"True","Gran_healthy-3",2216.06448306533,2216.06448306533,"Control"
"2019.08.01.count.2.GAGGCCTCAACGGGTA","healthy-3","2019-08-01-count-2:GAGGCCTCAACGGGTA",3.51780499991719,-7.43437578594359,"2019-08-01-count-2","Control3","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GAGGCCTCAACGGGTA","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2518.62078872425,39.8907894166747,0.0158383467631427,1624,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2508.02914934995,2508.02914934995,"Control"
"2019.08.01.count.3.TTCCTAATCCTACCGT","healthy-3","2019-08-01-count-3:TTCCTAATCCTACCGT",-0.409995387226897,7.90537974918214,"2019-08-01-count-3","Control3","CD4+ T","CD4+ Naive",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TTCCTAATCCTACCGT","CD4+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2189.53756531534,38.7618650921195,0.0177032199429458,1208,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2180.38975451481,2180.38975451481,"Control"
"2019.08.01.count.2.TATCAGGCAAGGACAC","healthy-3","2019-08-01-count-2:TATCAGGCAAGGACAC",0.408649613230866,8.21270749652711,"2019-08-01-count-2","Control3","CD4+ T","CD4+ Naive",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TATCAGGCAAGGACAC","CD4+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1818.11742026569,40.4385498961462,0.0222419902286822,941,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1811.7807270525,1811.7807270525,"Control"
"2019.08.01.count.3.CTAGACACACTACACA","healthy-3","2019-08-01-count-3:CTAGACACACTACACA",3.86507691916768,-6.8690805665222,"2019-08-01-count-3","Control3","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTAGACACACTACACA","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2638.18889884072,47.5215475859322,0.0180129435033307,2014,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2633.65427129042,2633.65427129042,"Control"
"2019.08.01.count.4.CGTTCTGAGGATTTCC","healthy-3","2019-08-01-count-4:CGTTCTGAGGATTTCC",-4.2992733520573,12.3239698179993,"2019-08-01-count-4","Control3","NK","CD56bright NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CGTTCTGAGGATTTCC","NK","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2281.48525528674,43.3089613028749,0.0189827925481955,1209,30000,1100,500,"True","True","True","True",5,273,"True","NK_healthy-3",2275.07416326764,2275.07416326764,"Control"
"2019.08.01.count.4.TCATTACAGCAGCCCT","healthy-3","2019-08-01-count-4:TCATTACAGCAGCCCT",-3.77336345139201,13.2773780592713,"2019-08-01-count-4","Control3","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TCATTACAGCAGCCCT","NK","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2267.82138879246,44.2960399812408,0.0195324200574839,1183,30000,1100,500,"True","True","True","True",5,273,"True","NK_healthy-3",2261.11921566144,2261.11921566144,"Control"
"2019.08.01.count.3.ATTTACCTCCATGATG","healthy-3","2019-08-01-count-3:ATTTACCTCCATGATG",3.75479569014851,-6.82835485851439,"2019-08-01-count-3","Control3","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ATTTACCTCCATGATG","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2640.54878070839,47.4605776577477,0.017973755305901,1916,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2632.44011611528,2632.44011611528,"Control"
"2019.08.01.count.2.ATTGGGTGTTTCGCTC","healthy-3","2019-08-01-count-2:ATTGGGTGTTTCGCTC",-1.09964583340343,8.3638238676819,"2019-08-01-count-2","Control3","CD4+ T","CD4+ Activated",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ATTGGGTGTTTCGCTC","CD4+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2093.72422082079,38.1956235823555,0.0182429105048906,1060,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2085.26628127439,2085.26628127439,"Control"
"2019.08.01.count.4.TCCTCCCAGTGAGCCA","healthy-3","2019-08-01-count-4:TCCTCCCAGTGAGCCA",4.37289871749226,-8.13102152263793,"2019-08-01-count-4","Control3","CD14+ monocyte","CD14+ IFN+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TCCTCCCAGTGAGCCA","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2339.16515028421,46.6769472922449,0.0199545326188591,1437,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2330.46905069976,2330.46905069976,"Control"
"2019.08.01.count.2.TTACCATTCAAGCCTA","healthy-3","2019-08-01-count-2:TTACCATTCAAGCCTA",2.70053472098653,-4.5359359017578,"2019-08-01-count-2","Control3","cDC2","cDC2",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TTACCATTCAAGCCTA","cDC2","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",3004.65092058599,39.0563517373824,0.0129986320440064,3272,30000,1100,500,"True","True","True","True",5,113,"True","DC_healthy-3",2999.80399414155,2999.80399414155,"Control"
"2019.08.01.count.2.AAATGGAGTACCTAAC","healthy-3","2019-08-01-count-2:AAATGGAGTACCTAAC",-2.81988344612773,9.50726411426393,"2019-08-01-count-2","Control3","gd T","gd T",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AAATGGAGTACCTAAC","gd T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","gd_T",1929.01605608985,50.7111296026606,0.0262885990205043,940,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1927.22335525886,1927.22335525886,"Control"
"2019.08.01.count.2.TCATGCCCAATACGAA","healthy-3","2019-08-01-count-2:TCATGCCCAATACGAA",4.71748365935628,-8.2744293442932,"2019-08-01-count-2","Control3","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCATGCCCAATACGAA","HLA-II+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2717.46160574934,44.716130515788,0.0164551103210371,2304,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2712.8538446493,2712.8538446493,"Control"
"2019.08.01.count.2.CATAGACCAGCATCTA","healthy-3","2019-08-01-count-2:CATAGACCAGCATCTA",-0.443659017712432,8.35117051685182,"2019-08-01-count-2","Control3","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CATAGACCAGCATCTA","CD4+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2217.14895402151,44.2791340338528,0.0199712039885902,1322,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2213.0351953214,2213.0351953214,"Control"
"2019.08.01.count.4.AGAAATGCAAAGCTAA","healthy-3","2019-08-01-count-4:AGAAATGCAAAGCTAA",3.98794641074483,-7.40517570888671,"2019-08-01-count-4","Control3","CD14+ monocyte","CD14+ IFN+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.AGAAATGCAAAGCTAA","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2727.77219537055,42.7606775261265,0.0156760442087862,2084,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2723.16886635131,2723.16886635131,"Control"
"2019.08.01.count.3.TACCTGCTCACCTCGT","healthy-3","2019-08-01-count-3:TACCTGCTCACCTCGT",-1.57785151425059,8.45729730213014,"2019-08-01-count-3","Control3","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TACCTGCTCACCTCGT","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2231.42870752643,43.3357930991223,0.0194206487318883,1350,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2220.67607646661,2220.67607646661,"Control"
"2019.08.01.count.3.CTGTAGATCCTTGAAG","healthy-3","2019-08-01-count-3:CTGTAGATCCTTGAAG",0.023979657411021,7.96789548480836,"2019-08-01-count-3","Control3","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTGTAGATCCTTGAAG","CD4+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1853.4183888239,37.9837808650779,0.0204939052585859,1113,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1843.41820666168,1843.41820666168,"Control"
"2019.08.01.count.3.CTTAGGACAACCCTAA","healthy-3","2019-08-01-count-3:CTTAGGACAACCCTAA",0.0590039185131013,8.65212247455446,"2019-08-01-count-3","Control3","CD4+ T","CD4+ Naive",4,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTTAGGACAACCCTAA","CD4+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2223.38784534461,35.9766622392306,0.016181010575622,1383,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2218.16592225868,2218.16592225868,"Control"
"2019.08.01.count.4.GTGGGAACATAACGGG","healthy-3","2019-08-01-count-4:GTGGGAACATAACGGG",-3.91143784943278,13.1971711882385,"2019-08-01-count-4","Control3","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GTGGGAACATAACGGG","NK","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2052.44834131284,39.1843281177217,0.0190915051692154,1011,30000,1100,500,"True","True","True","True",5,273,"True","NK_healthy-3",2048.88853109559,2048.88853109559,"Control"
"2019.08.01.count.2.CAGGTATAGGACTTCT","healthy-3","2019-08-01-count-2:CAGGTATAGGACTTCT",-2.22491488876994,8.73555085742799,"2019-08-01-count-2","Control3","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CAGGTATAGGACTTCT","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1983.21432954365,43.2076948083308,0.0217866995839392,1000,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1978.15096343367,1978.15096343367,"Control"
"2019.08.01.count.2.GATTTCTTCACGATCA","healthy-3","2019-08-01-count-2:GATTTCTTCACGATCA",-3.77615151825603,10.3246564635071,"2019-08-01-count-2","Control3","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GATTTCTTCACGATCA","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2067.84809897477,46.3042495050135,0.0223924811150157,1103,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2056.17885520702,2056.17885520702,"Control"
"2019.08.01.count.4.TTGGATGAGTACAGAT","healthy-3","2019-08-01-count-4:TTGGATGAGTACAGAT",2.44274105605428,-6.25877525722655,"2019-08-01-count-4","Control3","Granulocyte","Granulocytes",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TTGGATGAGTACAGAT","Granulocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2534.57371534205,45.8581586223652,0.0180930459212059,2111,30000,1100,500,"True","True","True","True",5,148,"True","Gran_healthy-3",2533.7528621512,2533.7528621512,"Control"
"2019.08.01.count.3.TTCTTCCGTTTGTGGT","healthy-3","2019-08-01-count-3:TTCTTCCGTTTGTGGT",10.5037418800289,6.99144408786622,"2019-08-01-count-3","Control3","B","Naive B",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TTCTTCCGTTTGTGGT","B","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1850.59619251033,44.3648675139296,0.023973283687431,937,30000,1100,500,"True","True","True","True",5,517,"True","B_healthy-3",1843.99392477642,1843.99392477642,"Control"
"2019.08.01.count.2.AGAAATGTCTCAAAGC","healthy-3","2019-08-01-count-2:AGAAATGTCTCAAAGC",-3.67433414879497,10.3844632872376,"2019-08-01-count-2","Control3","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AGAAATGTCTCAAAGC","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2032.31515743014,46.805742527908,0.0230307501062453,1069,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2025.90354206438,2025.90354206438,"Control"
"2019.08.01.count.4.TACCGGGAGCCAAGCA","healthy-3","2019-08-01-count-4:TACCGGGAGCCAAGCA",-3.15189037743266,9.95910451495973,"2019-08-01-count-4","Control3","CD8+ T","CD8+ GZMK+",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TACCGGGAGCCAAGCA","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2053.16986304645,35.7981633107458,0.0174355585258929,1035,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2043.10471693845,2043.10471693845,"Control"
"2019.08.01.count.3.CCTCTAGCACCAACAT","healthy-3","2019-08-01-count-3:CCTCTAGCACCAACAT",-4.05800233307536,12.9652890929016,"2019-08-01-count-3","Control3","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CCTCTAGCACCAACAT","NK","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2208.34549848391,43.072269263166,0.01950431637293,1131,30000,1100,500,"True","True","True","True",5,273,"True","NK_healthy-3",2203.24075198038,2203.24075198038,"Control"
"2019.08.01.count.2.TAAGCACTCAACTACG","healthy-3","2019-08-01-count-2:TAAGCACTCAACTACG",4.61543764647786,-8.35600569164427,"2019-08-01-count-2","Control3","CD14+ monocyte","CD14+ IFN+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TAAGCACTCAACTACG","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2605.81160370978,45.2656462496954,0.01737103564404,1835,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2600.56748844525,2600.56748844525,"Control"
"2019.08.01.count.3.AGGCCACAGTCAGCCC","healthy-3","2019-08-01-count-3:AGGCCACAGTCAGCCC",4.88814701613728,-8.11491777813109,"2019-08-01-count-3","Control3","cDC1","cDC1",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AGGCCACAGTCAGCCC","cDC1","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",3090.05557411121,43.7729292378927,0.0141657417441377,3998,30000,1100,500,"True","True","True","True",5,113,"True","DC_healthy-3",3085.00667930708,3085.00667930708,"Control"
"2019.08.01.count.2.GGAGCAAGTTGCATGT","healthy-3","2019-08-01-count-2:GGAGCAAGTTGCATGT",4.80922331389729,-9.10375883495482,"2019-08-01-count-2","Control3","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GGAGCAAGTTGCATGT","HLA-II+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2364.7784902079,46.9013093935945,0.0198332780798726,1646,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2361.6196436116,2361.6196436116,"Control"
"2019.08.01.count.2.GATCGTAGTCCGGATC","healthy-3","2019-08-01-count-2:GATCGTAGTCCGGATC",-1.87876794758495,9.35408017719118,"2019-08-01-count-2","Control3","MAIT","MAIT",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GATCGTAGTCCGGATC","MAIT","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","MAIT",2044.69397401653,43.0952613480533,0.0210766314645112,1176,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2033.48974722691,2033.48974722691,"Control"
"2019.08.01.count.3.GGTAATCTCTAACGCA","healthy-3","2019-08-01-count-3:GGTAATCTCTAACGCA",4.3008619743282,-6.73342039501341,"2019-08-01-count-3","Control3","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GGTAATCTCTAACGCA","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2558.48731335197,42.9491223495852,0.0167869201951664,1755,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2551.97237117799,2551.97237117799,"Control"
"2019.08.01.count.3.TGACCCTCAGACAATA","healthy-3","2019-08-01-count-3:TGACCCTCAGACAATA",3.6454037624294,-6.84667637264403,"2019-08-01-count-3","Control3","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TGACCCTCAGACAATA","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2455.57805319827,46.4898629491312,0.0189323499159721,1767,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2449.49876776405,2449.49876776405,"Control"
"2019.08.01.count.3.TAAGCCATCTATTTCG","healthy-3","2019-08-01-count-3:TAAGCCATCTATTTCG",-0.284218977124053,8.45285317981569,"2019-08-01-count-3","Control3","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TAAGCCATCTATTTCG","CD4+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2241.85861507733,45.2779217439731,0.0201966000172635,1301,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2229.11030098858,2229.11030098858,"Control"
"2019.08.01.count.2.TCGGGCAGTTCCACAA","healthy-3","2019-08-01-count-2:TCGGGCAGTTCCACAA",-2.73353467407878,9.27941606128541,"2019-08-01-count-2","Control3","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCGGGCAGTTCCACAA","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1956.99830853432,42.877560600459,0.0219098608381383,1006,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1953.71430688597,1953.71430688597,"Control"
"2019.08.01.count.3.GTAGGAGTCTCGTCAC","healthy-3","2019-08-01-count-3:GTAGGAGTCTCGTCAC",-4.14245543900188,11.9148883589539,"2019-08-01-count-3","Control3","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GTAGGAGTCTCGTCAC","NK","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1657.5441770219,48.4332246619837,0.029219869571744,687,30000,1100,500,"True","True","True","True",5,273,"True","NK_healthy-3",1653.18784260003,1653.18784260003,"Control"
"2019.08.01.count.3.CTCATGCGTGGCTGAA","healthy-3","2019-08-01-count-3:CTCATGCGTGGCTGAA",4.23548426207845,-7.43298437511595,"2019-08-01-count-3","Control3","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTCATGCGTGGCTGAA","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2659.77783803925,41.1033931579635,0.0154536941281774,1742,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2655.04116882969,2655.04116882969,"Control"
"2019.08.01.count.2.TCACGCTGTATTGAGA","healthy-3","2019-08-01-count-2:TCACGCTGTATTGAGA",-1.83851132813151,9.04566953265993,"2019-08-01-count-2","Control3","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCACGCTGTATTGAGA","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2002.24287747554,41.9183488548271,0.0209356963265508,1088,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1996.11285684886,1996.11285684886,"Control"
"2019.08.01.count.2.GGAGAACGTCACTGAT","healthy-3","2019-08-01-count-2:GGAGAACGTCACTGAT",-2.55684409561809,8.97098634326784,"2019-08-01-count-2","Control3","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GGAGAACGTCACTGAT","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1831.29520139032,45.824620461165,0.0250230658751112,899,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1824.52120608403,1824.52120608403,"Control"
"2019.08.01.count.3.CTGGTCTCATCGCTAA","healthy-3","2019-08-01-count-3:CTGGTCTCATCGCTAA",2.60329069670979,-4.3997807732788,"2019-08-01-count-3","Control3","cDC2","cDC2",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTGGTCTCATCGCTAA","cDC2","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",3055.69958712115,43.319054254971,0.014176476783761,3235,30000,1100,500,"True","True","True","True",5,113,"True","DC_healthy-3",3050.01835584884,3050.01835584884,"Control"
"2019.08.01.count.2.GGGACTCGTTTAGAGA","healthy-3","2019-08-01-count-2:GGGACTCGTTTAGAGA",-2.78886948052104,10.8731336363587,"2019-08-01-count-2","Control3","CD8+ T","CD8+ NK-like",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GGGACTCGTTTAGAGA","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1594.15664468621,39.4821442052727,0.0247667908526294,619,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1594.15664468621,1594.15664468621,"Control"
"2019.08.01.count.4.TGATGCAGTTTAGACC","healthy-3","2019-08-01-count-4:TGATGCAGTTTAGACC",-1.35340533676799,8.64739987933961,"2019-08-01-count-4","Control3","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TGATGCAGTTTAGACC","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2060.51160341719,42.3595476414405,0.0205577816553862,1178,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2051.80097388675,2051.80097388675,"Control"
"2019.08.01.count.2.TCTATACCAAATAAGC","healthy-3","2019-08-01-count-2:TCTATACCAAATAAGC",-3.64441476288493,13.1941184767517,"2019-08-01-count-2","Control3","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCTATACCAAATAAGC","NK","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2118.53077536567,43.9339916591536,0.0207379530049877,1093,30000,1100,500,"True","True","True","True",5,273,"True","NK_healthy-3",2110.14367296885,2110.14367296885,"Control"
"2019.08.01.count.3.ACACCAAGTGATTGGG","healthy-3","2019-08-01-count-3:ACACCAAGTGATTGGG",-7.12686763230022,3.258837676886,"2019-08-01-count-3","Control3","HSC","HSC",65,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ACACCAAGTGATTGGG","HSC","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2732.49752005015,41.4147924909938,0.0151563879517204,2790,30000,1100,500,"True","True","True","True",5,107,"True","HSPC_healthy-3",2714.87845314561,2714.87845314561,"Control"
"2019.08.01.count.3.CAGGGCTGTGGATTTC","healthy-3","2019-08-01-count-3:CAGGGCTGTGGATTTC",2.51031436499898,-6.20200111782225,"2019-08-01-count-3","Control3","Granulocyte","Granulocytes",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CAGGGCTGTGGATTTC","Granulocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2541.06410330698,44.5720753903796,0.0175407127007827,1827,30000,1100,500,"True","True","True","True",5,148,"True","Gran_healthy-3",2538.07371136748,2538.07371136748,"Control"
"2019.08.01.count.2.TTTGACTTCTTTGCTA","healthy-3","2019-08-01-count-2:TTTGACTTCTTTGCTA",-0.232709656388122,8.33946893298952,"2019-08-01-count-2","Control3","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TTTGACTTCTTTGCTA","CD4+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1969.70117625052,40.4420419414926,0.0205320697520611,1012,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1966.42802229011,1966.42802229011,"Control"
"2019.08.01.count.3.GGCTGTGCACTCGATA","healthy-3","2019-08-01-count-3:GGCTGTGCACTCGATA",2.37743248519246,-6.79800846492919,"2019-08-01-count-3","Control3","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GGCTGTGCACTCGATA","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1967.46758851933,52.4262860902212,0.0266465818273917,973,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",1964.01471835944,1964.01471835944,"Control"
"2019.08.01.count.4.TGGGATTAGATGCTTC","healthy-3","2019-08-01-count-4:TGGGATTAGATGCTTC",10.5256678062374,6.35860393131105,"2019-08-01-count-4","Control3","B","Naive B",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TGGGATTAGATGCTTC","B","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1933.74958071174,44.4037700434295,0.0229625234240962,1003,30000,1100,500,"True","True","True","True",5,517,"True","B_healthy-3",1925.69860975296,1925.69860975296,"Control"
"2019.08.01.count.4.GGCAGTCCAGGAATAT","healthy-3","2019-08-01-count-4:GGCAGTCCAGGAATAT",3.24581350859944,-6.58812239086302,"2019-08-01-count-4","Control3","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GGCAGTCCAGGAATAT","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2643.36859974366,43.7529643138813,0.0165519724786488,2205,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2640.03157252227,2640.03157252227,"Control"
"2019.08.01.count.4.TGTCAGATCACCACAA","healthy-3","2019-08-01-count-4:TGTCAGATCACCACAA",-2.04482779923137,8.70621011340944,"2019-08-01-count-4","Control3","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TGTCAGATCACCACAA","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2157.88156028754,43.1254244875553,0.0199850748443343,1128,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2154.62791053353,2154.62791053353,"Control"
"2019.08.01.count.2.TTCCAATTCGCTTACC","healthy-3","2019-08-01-count-2:TTCCAATTCGCTTACC",9.79906811293904,7.71107909763185,"2019-08-01-count-2","Control3","B","Activated AP-1",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TTCCAATTCGCTTACC","B","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2113.17280749037,44.8698724914707,0.021233413723868,1203,30000,1100,500,"True","True","True","True",5,517,"True","B_healthy-3",2105.92293482711,2105.92293482711,"Control"
"2019.08.01.count.2.ACGTCCTTCCGTGACG","healthy-3","2019-08-01-count-2:ACGTCCTTCCGTGACG",-6.91646371308024,3.50522539699403,"2019-08-01-count-2","Control3","HSC","HSC",65,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ACGTCCTTCCGTGACG","HSC","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2585.97115854715,42.5362933807033,0.0164488661213844,2677,30000,1100,500,"True","True","True","True",5,107,"True","HSPC_healthy-3",2575.09274865406,2575.09274865406,"Control"
"2019.08.01.count.3.TAAGCCAAGACCTCAT","healthy-3","2019-08-01-count-3:TAAGCCAAGACCTCAT",-6.59712777558024,0.569370127561964,"2019-08-01-count-3","Control3","MPP","MPP_GMP",41,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TAAGCCAAGACCTCAT","MPP","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2601.4706412318,39.39463532654,0.0151432173410524,2027,30000,1100,500,"True","True","True","True",5,107,"True","HSPC_healthy-3",2592.42228243206,2592.42228243206,"Control"
"2019.08.01.count.2.GAAGCGACATCACGGC","healthy-3","2019-08-01-count-2:GAAGCGACATCACGGC",-2.21443567696269,9.01077077472535,"2019-08-01-count-2","Control3","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GAAGCGACATCACGGC","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1952.97102089271,46.3562831224408,0.0237362882636381,1038,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1946.75371352626,1946.75371352626,"Control"
"2019.08.01.count.4.AGAAGCGGTCAACATC","healthy-3","2019-08-01-count-4:AGAAGCGGTCAACATC",-2.21973715248759,8.84260652149049,"2019-08-01-count-4","Control3","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.AGAAGCGGTCAACATC","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1925.63170432701,43.1727401977398,0.0224200401877098,935,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1925.63170432701,1925.63170432701,"Control"
"2019.08.01.count.3.AGATCCACAAGTGCTT","healthy-3","2019-08-01-count-3:AGATCCACAAGTGCTT",-3.9659403366154,10.8245057829651,"2019-08-01-count-3","Control3","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AGATCCACAAGTGCTT","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2013.36923603855,43.9609494902413,0.0218345193238066,1028,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2011.69188603531,2011.69188603531,"Control"
"2019.08.01.count.3.AGCGCTGTCCTCACTG","healthy-3","2019-08-01-count-3:AGCGCTGTCCTCACTG",2.73447408255879,-6.61572124874266,"2019-08-01-count-3","Control3","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AGCGCTGTCCTCACTG","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2374.19904264883,46.8698891495038,0.0197413478430235,1798,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2369.59756577652,2369.59756577652,"Control"
"2019.08.01.count.2.GAGTTACCAGATCACT","healthy-3","2019-08-01-count-2:GAGTTACCAGATCACT",4.46390738066976,-8.36627390300902,"2019-08-01-count-2","Control3","CD11c+","CD11c+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GAGTTACCAGATCACT","CD11c+","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2358.95888822831,48.4245946430845,0.0205279519218131,1747,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2351.96288023107,2351.96288023107,"Control"
"2019.08.01.count.3.AGACTCACATAGGTTC","healthy-3","2019-08-01-count-3:AGACTCACATAGGTTC",-3.96554503861125,11.5843057402405,"2019-08-01-count-3","Control3","NK","Activated NK",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AGACTCACATAGGTTC","NK","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2174.45186291098,43.0682201021197,0.019806472075433,1162,30000,1100,500,"True","True","True","True",5,273,"True","NK_healthy-3",2172.85524289333,2172.85524289333,"Control"
"2019.08.01.count.2.AGTAGTCGTAGTACGG","healthy-3","2019-08-01-count-2:AGTAGTCGTAGTACGG",3.58310379561726,-6.16655065929564,"2019-08-01-count-2","Control3","Granulocyte","Granulocytes",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AGTAGTCGTAGTACGG","Granulocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2599.64921923731,48.2839159991305,0.0185732427443792,2178,30000,1100,500,"True","True","True","True",5,148,"True","Gran_healthy-3",2593.24209124723,2593.24209124723,"Control"
"2019.08.01.count.3.AATTCCTTCGCCTATC","healthy-3","2019-08-01-count-3:AATTCCTTCGCCTATC",-3.3558431667393,10.0151481398377,"2019-08-01-count-3","Control3","CD8+ T","CD8+ NK-like",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AATTCCTTCGCCTATC","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2136.03513954165,48.480707567467,0.0226965870879212,1106,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2131.08342047751,2131.08342047751,"Control"
"2019.08.01.count.2.GCTACCTAGACCAGCA","healthy-3","2019-08-01-count-2:GCTACCTAGACCAGCA",10.2924200492794,7.70370576465455,"2019-08-01-count-2","Control3","B","Memory",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GCTACCTAGACCAGCA","B","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2086.57064647598,47.5951792117584,0.0228102409530884,1369,30000,1100,500,"True","True","True","True",5,517,"True","B_healthy-3",2080.68710447504,2080.68710447504,"Control"
"2019.08.01.count.4.CGAGTTACAGTCGGAA","healthy-3","2019-08-01-count-4:CGAGTTACAGTCGGAA",-2.11511359635051,8.80921170795289,"2019-08-01-count-4","Control3","MAIT","MAIT",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CGAGTTACAGTCGGAA","MAIT","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","MAIT",2162.20257867242,40.2747273957943,0.0186267132381845,1152,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2155.8262141472,2155.8262141472,"Control"
"2019.08.01.count.2.TCATCATGTGGCTACC","healthy-3","2019-08-01-count-2:TCATCATGTGGCTACC",2.67030539092366,-4.56385567104491,"2019-08-01-count-2","Control3","cDC2","cDC2",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCATCATGTGGCTACC","cDC2","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2968.7470700382,41.4750967684385,0.0139705726995142,3138,30000,1100,500,"True","True","True","True",5,113,"True","DC_healthy-3",2964.33064873022,2964.33064873022,"Control"
"2019.08.01.count.2.TGACGCGTCGGCTATA","healthy-3","2019-08-01-count-2:TGACGCGTCGGCTATA",1.86861683902089,-6.04035141384276,"2019-08-01-count-2","Control3","Granulocyte","Granulocytes",38,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TGACGCGTCGGCTATA","Granulocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2117.23192126869,50.3801547900328,0.0237952934130352,1063,30000,1100,500,"True","True","True","True",5,148,"True","Gran_healthy-3",2115.54998846197,2115.54998846197,"Control"
"2019.08.01.count.4.CCTTGTGGTAATCAAG","healthy-3","2019-08-01-count-4:CCTTGTGGTAATCAAG",4.09295668181722,-7.44849398052367,"2019-08-01-count-4","Control3","CD14+ monocyte","CD14+ IFN+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CCTTGTGGTAATCAAG","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2606.48299784074,47.4687114230192,0.0182117863275315,2029,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2598.75037347107,2598.75037347107,"Control"
"2019.08.01.count.3.ATTCACTTCACTAGCA","healthy-3","2019-08-01-count-3:ATTCACTTCACTAGCA",2.11269368705098,-6.29110147869261,"2019-08-01-count-3","Control3","Granulocyte","Granulocytes",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ATTCACTTCACTAGCA","Granulocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2608.37498216548,47.9009977605944,0.0183643065464563,1909,30000,1100,500,"True","True","True","True",5,148,"True","Gran_healthy-3",2606.50465078002,2606.50465078002,"Control"
"2019.08.01.count.2.GGATCTAAGCAAATGT","healthy-3","2019-08-01-count-2:GGATCTAAGCAAATGT",-4.39353738251384,-4.58987667476805,"2019-08-01-count-2","Control3","cDC1","cDC1",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GGATCTAAGCAAATGT","cDC1","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2951.63999364688,43.5293770463175,0.0147475224417647,3209,30000,1100,500,"True","True","True","True",5,113,"True","DC_healthy-3",2945.29985535755,2945.29985535755,"Control"
"2019.08.01.count.4.TCTAACTCAACTAGAA","healthy-3","2019-08-01-count-4:TCTAACTCAACTAGAA",10.3558632331783,7.42651412570802,"2019-08-01-count-4","Control3","B","Activated NFkB",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TCTAACTCAACTAGAA","B","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2000.49544754235,40.194056549384,0.0200920509960486,1192,30000,1100,500,"True","True","True","True",5,517,"True","B_healthy-3",1986.36140675698,1986.36140675698,"Control"
"2019.08.01.count.2.CTCAAGAAGAATCTAG","healthy-3","2019-08-01-count-2:CTCAAGAAGAATCTAG",-0.300557057291824,8.6762714155945,"2019-08-01-count-2","Control3","CD4+ T","CD4+ Naive",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTCAAGAAGAATCTAG","CD4+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2102.13242132055,40.9799854739617,0.0194944833438315,1350,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2096.0961768958,2096.0961768958,"Control"
"2019.08.01.count.2.CTACATTAGGGTTGCA","healthy-3","2019-08-01-count-2:CTACATTAGGGTTGCA",10.7629324394161,6.89375207507936,"2019-08-01-count-2","Control3","B","Memory",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTACATTAGGGTTGCA","B","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2173.27352865484,42.9625997961258,0.0197686113734233,1368,30000,1100,500,"True","True","True","True",5,517,"True","B_healthy-3",2169.46817003421,2169.46817003421,"Control"
"2019.08.01.count.2.CTGAATGTCTCGGCTT","healthy-3","2019-08-01-count-2:CTGAATGTCTCGGCTT",-1.88721177998241,8.71292493427125,"2019-08-01-count-2","Control3","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTGAATGTCTCGGCTT","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1971.54858475235,48.0939510728241,0.0243939974113624,1019,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1963.44792000094,1963.44792000094,"Control"
"2019.08.01.count.3.TACAGGTTCCTAGAGT","healthy-3","2019-08-01-count-3:TACAGGTTCCTAGAGT",-2.75284848633464,3.47047088229982,"2019-08-01-count-3","Control3","Ery","Ery-1",53,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TACAGGTTCCTAGAGT","Ery","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Ery","Ery",3203.09624378397,46.3380667623398,0.0144666482789161,5844,30000,1100,500,"True","True","True","True",5,34,"True","Ery_healthy-3",3194.12972332812,3194.12972332812,"Control"
"2019.08.01.count.2.GTAACACGTGAGACCA","healthy-3","2019-08-01-count-2:GTAACACGTGAGACCA",-3.54086766663249,9.80088613117067,"2019-08-01-count-2","Control3","gd T","gd T",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GTAACACGTGAGACCA","gd T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","gd_T",1962.04573977574,40.4605768915164,0.020621627758862,979,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1958.81285671071,1958.81285671071,"Control"
"2019.08.01.count.1.ACTGTCCTCGTTCAGA","healthy-3","2019-08-01-count-1:ACTGTCCTCGTTCAGA",10.9498106437618,6.49896285617677,"2019-08-01-count-1","Control3","B","Activated AP-1",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613747","2019-08-01-count-1_metadata.csv.gz","2019.08.01.count.1.ACTGTCCTCGTTCAGA","B","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2237.85936011659,43.7677902889674,0.0195578824429284,1428,30000,1100,500,"True","True","True","True",5,517,"True","B_healthy-3",2223.96255161746,2223.96255161746,"Control"
"2019.08.01.count.3.GGGCGTTCATTGTCGA","healthy-3","2019-08-01-count-3:GGGCGTTCATTGTCGA",4.95485987243001,-8.4731540909973,"2019-08-01-count-3","Control3","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GGGCGTTCATTGTCGA","HLA-II+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2463.36800591662,46.2003674478905,0.0187549596068977,1692,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2459.03342527705,2459.03342527705,"Control"
"2019.08.01.count.4.CACAGATAGGTAAACT","healthy-3","2019-08-01-count-4:CACAGATAGGTAAACT",2.76328672942464,-7.02911903774413,"2019-08-01-count-4","Control3","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CACAGATAGGTAAACT","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2194.51818384752,47.8323827107065,0.0217963027432495,1340,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2190.67010840681,2190.67010840681,"Control"
"2019.08.01.count.4.CTGGTCTAGACTTCAC","healthy-3","2019-08-01-count-4:CTGGTCTAGACTTCAC",10.9954334693844,5.1220378645691,"2019-08-01-count-4","Control3","Pre-B","Pre-B",48,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CTGGTCTAGACTTCAC","Pre-B","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1626.1802353267,32.4925605480645,0.0199809097676905,618,30000,1100,500,"True","True","True","True",5,517,"True","B_healthy-3",1626.1802353267,1626.1802353267,"Control"
"2019.08.01.count.1.AATTTCCTCAGGGATG","healthy-3","2019-08-01-count-1:AATTTCCTCAGGGATG",10.8041902976925,6.29338023746339,"2019-08-01-count-1","Control3","B","Naive B",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613747","2019-08-01-count-1_metadata.csv.gz","2019.08.01.count.1.AATTTCCTCAGGGATG","B","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2140.65215332409,42.6397002368267,0.0199190233549221,1363,30000,1100,500,"True","True","True","True",5,517,"True","B_healthy-3",2131.82085447802,2131.82085447802,"Control"
"2019.08.01.count.2.TTGGTTTTCGGTTAGT","healthy-3","2019-08-01-count-2:TTGGTTTTCGGTTAGT",-4.32670865479167,10.8791332014832,"2019-08-01-count-2","Control3","CD8+ T","CD8+ NK-like",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TTGGTTTTCGGTTAGT","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2036.96149020769,45.7955409602603,0.0224822811724295,1058,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2028.70417380508,2028.70417380508,"Control"
"2019.08.01.count.4.GTGTAACAGCCGTCGT","healthy-3","2019-08-01-count-4:GTGTAACAGCCGTCGT",3.31185116347615,-6.79973843013915,"2019-08-01-count-4","Control3","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GTGTAACAGCCGTCGT","CD14+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2304.47755092957,50.8243919425637,0.0220546266211456,1466,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2298.33959803792,2298.33959803792,"Control"
"2019.08.01.count.4.ATCACAGCACGCGTCA","healthy-3","2019-08-01-count-4:ATCACAGCACGCGTCA",-5.21381602707561,-4.31691934978636,"2019-08-01-count-4","Control3","Granulocyte","Granulocytes (cycling)",38,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.ATCACAGCACGCGTCA","Granulocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",3321.67145555154,43.2192506974663,0.0130112960525441,4820,30000,1100,500,"True","True","True","True",5,148,"True","Gran_healthy-3",3317.39913590138,3317.39913590138,"Control"
"2019.08.01.count.4.CGTGTCTGTCTTCTAT","healthy-3","2019-08-01-count-4:CGTGTCTGTCTTCTAT",-3.42040477219279,10.0038757094177,"2019-08-01-count-4","Control3","gd T","gd T",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CGTGTCTGTCTTCTAT","gd T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","gd_T",1784.46571218239,43.4144313666334,0.0243290924954438,786,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1780.48774480762,1780.48774480762,"Control"
"2019.08.01.count.4.AGCCAATTCCGTAATG","healthy-3","2019-08-01-count-4:AGCCAATTCCGTAATG",9.54039444503133,8.11768434131471,"2019-08-01-count-4","Control3","B","Activated NFkB",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.AGCCAATTCCGTAATG","B","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2056.94290480896,41.3598648515493,0.0201074442828983,1210,30000,1100,500,"True","True","True","True",5,517,"True","B_healthy-3",2051.65890707346,2051.65890707346,"Control"
"2019.08.01.count.2.TGCTTGCGTAGCGCTC","healthy-3","2019-08-01-count-2:TGCTTGCGTAGCGCTC",-1.15517661991771,9.11342427814332,"2019-08-01-count-2","Control3","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TGCTTGCGTAGCGCTC","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1894.55068428505,48.9000857589838,0.0258109145163553,964,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1892.92042080371,1892.92042080371,"Control"
"2019.08.01.count.2.CGAGGCTTCCGTCCTA","healthy-3","2019-08-01-count-2:CGAGGCTTCCGTCCTA",-2.74073014679607,8.8686370619568,"2019-08-01-count-2","Control3","CD8+ T","CD8+ NK-like",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CGAGGCTTCCGTCCTA","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2104.23737026048,42.9686404455819,0.0204200538650556,1078,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2100.89839502037,2100.89839502037,"Control"
"2019.08.01.count.4.TCTTAGTCAAACACCT","healthy-3","2019-08-01-count-4:TCTTAGTCAAACACCT",-2.48816309395488,9.42423913562623,"2019-08-01-count-4","Control3","CD8+ T","CD8+ Cytotoxic",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TCTTAGTCAAACACCT","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2263.75121819327,40.1975803146745,0.017757066232197,1296,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2252.07494191417,2252.07494191417,"Control"
"2019.08.01.count.4.TTACGTTCACTAGGTT","healthy-3","2019-08-01-count-4:TTACGTTCACTAGGTT",4.94776787337605,-8.57883360302123,"2019-08-01-count-4","Control3","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TTACGTTCACTAGGTT","HLA-II+ monocyte","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2844.61282392343,43.401420011179,0.0152574085464881,2538,30000,1100,500,"True","True","True","True",5,976,"True","Mono_healthy-3",2836.70565938879,2836.70565938879,"Control"
"2019.08.01.count.3.CGTCCATTCAAATGAG","healthy-3","2019-08-01-count-3:CGTCCATTCAAATGAG",-3.31615815582927,9.43840501392213,"2019-08-01-count-3","Control3","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CGTCCATTCAAATGAG","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2173.59433913724,41.7752352066147,0.0192194258396884,1203,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2173.59433913724,2173.59433913724,"Control"
"2019.08.01.count.4.GCTTCACCAACGAGGT","healthy-3","2019-08-01-count-4:GCTTCACCAACGAGGT",0.0338272425228774,8.28567311847535,"2019-08-01-count-4","Control3","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GCTTCACCAACGAGGT","CD4+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2005.0379256183,41.7653741284874,0.0208302165235145,1094,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1994.29963389847,1994.29963389847,"Control"
"2019.08.01.count.3.CATTGAGAGTCGAATA","healthy-3","2019-08-01-count-3:CATTGAGAGTCGAATA",10.4625431495601,6.7739047774109,"2019-08-01-count-3","Control3","B","Naive B",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CATTGAGAGTCGAATA","B","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1781.31244085478,39.3687827290261,0.0221009980203892,967,30000,1100,500,"True","True","True","True",5,517,"True","B_healthy-3",1773.99925932445,1773.99925932445,"Control"
"2019.08.01.count.2.TCACTCGAGCGAGAAA","healthy-3","2019-08-01-count-2:TCACTCGAGCGAGAAA",-3.40681991997417,10.4817819365296,"2019-08-01-count-2","Control3","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCACTCGAGCGAGAAA","CD8+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1897.16469628932,46.8882478555315,0.024714906379631,927,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",1897.16469628932,1897.16469628932,"Control"
"2019.08.01.count.4.TGAGGAGGTACCATAC","healthy-3","2019-08-01-count-4:TGAGGAGGTACCATAC",-1.89267895641978,8.81277940357057,"2019-08-01-count-4","Control3","CD4+ T","CD4+ Naive",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","female","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TGAGGAGGTACCATAC","CD4+ T","3","F",50,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2087.76196603813,47.7566111151746,0.0228745479092142,1117,30000,1100,500,"True","True","True","True",5,1795,"True","T_healthy-3",2086.17729740026,2086.17729740026,"Control"
"2019.08.01.count.4.GCCAACGGTGTCATGT","healthy-4","2019-08-01-count-4:GCCAACGGTGTCATGT",2.63183297690694,-5.95913793956908,"2019-08-01-count-4","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GCCAACGGTGTCATGT","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2592.76964277443,40.0566665118439,0.0154493734618787,1993,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2586.37365549925,2586.37365549925,"Control"
"2019.08.01.count.1.CTGGTCTTCCAGTGCG","healthy-4","2019-08-01-count-1:CTGGTCTTCCAGTGCG",0.388257165520829,7.99598405444948,"2019-08-01-count-1","Control4","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613747","2019-08-01-count-1_metadata.csv.gz","2019.08.01.count.1.CTGGTCTTCCAGTGCG","CD4+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1914.6699149863,46.5535065144636,0.0243141160521116,1140,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1902.44211834249,1902.44211834249,"Control"
"2019.08.01.count.4.GGAGCAACATACATCG","healthy-4","2019-08-01-count-4:GGAGCAACATACATCG",-1.80903528156932,8.83328435504762,"2019-08-01-count-4","Control4","MAIT","MAIT",15,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GGAGCAACATACATCG","MAIT","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","MAIT",1898.66927630387,41.752855982177,0.0219905891474987,1003,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1895.47935739466,1895.47935739466,"Control"
"2019.08.01.count.2.CACGAATCAAGAGAGA","healthy-4","2019-08-01-count-2:CACGAATCAAGAGAGA",3.65624990042989,-6.54925396358641,"2019-08-01-count-2","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CACGAATCAAGAGAGA","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2492.12856858895,43.2153464269231,0.017340737139975,1665,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2488.71491570458,2488.71491570458,"Control"
"2019.08.01.count.3.ATCACAGAGTCGCCCA","healthy-4","2019-08-01-count-3:ATCACAGAGTCGCCCA",2.41001500663106,-6.16429617321166,"2019-08-01-count-3","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ATCACAGAGTCGCCCA","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2173.24803883395,43.0235571851693,0.0197968922168007,1240,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2164.85874435927,2164.85874435927,"Control"
"2019.08.01.count.2.TACGTCCGTCGGATTT","healthy-4","2019-08-01-count-2:TACGTCCGTCGGATTT",2.27146305617635,-6.2380204430786,"2019-08-01-count-2","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TACGTCCGTCGGATTT","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2544.34695374373,43.2182196358879,0.0169859773142562,1951,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2541.47394488226,2541.47394488226,"Control"
"2019.08.01.count.4.CGCATAAAGTATAACG","healthy-4","2019-08-01-count-4:CGCATAAAGTATAACG",0.136600655584973,7.88408324802247,"2019-08-01-count-4","Control4","CD8+ T","CD8+ Naive",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CGCATAAAGTATAACG","CD8+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1964.55213815178,42.914395796308,0.021844365930996,1156,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1957.70020225523,1957.70020225523,"Control"
"2019.08.01.count.3.GAGTCTAAGATTAGTG","healthy-4","2019-08-01-count-3:GAGTCTAAGATTAGTG",-2.47562466087993,3.39487383449403,"2019-08-01-count-3","Control4","Ery","Ery-4",53,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GAGTCTAAGATTAGTG","Ery","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Ery","Ery",3008.56285511738,49.3031609714183,0.0163876120745015,4136,30000,1100,500,"True","True","True","True",5,206,"True","Ery_healthy-4",2999.51183206163,2999.51183206163,"Control"
"2019.08.01.count.2.CGGAATTTCTGCGGAC","healthy-4","2019-08-01-count-2:CGGAATTTCTGCGGAC",11.0771948295528,6.0464730032715,"2019-08-01-count-2","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CGGAATTTCTGCGGAC","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1894.76861661573,46.7320146540671,0.0246637052378119,980,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1886.82805765891,1886.82805765891,"Control"
"2019.08.01.count.4.AGGAGGTAGTTAGTGA","healthy-4","2019-08-01-count-4:AGGAGGTAGTTAGTGA",4.51694454726521,-6.73707678234252,"2019-08-01-count-4","Control4","CD11c+","CD11c+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.AGGAGGTAGTTAGTGA","CD11c+","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2905.75737397624,46.0836063218897,0.0158594130172778,2225,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2899.02199256581,2899.02199256581,"Control"
"2019.08.01.count.2.GTCTAGAAGCAGTAAT","healthy-4","2019-08-01-count-2:GTCTAGAAGCAGTAAT",10.3295656639034,7.57936952197877,"2019-08-01-count-2","Control4","B","Memory",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GTCTAGAAGCAGTAAT","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2031.93005883354,42.0058894687979,0.02067290125769,1198,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",2029.15225791453,2029.15225791453,"Control"
"2019.08.01.count.2.ATGGAGGGTTAGCGGA","healthy-4","2019-08-01-count-2:ATGGAGGGTTAGCGGA",-3.10459933701213,10.3145417937073,"2019-08-01-count-2","Control4","gd T","gd T",9,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ATGGAGGGTTAGCGGA","gd T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","gd_T",2031.31501786082,47.1926691682579,0.023232570405528,1116,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",2023.72123735941,2023.72123735941,"Control"
"2019.08.01.count.2.TGGAGAGTCGTTCTCG","healthy-4","2019-08-01-count-2:TGGAGAGTCGTTCTCG",-2.15935597840007,9.18933580005494,"2019-08-01-count-2","Control4","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TGGAGAGTCGTTCTCG","CD8+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1593.95923596724,52.1269090872615,0.0327027868160191,646,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1589.5991539184,1589.5991539184,"Control"
"2019.08.01.count.2.CCGAACGCACCCTAGG","healthy-4","2019-08-01-count-2:CCGAACGCACCCTAGG",4.79377665099446,-7.12715103542479,"2019-08-01-count-2","Control4","CD14+ monocyte","CD14+ IFN+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CCGAACGCACCCTAGG","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2882.03600544511,42.7984425301271,0.0148500721189002,2285,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2878.42576022082,2878.42576022082,"Control"
"2019.08.01.count.2.GGTTAACCATTCTTCA","healthy-4","2019-08-01-count-2:GGTTAACCATTCTTCA",11.3032547431881,5.20338246906129,"2019-08-01-count-2","Control4","Pre-B","Pre-B",48,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GGTTAACCATTCTTCA","Pre-B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2112.19312963881,39.6012775727398,0.0187488904385896,1063,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",2107.17243790729,2107.17243790729,"Control"
"2019.08.01.count.4.GGGTGTCAGTCTGCAT","healthy-4","2019-08-01-count-4:GGGTGTCAGTCTGCAT",3.11589016494099,-6.33904030239256,"2019-08-01-count-4","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GGGTGTCAGTCTGCAT","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2620.01375842551,43.5486188864065,0.0166215229772598,2054,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2612.73848187397,2612.73848187397,"Control"
"2019.08.01.count.3.GCTACCTCATCGCTAA","healthy-4","2019-08-01-count-3:GCTACCTCATCGCTAA",-0.14353227141555,7.83598277652589,"2019-08-01-count-3","Control4","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GCTACCTCATCGCTAA","CD4+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2121.17083514767,42.5663478459935,0.020067383136083,1464,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",2114.40921944955,2114.40921944955,"Control"
"2019.08.01.count.4.CTCAGTCAGTCATGAA","healthy-4","2019-08-01-count-4:CTCAGTCAGTCATGAA",6.83283819732015,-1.6718937388626,"2019-08-01-count-4","Control4","pDC","pDC",32,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CTCAGTCAGTCATGAA","pDC","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","pDC",2796.84159346269,36.7293051642345,0.0131324223903439,2191,30000,1100,500,"True","True","True","True",5,178,"True","DC_healthy-4",2786.3002508024,2786.3002508024,"Control"
"2019.08.01.count.2.CGGAACCGTTATGTCG","healthy-4","2019-08-01-count-2:CGGAACCGTTATGTCG",3.27733339843099,-6.1610465279785,"2019-08-01-count-2","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CGGAACCGTTATGTCG","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2655.01207129914,47.4646869421553,0.0178773902594462,1976,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2651.05600723684,2651.05600723684,"Control"
"2019.08.01.count.4.CATCCCATCGAATCCA","healthy-4","2019-08-01-count-4:CATCCCATCGAATCCA",3.10065116462056,-6.04911281978758,"2019-08-01-count-4","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CATCCCATCGAATCCA","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2745.71239788985,43.9869741304639,0.0160202409270064,2186,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2742.96501358768,2742.96501358768,"Control"
"2019.08.01.count.3.AGGTGTTTCCACTAGA","healthy-4","2019-08-01-count-3:AGGTGTTTCCACTAGA",4.42703165587727,-6.58507683193358,"2019-08-01-count-3","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AGGTGTTTCCACTAGA","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2574.54503873414,45.360263799076,0.0176187493777071,1660,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2569.70264517329,2569.70264517329,"Control"
"2019.08.01.count.2.CCGCAAGTCCTTGAAG","healthy-4","2019-08-01-count-2:CCGCAAGTCCTTGAAG",10.310976644128,6.38622520053712,"2019-08-01-count-2","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CCGCAAGTCCTTGAAG","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1849.9706148261,48.1195934491278,0.0260110042091945,927,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1844.91852975322,1844.91852975322,"Control"
"2019.08.01.count.2.ACGTTCCGTTGCAAGG","healthy-4","2019-08-01-count-2:ACGTTCCGTTGCAAGG",-0.217774937779266,8.41425321185914,"2019-08-01-count-2","Control4","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ACGTTCCGTTGCAAGG","CD4+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1848.09742228293,42.4890828486049,0.0229907159310458,973,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1833.87671105583,1833.87671105583,"Control"
"2019.08.01.count.4.TCCAGAATCCCAGGCA","healthy-4","2019-08-01-count-4:TCCAGAATCCCAGGCA",10.9494759040767,5.83032653415529,"2019-08-01-count-4","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TCCAGAATCCCAGGCA","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1998.3519569848,48.1248863791401,0.0240822875124325,1039,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1991.91605237808,1991.91605237808,"Control"
"2019.08.01.count.4.AGATCCATCGTCGGGT","healthy-4","2019-08-01-count-4:AGATCCATCGTCGGGT",-1.49911079827006,8.65142438495485,"2019-08-01-count-4","Control4","CD8+ T","CD8+ TRM",15,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.AGATCCATCGTCGGGT","CD8+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1947.74593000665,46.9360671917234,0.0240976333045467,935,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1942.32371430678,1942.32371430678,"Control"
"2019.08.01.count.3.ATGAAAGCATAGTCAC","healthy-4","2019-08-01-count-3:ATGAAAGCATAGTCAC",4.65979494628255,-6.78083565151366,"2019-08-01-count-3","Control4","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ATGAAAGCATAGTCAC","HLA-II+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2652.87093182019,39.9574109685783,0.0150619506170859,1827,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2649.58658660196,2649.58658660196,"Control"
"2019.08.01.count.4.GCTTGGGTCCGCAACG","healthy-4","2019-08-01-count-4:GCTTGGGTCCGCAACG",2.15170445021932,-5.96548511898192,"2019-08-01-count-4","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GCTTGGGTCCGCAACG","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2592.78275334284,47.5376057923945,0.0183345888625281,1904,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2587.70124837153,2587.70124837153,"Control"
"2019.08.01.count.3.ATGCCTCGTACGTGTT","healthy-4","2019-08-01-count-3:ATGCCTCGTACGTGTT",14.2356602149898,2.15224025333253,"2019-08-01-count-3","Control4","Plasmablast","Plasmablast",69,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ATGCCTCGTACGTGTT","Plasmablast","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","Plasma",1336.41575211941,39.0042173342678,0.029185691108782,1310,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1320.03015669686,1320.03015669686,"Control"
"2019.08.01.count.3.AACAGGGCATGATCTG","healthy-4","2019-08-01-count-3:AACAGGGCATGATCTG",-1.29631827297862,8.37325570667116,"2019-08-01-count-3","Control4","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AACAGGGCATGATCTG","CD8+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2035.8243552219,46.9187032983275,0.0230465379677676,1106,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",2028.26032197713,2028.26032197713,"Control"
"2019.08.01.count.4.CGATCGGTCACGGACC","healthy-4","2019-08-01-count-4:CGATCGGTCACGGACC",0.646166999905747,7.96088836276857,"2019-08-01-count-4","Control4","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CGATCGGTCACGGACC","CD4+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1877.65162735204,42.4517160483684,0.0226089416321791,1076,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1870.54306426625,1870.54306426625,"Control"
"2019.08.01.count.3.AACCATGCAGTAGATA","healthy-4","2019-08-01-count-3:AACCATGCAGTAGATA",-3.6026180786198,10.9268989332947,"2019-08-01-count-3","Control4","gd T","gd T",9,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AACCATGCAGTAGATA","gd T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","gd_T",2037.33673132284,48.2689834331341,0.0236921971174559,1068,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",2032.44039133832,2032.44039133832,"Control"
"2019.08.01.count.3.GTTCTATTCCATTCAT","healthy-4","2019-08-01-count-3:GTTCTATTCCATTCAT",4.41289915618245,-6.5591726533142,"2019-08-01-count-3","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GTTCTATTCCATTCAT","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2903.17686005289,43.1145569803871,0.0148508200012319,2254,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2893.02691120375,2893.02691120375,"Control"
"2019.08.01.count.4.TGAGGGAAGGAAACGA","healthy-4","2019-08-01-count-4:TGAGGGAAGGAAACGA",-0.0603548688000024,7.52579305255739,"2019-08-01-count-4","Control4","CD8+ T","CD8+ Naive",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TGAGGGAAGGAAACGA","CD8+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2061.1280043893,46.0368049389443,0.0223357330747562,1311,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",2057.38061058532,2057.38061058532,"Control"
"2019.08.01.count.2.ACAAAGACAGACTCTA","healthy-4","2019-08-01-count-2:ACAAAGACAGACTCTA",3.94567551192586,-6.86314203655394,"2019-08-01-count-2","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ACAAAGACAGACTCTA","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2515.97309272565,42.9437562838333,0.0170684481515304,1575,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2507.27163681621,2507.27163681621,"Control"
"2019.08.01.count.2.TGATGCAAGGGAGGGT","healthy-4","2019-08-01-count-2:TGATGCAAGGGAGGGT",11.3428789573604,5.89839933002321,"2019-08-01-count-2","Control4","B","Activated AP-1",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TGATGCAAGGGAGGGT","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2013.10332000682,48.8963736968696,0.024289053229868,1238,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",2007.96107067116,2007.96107067116,"Control"
"2019.08.01.count.3.CCCTAACAGGTTGCCC","healthy-4","2019-08-01-count-3:CCCTAACAGGTTGCCC",0.182893578975838,8.00063798511354,"2019-08-01-count-3","Control4","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CCCTAACAGGTTGCCC","CD4+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1912.48094751264,39.3780896733025,0.0205900559294551,1094,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1908.2227187742,1908.2227187742,"Control"
"2019.08.01.count.3.GCTACCTAGAGTGTTA","healthy-4","2019-08-01-count-3:GCTACCTAGAGTGTTA",4.97872700270955,-7.46154882824095,"2019-08-01-count-3","Control4","CD11c+","CD11c+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GCTACCTAGAGTGTTA","CD11c+","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2498.44514064405,49.7920011596431,0.0199291953021661,1633,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2496.0753999694,2496.0753999694,"Control"
"2019.08.01.count.4.TACGGGCTCCGATAGT","healthy-4","2019-08-01-count-4:TACGGGCTCCGATAGT",-4.44434628906901,12.6801652678284,"2019-08-01-count-4","Control4","NK","CD56dim NK",26,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TACGGGCTCCGATAGT","NK","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2366.55570911768,45.2798493630643,0.0191332277489237,1358,30000,1100,500,"True","True","True","True",5,162,"True","NK_healthy-4",2365.08741378123,2365.08741378123,"Control"
"2019.08.01.count.4.TCATCATTCCGCAGTG","healthy-4","2019-08-01-count-4:TCATCATTCCGCAGTG",10.997967382043,6.6890020140442,"2019-08-01-count-4","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TCATCATTCCGCAGTG","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1779.15519935381,40.8823192405553,0.0229785008387147,823,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1769.87025284122,1769.87025284122,"Control"
"2019.08.01.count.2.CATCGGGAGGATGCGT","healthy-4","2019-08-01-count-2:CATCGGGAGGATGCGT",-0.160899530083495,7.57010839069215,"2019-08-01-count-2","Control4","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CATCGGGAGGATGCGT","CD4+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1899.66253399922,42.9398842503708,0.0226039538506729,1322,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1895.30915843224,1895.30915843224,"Control"
"2019.08.01.count.2.TCAATTCCAATGGCAG","healthy-4","2019-08-01-count-2:TCAATTCCAATGGCAG",-2.43733606758769,9.27265546405641,"2019-08-01-count-2","Control4","MAIT","MAIT",15,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCAATTCCAATGGCAG","MAIT","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","MAIT",2020.9602688394,46.5868179515057,0.0230518227744575,1156,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",2016.72670817435,2016.72670817435,"Control"
"2019.08.01.count.2.ATCCACCAGAGGCGTT","healthy-4","2019-08-01-count-2:ATCCACCAGAGGCGTT",9.8764120536739,7.246959186438,"2019-08-01-count-2","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ATCCACCAGAGGCGTT","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1853.19109321391,44.7431892349613,0.0241438615795228,967,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1846.85630465063,1846.85630465063,"Control"
"2019.08.01.count.4.GTGAGCCCAGAAACCG","healthy-4","2019-08-01-count-4:GTGAGCCCAGAAACCG",-3.8210953277653,12.7750215300354,"2019-08-01-count-4","Control4","NK","CD56dim NK",26,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GTGAGCCCAGAAACCG","NK","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1763.20818543197,47.4045483190614,0.026885394878908,770,30000,1100,500,"True","True","True","True",5,162,"True","NK_healthy-4",1761.14860258432,1761.14860258432,"Control"
"2019.08.01.count.2.AGGATCTTCATGAGAA","healthy-4","2019-08-01-count-2:AGGATCTTCATGAGAA",3.64454998549764,-6.67498400127562,"2019-08-01-count-2","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.AGGATCTTCATGAGAA","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2437.95840366637,46.2091512379687,0.0189540359542133,1680,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2434.70898987686,2434.70898987686,"Control"
"2019.08.01.count.3.CTTGAGAGTCGCGTTG","healthy-4","2019-08-01-count-3:CTTGAGAGTCGCGTTG",2.41514434394185,-6.28783180629881,"2019-08-01-count-3","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTTGAGAGTCGCGTTG","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2202.77069291062,47.0892283475241,0.0213772720415592,1428,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2198.14628510799,2198.14628510799,"Control"
"2019.08.01.count.2.TCGAAGTAGAGTGACC","healthy-4","2019-08-01-count-2:TCGAAGTAGAGTGACC",10.4761816459591,6.34213683688966,"2019-08-01-count-2","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCGAAGTAGAGTGACC","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1805.88661452101,47.9460092563141,0.0265498447525905,837,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1804.07174198908,1804.07174198908,"Control"
"2019.08.01.count.3.TAATCTCGTGATAGAT","healthy-4","2019-08-01-count-3:TAATCTCGTGATAGAT",3.11730684813802,-5.93467047130736,"2019-08-01-count-3","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TAATCTCGTGATAGAT","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2502.08714580868,44.1137333491121,0.0176307741411039,1754,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2496.79125589044,2496.79125589044,"Control"
"2019.08.01.count.3.GACATCAGTAGGCAGT","healthy-4","2019-08-01-count-3:GACATCAGTAGGCAGT",-2.6036847633427,3.43261811817018,"2019-08-01-count-3","Control4","Ery","Ery-4",53,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GACATCAGTAGGCAGT","Ery","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Ery","Ery",3354.49954002677,45.6954005695798,0.0136221215785932,5730,30000,1100,500,"True","True","True","True",5,206,"True","Ery_healthy-4",3348.03241305685,3348.03241305685,"Control"
"2019.08.01.count.4.CACGTTCGTCATGACT","healthy-4","2019-08-01-count-4:CACGTTCGTCATGACT",10.1013618904049,6.84765670383302,"2019-08-01-count-4","Control4","B","Activated AP-1",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CACGTTCGTCATGACT","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2070.25263269468,48.9125908952291,0.0236263874866148,1202,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",2063.14337264243,2063.14337264243,"Control"
"2019.08.01.count.3.AGTAGCTCAGGGATAC","healthy-4","2019-08-01-count-3:AGTAGCTCAGGGATAC",10.6306129890377,6.48082730853883,"2019-08-01-count-3","Control4","B","Memory",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AGTAGCTCAGGGATAC","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1825.86595226877,43.0266234249899,0.0235650505293262,883,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1822.337273673,1822.337273673,"Control"
"2019.08.01.count.3.TCTATCAGTGGGACAT","healthy-4","2019-08-01-count-3:TCTATCAGTGGGACAT",3.26878203925435,-6.57511141216429,"2019-08-01-count-3","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TCTATCAGTGGGACAT","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2491.80456531987,48.1963745201926,0.0193419561032089,1562,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2486.75395553105,2486.75395553105,"Control"
"2019.08.01.count.3.GGGTGTCAGTAGTCCT","healthy-4","2019-08-01-count-3:GGGTGTCAGTAGTCCT",2.650491853326,-6.11660053646239,"2019-08-01-count-3","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GGGTGTCAGTAGTCCT","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2359.89082048049,48.1191632912361,0.0203904192828033,1412,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2358.55151106091,2358.55151106091,"Control"
"2019.08.01.count.3.TGAACGTAGACCAACG","healthy-4","2019-08-01-count-3:TGAACGTAGACCAACG",-3.0178955596989,-5.96127321636351,"2019-08-01-count-3","Control4","Granulocyte","Granulocytes",63,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TGAACGTAGACCAACG","Granulocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2807.00020881872,46.8892742052197,0.0167044070954851,1960,30000,1100,500,"True","True","True","True",5,273,"True","Gran_healthy-4",2797.98493658816,2797.98493658816,"Control"
"2019.08.01.count.3.TGATGGTTCACCACAA","healthy-4","2019-08-01-count-3:TGATGGTTCACCACAA",4.27245773848836,-6.55988075649413,"2019-08-01-count-3","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TGATGGTTCACCACAA","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2447.90411279337,41.4035085456699,0.0169138604446492,1493,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2441.32493684597,2441.32493684597,"Control"
"2019.08.01.count.4.GCCAACGGTCTCGGAC","healthy-4","2019-08-01-count-4:GCCAACGGTCTCGGAC",2.52577628669087,-6.14164545452269,"2019-08-01-count-4","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GCCAACGGTCTCGGAC","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2381.23645850778,43.6482312023355,0.0183300700971494,1574,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2380.08642672811,2380.08642672811,"Control"
"2019.08.01.count.3.ACAAAGAAGTCCTGTA","healthy-4","2019-08-01-count-3:ACAAAGAAGTCCTGTA",0.052386140064757,7.81389663303224,"2019-08-01-count-3","Control4","CD8+ T","CD8+ Naive",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ACAAAGAAGTCCTGTA","CD8+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1919.359482313,44.4192585831591,0.0231427510023448,1155,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1916.73512533993,1916.73512533993,"Control"
"2019.08.01.count.2.GGAATCTGTTTGGAGG","healthy-4","2019-08-01-count-2:GGAATCTGTTTGGAGG",2.77977170523946,-6.40048172390135,"2019-08-01-count-2","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GGAATCTGTTTGGAGG","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2366.0495544792,46.126178540261,0.0194950179521553,1591,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2360.30785305563,2360.30785305563,"Control"
"2019.08.01.count.3.GTGGAAGGTCAGATTC","healthy-4","2019-08-01-count-3:GTGGAAGGTCAGATTC",-1.8793355030125,4.16115806186525,"2019-08-01-count-3","Control4","Ery","Heat shock proteins",53,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.GTGGAAGGTCAGATTC","Ery","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Ery","Ery",3179.94000485154,45.6010069293932,0.0143402098340916,5360,30000,1100,500,"True","True","True","True",5,206,"True","Ery_healthy-4",3174.0327319377,3174.0327319377,"Control"
"2019.08.01.count.3.AAAGGGCGTGGCCCAT","healthy-4","2019-08-01-count-3:AAAGGGCGTGGCCCAT",4.06339087065999,-7.60342647945555,"2019-08-01-count-3","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AAAGGGCGTGGCCCAT","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2361.28984289962,49.8146321168781,0.0210963648815372,1295,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2356.73585098546,2356.73585098546,"Control"
"2019.08.01.count.3.CAACGGCCAAGAGCTG","healthy-4","2019-08-01-count-3:CAACGGCCAAGAGCTG",2.38008131560628,-4.37404730236205,"2019-08-01-count-3","Control4","cDC2","cDC2",36,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CAACGGCCAAGAGCTG","cDC2","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2997.67480436569,41.629084399234,0.0138871248938034,3368,30000,1100,500,"True","True","True","True",5,178,"True","DC_healthy-4",2987.49112956777,2987.49112956777,"Control"
"2019.08.01.count.2.TATCCTACAATGCAAA","healthy-4","2019-08-01-count-2:TATCCTACAATGCAAA",0.846689184277695,8.17910001361696,"2019-08-01-count-2","Control4","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TATCCTACAATGCAAA","CD4+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1728.15427543487,40.658206240792,0.0235269540565531,895,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1716.38330641295,1716.38330641295,"Control"
"2019.08.01.count.2.CTACTATCAATGTTGC","healthy-4","2019-08-01-count-2:CTACTATCAATGTTGC",4.0578896003658,-6.83271267330321,"2019-08-01-count-2","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTACTATCAATGTTGC","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2546.63904933158,42.713757853723,0.0167725998959036,1622,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2546.63904933158,2546.63904933158,"Control"
"2019.08.01.count.3.TACGGTAAGAGTCACG","healthy-4","2019-08-01-count-3:TACGGTAAGAGTCACG",11.2578884559566,5.38635871494142,"2019-08-01-count-3","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TACGGTAAGAGTCACG","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2056.74100791607,44.8033343010814,0.0217836539110372,1189,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",2045.38229876534,2045.38229876534,"Control"
"2019.08.01.count.3.ACAGCCGTCCCTTGTG","healthy-4","2019-08-01-count-3:ACAGCCGTCCCTTGTG",4.9095684486324,-7.07331135189208,"2019-08-01-count-3","Control4","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ACAGCCGTCCCTTGTG","HLA-II+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2591.02709093211,46.0140746509549,0.0177590094723407,1769,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2589.92815859699,2589.92815859699,"Control"
"2019.08.01.count.4.CTCACTGCACCTGTCT","healthy-4","2019-08-01-count-4:CTCACTGCACCTGTCT",-4.27153907242473,13.0489949950012,"2019-08-01-count-4","Control4","NK","CD56bright NK",26,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CTCACTGCACCTGTCT","NK","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2599.98850565152,37.022343458606,0.0142394258198186,1423,30000,1100,500,"True","True","True","True",5,162,"True","NK_healthy-4",2598.41510682296,2598.41510682296,"Control"
"2019.08.01.count.3.ACATGCAAGGATGGCT","healthy-4","2019-08-01-count-3:ACATGCAAGGATGGCT",5.21046175536458,-8.12744905864867,"2019-08-01-count-3","Control4","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ACATGCAAGGATGGCT","HLA-II+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2705.35107155767,43.6514898391075,0.0161352403752812,2176,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2700.84745786919,2700.84745786919,"Control"
"2019.08.01.count.2.CTGCAGGCACGTCATA","healthy-4","2019-08-01-count-2:CTGCAGGCACGTCATA",-0.177531669766265,7.49804780567018,"2019-08-01-count-2","Control4","CD8+ T","CD8+ Naive",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CTGCAGGCACGTCATA","CD8+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1999.32239510442,45.0820185929909,0.0225486488339147,1338,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1991.8094198304,1991.8094198304,"Control"
"2019.08.01.count.2.CCGCAAGTCGGTCACG","healthy-4","2019-08-01-count-2:CCGCAAGTCGGTCACG",-3.66137061539348,9.56137559497682,"2019-08-01-count-2","Control4","gd T","gd T",9,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CCGCAAGTCGGTCACG","gd T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","gd_T",2523.33958820179,47.3558700697146,0.0187671410899799,1684,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",2513.6087963965,2513.6087963965,"Control"
"2019.08.01.count.4.CAAGACTGTCGAAGCA","healthy-4","2019-08-01-count-4:CAAGACTGTCGAAGCA",10.274822850793,7.28502843463746,"2019-08-01-count-4","Control4","B","Atypical memory",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CAAGACTGTCGAAGCA","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1698.87233238341,39.6555362990549,0.0233422697769294,716,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1684.32352326164,1684.32352326164,"Control"
"2019.08.01.count.4.GCAACCGGTCTGTGCG","healthy-4","2019-08-01-count-4:GCAACCGGTCTGTGCG",4.96066155013387,-7.70897581493529,"2019-08-01-count-4","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GCAACCGGTCTGTGCG","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2238.06572224067,45.749871375067,0.0204417014748181,1179,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2236.48760062468,2236.48760062468,"Control"
"2019.08.01.count.2.TGGAGGAAGTCCTGTA","healthy-4","2019-08-01-count-2:TGGAGGAAGTCCTGTA",10.862360616296,6.42675111377565,"2019-08-01-count-2","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TGGAGGAAGTCCTGTA","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1860.17992059716,47.6733540083228,0.025628356418888,937,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1860.17992059716,1860.17992059716,"Control"
"2019.08.01.count.3.TCCACCAAGGAGGGTG","healthy-4","2019-08-01-count-3:TCCACCAAGGAGGGTG",5.65420450743977,-9.79735090648802,"2019-08-01-count-3","Control4","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TCCACCAAGGAGGGTG","CD16+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2597.21974273891,44.837737949299,0.0172637444616123,1875,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2589.02459690735,2589.02459690735,"Control"
"2019.08.01.count.1.TGTAAGCTCGCCAGTG","healthy-4","2019-08-01-count-1:TGTAAGCTCGCCAGTG",11.1298891502315,5.88074920261232,"2019-08-01-count-1","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613747","2019-08-01-count-1_metadata.csv.gz","2019.08.01.count.1.TGTAAGCTCGCCAGTG","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2087.66054076336,44.7170850644483,0.0214197108156757,1259,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",2076.4586036996,2076.4586036996,"Control"
"2019.08.01.count.3.CTCCAACTCACTCACC","healthy-4","2019-08-01-count-3:CTCCAACTCACTCACC",0.14465588805024,7.75831077182619,"2019-08-01-count-3","Control4","CD4+ T","CD4+ Naive",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTCCAACTCACTCACC","CD4+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2024.65410180006,42.549702093289,0.0210157883539017,1174,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",2013.29478279292,2013.29478279292,"Control"
"2019.08.01.count.3.AGCCAGCCACAAACGG","healthy-4","2019-08-01-count-3:AGCCAGCCACAAACGG",11.1132656532222,6.40442226016847,"2019-08-01-count-3","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AGCCAGCCACAAACGG","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1993.20775397514,37.8204018540274,0.0189746411424501,1066,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1987.17377687832,1987.17377687832,"Control"
"2019.08.01.count.4.CAGGTATGTTTCGTGA","healthy-4","2019-08-01-count-4:CAGGTATGTTTCGTGA",2.80378379401509,-5.93393614208373,"2019-08-01-count-4","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CAGGTATGTTTCGTGA","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2447.72445363698,39.7628221110019,0.0162448114010218,1728,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2443.62646035678,2443.62646035678,"Control"
"2019.08.01.count.4.CGAAGTTGTACCTAAC","healthy-4","2019-08-01-count-4:CGAAGTTGTACCTAAC",2.56473030623738,-6.36656382000121,"2019-08-01-count-4","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.CGAAGTTGTACCTAAC","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2098.49257964119,48.3759616180128,0.0230527198844251,1165,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2097.03258791399,2097.03258791399,"Control"
"2019.08.01.count.4.TTGGTTTAGCGTCAAG","healthy-4","2019-08-01-count-4:TTGGTTTAGCGTCAAG",1.10262050208394,-6.02538063442381,"2019-08-01-count-4","Control4","Granulocyte","Granulocytes",63,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TTGGTTTAGCGTCAAG","Granulocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2617.27249797067,45.6200914642436,0.0174303942366015,1838,30000,1100,500,"True","True","True","True",5,273,"True","Gran_healthy-4",2612.94721420697,2612.94721420697,"Control"
"2019.08.01.count.3.CTTCAATGTGATAGTA","healthy-4","2019-08-01-count-3:CTTCAATGTGATAGTA",2.57391299781148,-6.07339908992919,"2019-08-01-count-3","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTTCAATGTGATAGTA","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2582.75862083857,46.8645362110833,0.0181451475306149,1800,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2579.45894021418,2579.45894021418,"Control"
"2019.08.01.count.2.GTTCTATTCCACGTAA","healthy-4","2019-08-01-count-2:GTTCTATTCCACGTAA",3.42636122283284,-6.59858562862548,"2019-08-01-count-2","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GTTCTATTCCACGTAA","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2350.82472458952,48.1574067701039,0.0204853242635997,1367,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2345.23300460321,2345.23300460321,"Control"
"2019.08.01.count.3.ATCTCTAAGCGACCCT","healthy-4","2019-08-01-count-3:ATCTCTAAGCGACCCT",10.3428484397823,5.75112578952638,"2019-08-01-count-3","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ATCTCTAAGCGACCCT","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1816.10721730144,46.262134990928,0.0254732399883687,871,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1807.31443748788,1807.31443748788,"Control"
"2019.08.01.count.4.GACCTTCCAGAGGGTT","healthy-4","2019-08-01-count-4:GACCTTCCAGAGGGTT",-0.188252965838271,8.65839955890504,"2019-08-01-count-4","Control4","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.GACCTTCCAGAGGGTT","CD4+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1908.20463358914,40.7855258639712,0.0213737694301987,1124,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1895.82251227221,1895.82251227221,"Control"
"2019.08.01.count.2.TACCGAAGTCCCGTGA","healthy-4","2019-08-01-count-2:TACCGAAGTCCCGTGA",10.1396013694698,7.69556329334108,"2019-08-01-count-2","Control4","B","Activated AP-1",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TACCGAAGTCCCGTGA","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1910.01001871141,43.3412221821667,0.0226916203357963,1181,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1903.51507460256,1903.51507460256,"Control"
"2019.08.01.count.2.GTCATTTTCCAGTGCG","healthy-4","2019-08-01-count-2:GTCATTTTCCAGTGCG",10.5131832557613,6.64963576877443,"2019-08-01-count-2","Control4","B","Activated NFkB",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GTCATTTTCCAGTGCG","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1920.65751045848,43.8554681887986,0.0228335702487269,972,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1912.3807205381,1912.3807205381,"Control"
"2019.08.01.count.2.GTTAGACTCAATCCAG","healthy-4","2019-08-01-count-2:GTTAGACTCAATCCAG",2.04753555831258,-6.15220549022826,"2019-08-01-count-2","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GTTAGACTCAATCCAG","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2486.64952953879,45.8577010038618,0.0184415618120368,1781,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2481.48870406371,2481.48870406371,"Control"
"2019.08.01.count.2.TCTCCGAAGAGTCAGC","healthy-4","2019-08-01-count-2:TCTCCGAAGAGTCAGC",4.789887090295,-7.31397249614867,"2019-08-01-count-2","Control4","CD11c+","CD11c+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TCTCCGAAGAGTCAGC","CD11c+","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2436.14833863936,45.8224107101114,0.0188093680435339,1500,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2433.56321383363,2433.56321383363,"Control"
"2019.08.01.count.4.ATGACCAAGCTAGTTC","healthy-4","2019-08-01-count-4:ATGACCAAGCTAGTTC",4.53195347365682,-6.7319636574951,"2019-08-01-count-4","Control4","CD11c+","CD11c+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.ATGACCAAGCTAGTTC","CD11c+","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2627.10517115985,45.7874809910959,0.0174288724691144,2061,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2622.70074209092,2622.70074209092,"Control"
"2019.08.01.count.2.ATACTTCCACAGTGAG","healthy-4","2019-08-01-count-2:ATACTTCCACAGTGAG",11.0764910179073,5.56615159595338,"2019-08-01-count-2","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ATACTTCCACAGTGAG","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1791.46487433845,39.8999836966936,0.022272266829361,847,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1789.66870316761,1789.66870316761,"Control"
"2019.08.01.count.4.TGCTTCGGTGTAGTGG","healthy-4","2019-08-01-count-4:TGCTTCGGTGTAGTGG",-3.80705342713054,-5.48335697567137,"2019-08-01-count-4","Control4","Granulocyte","Granulocytes",63,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613750","2019-08-01-count-4_metadata.csv.gz","2019.08.01.count.4.TGCTTCGGTGTAGTGG","Granulocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2098.77067119505,46.359114498577,0.0220886994157299,1043,30000,1100,500,"True","True","True","True",5,273,"True","Gran_healthy-4",2098.77067119505,2098.77067119505,"Control"
"2019.08.01.count.3.CATTGTTCAACTAGAA","healthy-4","2019-08-01-count-3:CATTGTTCAACTAGAA",-4.4362567466801,12.7305593260559,"2019-08-01-count-3","Control4","NK","CD56dim NK",26,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CATTGTTCAACTAGAA","NK","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2175.55894710181,40.5491912317161,0.0186385164537758,1105,30000,1100,500,"True","True","True","True",5,162,"True","NK_healthy-4",2172.1325320418,2172.1325320418,"Control"
"2019.08.01.count.3.TGAGACTCAGGCGAAT","healthy-4","2019-08-01-count-3:TGAGACTCAGGCGAAT",2.17913569983785,-5.88691475307616,"2019-08-01-count-3","Control4","Granulocyte","Granulocytes",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.TGAGACTCAGGCGAAT","Granulocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2668.85706469345,45.5720116529697,0.0170754785843895,2256,30000,1100,500,"True","True","True","True",5,273,"True","Gran_healthy-4",2664.79741317208,2664.79741317208,"Control"
"2019.08.01.count.3.AGCGATTTCTGATGGT","healthy-4","2019-08-01-count-3:AGCGATTTCTGATGGT",10.7413860755855,6.87872407520143,"2019-08-01-count-3","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.AGCGATTTCTGATGGT","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1928.45128910098,46.5501640146167,0.0241386257862484,941,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1919.83331191293,1919.83331191293,"Control"
"2019.08.01.count.3.CTACCTGGTCCAAAGG","healthy-4","2019-08-01-count-3:CTACCTGGTCCAAAGG",0.0651578652555167,7.8731274374756,"2019-08-01-count-3","Control4","CD8+ T","CD8+ Naive",18,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.CTACCTGGTCCAAAGG","CD8+ T","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1983.99483177322,42.0937676115964,0.0212166720081496,1291,30000,1100,500,"True","True","True","True",5,1298,"True","T_healthy-4",1974.54218626389,1974.54218626389,"Control"
"2019.08.01.count.2.TTCTTCCCAAACACCT","healthy-4","2019-08-01-count-2:TTCTTCCCAAACACCT",3.09035338935201,-6.15240671550902,"2019-08-01-count-2","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TTCTTCCCAAACACCT","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2764.17750910698,42.9404099355796,0.0155346065128257,2035,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2750.96902832307,2750.96902832307,"Control"
"2019.08.01.count.2.TGGGAGACAAGAGTGC","healthy-4","2019-08-01-count-2:TGGGAGACAAGAGTGC",3.24147166785542,-6.5974536172119,"2019-08-01-count-2","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TGGGAGACAAGAGTGC","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2004.34983219496,40.3849748726399,0.0201486657787749,940,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",1996.98615768857,1996.98615768857,"Control"
"2019.08.01.count.2.GTAATGCGTACCAATC","healthy-4","2019-08-01-count-2:GTAATGCGTACCAATC",11.1944986778194,6.08888576114503,"2019-08-01-count-2","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.GTAATGCGTACCAATC","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2002.28716122115,50.152038983662,0.0250473757985221,1072,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",1994.52278401014,1994.52278401014,"Control"
"2019.08.01.count.2.ATCGTCCTCCACGTCT","healthy-4","2019-08-01-count-2:ATCGTCCTCCACGTCT",11.3755661445553,6.05612418735353,"2019-08-01-count-2","Control4","B","Naive B",2,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.ATCGTCCTCCACGTCT","B","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2224.40078294047,37.1423977010674,0.016697709327349,1237,30000,1100,500,"True","True","True","True",5,1631,"True","B_healthy-4",2214.04325946518,2214.04325946518,"Control"
"2019.08.01.count.2.TAAGTCGCATACTTTC","healthy-4","2019-08-01-count-2:TAAGTCGCATACTTTC",2.04080512103383,-6.12569096004637,"2019-08-01-count-2","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.TAAGTCGCATACTTTC","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2504.7845311828,44.3195650139425,0.0176939630783387,1621,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2490.34075346019,2490.34075346019,"Control"
"2019.08.01.count.3.ACAAGCTGTGATCGTT","healthy-4","2019-08-01-count-3:ACAAGCTGTGATCGTT",2.75802053984944,-6.16450264370116,"2019-08-01-count-3","Control4","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613749","2019-08-01-count-3_metadata.csv.gz","2019.08.01.count.3.ACAAGCTGTGATCGTT","CD14+ monocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2612.78724306316,44.3676290555318,0.0169809574711167,2046,30000,1100,500,"True","True","True","True",5,1657,"True","Mono_healthy-4",2608.17859021217,2608.17859021217,"Control"
"2019.08.01.count.2.CAAGAGGGTTCGGACC","healthy-4","2019-08-01-count-2:CAAGAGGGTTCGGACC",-3.90133557739909,-5.37102415477904,"2019-08-01-count-2","Control4","Granulocyte","Granulocytes (cycling)",63,"Control","Control","Control","control_19to26yrs","control_19to26yrs","male","Control",NA,"GSM5613748","2019-08-01-count-2_metadata.csv.gz","2019.08.01.count.2.CAAGAGGGTTCGGACC","Granulocyte","4","M",20,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2846.11119287519,45.6769975505427,0.0160489153287082,2448,30000,1100,500,"True","True","True","True",5,273,"True","Gran_healthy-4",2840.0718774144,2840.0718774144,"Control"
"2020.08.26.Control4003.c2.ATCCTATTCATGGATC","healthy-4003","2020-08-26-Control4003-c2:ATCCTATTCATGGATC",4.07004704055135,-6.85136415874632,"2020-08-26-Control4003-c2","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.ATCCTATTCATGGATC","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2541.82905699,8.96128305132589,0.0035255254584026,1558,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2537.90629728216,2537.90629728216,"Control"
"2020.08.26.Control4003.c2.GTGGAAGAGGGTATAT","healthy-4003","2020-08-26-Control4003-c2:GTGGAAGAGGGTATAT",-0.666673819453079,8.84824178302614,"2020-08-26-Control4003-c2","Control4003","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.GTGGAAGAGGGTATAT","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1807.92860994127,28.2280202842942,0.0156134595852273,833,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1798.59203852653,1798.59203852653,"Control"
"2020.08.26.Control4003.c2.TACCTCGTCAGTCTTT","healthy-4003","2020-08-26-Control4003-c2:TACCTCGTCAGTCTTT",-3.14572916451152,9.46574208820192,"2020-08-26-Control4003-c2","Control4003","CD8+ T","CD8+ Cytotoxic",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.TACCTCGTCAGTCTTT","CD8+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2533.45580296722,40.9907352110515,0.0161797711896306,1614,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",2525.70696508489,2525.70696508489,"Control"
"2020.08.26.Control4003.c2.TAGGAGGGTTTGTTCT","healthy-4003","2020-08-26-Control4003-c2:TAGGAGGGTTTGTTCT",-4.11196790161784,12.4896754988464,"2020-08-26-Control4003-c2","Control4003","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.TAGGAGGGTTTGTTCT","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2347.66987949053,39.2403834168444,0.0167146087103865,1165,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",2342.33035677996,2342.33035677996,"Control"
"2020.08.26.Control4003.c2.TATCTGTCAACCACAT","healthy-4003","2020-08-26-Control4003-c2:TATCTGTCAACCACAT",5.41342558440511,-9.3371792069641,"2020-08-26-Control4003-c2","Control4003","HLA-II+ monocyte","HLA-II+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.TATCTGTCAACCACAT","HLA-II+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2692.16839819774,4.87912412573561,0.0018123398703446,1776,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2685.15530644253,2685.15530644253,"Control"
"2020.08.26.Control4003.c2.TCACGGGTCTTCGGTC","healthy-4003","2020-08-26-Control4003-c2:TCACGGGTCTTCGGTC",3.08504023131673,-5.07958605205687,"2020-08-26-Control4003-c2","Control4003","cDC2","cDC2",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.TCACGGGTCTTCGGTC","cDC2","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2602.59533174004,20.9843009980219,0.0080628366392989,1932,30000,1100,500,"True","True","True","True",5,351,"True","DC_healthy-4003",2597.13201556399,2597.13201556399,"Control"
"2020.08.26.Control4003.c2.TCCGAAAGTAGATGTA","healthy-4003","2020-08-26-Control4003-c2:TCCGAAAGTAGATGTA",0.381643076508683,9.13222787463991,"2020-08-26-Control4003-c2","Control4003","CD4+ T","CD4+ Naive",4,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.TCCGAAAGTAGATGTA","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1572.96606418205,5.47516500928155,0.0034807902941813,640,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1568.70615941783,1568.70615941783,"Control"
"2020.08.26.Control4003.c2.ACTATCTGTTCTCAGA","healthy-4003","2020-08-26-Control4003-c2:ACTATCTGTTCTCAGA",4.04022016105,-6.80834057247313,"2020-08-26-Control4003-c2","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.ACTATCTGTTCTCAGA","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2361.48617177387,22.7618828402393,0.0096387957347814,1348,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2358.61985177246,2358.61985177246,"Control"
"2020.08.26.Control4003.c2.ACTATGGGTAACATGA","healthy-4003","2020-08-26-Control4003-c2:ACTATGGGTAACATGA",-4.3231032890385,12.9498615034851,"2020-08-26-Control4003-c2","Control4003","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.ACTATGGGTAACATGA","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2120.96669592443,28.3008205765361,0.0133433592478929,988,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",2119.00030015182,2119.00030015182,"Control"
"2020.08.26.Control4003.c2.AGTCTCCTCCATCGTC","healthy-4003","2020-08-26-Control4003-c2:AGTCTCCTCCATCGTC",5.55359329757039,-9.82842352306517,"2020-08-26-Control4003-c2","Control4003","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.AGTCTCCTCCATCGTC","CD16+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2618.04670637238,15.1349018171164,0.0057809899954335,1615,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2613.83933640926,2613.83933640926,"Control"
"2020.08.26.Control4003.c2.TGTTGGAGTTTATGCG","healthy-4003","2020-08-26-Control4003-c2:TGTTGGAGTTTATGCG",-4.01406703415568,12.69370935047,"2020-08-26-Control4003-c2","Control4003","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.TGTTGGAGTTTATGCG","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1716.59949013623,25.0673836424339,0.0146029308446576,695,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",1714.3804598008,1714.3804598008,"Control"
"2020.08.26.Control4003.c2.TTCCTAAAGATGTTGA","healthy-4003","2020-08-26-Control4003-c2:TTCCTAAAGATGTTGA",-3.92525420609172,12.855236984137,"2020-08-26-Control4003-c2","Control4003","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.TTCCTAAAGATGTTGA","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1521.37032271938,45.6453195327373,0.0300027671442601,589,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",1521.37032271938,1521.37032271938,"Control"
"2020.08.26.Control4003.c2.TTGGGTAAGCCATCCG","healthy-4003","2020-08-26-Control4003-c2:TTGGGTAAGCCATCCG",-0.62833265486415,8.89462945545045,"2020-08-26-Control4003-c2","Control4003","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.TTGGGTAAGCCATCCG","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1952.84640760248,32.3222622644048,0.0165513591537837,1051,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1949.82820573812,1949.82820573812,"Control"
"2020.08.26.Control4003.c2.TTTGGAGGTGTGTCGC","healthy-4003","2020-08-26-Control4003-c2:TTTGGAGGTGTGTCGC",5.46762337264363,-9.79454328930052,"2020-08-26-Control4003-c2","Control4003","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.TTTGGAGGTGTGTCGC","CD16+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2145.11462457783,33.7873183657359,0.0157508218808519,1126,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2140.83074692524,2140.83074692524,"Control"
"2020.08.26.Control4003.c3.AACAGGGTCTACGCGG","healthy-4003","2020-08-26-Control4003-c3:AACAGGGTCTACGCGG",-4.1386230987614,12.9835138090881,"2020-08-26-Control4003-c3","Control4003","NK","CD56bright NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.AACAGGGTCTACGCGG","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1662.3225167112,4.35864867798461,0.0026220234847133,668,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",1662.3225167112,1662.3225167112,"Control"
"2020.08.26.Control4003.c3.AACGAAACAGACCGCT","healthy-4003","2020-08-26-Control4003-c3:AACGAAACAGACCGCT",2.01774980601613,-6.52446224605712,"2020-08-26-Control4003-c3","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.AACGAAACAGACCGCT","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2507.48451255367,34.4094910518564,0.0137227132927785,1587,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2499.94673260366,2499.94673260366,"Control"
"2020.08.26.Control4003.c3.AAGCGTTGTTAACCTG","healthy-4003","2020-08-26-Control4003-c3:AAGCGTTGTTAACCTG",-3.93206797066386,12.7111406096253,"2020-08-26-Control4003-c3","Control4003","NK","CD56bright NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.AAGCGTTGTTAACCTG","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1663.65182540043,5.54305331021545,0.0033318590017363,646,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",1663.65182540043,1663.65182540043,"Control"
"2020.08.26.Control4003.c3.AATTCCTAGCGACTAG","healthy-4003","2020-08-26-Control4003-c3:AATTCCTAGCGACTAG",-4.333816866309,12.0220060118469,"2020-08-26-Control4003-c3","Control4003","CD8+ T","CD8+ Cytotoxic",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.AATTCCTAGCGACTAG","CD8+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2434.41619495646,39.9022288607276,0.0163908821110358,1461,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",2424.54726320034,2424.54726320034,"Control"
"2020.08.26.Control4003.c3.AGATAGACATTGAAAG","healthy-4003","2020-08-26-Control4003-c3:AGATAGACATTGAAAG",5.10411800917928,-10.2906952134338,"2020-08-26-Control4003-c3","Control4003","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.AGATAGACATTGAAAG","CD16+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1424.13188250348,44.155386755519,0.0310051248048027,522,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",1424.13188250348,1424.13188250348,"Control"
"2020.08.26.Control4003.c3.AGTAGTCCAGCACAAG","healthy-4003","2020-08-26-Control4003-c3:AGTAGTCCAGCACAAG",3.71955647048299,-7.66365530407103,"2020-08-26-Control4003-c3","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.AGTAGTCCAGCACAAG","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2213.40241421985,33.4103144687587,0.0150945504776341,1129,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2210.11162432089,2210.11162432089,"Control"
"2020.08.26.Control4003.c3.AGTGTTGCAAGCTGTT","healthy-4003","2020-08-26-Control4003-c3:AGTGTTGCAAGCTGTT",-0.644091467291671,8.42995736682741,"2020-08-26-Control4003-c3","Control4003","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.AGTGTTGCAAGCTGTT","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1688.80718016289,43.3631280554589,0.025676778595456,807,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1685.33313846121,1685.33313846121,"Control"
"2020.08.26.Control4003.c3.AGTGTTGGTAGCTAAA","healthy-4003","2020-08-26-Control4003-c3:AGTGTTGGTAGCTAAA",-4.19250951233562,12.9038429030213,"2020-08-26-Control4003-c3","Control4003","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.AGTGTTGGTAGCTAAA","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1944.30047604466,39.1575727842819,0.0201396714482842,864,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",1942.34378291609,1942.34378291609,"Control"
"2020.08.26.Control4003.c3.ATAGAGATCGGTAGGA","healthy-4003","2020-08-26-Control4003-c3:ATAGAGATCGGTAGGA",-1.19640348377879,9.92099664295045,"2020-08-26-Control4003-c3","Control4003","CD4+ T","CD4+ Naive",5,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.ATAGAGATCGGTAGGA","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1417.46327043913,1.94350323500083,0.0013711136475506,563,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1415.31301146066,1415.31301146066,"Control"
"2020.08.26.Control4003.c3.ATGATCGTCATCTATC","healthy-4003","2020-08-26-Control4003-c3:ATGATCGTCATCTATC",3.83441962775533,-7.21827032482298,"2020-08-26-Control4003-c3","Control4003","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.ATGATCGTCATCTATC","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1845.39170941781,39.8185906215262,0.0215773108865262,837,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",1845.39170941781,1845.39170941781,"Control"
"2020.08.26.Control4003.c2.TGCTTCGCAGAAGCGT","healthy-4003","2020-08-26-Control4003-c2:TGCTTCGCAGAAGCGT",4.02473845061604,-8.16543295299681,"2020-08-26-Control4003-c2","Control4003","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.TGCTTCGCAGAAGCGT","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1975.99634437362,35.292874076934,0.0178607992759833,922,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",1972.35661064705,1972.35661064705,"Control"
"2020.08.26.Control4003.c2.TGCTTCGTCGACATAC","healthy-4003","2020-08-26-Control4003-c2:TGCTTCGTCGACATAC",-3.11772761765178,-5.61150553142699,"2020-08-26-Control4003-c2","Control4003","Granulocyte","Granulocytes",63,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.TGCTTCGTCGACATAC","Granulocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2630.95115949114,38.1945198163507,0.0145173807877673,1732,30000,1100,500,"True","True","True","True",5,168,"True","Gran_healthy-4003",2627.33384459112,2627.33384459112,"Control"
"2020.08.26.Control4003.c2.CAGATTGCAACGGTAG","healthy-4003","2020-08-26-Control4003-c2:CAGATTGCAACGGTAG",-3.91294370117839,12.811011291388,"2020-08-26-Control4003-c2","Control4003","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.CAGATTGCAACGGTAG","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1857.15231903772,39.7238422292305,0.0213896522229331,804,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",1852.93900345558,1852.93900345558,"Control"
"2020.08.26.Control4003.c2.CAGCAATTCATTGAGC","healthy-4003","2020-08-26-Control4003-c2:CAGCAATTCATTGAGC",4.97837414321248,-8.66141035473021,"2020-08-26-Control4003-c2","Control4003","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.CAGCAATTCATTGAGC","HLA-II+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2154.07464637991,9.88538204690052,0.0045891548203836,1109,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2144.48893113056,2144.48893113056,"Control"
"2020.08.26.Control4003.c2.CATGGATGTGGATTTC","healthy-4003","2020-08-26-Control4003-c2:CATGGATGTGGATTTC",5.50706352767293,-10.1780271760193,"2020-08-26-Control4003-c2","Control4003","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.CATGGATGTGGATTTC","CD16+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2369.77288210314,45.7346519915534,0.0192991709614656,1427,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2365.84497772484,2365.84497772484,"Control"
"2020.08.26.Control4003.c2.CCCTCTCGTATGGTTC","healthy-4003","2020-08-26-Control4003-c2:CCCTCTCGTATGGTTC",2.87899174269978,-6.8871379128662,"2020-08-26-Control4003-c2","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.CCCTCTCGTATGGTTC","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2275.37685269186,9.47124811030172,0.0041624964669465,1329,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2271.29074403825,2271.29074403825,"Control"
"2020.08.26.Control4003.c2.CCCTCTCTCCAACACA","healthy-4003","2020-08-26-Control4003-c2:CCCTCTCTCCAACACA",11.0350204902584,6.43054864490358,"2020-08-26-Control4003-c2","Control4003","B","Naive B",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.CCCTCTCTCCAACACA","B","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",2104.12653563589,29.5115434543116,0.0140255554761077,1159,30000,1100,500,"True","True","True","True",5,365,"True","B_healthy-4003",2089.23305516654,2089.23305516654,"Control"
"2020.08.26.Control4003.c2.CCTAAGAAGAAACTGT","healthy-4003","2020-08-26-Control4003-c2:CCTAAGAAGAAACTGT",4.52131571349446,-6.82263805782469,"2020-08-26-Control4003-c2","Control4003","Granulocyte","Granulocytes",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.CCTAAGAAGAAACTGT","Granulocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2303.85820546861,35.2136275536921,0.0152846331732163,1299,30000,1100,500,"True","True","True","True",5,168,"True","Gran_healthy-4003",2302.43987359359,2302.43987359359,"Control"
"2020.08.26.Control4003.c2.CGGTCAGCAATCGAAA","healthy-4003","2020-08-26-Control4003-c2:CGGTCAGCAATCGAAA",-3.56356487694438,10.8360080488953,"2020-08-26-Control4003-c2","Control4003","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.CGGTCAGCAATCGAAA","CD8+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1444.82225379443,48.6160882402116,0.0336484907486264,560,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1440.14762851004,1440.14762851004,"Control"
"2020.08.26.Control4003.c2.CTCAGAAAGGATATGT","healthy-4003","2020-08-26-Control4003-c2:CTCAGAAAGGATATGT",5.10520519789998,-8.61837580120238,"2020-08-26-Control4003-c2","Control4003","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.CTCAGAAAGGATATGT","HLA-II+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2620.35684996195,33.0844373321233,0.0126259281565424,1738,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2615.7703737703,2615.7703737703,"Control"
"2020.08.26.Control4003.c2.CTGAGCGCATGGCCCA","healthy-4003","2020-08-26-Control4003-c2:CTGAGCGCATGGCCCA",-3.43432603302653,10.4190168150696,"2020-08-26-Control4003-c2","Control4003","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.CTGAGCGCATGGCCCA","CD8+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1798.00864641217,19.3786335330393,0.0107778311142765,760,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1791.04325009978,1791.04325009978,"Control"
"2020.08.26.Control4003.c2.CTGCATCCATATACCG","healthy-4003","2020-08-26-Control4003-c2:CTGCATCCATATACCG",-2.08766112747844,9.01320836627809,"2020-08-26-Control4003-c2","Control4003","CD8+ T","CD8+ Cytotoxic",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.CTGCATCCATATACCG","CD8+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2120.77307924621,25.8425118276656,0.012185420533936,1052,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",2101.53572458265,2101.53572458265,"Control"
"2020.08.26.Control4003.c3.CATGAGTCAATTCTCT","healthy-4003","2020-08-26-Control4003-c3:CATGAGTCAATTCTCT",2.68935670432393,-7.08432581340941,"2020-08-26-Control4003-c3","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.CATGAGTCAATTCTCT","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2002.99652394714,33.9865312387114,0.0169678433448986,1082,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",1999.99901511316,1999.99901511316,"Control"
"2020.08.26.Control4003.c3.CATGCGGTCATGCCAA","healthy-4003","2020-08-26-Control4003-c3:CATGCGGTCATGCCAA",0.124396164982957,8.37929818713991,"2020-08-26-Control4003-c3","Control4003","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.CATGCGGTCATGCCAA","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1714.13713080302,29.470012762296,0.0171923309009065,941,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1705.26245882183,1705.26245882183,"Control"
"2020.08.26.Control4003.c2.GCCTGTTAGCGCCATC","healthy-4003","2020-08-26-Control4003-c2:GCCTGTTAGCGCCATC",-1.17315206947978,8.74401757800905,"2020-08-26-Control4003-c2","Control4003","CD4+ T","CD4+ Naive",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.GCCTGTTAGCGCCATC","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1893.96215519011,47.1680853622727,0.0249044497710875,863,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1890.11259283217,1890.11259283217,"Control"
"2020.08.26.Control4003.c2.GCGGATCTCTACGCAA","healthy-4003","2020-08-26-Control4003-c2:GCGGATCTCTACGCAA",5.2095385986263,-10.0234737626282,"2020-08-26-Control4003-c2","Control4003","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.GCGGATCTCTACGCAA","CD16+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2589.52253612022,32.5819594839719,0.0125822266574239,1665,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2583.576561924,2583.576561924,"Control"
"2020.08.26.Control4003.c2.GGAGATGGTACCTAAC","healthy-4003","2020-08-26-Control4003-c2:GGAGATGGTACCTAAC",3.27406086501424,-6.21663620388182,"2020-08-26-Control4003-c2","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.GGAGATGGTACCTAAC","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2411.22612244658,0,0,1468,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2405.99554980516,2405.99554980516,"Control"
"2020.08.26.Control4003.c2.GGCTGTGTCAAGATAG","healthy-4003","2020-08-26-Control4003-c2:GGCTGTGTCAAGATAG",5.51300491866414,-10.1844005814758,"2020-08-26-Control4003-c2","Control4003","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.GGCTGTGTCAAGATAG","CD16+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2487.49452823469,32.9505379252422,0.0132464765454686,1448,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2477.7928897932,2477.7928897932,"Control"
"2020.08.26.Control4003.c2.GGTAATCGTCAGCGTC","healthy-4003","2020-08-26-Control4003-c2:GGTAATCGTCAGCGTC",-2.77635536614116,10.6329774626526,"2020-08-26-Control4003-c2","Control4003","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.GGTAATCGTCAGCGTC","CD8+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1505.90610790051,39.500126130503,0.02623013873393,557,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1505.90610790051,1505.90610790051,"Control"
"2020.08.26.Control4003.c2.GGTTGTAAGCGCCATC","healthy-4003","2020-08-26-Control4003-c2:GGTTGTAAGCGCCATC",-1.0083888572758,10.5369043120178,"2020-08-26-Control4003-c2","Control4003","MAIT","MAIT",5,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.GGTTGTAAGCGCCATC","MAIT","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","MAIT",1738.15091129132,40.5894933657477,0.0233521112016636,800,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1734.41438502413,1734.41438502413,"Control"
"2020.08.26.Control4003.c2.GGTTGTATCGGTCTGG","healthy-4003","2020-08-26-Control4003-c2:GGTTGTATCGGTCTGG",3.95908393439595,-6.50168754970702,"2020-08-26-Control4003-c2","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.GGTTGTATCGGTCTGG","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2366.11303966817,35.1474236297944,0.0148544989358258,1374,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2361.91886238932,2361.91886238932,"Control"
"2020.08.26.Control4003.c2.GTAAGTCTCTCCATAT","healthy-4003","2020-08-26-Control4003-c2:GTAAGTCTCTCCATAT",-2.89472208443339,10.8326205977234,"2020-08-26-Control4003-c2","Control4003","gd T","gd T",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.GTAAGTCTCTCCATAT","gd T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","gd_T",1897.93422214451,35.3720859829228,0.0186371506294645,901,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1892.45549409313,1892.45549409313,"Control"
"2020.08.26.Control4003.c2.GTAGGAGCAACCTATG","healthy-4003","2020-08-26-Control4003-c2:GTAGGAGCAACCTATG",-4.38953051987346,13.117459274176,"2020-08-26-Control4003-c2","Control4003","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.GTAGGAGCAACCTATG","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1921.99051030047,33.5874129641526,0.0174753271590825,845,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",1919.93851710082,1919.93851710082,"Control"
"2020.08.26.Control4003.c2.GTGAGCCCAAGACGAC","healthy-4003","2020-08-26-Control4003-c2:GTGAGCCCAAGACGAC",-3.56803427162822,10.3676757582459,"2020-08-26-Control4003-c2","Control4003","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.GTGAGCCCAAGACGAC","CD8+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1954.05430338545,35.193636301378,0.0180105722959715,898,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1950.21795572826,1950.21795572826,"Control"
"2020.08.26.Control4003.c2.GTGAGGACAATAAGGT","healthy-4003","2020-08-26-Control4003-c2:GTGAGGACAATAAGGT",-4.23347077789958,12.8839807280335,"2020-08-26-Control4003-c2","Control4003","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.GTGAGGACAATAAGGT","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1973.53851632861,23.4001637638765,0.0118569582353062,845,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",1969.26220712693,1969.26220712693,"Control"
"2020.08.26.Control4003.c1.AAGTACCTCTGACGCG","healthy-4003","2020-08-26-Control4003-c1:AAGTACCTCTGACGCG",-1.31020996990855,8.56202123248903,"2020-08-26-Control4003-c1","Control4003","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.AAGTACCTCTGACGCG","CD8+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1877.0807656056,34.8828524354115,0.018583565009339,881,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1867.88612294644,1867.88612294644,"Control"
"2020.08.26.Control4003.c1.AGCCAGCGTGGTCTTA","healthy-4003","2020-08-26-Control4003-c1:AGCCAGCGTGGTCTTA",-0.58035252514537,8.17800328815309,"2020-08-26-Control4003-c1","Control4003","CD4+ T","CD4+ Naive",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.AGCCAGCGTGGTCTTA","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1758.31987164839,32.0552819897466,0.0182306316993935,847,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1754.1956333372,1754.1956333372,"Control"
"2020.08.26.Control4003.c1.CAACGATGTTACCTGA","healthy-4003","2020-08-26-Control4003-c1:CAACGATGTTACCTGA",-2.73246059837993,9.67668340289918,"2020-08-26-Control4003-c1","Control4003","gd T","gd T",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.CAACGATGTTACCTGA","gd T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","gd_T",2311.3970787578,29.9106165309745,0.0129404924864962,1229,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",2306.473897716,2306.473897716,"Control"
"2020.08.26.Control4003.c1.CAGGGCTTCATCGCCT","healthy-4003","2020-08-26-Control4003-c1:CAGGGCTTCATCGCCT",9.85546745833699,7.00031564319459,"2020-08-26-Control4003-c1","Control4003","B","Atypical memory",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.CAGGGCTTCATCGCCT","B","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1935.94705654147,34.7811664273572,0.0179659698388101,972,30000,1100,500,"True","True","True","True",5,365,"True","B_healthy-4003",1929.20924917881,1929.20924917881,"Control"
"2020.08.26.Control4003.c1.CGTCAAATCGTGGGTC","healthy-4003","2020-08-26-Control4003-c1:CGTCAAATCGTGGGTC",-1.20269487324412,8.48278043353883,"2020-08-26-Control4003-c1","Control4003","CD4+ T","CD4+ TCM",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.CGTCAAATCGTGGGTC","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1995.80885328101,25.4933285253261,0.0127734319263172,1077,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1991.25106743395,1991.25106743395,"Control"
"2020.08.26.Control4003.c1.CGTCCATCAACCGATT","healthy-4003","2020-08-26-Control4003-c1:CGTCCATCAACCGATT",3.81350435790364,-7.37246181881102,"2020-08-26-Control4003-c1","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.CGTCCATCAACCGATT","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2193.23843193441,36.3670193279875,0.0165814253473172,1147,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2191.66219977441,2191.66219977441,"Control"
"2020.08.26.Control4003.c1.CTAAGTGAGCTTGTTG","healthy-4003","2020-08-26-Control4003-c1:CTAAGTGAGCTTGTTG",5.43986954268758,-10.0434341660705,"2020-08-26-Control4003-c1","Control4003","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.CTAAGTGAGCTTGTTG","CD16+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2078.2975596511,10.0958068260123,0.004857729240517,1057,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2076.68498586916,2076.68498586916,"Control"
"2020.08.26.Control4003.c1.GAGAGGTGTCGTGTTA","healthy-4003","2020-08-26-Control4003-c1:GAGAGGTGTCGTGTTA",5.30445494231526,-10.0582914582458,"2020-08-26-Control4003-c1","Control4003","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.GAGAGGTGTCGTGTTA","CD16+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2379.89726105485,38.1340355908664,0.0160233957216977,1445,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2376.09611296963,2376.09611296963,"Control"
"2020.08.26.Control4003.c1.TACCTGCTCGCCGAAC","healthy-4003","2020-08-26-Control4003-c1:TACCTGCTCGCCGAAC",6.67654099044148,-1.56292250072631,"2020-08-26-Control4003-c1","Control4003","pDC","pDC",32,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.TACCTGCTCGCCGAAC","pDC","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","pDC",2640.36469656163,20.4536653941614,0.0077465304019542,1607,30000,1100,500,"True","True","True","True",5,351,"True","DC_healthy-4003",2635.09536163854,2635.09536163854,"Control"
"2020.08.26.Control4003.c1.TAGTGCAAGGTAGTAT","healthy-4003","2020-08-26-Control4003-c1:TAGTGCAAGGTAGTAT",-3.01361809197124,10.3452939757141,"2020-08-26-Control4003-c1","Control4003","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.TAGTGCAAGGTAGTAT","CD8+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1723.94032301717,37.4449991680393,0.0217205889717253,752,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1717.93068300379,1717.93068300379,"Control"
"2020.08.26.Control4003.c1.TCACTCGAGAGTATAC","healthy-4003","2020-08-26-Control4003-c1:TCACTCGAGAGTATAC",4.80562986907308,-7.96079256450804,"2020-08-26-Control4003-c1","Control4003","CD11c+","CD11c+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.TCACTCGAGAGTATAC","CD11c+","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2438.58349661483,33.8894665560264,0.01389719343343,1520,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2433.63550312209,2433.63550312209,"Control"
"2020.08.26.Control4003.c1.TCAGGTATCGTTCTAT","healthy-4003","2020-08-26-Control4003-c1:TCAGGTATCGTTCTAT",5.56577648696248,-9.59996702587279,"2020-08-26-Control4003-c1","Control4003","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.TCAGGTATCGTTCTAT","CD16+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2174.04200784185,16.5890580928605,0.007630514053097,1193,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2169.7369175938,2169.7369175938,"Control"
"2020.08.26.Control4003.c1.TCTGCCAGTCGTATTG","healthy-4003","2020-08-26-Control4003-c1:TCTGCCAGTCGTATTG",-0.821744362742263,8.93251130664674,"2020-08-26-Control4003-c1","Control4003","CD4+ T","CD4+ TCM",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.TCTGCCAGTCGTATTG","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1792.83895570827,34.7884497973914,0.0194041130613698,849,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1780.09136572897,1780.09136572897,"Control"
"2020.08.26.Control4003.c1.TGCAGGCGTAAGTAGT","healthy-4003","2020-08-26-Control4003-c1:TGCAGGCGTAAGTAGT",-5.3691066307133,3.80293438518373,"2020-08-26-Control4003-c1","Control4003","MEP","MEP",39,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.TGCAGGCGTAAGTAGT","MEP","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2242.66603298931,33.4413848299051,0.0149114421576761,1877,30000,1100,500,"True","True","True","True",5,135,"True","HSPC_healthy-4003",2233.78411328375,2233.78411328375,"Control"
"2020.08.26.Control4003.c1.TTCCAATAGGCTTCCG","healthy-4003","2020-08-26-Control4003-c1:TTCCAATAGGCTTCCG",-6.95802436295207,3.37537095630494,"2020-08-26-Control4003-c1","Control4003","HSC","HSC",65,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.TTCCAATAGGCTTCCG","HSC","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2098.92533742255,29.9192014514808,0.0142545334595947,1124,30000,1100,500,"True","True","True","True",5,135,"True","HSPC_healthy-4003",2083.02604777045,2083.02604777045,"Control"
"2020.08.26.Control4003.c1.TTTGATCAGAGGTGCT","healthy-4003","2020-08-26-Control4003-c1:TTTGATCAGAGGTGCT",0.032806052907747,8.51205918872682,"2020-08-26-Control4003-c1","Control4003","CD4+ T","CD4+ Naive",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613774","2020-08-26","2020.08.26.Control4003.c1.TTTGATCAGAGGTGCT","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1771.37247358783,24.950718379003,0.014085529018336,810,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1761.96883001861,1761.96883001861,"Control"
"2020.08.26.Control4003.c2.AAGACTCAGCGACCCT","healthy-4003","2020-08-26-Control4003-c2:AAGACTCAGCGACCCT",2.94794382628743,-5.1258206597534,"2020-08-26-Control4003-c2","Control4003","cDC2","cDC2",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.AAGACTCAGCGACCCT","cDC2","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2557.44555888224,29.4635452284409,0.0115206930314162,1943,30000,1100,500,"True","True","True","True",5,351,"True","DC_healthy-4003",2551.39664337872,2551.39664337872,"Control"
"2020.08.26.Control4003.c2.GCACATACATGACAGG","healthy-4003","2020-08-26-Control4003-c2:GCACATACATGACAGG",-4.59830365601237,2.93044183338014,"2020-08-26-Control4003-c2","Control4003","MEP","MEP",39,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613775","2020-08-26","2020.08.26.Control4003.c2.GCACATACATGACAGG","MEP","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2657.96763030637,28.581506897417,0.0107531433308398,2817,30000,1100,500,"True","True","True","True",5,135,"True","HSPC_healthy-4003",2650.03781311824,2650.03781311824,"Control"
"2020.08.26.Control4003.c3.CGGGCATAGCTGTACT","healthy-4003","2020-08-26-Control4003-c3:CGGGCATAGCTGTACT",4.82591118392293,-8.29573728954466,"2020-08-26-Control4003-c3","Control4003","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.CGGGCATAGCTGTACT","HLA-II+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2811.7914195643,33.6268322778853,0.0119592200345699,2270,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2802.91565574367,2802.91565574367,"Control"
"2020.08.26.Control4003.c3.CGTCCATGTACCGCGT","healthy-4003","2020-08-26-Control4003-c3:CGTCCATGTACCGCGT",-3.987776140601,12.8426379927429,"2020-08-26-Control4003-c3","Control4003","NK","Activated NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.CGTCCATGTACCGCGT","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2120.714012836,28.0240932920427,0.0132144613193584,1041,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",2119.06076762844,2119.06076762844,"Control"
"2020.08.26.Control4003.c3.CTCAGTCTCTGGCTGG","healthy-4003","2020-08-26-Control4003-c3:CTCAGTCTCTGGCTGG",5.24557747420613,-10.2406549683777,"2020-08-26-Control4003-c3","Control4003","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.CTCAGTCTCTGGCTGG","CD16+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1956.70238715398,26.3361300855798,0.0134594459834465,899,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",1956.70238715398,1956.70238715398,"Control"
"2020.08.26.Control4003.c3.CTGGCAGGTTCGTACA","healthy-4003","2020-08-26-Control4003-c3:CTGGCAGGTTCGTACA",2.62789787825887,-6.17865993892821,"2020-08-26-Control4003-c3","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.CTGGCAGGTTCGTACA","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2040.15047348975,19.7257022194619,0.0096687486907376,1140,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2031.40085743243,2031.40085743243,"Control"
"2020.08.26.Control4003.c3.CTTACCGGTCCTACAA","healthy-4003","2020-08-26-Control4003-c3:CTTACCGGTCCTACAA",-0.005105405033189,8.45754525745241,"2020-08-26-Control4003-c3","Control4003","CD4+ T","CD4+ Naive",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.CTTACCGGTCCTACAA","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1860.18847381846,1.83863074047362,0.0009884109950963,1007,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1849.82219003868,1849.82219003868,"Control"
"2020.08.26.Control4003.c3.GAAGGGTTCCCATTCG","healthy-4003","2020-08-26-Control4003-c3:GAAGGGTTCCCATTCG",10.0294166999752,5.58052060687868,"2020-08-26-Control4003-c3","Control4003","B","Naive B",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GAAGGGTTCCCATTCG","B","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1503.58427201469,38.976222083477,0.0259222065626237,578,30000,1100,500,"True","True","True","True",5,365,"True","B_healthy-4003",1494.15985775435,1494.15985775435,"Control"
"2020.08.26.Control4003.c3.GACCCTTTCCATCCGT","healthy-4003","2020-08-26-Control4003-c3:GACCCTTTCCATCCGT",2.65077795562093,-4.34773256694945,"2020-08-26-Control4003-c3","Control4003","cDC2","cDC2",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GACCCTTTCCATCCGT","cDC2","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2291.00633314582,13.9387047822779,0.0060840970103903,1622,30000,1100,500,"True","True","True","True",5,351,"True","DC_healthy-4003",2286.85264881565,2286.85264881565,"Control"
"2020.08.26.Control4003.c3.GACGCTGTCTCTGAGA","healthy-4003","2020-08-26-Control4003-c3:GACGCTGTCTCTGAGA",4.87509407576863,-8.54945757305297,"2020-08-26-Control4003-c3","Control4003","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GACGCTGTCTCTGAGA","HLA-II+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2030.25706811477,41.6211636146856,0.0205004401995919,1097,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2027.26200480497,2027.26200480497,"Control"
"2020.08.26.Control4003.c3.GACTTCCAGCCAAGGT","healthy-4003","2020-08-26-Control4003-c3:GACTTCCAGCCAAGGT",6.81010498580281,-1.58693470871123,"2020-08-26-Control4003-c3","Control4003","pDC","pDC",32,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GACTTCCAGCCAAGGT","pDC","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","pDC",2833.94123618461,41.4197151024658,0.0146155871454236,2073,30000,1100,500,"True","True","True","True",5,351,"True","DC_healthy-4003",2820.09257570403,2820.09257570403,"Control"
"2020.08.26.Control4003.c3.GACTTCCCACGTAACT","healthy-4003","2020-08-26-Control4003-c3:GACTTCCCACGTAACT",4.17311014708821,-7.14282514965209,"2020-08-26-Control4003-c3","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GACTTCCCACGTAACT","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2270.1307123267,27.403502013613,0.0120713322210097,1227,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2265.49782063759,2265.49782063759,"Control"
"2020.08.26.Control4003.c3.GATTCGACAGAACGCA","healthy-4003","2020-08-26-Control4003-c3:GATTCGACAGAACGCA",9.80349411544148,6.01119563663331,"2020-08-26-Control4003-c3","Control4003","B","Naive B",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GATTCGACAGAACGCA","B","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1370.09379810466,33.9905482351786,0.0248089205879189,509,30000,1100,500,"True","True","True","True",5,365,"True","B_healthy-4003",1370.09379810466,1370.09379810466,"Control"
"2020.08.26.Control4003.c3.GCATCGGTCAGTCACA","healthy-4003","2020-08-26-Control4003-c3:GCATCGGTCAGTCACA",5.44779266890828,-9.76444246685179,"2020-08-26-Control4003-c3","Control4003","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GCATCGGTCAGTCACA","CD16+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2417.96442691199,37.7766785623217,0.0156233392608537,1420,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2412.42688798315,2412.42688798315,"Control"
"2020.08.26.Control4003.c3.GCGGAAACATGCTGCG","healthy-4003","2020-08-26-Control4003-c3:GCGGAAACATGCTGCG",4.23434652861897,-7.36281492626341,"2020-08-26-Control4003-c3","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GCGGAAACATGCTGCG","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2031.94635477838,31.7089829634821,0.0156052264317483,973,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2024.88562470246,2024.88562470246,"Control"
"2020.08.26.Control4003.c3.GCGTTTCTCTTCCCGA","healthy-4003","2020-08-26-Control4003-c3:GCGTTTCTCTTCCCGA",-2.06197653237041,9.59869000995485,"2020-08-26-Control4003-c3","Control4003","MAIT","MAIT",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GCGTTTCTCTTCCCGA","MAIT","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","MAIT",1719.2515780406,18.136502289831,0.0105490682815024,734,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1715.19365195998,1715.19365195998,"Control"
"2020.08.26.Control4003.c3.GCTTGGGTCACCTCGT","healthy-4003","2020-08-26-Control4003-c3:GCTTGGGTCACCTCGT",4.26709522780721,-8.1838703385559,"2020-08-26-Control4003-c3","Control4003","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GCTTGGGTCACCTCGT","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1810.04924521706,0,0,832,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",1810.04924521706,1810.04924521706,"Control"
"2020.08.26.Control4003.c3.GGGTAGAAGTTCTCTT","healthy-4003","2020-08-26-Control4003-c3:GGGTAGAAGTTCTCTT",-4.35718951645549,12.9595746763977,"2020-08-26-Control4003-c3","Control4003","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GGGTAGAAGTTCTCTT","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",2046.16552231616,33.8916992549102,0.0165635178998356,915,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",2044.15002327527,2044.15002327527,"Control"
"2020.08.26.Control4003.c3.GTACAACAGGGCAGTT","healthy-4003","2020-08-26-Control4003-c3:GTACAACAGGGCAGTT",-0.436807433993179,8.25713250720827,"2020-08-26-Control4003-c3","Control4003","CD4+ T","CD4+ Naive",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GTACAACAGGGCAGTT","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1799.38153185816,1.11294237957043,0.000618513839264,986,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1793.42721587721,1793.42721587721,"Control"
"2020.08.26.Control4003.c3.GTACAGTCAGGTTACT","healthy-4003","2020-08-26-Control4003-c3:GTACAGTCAGGTTACT",-0.531754176050979,8.77389524066774,"2020-08-26-Control4003-c3","Control4003","CD4+ T","CD4+ Naive",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GTACAGTCAGGTTACT","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1946.61085281531,33.0045292674479,0.0169548675944731,1062,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1939.01028882052,1939.01028882052,"Control"
"2020.08.26.Control4003.c3.GTGTGATAGGCTAGCA","healthy-4003","2020-08-26-Control4003-c3:GTGTGATAGGCTAGCA",4.96533741530721,-8.6217193833557,"2020-08-26-Control4003-c3","Control4003","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GTGTGATAGGCTAGCA","HLA-II+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2359.15269004679,5.39577324683589,0.0022871657564177,1249,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2357.59366836334,2357.59366836334,"Control"
"2020.08.26.Control4003.c3.GTTCTATGTAATGTGA","healthy-4003","2020-08-26-Control4003-c3:GTTCTATGTAATGTGA",6.76882566985433,-1.62453141128691,"2020-08-26-Control4003-c3","Control4003","pDC","pDC",32,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.GTTCTATGTAATGTGA","pDC","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","pDC",2509.45608049802,27.5330289256472,0.0109717118142124,1450,30000,1100,500,"True","True","True","True",5,351,"True","DC_healthy-4003",2497.97895910134,2497.97895910134,"Control"
"2020.08.26.Control4003.c3.TAGGGTTCATAGAGGC","healthy-4003","2020-08-26-Control4003-c3:TAGGGTTCATAGAGGC",1.86084916171376,-6.81079962169798,"2020-08-26-Control4003-c3","Control4003","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.TAGGGTTCATAGAGGC","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1900.4535672148,36.6723274283798,0.0192966184815158,1044,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",1894.55418497492,1894.55418497492,"Control"
"2020.08.26.Control4003.c3.TAGGTACCACGACAAG","healthy-4003","2020-08-26-Control4003-c3:TAGGTACCACGACAAG",4.66746820983235,-8.69463255321654,"2020-08-26-Control4003-c3","Control4003","CD14+ monocyte","CD14+ IFN+",21,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.TAGGTACCACGACAAG","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1912.8078790958,18.9280053279497,0.0098954032628185,922,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",1911.08938515815,1911.08938515815,"Control"
"2020.08.26.Control4003.c3.TAGGTACCACGTCGTG","healthy-4003","2020-08-26-Control4003-c3:TAGGTACCACGTCGTG",3.85261454161946,-7.15724041378173,"2020-08-26-Control4003-c3","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.TAGGTACCACGTCGTG","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1689.02216629192,1.44923918583319,0.0008580344383607,725,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",1689.02216629192,1689.02216629192,"Control"
"2020.08.26.Control4003.c3.TCGTAGAAGTCGGGAT","healthy-4003","2020-08-26-Control4003-c3:TCGTAGAAGTCGGGAT",-3.64805159989055,12.55565831745,"2020-08-26-Control4003-c3","Control4003","NK","CD56bright NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.TCGTAGAAGTCGGGAT","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1615.43084871338,31.6093644015974,0.0195671417484523,622,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",1610.70373938779,1610.70373938779,"Control"
"2020.08.26.Control4003.c3.TCTCCGATCCACAGGC","healthy-4003","2020-08-26-Control4003-c3:TCTCCGATCCACAGGC",-4.17119203034099,12.7905587919983,"2020-08-26-Control4003-c3","Control4003","NK","CD56bright NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.TCTCCGATCCACAGGC","NK","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1842.79231974312,32.3482674127895,0.0175539408680077,829,30000,1100,500,"True","True","True","True",5,645,"True","NK_healthy-4003",1842.79231974312,1842.79231974312,"Control"
"2020.08.26.Control4003.c3.TCTGGCTTCATTACTC","healthy-4003","2020-08-26-Control4003-c3:TCTGGCTTCATTACTC",5.14149584349934,-8.8561697236267,"2020-08-26-Control4003-c3","Control4003","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.TCTGGCTTCATTACTC","HLA-II+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2328.47339635843,7.63468872607439,0.0032788387181122,1256,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2325.40843603495,2325.40843603495,"Control"
"2020.08.26.Control4003.c3.TCTTAGTCACTATCCC","healthy-4003","2020-08-26-Control4003-c3:TCTTAGTCACTATCCC",3.97322096404378,-6.97990705883177,"2020-08-26-Control4003-c3","Control4003","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.TCTTAGTCACTATCCC","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2407.26049784967,18.6594390054932,0.0077513169107211,1592,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2404.96502564988,2404.96502564988,"Control"
"2020.08.26.Control4003.c3.TGAACGTCAACCAGAG","healthy-4003","2020-08-26-Control4003-c3:TGAACGTCAACCAGAG",-0.954663614661056,8.56379220569459,"2020-08-26-Control4003-c3","Control4003","CD4+ T","CD4+ TCM",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.TGAACGTCAACCAGAG","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1704.22154052475,31.7946681748694,0.0186564172666656,771,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1704.22154052475,1704.22154052475,"Control"
"2020.08.26.Control4003.c3.TGAGCGCCAGTTCCAA","healthy-4003","2020-08-26-Control4003-c3:TGAGCGCCAGTTCCAA",-3.71220455589946,10.4394826658997,"2020-08-26-Control4003-c3","Control4003","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.TGAGCGCCAGTTCCAA","CD8+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1930.42218940452,38.668930563623,0.0200313334439816,853,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1918.21800580833,1918.21800580833,"Control"
"2020.08.26.Control4003.c3.TGGATCAAGTAGGCCA","healthy-4003","2020-08-26-Control4003-c3:TGGATCAAGTAGGCCA",4.97150530394856,-8.37992098247679,"2020-08-26-Control4003-c3","Control4003","CD14+ monocyte","CD14+ IFN+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.TGGATCAAGTAGGCCA","CD14+ monocyte","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2207.88177587222,28.4855125271061,0.0129017381448574,1296,30000,1100,500,"True","True","True","True",5,2986,"True","Mono_healthy-4003",2205.25068085632,2205.25068085632,"Control"
"2020.08.26.Control4003.c3.TTCAATCTCATCTCTA","healthy-4003","2020-08-26-Control4003-c3:TTCAATCTCATCTCTA",-1.09454057636912,8.8434734114441,"2020-08-26-Control4003-c3","Control4003","CD4+ T","CD4+ TCM",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.TTCAATCTCATCTCTA","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2444.39720356067,29.0193648168707,0.0118717877661614,1518,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",2436.44092476772,2436.44092476772,"Control"
"2020.08.26.Control4003.c3.TTTACCAGTTGCTCCT","healthy-4003","2020-08-26-Control4003-c3:TTTACCAGTTGCTCCT",-2.4271002811497,9.24252603137819,"2020-08-26-Control4003-c3","Control4003","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.TTTACCAGTTGCTCCT","CD8+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",2060.99701130182,33.0570812153148,0.0160393639748339,985,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",2055.91831903134,2055.91831903134,"Control"
"2020.08.26.Control4003.c3.TTTGACTGTAGCGAGT","healthy-4003","2020-08-26-Control4003-c3:TTTGACTGTAGCGAGT",0.478658665984315,8.83704278552858,"2020-08-26-Control4003-c3","Control4003","CD4+ T","CD4+ Naive",18,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613776","2020-08-26","2020.08.26.Control4003.c3.TTTGACTGTAGCGAGT","CD4+ T","4003","M",42,"CITE-Seq + scTCR-seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1721.1751963095,0,0,844,30000,1100,500,"True","True","True","True",5,2108,"True","T_healthy-4003",1719.45965330188,1719.45965330188,"Control"
"2019.08.29.count.1.AGCTACACAGAAGTTA","healthy-5","2019-08-29-count-1:AGCTACACAGAAGTTA",-5.65112338486369,-5.55309441005858,"2019-08-29-count-1","Control5","Granulocyte","Granulocytes (cycling)",38,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.AGCTACACAGAAGTTA","Granulocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2282.96864733245,52.3967384871856,0.0229511423857743,1202,30000,1100,500,"True","True","True","True",5,254,"True","Gran_healthy-5",2276.40145574439,2276.40145574439,"Control"
"2019.08.29.count.1.GAGGGATTCGAAGCCC","healthy-5","2019-08-29-count-1:GAGGGATTCGAAGCCC",3.568291802972,-7.72805550014647,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GAGGGATTCGAAGCCC","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1821.4483597027,49.6483197137918,0.0272576048886149,780,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1815.03114641215,1815.03114641215,"Control"
"2019.08.29.count.1.GCATTAGGTTAGGACG","healthy-5","2019-08-29-count-1:GCATTAGGTTAGGACG",-2.992823223502,10.6089963682922,"2019-08-29-count-1","Control5","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GCATTAGGTTAGGACG","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1467.35465670307,31.4755263002623,0.0214505240137263,551,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1467.35465670307,1467.35465670307,"Control"
"2019.08.29.count.1.GCATCTCCAGCTCGGT","healthy-5","2019-08-29-count-1:GCATCTCCAGCTCGGT",3.64207615432088,-7.23135664379271,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",29,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GCATCTCCAGCTCGGT","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2362.02849813667,42.0840532800425,0.0178169117405828,1261,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2350.73686058538,2350.73686058538,"Control"
"2019.08.29.count.1.ACGGAAGTCCCATAAG","healthy-5","2019-08-29-count-1:ACGGAAGTCCCATAAG",-3.34643087807353,10.9341115721497,"2019-08-29-count-1","Control5","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.ACGGAAGTCCCATAAG","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1696.10933156678,35.1434007565278,0.0207200090834144,691,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1687.33645126538,1687.33645126538,"Control"
"2019.08.29.count.1.GGAGAACTCGTCCTCA","healthy-5","2019-08-29-count-1:GGAGAACTCGTCCTCA",-3.00222359123881,10.1378755339417,"2019-08-29-count-1","Control5","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GGAGAACTCGTCCTCA","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1589.247047222,37.2590729137876,0.0234444814473095,610,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1584.49908937385,1584.49908937385,"Control"
"2019.08.29.count.1.ATTCTTGCAGGAGACT","healthy-5","2019-08-29-count-1:ATTCTTGCAGGAGACT",-3.99947534027751,-5.36837580120238,"2019-08-29-count-1","Control5","Granulocyte","Granulocytes (cycling)",63,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.ATTCTTGCAGGAGACT","Granulocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2235.926696936,47.6726800494392,0.0213212177817669,1121,30000,1100,500,"True","True","True","True",5,254,"True","Gran_healthy-5",2235.926696936,2235.926696936,"Control"
"2019.08.29.count.1.AAGACTCCATCCTATT","healthy-5","2019-08-29-count-1:AAGACTCCATCCTATT",-7.61768994751628,0.908674753549971,"2019-08-29-count-1","Control5","MPP","MPP_GMP",42,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.AAGACTCCATCCTATT","MPP","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",2772.5058382532,45.8276223707935,0.0165293150111694,2482,30000,1100,500,"True","True","True","True",5,113,"True","HSPC_healthy-5",2765.22483730174,2765.22483730174,"Control"
"2019.08.29.count.1.CAGTTAGCAAATGGCG","healthy-5","2019-08-29-count-1:CAGTTAGCAAATGGCG",3.18149509009663,-6.75022938167723,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.CAGTTAGCAAATGGCG","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1546.51930557207,50.19889429679,0.032459274265717,595,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1541.7857344894,1541.7857344894,"Control"
"2019.08.29.count.2.ATCCGTCTCAGTAGGG","healthy-5","2019-08-29-count-2:ATCCGTCTCAGTAGGG",-2.70815740051921,9.90879151904909,"2019-08-29-count-2","Control5","CD8+ T","CD8+ GZMK+",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.ATCCGTCTCAGTAGGG","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1500.74438437376,43.9641122736315,0.0292948704199064,570,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1493.48558389525,1493.48558389525,"Control"
"2019.08.29.count.1.ACCAAACAGTGCTCAT","healthy-5","2019-08-29-count-1:ACCAAACAGTGCTCAT",-1.27154550972636,9.93762300098268,"2019-08-29-count-1","Control5","CD4+ T","CD4+ Naive",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.ACCAAACAGTGCTCAT","CD4+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",2051.66238237823,38.4218205072395,0.0187271652671732,1089,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",2046.79745748542,2046.79745748542,"Control"
"2019.08.29.count.1.GTCAAACCAGAGCGTA","healthy-5","2019-08-29-count-1:GTCAAACCAGAGCGTA",-2.52150664749797,12.1037740477356,"2019-08-29-count-1","Control5","NK","CD56dim NK",6,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GTCAAACCAGAGCGTA","NK","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1417.16601975088,45.2971491269323,0.0319631916766499,527,30000,1100,500,"True","True","True","True",5,344,"True","NK_healthy-5",1412.34296379137,1412.34296379137,"Control"
"2019.08.29.count.1.GTCACGGAGGCGTTGA","healthy-5","2019-08-29-count-1:GTCACGGAGGCGTTGA",3.37695922431294,-7.84571220791014,"2019-08-29-count-1","Control5","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GTCACGGAGGCGTTGA","HLA-II+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1690.38097392157,43.514571338509,0.0257424639828725,672,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1690.38097392157,1690.38097392157,"Control"
"2019.08.29.count.1.AGATCGTAGTCTTGGT","healthy-5","2019-08-29-count-1:AGATCGTAGTCTTGGT",-2.36133132401164,9.8770599135193,"2019-08-29-count-1","Control5","CD8+ T","CD8+ GZMK+",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.AGATCGTAGTCTTGGT","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1414.02663036283,43.6681024933489,0.0308820934172534,520,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1404.29277664318,1404.29277664318,"Control"
"2019.08.29.count.1.CGTCCATAGAAAGCGA","healthy-5","2019-08-29-count-1:CGTCCATAGAAAGCGA",3.84424175795857,-7.91649439251097,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+ IFN+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.CGTCCATAGAAAGCGA","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2090.80498215274,39.4667137493045,0.0188763247104322,1001,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2081.79417188132,2081.79417188132,"Control"
"2019.08.29.count.1.CCTCTAGAGTGTAGAT","healthy-5","2019-08-29-count-1:CCTCTAGAGTGTAGAT",3.13312115248982,-5.36351540004881,"2019-08-29-count-1","Control5","cDC2","cDC2",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.CCTCTAGAGTGTAGAT","cDC2","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","cDC",2360.3282055414,42.6756387587782,0.018080383337617,1405,30000,1100,500,"True","True","True","True",5,212,"True","DC_healthy-5",2356.27164889297,2356.27164889297,"Control"
"2019.08.29.count.1.CCTGTTGCATCTAGAC","healthy-5","2019-08-29-count-1:CCTGTTGCATCTAGAC",1.81106831607167,-7.4586653939453,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.CCTGTTGCATCTAGAC","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1738.1215227773,43.189577358219,0.0248484221570466,724,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1738.1215227773,1738.1215227773,"Control"
"2019.08.29.count.2.CTGAGGCCAGCTACCG","healthy-5","2019-08-29-count-2:CTGAGGCCAGCTACCG",-3.61432753029521,12.6047782667908,"2019-08-29-count-2","Control5","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.CTGAGGCCAGCTACCG","NK","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1612.42528993574,48.3612873444805,0.029992885652648,634,30000,1100,500,"True","True","True","True",5,344,"True","NK_healthy-5",1610.15029354601,1610.15029354601,"Control"
"2019.08.29.count.1.TATTTCGGTTCGGTAT","healthy-5","2019-08-29-count-1:TATTTCGGTTCGGTAT",2.97901763495747,-7.85922291195067,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TATTTCGGTTCGGTAT","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1583.9997803262,50.5810846906799,0.0319325073897823,628,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1581.79002192281,1581.79002192281,"Control"
"2019.08.29.count.2.CTACATTCAAACCACT","healthy-5","2019-08-29-count-2:CTACATTCAAACCACT",2.92459287223164,-7.385937713739,"2019-08-29-count-2","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.CTACATTCAAACCACT","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1986.46274655911,44.8865255365233,0.0225962080659576,918,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1982.66673026965,1982.66673026965,"Control"
"2019.08.29.count.2.TCTATACTCTTGGTCC","healthy-5","2019-08-29-count-2:TCTATACTCTTGGTCC",-2.46029458466228,12.5359382399353,"2019-08-29-count-2","Control5","NK","CD56dim NK",6,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TCTATACTCTTGGTCC","NK","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1621.12081650172,34.502928899275,0.0212833790967722,599,30000,1100,500,"True","True","True","True",5,344,"True","NK_healthy-5",1613.39763482281,1613.39763482281,"Control"
"2019.08.29.count.1.GTTATGGAGGAACGTC","healthy-5","2019-08-29-count-1:GTTATGGAGGAACGTC",-0.899479309946853,9.36089322650758,"2019-08-29-count-1","Control5","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GTTATGGAGGAACGTC","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1430.02626654388,40.6721193693579,0.0284415190971669,526,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1427.57870140941,1427.57870140941,"Control"
"2019.08.29.count.2.CTGTGAAAGTTTCGGT","healthy-5","2019-08-29-count-2:CTGTGAAAGTTTCGGT",3.84616341170613,-8.61643316661986,"2019-08-29-count-2","Control5","CD11c+","CD11c+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.CTGTGAAAGTTTCGGT","CD11c+","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1757.90653813596,39.7245749707631,0.0225976604039973,709,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1753.47312751947,1753.47312751947,"Control"
"2019.08.29.count.2.TCCTAATTCAACACGT","healthy-5","2019-08-29-count-2:TCCTAATTCAACACGT",3.34007062491719,-7.62672474300536,"2019-08-29-count-2","Control5","CD14+ monocyte","CD14+ IFN+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TCCTAATTCAACACGT","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1750.72857547053,44.8351585771736,0.0256094286717881,705,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1744.02884368564,1744.02884368564,"Control"
"2019.08.29.count.1.AGGCATTAGCTGACTT","healthy-5","2019-08-29-count-1:AGGCATTAGCTGACTT",-2.23948488655742,9.60404775226442,"2019-08-29-count-1","Control5","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.AGGCATTAGCTGACTT","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1409.59777213296,32.6162521328019,0.0231386944400799,511,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1399.4140796895,1399.4140796895,"Control"
"2019.08.29.count.1.CAACGGCCAAGTACCT","healthy-5","2019-08-29-count-1:CAACGGCCAAGTACCT",-3.79741082611735,-7.19512369548949,"2019-08-29-count-1","Control5","Granulocyte","Granulocytes",40,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.CAACGGCCAAGTACCT","Granulocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2305.07319823456,53.3823102494047,0.0231586182557195,1193,30000,1100,500,"True","True","True","True",5,254,"True","Gran_healthy-5",2301.74877367396,2301.74877367396,"Control"
"2019.08.29.count.2.CATCCCATCCACTAGA","healthy-5","2019-08-29-count-2:CATCCCATCCACTAGA",3.96195354041402,-7.86871292507323,"2019-08-29-count-2","Control5","CD11c+","CD11c+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.CATCCCATCCACTAGA","CD11c+","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2222.7830928642,45.2376066169171,0.0203517863538477,1136,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2221.26269459881,2221.26269459881,"Control"
"2019.08.29.count.2.CTCAATTGTTGTGCCG","healthy-5","2019-08-29-count-2:CTCAATTGTTGTGCCG",6.85914816436116,-1.37271752273711,"2019-08-29-count-2","Control5","pDC","pDC",32,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.CTCAATTGTTGTGCCG","pDC","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","pDC",2156.61604431776,36.416640618354,0.0168860102447556,1053,30000,1100,500,"True","True","True","True",5,212,"True","DC_healthy-5",2156.61604431776,2156.61604431776,"Control"
"2019.08.29.count.1.ATCGGATGTCTTTCAT","healthy-5","2019-08-29-count-1:ATCGGATGTCTTTCAT",4.66225161132161,-8.19022085582884,"2019-08-29-count-1","Control5","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.ATCGGATGTCTTTCAT","HLA-II+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2328.94284814895,40.2157842556425,0.0172678278849162,1327,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2324.64372809038,2324.64372809038,"Control"
"2019.08.29.count.1.GTGCTTCTCTCCCAAC","healthy-5","2019-08-29-count-1:GTGCTTCTCTCCCAAC",-5.60056529465373,-5.46486236965331,"2019-08-29-count-1","Control5","Granulocyte","Granulocytes (cycling)",38,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GTGCTTCTCTCCCAAC","Granulocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2195.38131404112,47.1549294594754,0.0214791522355976,1048,30000,1100,500,"True","True","True","True",5,254,"True","Gran_healthy-5",2191.68009339765,2191.68009339765,"Control"
"2019.08.29.count.2.TTCTTCCGTTACGATC","healthy-5","2019-08-29-count-2:TTCTTCCGTTACGATC",14.4257208305294,2.07140491092531,"2019-08-29-count-2","Control5","Plasmablast","Plasmablast",69,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TTCTTCCGTTACGATC","Plasmablast","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","Plasma",1484.69091499794,31.3289107546943,0.0211013015828535,1326,30000,1100,500,"True","True","True","True",5,313,"True","B_healthy-5",1469.49627958198,1469.49627958198,"Control"
"2019.08.29.count.2.ATCGTAGGTCATATGC","healthy-5","2019-08-29-count-2:ATCGTAGGTCATATGC",3.34777249869649,-7.42912485515746,"2019-08-29-count-2","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.ATCGTAGGTCATATGC","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1656.22379565162,38.964973502752,0.0235263939601966,648,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1649.32183694416,1649.32183694416,"Control"
"2019.08.29.count.2.TTGGGTACATCGCCTT","healthy-5","2019-08-29-count-2:TTGGGTACATCGCCTT",-3.42910514298137,-5.56594231044921,"2019-08-29-count-2","Control5","Granulocyte","Granulocytes",63,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TTGGGTACATCGCCTT","Granulocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Gran","Gran",2283.00774702066,47.1862232393437,0.0206684463952967,1251,30000,1100,500,"True","True","True","True",5,254,"True","Gran_healthy-5",2277.13684289277,2277.13684289277,"Control"
"2019.08.29.count.1.CTGGCAGCACCGAATT","healthy-5","2019-08-29-count-1:CTGGCAGCACCGAATT",2.85521044310872,-7.45371248638304,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.CTGGCAGCACCGAATT","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1556.26017324891,45.7228621662978,0.0293799603384085,612,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1554.0009820616,1554.0009820616,"Control"
"2019.08.29.count.1.CTGTAGAGTCTACACA","healthy-5","2019-08-29-count-1:CTGTAGAGTCTACACA",-3.08489189568217,10.7981796034607,"2019-08-29-count-1","Control5","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.CTGTAGAGTCTACACA","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1633.50862346411,33.6052551978098,0.0205724381953641,633,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1631.15763110517,1631.15763110517,"Control"
"2019.08.29.count.2.CATCGTCCAACATACC","healthy-5","2019-08-29-count-2:CATCGTCCAACATACC",3.98568429526631,-8.21525862133177,"2019-08-29-count-2","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.CATCGTCCAACATACC","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1900.55312942282,45.838066952761,0.0241182770653097,846,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1894.66248691429,1894.66248691429,"Control"
"2019.08.29.count.2.TGAACGTTCACCTTAT","healthy-5","2019-08-29-count-2:TGAACGTTCACCTTAT",-3.0530038875645,3.74593088710634,"2019-08-29-count-2","Control5","Ery","Ery-1",53,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TGAACGTTCACCTTAT","Ery","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Ery","Ery",3081.61967899874,46.5365083181968,0.0151013146220941,3027,30000,1100,500,"True","True","True","True",5,241,"True","Ery_healthy-5",3076.15866713507,3076.15866713507,"Control"
"2019.08.29.count.1.TCGCAGGTCCGAGATT","healthy-5","2019-08-29-count-1:TCGCAGGTCCGAGATT",3.16145481643025,-8.12271597301634,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TCGCAGGTCCGAGATT","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1766.88791119536,41.9965815345123,0.0237686733088236,732,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1762.5599305565,1762.5599305565,"Control"
"2019.08.29.count.1.TCGGGCAAGTGTAGTA","healthy-5","2019-08-29-count-1:TCGGGCAAGTGTAGTA",3.24228324469869,-7.69126369869383,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TCGGGCAAGTGTAGTA","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1610.40980885259,42.2949809670562,0.0262634894140338,618,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1608.02589423232,1608.02589423232,"Control"
"2019.08.29.count.2.TAGACTGCACCCTGAG","healthy-5","2019-08-29-count-2:TAGACTGCACCCTGAG",3.71689881858174,-8.01640703594359,"2019-08-29-count-2","Control5","CD11c+","CD11c+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TAGACTGCACCCTGAG","CD11c+","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1957.07641917611,40.6422969551758,0.0207668420900424,890,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1957.07641917611,1957.07641917611,"Control"
"2019.08.29.count.2.ACTGCAACAAGTATCC","healthy-5","2019-08-29-count-2:ACTGCAACAAGTATCC",-1.49316749993022,9.30193040454713,"2019-08-29-count-2","Control5","CD8+ T","CD8+ TRM",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.ACTGCAACAAGTATCC","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1477.68439129245,47.9816603427478,0.032470844671223,572,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1475.36723891317,1475.36723891317,"Control"
"2019.08.29.count.2.TTGATGGCACACCGAC","healthy-5","2019-08-29-count-2:TTGATGGCACACCGAC",10.9385620551998,5.74966952884523,"2019-08-29-count-2","Control5","Pre-B","Pre-B",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TTGATGGCACACCGAC","Pre-B","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1900.16506755197,47.9545583404267,0.0252370486960945,903,30000,1100,500,"True","True","True","True",5,313,"True","B_healthy-5",1894.75402781887,1894.75402781887,"Control"
"2019.08.29.count.2.TATATCCGTAGTTACC","healthy-5","2019-08-29-count-2:TATATCCGTAGTTACC",0.783689876168412,9.33091924274293,"2019-08-29-count-2","Control5","CD4+ T","CD4+ TCM",4,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TATATCCGTAGTTACC","CD4+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1370.62045264992,45.7695525288633,0.033393309169124,503,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1370.62045264992,1370.62045264992,"Control"
"2019.08.29.count.1.TCTTAGTTCCAGCACG","healthy-5","2019-08-29-count-1:TCTTAGTTCCAGCACG",2.20321478423421,-6.96217777645262,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TCTTAGTTCCAGCACG","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1950.63118237693,50.0822169923612,0.0256748776728432,901,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1950.63118237693,1950.63118237693,"Control"
"2019.08.29.count.1.AGCGCCATCTCCACTG","healthy-5","2019-08-29-count-1:AGCGCCATCTCCACTG",3.64905347403828,-8.15575125133666,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.AGCGCCATCTCCACTG","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1693.88792288524,40.0631104590942,0.0236515709911042,676,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1691.62956672311,1691.62956672311,"Control"
"2019.08.29.count.1.TGAGCGCGTTCCTTGC","healthy-5","2019-08-29-count-1:TGAGCGCGTTCCTTGC",5.27737917479817,-9.35284140026244,"2019-08-29-count-1","Control5","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TGAGCGCGTTCCTTGC","CD16+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2090.89266704495,43.1064955291182,0.0206163119745599,1014,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2090.89266704495,2090.89266704495,"Control"
"2019.08.29.count.2.GAGACTTAGGCTTCCG","healthy-5","2019-08-29-count-2:GAGACTTAGGCTTCCG",11.0228401618892,4.28410384738771,"2019-08-29-count-2","Control5","Pre-B","Pre-B",48,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.GAGACTTAGGCTTCCG","Pre-B","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1449.42793112947,35.8198951583619,0.0247131260472185,511,30000,1100,500,"True","True","True","True",5,313,"True","B_healthy-5",1436.13510334969,1436.13510334969,"Control"
"2019.08.29.count.2.TCACAAGTCAGTGGGA","healthy-5","2019-08-29-count-2:TCACAAGTCAGTGGGA",-3.39575252953227,10.1216916807922,"2019-08-29-count-2","Control5","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TCACAAGTCAGTGGGA","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1606.6523513247,38.5087070920418,0.0239682885101378,633,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1604.34087336366,1604.34087336366,"Control"
"2019.08.29.count.1.TGATCTTAGCTGCGAA","healthy-5","2019-08-29-count-1:TGATCTTAGCTGCGAA",2.78632130202596,-8.13382341777953,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TGATCTTAGCTGCGAA","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1475.79671264271,51.3938252658733,0.034824461137227,580,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1473.49969513331,1473.49969513331,"Control"
"2019.08.29.count.2.GTCAAGTTCGTTCCCA","healthy-5","2019-08-29-count-2:GTCAAGTTCGTTCCCA",-2.8146952194279,10.8770169981751,"2019-08-29-count-2","Control5","NK","CD56bright NK",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.GTCAAGTTCGTTCCCA","NK","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1414.38422001362,44.968590849978,0.0317937588765978,514,30000,1100,500,"True","True","True","True",5,344,"True","NK_healthy-5",1414.38422001362,1414.38422001362,"Control"
"2019.08.29.count.1.TGCGATATCTTGGAAC","healthy-5","2019-08-29-count-1:TGCGATATCTTGGAAC",-3.10608349266704,12.6060456999573,"2019-08-29-count-1","Control5","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TGCGATATCTTGGAAC","NK","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1548.25914347813,36.8702486281911,0.0238140034783601,581,30000,1100,500,"True","True","True","True",5,344,"True","NK_healthy-5",1545.80739798253,1545.80739798253,"Control"
"2019.08.29.count.2.GTGACGCTCGAGTGGA","healthy-5","2019-08-29-count-2:GTGACGCTCGAGTGGA",-2.28727970543559,12.1344442137512,"2019-08-29-count-2","Control5","NK","CD56bright NK",6,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.GTGACGCTCGAGTGGA","NK","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1573.20634316988,46.7403651042532,0.0297102572127157,601,30000,1100,500,"True","True","True","True",5,344,"True","NK_healthy-5",1570.79276812537,1570.79276812537,"Control"
"2019.08.29.count.1.TGGGAGAAGACGTCCC","healthy-5","2019-08-29-count-1:TGGGAGAAGACGTCCC",4.39407171782796,-8.02073290264281,"2019-08-29-count-1","Control5","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TGGGAGAAGACGTCCC","HLA-II+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2062.60302159645,39.1741987794208,0.0189926022454385,957,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2058.85383928829,2058.85383928829,"Control"
"2019.08.29.count.1.AATTCCTAGTTTGCTG","healthy-5","2019-08-29-count-1:AATTCCTAGTTTGCTG",4.1444374519283,-8.43166067516478,"2019-08-29-count-1","Control5","CD11c+","CD11c+",13,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.AATTCCTAGTTTGCTG","CD11c+","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2020.98022218151,48.0335033687538,0.0237674287167962,957,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2019.17305641902,2019.17305641902,"Control"
"2019.08.29.count.1.TCAGCCTGTGAAAGTT","healthy-5","2019-08-29-count-1:TCAGCCTGTGAAAGTT",-3.04749737206157,10.50447938526,"2019-08-29-count-1","Control5","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TCAGCCTGTGAAAGTT","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1611.92358443558,32.2702942047654,0.020019741950773,619,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1607.16673459039,1607.16673459039,"Control"
"2019.08.29.count.2.GTGGAGATCACGATCA","healthy-5","2019-08-29-count-2:GTGGAGATCACGATCA",2.90292634543721,-6.96492912685546,"2019-08-29-count-2","Control5","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.GTGGAGATCACGATCA","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1833.33562049899,46.7146226225263,0.0254806714603689,778,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1831.23807015491,1831.23807015491,"Control"
"2019.08.29.count.1.ATCACGAGTCTACGAT","healthy-5","2019-08-29-count-1:ATCACGAGTCTACGAT",4.99068607863728,-10.1995716325012,"2019-08-29-count-1","Control5","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.ATCACGAGTCTACGAT","CD16+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1462.01966894392,48.4984957726623,0.0331722594455208,517,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1456.76685348901,1456.76685348901,"Control"
"2019.08.29.count.1.TCATTTGGTCTCTCTG","healthy-5","2019-08-29-count-1:TCATTTGGTCTCTCTG",10.4540049034053,6.46930024707643,"2019-08-29-count-1","Control5","B","Naive B",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TCATTTGGTCTCTCTG","B","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1555.48840200317,45.8414484671797,0.0294707748435442,597,30000,1100,500,"True","True","True","True",5,313,"True","B_healthy-5",1555.48840200317,1555.48840200317,"Control"
"2019.08.29.count.1.TCCTCCCAGAGCATTA","healthy-5","2019-08-29-count-1:TCCTCCCAGAGCATTA",-0.559378544718582,9.82881352985231,"2019-08-29-count-1","Control5","CD8+ T","CD8+ GZMK+",4,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TCCTCCCAGAGCATTA","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1604.63700790033,42.4361011801935,0.0264459195265109,644,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1600.13828312418,1600.13828312418,"Control"
"2019.08.29.count.1.TTAGGGTAGTATGGCG","healthy-5","2019-08-29-count-1:TTAGGGTAGTATGGCG",-1.99490533295329,3.85148212993471,"2019-08-29-count-1","Control5","Ery","Ery-6",53,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TTAGGGTAGTATGGCG","Ery","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Ery","Ery",3028.92643161421,47.3632094542244,0.0156369626412429,3380,30000,1100,500,"True","True","True","True",5,241,"True","Ery_healthy-5",3026.79625307679,3026.79625307679,"Control"
"2019.08.29.count.2.TTGGGCGTCATGCCAA","healthy-5","2019-08-29-count-2:TTGGGCGTCATGCCAA",11.018683095544,4.63059232318727,"2019-08-29-count-2","Control5","Pre-B","Pre-B",48,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TTGGGCGTCATGCCAA","Pre-B","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1439.83883229412,46.2053904648089,0.0320906683640343,530,30000,1100,500,"True","True","True","True",5,313,"True","B_healthy-5",1430.04703689276,1430.04703689276,"Control"
"2019.08.29.count.1.GCTGAATAGAGGGTGG","healthy-5","2019-08-29-count-1:GCTGAATAGAGGGTGG",-1.03429387036021,9.10490987384645,"2019-08-29-count-1","Control5","MAIT","MAIT",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GCTGAATAGAGGGTGG","MAIT","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","MAIT",1426.79348098888,41.1945673999214,0.028872130374026,524,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1421.95025555719,1421.95025555719,"Control"
"2019.08.29.count.2.TTCATTGGTCTAACTG","healthy-5","2019-08-29-count-2:TTCATTGGTCTAACTG",3.21205653724019,-7.63031246578368,"2019-08-29-count-2","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TTCATTGGTCTAACTG","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1762.55307646371,42.9404404094768,0.0243626367812028,746,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1760.44493090162,1760.44493090162,"Control"
"2019.08.29.count.1.ATTCCTAGTAGACACG","healthy-5","2019-08-29-count-1:ATTCCTAGTAGACACG",-2.52537641945537,3.90748498523561,"2019-08-29-count-1","Control5","Ery","Heat shock proteins",53,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.ATTCCTAGTAGACACG","Ery","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Ery","Ery",3237.92793965435,46.3469963435016,0.014313782519956,4327,30000,1100,500,"True","True","True","True",5,241,"True","Ery_healthy-5",3234.34124708887,3234.34124708887,"Control"
"2019.08.29.count.1.ACTTCGCGTACCGTCG","healthy-5","2019-08-29-count-1:ACTTCGCGTACCGTCG",5.2287093597347,-10.0077667466369,"2019-08-29-count-1","Control5","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.ACTTCGCGTACCGTCG","CD16+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2217.78605995894,42.9594897674397,0.0193704390802398,1091,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2205.54906336215,2205.54906336215,"Control"
"2019.08.29.count.1.TTCTAGTTCAAGGAGC","healthy-5","2019-08-29-count-1:TTCTAGTTCAAGGAGC",3.13087453421895,-7.96596147930297,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TTCTAGTTCAAGGAGC","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1568.02290054892,47.1942588305079,0.030097939777529,595,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1565.6309251674,1565.6309251674,"Control"
"2019.08.29.count.2.CCTCCTCAGTGATTCC","healthy-5","2019-08-29-count-2:CCTCCTCAGTGATTCC",-1.49585698071178,10.4077777632507,"2019-08-29-count-2","Control5","gd T","gd T",5,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.CCTCCTCAGTGATTCC","gd T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","gd_T",1552.83115020292,39.3144600830425,0.0253179233800822,608,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1550.53182179766,1550.53182179766,"Control"
"2019.08.29.count.1.TTGAGTGCATCATTTC","healthy-5","2019-08-29-count-1:TTGAGTGCATCATTTC",-3.93539057198222,12.8570384749207,"2019-08-29-count-1","Control5","NK","CD56dim NK",26,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TTGAGTGCATCATTTC","NK","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1505.48376025819,39.8849800129249,0.0264931320189629,548,30000,1100,500,"True","True","True","True",5,344,"True","NK_healthy-5",1497.92029674165,1497.92029674165,"Control"
"2019.08.29.count.2.CCTGCATCAACTACGT","healthy-5","2019-08-29-count-2:CCTGCATCAACTACGT",6.701921125024,-1.48983802711638,"2019-08-29-count-2","Control5","pDC","pDC",32,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.CCTGCATCAACTACGT","pDC","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","pDC",2588.05173802593,39.030100782569,0.0150808811930243,1457,30000,1100,500,"True","True","True","True",5,212,"True","DC_healthy-5",2585.00821783476,2585.00821783476,"Control"
"2019.08.29.count.1.TTGCCTGGTGTCCATA","healthy-5","2019-08-29-count-1:TTGCCTGGTGTCCATA",-2.68858991089519,10.4347314604553,"2019-08-29-count-1","Control5","CD8+ T","CD8+ GZMK+",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.TTGCCTGGTGTCCATA","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1688.92534596574,37.0028656087828,0.0219091185392947,680,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1684.45113228233,1684.45113228233,"Control"
"2019.08.29.count.1.GGGTAGACAAAGGAGA","healthy-5","2019-08-29-count-1:GGGTAGACAAAGGAGA",3.04194559630696,-7.07038738643798,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GGGTAGACAAAGGAGA","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1509.32716603273,41.3559393786716,0.027400248474541,568,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1509.32716603273,1509.32716603273,"Control"
"2019.08.29.count.1.GGTAGAGGTCTGTGGC","healthy-5","2019-08-29-count-1:GGTAGAGGTCTGTGGC",3.86148156699483,-8.59048368847045,"2019-08-29-count-1","Control5","CD11c+","CD11c+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GGTAGAGGTCTGTGGC","CD11c+","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1864.92366491541,35.3293162800718,0.0189441085148513,886,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1861.45156011163,1861.45156011163,"Control"
"2019.08.29.count.2.TCAGTGACAGAATCGG","healthy-5","2019-08-29-count-2:TCAGTGACAGAATCGG",4.25986256179158,-7.97269728099974,"2019-08-29-count-2","Control5","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TCAGTGACAGAATCGG","HLA-II+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2008.81922382102,41.8486533860435,0.020832463613347,925,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2006.95371385667,2006.95371385667,"Control"
"2019.08.29.count.1.CAGGGCTCACCCTGAG","healthy-5","2019-08-29-count-1:CAGGGCTCACCCTGAG",3.80689205703084,-8.45831873333129,"2019-08-29-count-1","Control5","CD11c+","CD11c+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.CAGGGCTCACCCTGAG","CD11c+","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1914.21402706369,42.3693105729452,0.0221340508291738,810,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1901.56413286578,1901.56413286578,"Control"
"2019.08.29.count.2.TCATTCACAATGCAGG","healthy-5","2019-08-29-count-2:TCATTCACAATGCAGG",-2.60812364044841,10.2753219374451,"2019-08-29-count-2","Control5","CD8+ T","CD8+ Cytotoxic",9,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TCATTCACAATGCAGG","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1661.41700947615,38.4833843456731,0.0231629892592752,667,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1656.24541607016,1656.24541607016,"Control"
"2019.08.29.count.2.TCCACCAGTGGTCTTA","healthy-5","2019-08-29-count-2:TCCACCAGTGGTCTTA",0.868721385567826,8.83761022174684,"2019-08-29-count-2","Control5","CD4+ T","CD4+ TCM",4,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TCCACCAGTGGTCTTA","CD4+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD4_T",1508.58205976497,34.2582773286155,0.0227089253162355,608,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1499.89532035909,1499.89532035909,"Control"
"2019.08.29.count.1.CATACCCTCGATACAC","healthy-5","2019-08-29-count-1:CATACCCTCGATACAC",3.22559656676595,-7.61230232631835,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.CATACCCTCGATACAC","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1940.89378834251,44.3043899047082,0.0228267977211383,874,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1939.12325610202,1939.12325610202,"Control"
"2019.08.29.count.2.AACCTTTGTCCAGAAG","healthy-5","2019-08-29-count-2:AACCTTTGTCCAGAAG",3.38099588927571,-7.42707397854003,"2019-08-29-count-2","Control5","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.AACCTTTGTCCAGAAG","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1868.43435225837,48.3384372943082,0.0258710921450795,843,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1862.62995826283,1862.62995826283,"Control"
"2019.08.29.count.1.GTCACTCGTGCCTACG","healthy-5","2019-08-29-count-1:GTCACTCGTGCCTACG",4.46427692946736,-8.46877195751341,"2019-08-29-count-1","Control5","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GTCACTCGTGCCTACG","HLA-II+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2366.69846114608,36.9226524894089,0.0156009111830533,1354,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2362.41266936134,2362.41266936134,"Control"
"2019.08.29.count.2.TCCCAGTCAAGGTCGA","healthy-5","2019-08-29-count-2:TCCCAGTCAAGGTCGA",4.08818211135213,-7.92496015941771,"2019-08-29-count-2","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TCCCAGTCAAGGTCGA","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2014.42730359194,32.7576224949789,0.016261506402623,929,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2012.56931969379,2012.56931969379,"Control"
"2019.08.29.count.1.GTCTAGATCAGGAAAT","healthy-5","2019-08-29-count-1:GTCTAGATCAGGAAAT",6.68356718596761,-0.881095134374224,"2019-08-29-count-1","Control5","pDC","pDC",32,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GTCTAGATCAGGAAAT","pDC","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","DC","pDC",1894.24993231111,40.271221102778,0.0212597189081825,924,30000,1100,500,"True","True","True","True",5,212,"True","DC_healthy-5",1887.46970490228,1887.46970490228,"Control"
"2019.08.29.count.2.CTCCTCCCACGCACCA","healthy-5","2019-08-29-count-2:CTCCTCCCACGCACCA",-5.8722485107487,-4.6298489800659,"2019-08-29-count-2","Control5","GMP","GMP",57,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.CTCCTCCCACGCACCA","GMP","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","HSPC","HSPC",3241.98731690265,38.7894732241187,0.0119647208432566,2915,30000,1100,500,"True","True","True","True",5,113,"True","HSPC_healthy-5",3234.59838531965,3234.59838531965,"Control"
"2019.08.29.count.1.GCATCGGAGGTACTGG","healthy-5","2019-08-29-count-1:GCATCGGAGGTACTGG",3.88905562934224,-8.38125326549681,"2019-08-29-count-1","Control5","HLA-II+ monocyte","HLA-II+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.GCATCGGAGGTACTGG","HLA-II+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1739.06982161726,41.0305399869038,0.0235933827824965,737,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1737.01422185961,1737.01422185961,"Control"
"2019.08.29.count.1.ATCCTATGTGGGATTG","healthy-5","2019-08-29-count-1:ATCCTATGTGGGATTG",3.74071135100667,-6.31697561657103,"2019-08-29-count-1","Control5","CD14+ monocyte","CD14+",14,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.ATCCTATGTGGGATTG","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1749.01895856165,45.2469214976578,0.0258698862446109,747,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1740.68954712674,1740.68954712674,"Control"
"2019.08.29.count.1.CCACCATTCTGTAAGC","healthy-5","2019-08-29-count-1:CCACCATTCTGTAAGC",8.92582287368123,6.74248836124269,"2019-08-29-count-1","Control5","B","Activated NFkB",0,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.CCACCATTCTGTAAGC","B","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1576.65855875621,43.5018657042232,0.0275911772162902,637,30000,1100,500,"True","True","True","True",5,313,"True","B_healthy-5",1574.48823369075,1574.48823369075,"Control"
"2019.08.29.count.2.CTGCATCTCTGGAGAG","healthy-5","2019-08-29-count-2:CTGCATCTCTGGAGAG",-1.12897799435313,9.02700421893922,"2019-08-29-count-2","Control5","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.CTGCATCTCTGGAGAG","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1434.39447091456,37.9819342038551,0.0264794203923821,527,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1434.39447091456,1434.39447091456,"Control"
"2019.08.29.count.2.CCATAAGAGAAGGTAG","healthy-5","2019-08-29-count-2:CCATAAGAGAAGGTAG",3.49039282378499,-6.03558542644652,"2019-08-29-count-2","Control5","HLA-II+ monocyte","HLA-II+",36,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.CCATAAGAGAAGGTAG","HLA-II+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2122.14541043214,42.3544713879408,0.0199583266913439,1131,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2120.58767215387,2120.58767215387,"Control"
"2019.08.29.count.2.ACCACAATCTTCTCAA","healthy-5","2019-08-29-count-2:ACCACAATCTTCTCAA",-2.15257583084758,9.82572362506715,"2019-08-29-count-2","Control5","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.ACCACAATCTTCTCAA","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1658.16943823833,44.8974612315109,0.0270765219742626,715,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1652.07956589638,1652.07956589638,"Control"
"2019.08.29.count.2.TTGTTGTGTGGACCAA","healthy-5","2019-08-29-count-2:TTGTTGTGTGGACCAA",3.38310279425923,-8.11277677929076,"2019-08-29-count-2","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TTGTTGTGTGGACCAA","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1426.66493304016,46.6704720274565,0.0327129874342701,532,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1421.85379886448,1421.85379886448,"Control"
"2019.08.29.count.2.ATGACCACAACAAGTA","healthy-5","2019-08-29-count-2:ATGACCACAACAAGTA",3.27760281142537,-7.92310621654662,"2019-08-29-count-2","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.ATGACCACAACAAGTA","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1828.48122567252,47.7507325708652,0.0261149701186035,759,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1826.29699894115,1826.29699894115,"Control"
"2019.08.29.count.2.TACACCCAGCCTTGAT","healthy-5","2019-08-29-count-2:TACACCCAGCCTTGAT",4.30946411666219,-8.06370642101439,"2019-08-29-count-2","Control5","HLA-II+ monocyte","HLA-II+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TACACCCAGCCTTGAT","HLA-II+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2166.86052322257,38.3705551320799,0.0177079026180305,1054,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2166.86052322257,2166.86052322257,"Control"
"2019.08.29.count.2.ATGGAGGGTCCAACGC","healthy-5","2019-08-29-count-2:ATGGAGGGTCCAACGC",4.32398905333821,-6.904248260614,"2019-08-29-count-2","Control5","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.ATGGAGGGTCCAACGC","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2147.48460453906,44.891693607947,0.0209043145236344,1054,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2136.83318690834,2136.83318690834,"Control"
"2019.08.29.count.2.ATTACTCCAATCAAGA","healthy-5","2019-08-29-count-2:ATTACTCCAATCAAGA",10.48104919967,6.09626290881959,"2019-08-29-count-2","Control5","B","Memory",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.ATTACTCCAATCAAGA","B","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1621.43943391126,39.4688960655282,0.0243418873625891,640,30000,1100,500,"True","True","True","True",5,313,"True","B_healthy-5",1616.94693051887,1616.94693051887,"Control"
"2019.08.29.count.1.CTTCTAAGTAAGTAGT","healthy-5","2019-08-29-count-1:CTTCTAAGTAAGTAGT",-2.83186231079753,3.98779318416444,"2019-08-29-count-1","Control5","Ery","Ery-2",53,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.CTTCTAAGTAAGTAGT","Ery","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Ery","Ery",3217.69723712958,47.0420665969409,0.0146197927058252,3652,30000,1100,500,"True","True","True","True",5,241,"True","Ery_healthy-5",3210.32966464478,3210.32966464478,"Control"
"2019.08.29.count.2.GGGCTACTCTCGCGTT","healthy-5","2019-08-29-count-2:GGGCTACTCTCGCGTT",-2.51884828034099,12.3704557188782,"2019-08-29-count-2","Control5","NK","CD56bright NK",6,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.GGGCTACTCTCGCGTT","NK","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","NK","NK",1495.00648501213,47.4628270686802,0.031747572699188,574,30000,1100,500,"True","True","True","True",5,344,"True","NK_healthy-5",1492.65768612188,1492.65768612188,"Control"
"2019.08.29.count.2.ATTCTTGAGGGACAGG","healthy-5","2019-08-29-count-2:ATTCTTGAGGGACAGG",3.16231169280354,-8.15578749096068,"2019-08-29-count-2","Control5","CD14+ monocyte","CD14+",8,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.ATTCTTGAGGGACAGG","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1743.81116811953,42.7034356789228,0.0244885664569822,731,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1741.68960204163,1741.68960204163,"Control"
"2019.08.29.count.1.CAAGACTCATCGATGT","healthy-5","2019-08-29-count-1:CAAGACTCATCGATGT",10.7690264182979,6.46165988529054,"2019-08-29-count-1","Control5","B","Naive B",2,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.CAAGACTCATCGATGT","B","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","B","B",1497.32528764912,44.1068365255922,0.0294570838343633,564,30000,1100,500,"True","True","True","True",5,313,"True","B_healthy-5",1492.61422879237,1492.61422879237,"Control"
"2019.08.29.count.2.ATTTCACCATGCAGGA","healthy-5","2019-08-29-count-2:ATTTCACCATGCAGGA",5.43731798705403,-9.92469599163207,"2019-08-29-count-2","Control5","CD16+ monocyte","CD16+",50,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.ATTTCACCATGCAGGA","CD16+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",2222.30365018672,37.4663695428299,0.0168592485278427,1170,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",2210.91022354498,2210.91022354498,"Control"
"2019.08.29.count.1.AACAAGACATCCGTTC","healthy-5","2019-08-29-count-1:AACAAGACATCCGTTC",-1.03509817543681,9.31876752460328,"2019-08-29-count-1","Control5","CD8+ T","CD8+ GZMK+",15,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613751","2019-08-29-count-1_metadata.csv.gz","2019.08.29.count.1.AACAAGACATCCGTTC","CD8+ T","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","T","CD8_T",1680.80726820541,36.6745828488993,0.0218196241429017,746,30000,1100,500,"True","True","True","True",5,710,"True","T_healthy-5",1670.96925835168,1670.96925835168,"Control"
"2019.08.29.count.2.TGGAGGAGTGAGATCG","healthy-5","2019-08-29-count-2:TGGAGGAGTGAGATCG",3.19795860823933,-7.00604965603026,"2019-08-29-count-2","Control5","CD14+ monocyte","CD14+",3,"Control","Control","Control","control_39to53yrs","control_39to53yrs","male","Control",NA,"GSM5613752","2019-08-29-count-2_metadata.csv.gz","2019.08.29.count.2.TGGAGGAGTGAGATCG","CD14+ monocyte","5","M",47,"CITE-Seq","","","","","",NA,"","","","","","","",NA,NA,"","","","",NA,NA,"","",NA,"",NA,NA,NA,NA,"",NA,"","",NA,NA,"",NA,NA,NA,"",NA,"","",NA,"",NA,"healthy","control","Mono","Mono",1761.00383696325,41.7440662034884,0.0237046991762799,722,30000,1100,500,"True","True","True","True",5,1687,"True","Mono_healthy-5",1758.79420135775,1758.79420135775,"Control"
